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In 1990, scientists began working together on one of the largest biological research projects 
ever proposed. The project proposed to sequence the three billion nucleotides in the human 
genome. The Human Genome Project took 13 years and was completed in April 2003, at a 
cost of approximately three billion dollars. It was a major scientific achievement that forever 
changed the understanding of our own nature. The sequencing of the human genome was in 
many ways a triumph for technology as much as it was for science. From the Human Genome 
Project, powerful technologies have been developed (e.g., microarrays and next generation 
sequencing) and new branches of science have emerged (e.g., functional genomics and 
pharmacogenomics), paving new ways for advancing genomic research and medical 
applications of genomics in the 21st century. The investigations have provided new tests and 
drug targets, as well as insights into the basis of human development and diagnosis/treatment 
of cancer and several mysterious humans diseases. This genomic revolution is prompting a 
new era in medicine, which brings both challenges and opportunities. Parallel to the 
promising advances over the last decade, the study of the human genome has also revealed 
how complicated human biology is, and how much remains to be understood. The legacy of 
the understanding of our genome has just begun. To celebrate the 10th anniversary of the 
essential completion of the Human Genome Project, in April 2013 Genes launched this 
Special Issue, which highlights the recent scientific breakthroughs in human genomics, with a 
collection of papers written by authors who are leading experts in the field. 
 
John Burn, James R. Lupski,  





Genes and Genetic Testing in Hereditary Ataxias 
Erin Sandford and Margit Burmeister  
Abstract: Ataxia is a neurological cerebellar disorder characterized by loss of coordination during 
muscle movements affecting walking, vision, and speech. Genetic ataxias are very heterogeneous, 
with causative variants reported in over 50 genes, which can be inherited in classical dominant, 
recessive, X-linked, or mitochondrial fashion. A common mechanism of dominant ataxias is repeat 
expansions, where increasing lengths of repeated DNA sequences result in non-functional proteins 
that accumulate in the body causing disease. Greater understanding of all ataxia genes has helped 
identify several different pathways, such as DNA repair, ubiquitination, and ion transport, which 
can be used to help further identify new genes and potential treatments. Testing for the most 
common mutations in these genes is now clinically routine to help with prognosis and treatment 
decisions, but next generation sequencing will revolutionize how genetic testing will be done. 
Despite the large number of known ataxia causing genes, however, many individuals with ataxia 
are unable to obtain a genetic diagnosis, suggesting that more genes need to be discovered. 
Utilization of next generation sequencing technologies, expression studies, and increased 
knowledge of ataxia pathways will aid in the identification of new ataxia genes. 
Reprinted from Genes. Cite as: Sandford, E.; Burmeister, M. Genes and Genetic Testing in 
Hereditary Ataxias. Genes 2014, 5, 586-603. 
1. Introduction 
Ataxia is a neurological sign that involves a lack of coordinated muscle movement, which 
impacts walking, speech, and vision. Ataxia can present as an isolated symptom, or present as one 
of many symptoms of a more complex disease. Acquired ataxias may be temporary or permanent, 
and can be caused by environmental factors, such as alcohol, trauma, or exposure to toxins, or by 
other underlying medical conditions such as stroke, infection, tumors, or vitamin deficiencies. 
However, many ataxias have an underlying genetic cause. Hereditary ataxias are a group of highly 
heterogeneous diseases, but each usually follows a typical Mendelian dominant, recessive, or  
X-linked inheritance. The prevalence of hereditary ataxias varies by population and has been 
estimated at 1–9 per 100,000 people [1–4]. Many hereditary diseases also present with ataxia as 
one symptom of a more complex phenotype. This review will focus on disorders classified 
primarily as ataxia, along with those ataxias that result in other symptoms like intellectual 
disability, with known genetic association. 
Early work on the genetic origins of ataxia began in 1993 with the discovery of a CAG repeat 
responsible for spinocerebellar ataxia (SCA) type 1 [5]. Continued screening for CAG repeat 
expansions identified several additional dominant SCAs that are caused by the same mechanism [6–10]. 
With the advancement of next generation sequencing technology, genome and exome sequencing 
have become an affordable option for screening for disease genes. Exome sequencing for 
Mendelian diseases first gained prominence in 2010 with the discovery of the disease gene for 
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Miller syndrome and since then, mutations in several new ataxia genes have been identified 
utilizing exome sequencing, including ATP2B3, KCND3, DNMT1, UCHL1, and TPP1, illustrating the 
utility of the technology [11–17]. While mutations in many of these new genes were found in only 
one family (“private” mutations), thus far, mutations in KCND3 were found in multiple different 
families on several continents [13,14]. Despite these advances, it is estimated that up to 40% of 
those with ataxia do not know the genetic cause, illustrating the need to continue research into the 
identification of ataxia genes in order to provide a diagnosis and potentially a treatment [18]. 
2. Phenotypes of Hereditary Ataxias 
Hereditary ataxias exhibit a wide range of phenotypes, in both clinical features and age of onset. 
Some ataxias are described as “pure cerebellar”, where symptoms are all related to cerebellar 
control of muscle movement. This can include ataxic gait and movement of body and limbs, along 
with nystagmus, dysarthia, and hypotonia. Many of these features are easily observed by external 
examination. Magnetic resonance imaging often provides the clearest explanation for the ataxia 
through the identification of cerebellar atrophy, but may appear normal in some cases [19,20]. 
Other ataxias can present with more extensive additional neurological symptoms, such as 
Parkinsonism, epilepsy, dementia, and neuropathy. Multisystem involvement can include 
symptoms such as deafness and intellectual disability. These symptoms may be progressive, 
gradually becoming more severe over time, or non-progressive, where the symptoms are stable. 
The age of symptom onset in affected individuals can vary dramatically, both within and across 
different ataxias, with symptoms present from birth through onset in the 7th and 8th decades of life. 
Late onset ataxias are more commonly progressive and can result in patients becoming wheelchair 
bound or even experience a reduced lifespan. Congenital ataxias display symptoms within the first 
year of life and are often non-progressive, however many congenital ataxias more often present as 
multisystem diseases. These children may display muscular hypotonia prior to onset of ataxia 
symptoms, resulting in “floppy baby syndrome”. 
A common phenomenon in the dominantly inherited ataxias is anticipation, where the younger 
generation exhibits symptoms at an earlier age. The rate of anticipation can vary, depending on 
genetic and environmental factors, but differences in age of onset, up to 20 years, have been 
reported. Much, but not all, of anticipation can be explained by increasing repeat length of the 
CAG expansions (see Section 3.1.1). Anticipation can be difficult for clinicians to correctly 
diagnose, as younger individuals with a family history of ataxia may describe more psychosomatic 
symptoms in the expectation of developing symptoms later in life. 
3. Ataxia Genetics 
Hereditary ataxias are genetically and phenotypically heterogeneous. Similar phenotypes may be 
caused by mutations in many different genes, and several genes cause different types of ataxia 
depending upon the mutation. While many ataxias appear worldwide, such as Friedreich’s ataxia or 
SCA3, others are more common in one population. Dentatorubral-pallidoluysian atrophy (DRPLA) 
is most common in Japan and SCA2 is prevalent in Cuba. Other ataxias may be completely 
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restricted to certain populations, such as Cayman ataxia on the Cayman Islands. Knowledge of a 
patient’s ethnic origin can, therefore, be helpful, along with phenotype and family history. In most 
newly diagnosed cases with ataxia, screening panels for many ataxia genes is recommended. As 
ataxia can be misdiagnosed as multiple sclerosis or Parkinson’s, finding a genetic cause often 
solidifies a diagnosis, not only for an individual, but for the whole family. 
3.1. Autosomal Dominant 
Many dominant ataxias have been classified as SCAs or episodic ataxias (EA). At least 34 
different SCAs and seven EAs have been described clinically, with 28 having known associated 
genetic mutations. Dominant ataxias tend to have an onset later in life and be slowly progressive. 
SCAs, particularly those caused by repeat expansions, can exhibit a larger range of symptom onset 
and a faster rate of progression. A detailed review of the clinical characteristics of SCAs was 
published in 2009 [21]. Individuals with EA experience episodes of ataxia that can range from 
minutes to hours in duration and are triggered by environmental stimuli such as stress, alcohol, or 
exercise [22–24]. 
In some cases, the causative gene was identical in several previously reported SCAs, so SCA15, 
SCA16, and SCA29 all are caused by mutations in ITPR1 and SCA19 and SCA22 are caused by 
mutations in KCND3 [13,14,25–27]. Repeat expansion in CACNA1A results in SCA6 while single 
nucleotide variants (SNV), insertions, and deletions result in EA2. Known autosomal dominant 
(AD) ataxia genes are reported in Table S1. 
3.1.1. Repeat Expansions 
The most common forms of dominant ataxias are caused by repeat expansion. Short repeats, 
typically three to six bases long, appear at variable repeat number within many genes. Occasionally 
these repeat regions become unstable during replication, leading to either deletions of repeats, 
which rarely causes problems, or to expansion of the number of repeats. Typically within a repeat 
region, there are instances of non-repeated bases, such as a CAA in a string of CAG. Mutations that 
convert these imperfections in the repeat region to match the surrounding repeats result in an 
unstable sequence and increased likelihood of expansion. In ataxias, the number of repeats may 
increase anywhere from less than 2 to over 100 fold, depending on the gene. The most common 
repeat expansions are CAG expansions. As CAG encodes glutamine, these are also referred to as a 
polyglutamine or polyQ repeats, as these repeats form strings of glutamines (Q) in the coding 
region. There are currently seven known AD ataxias caused by CAG polyglutamine expansions: 
SCA1, SCA2, SCA3 (also known as Machado Joseph disease or MJD), SCA6, SCA7, SCA17, and 
DRPLA. In addition, repeat expansions outside the coding region, in introns or the untranslated 
regions of the gene, also can cause ataxia without causing polyglutamine disease, but rather by 
interfering with the regulation of the gene: SCA8 (CTG), SCA10 (ATTCT), SCA12 (CAG), 
SCA31 (TGGAA), and SCA36 (GGCCTG). 
The most common SCAs reported are SCA1, SCA2, SCA3, SCA6, and SCA7. Rates for each 
vary by population; the National Ataxia Foundation reports that SCA6 is responsible for up the 
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30% of dominant ataxia cases in Japan, but only 15% in the U.S. and 2% in Italy. Together these five 
SCA make up about 60% of the reported dominant cases of ataxia [21]. With the high frequency of 
these SCAs, it is not surprising that they were the first genetic mutations responsible for SCA that 
were identified. 
Age of onset is highly variable with repeat expansion disorders, ranging from early childhood to 
the later decades of adulthood. There is an inverse correlation between repeat length and age of 
onset, with longer repeats resulting in symptoms at a younger age. Expansions often increase in 
length in each subsequent generation, leading to a phenomenon called anticipation, where the next 
generation starts exhibiting symptoms at an earlier age than the previous. Reduction of repeat 
length has been reported but this occurs more rarely. Many individuals have repeats at an 
intermediate length, resulting in incomplete penetrance of the disease, but these are more likely to 
expand in future generations. Expansion of repeat regions can therefore appear as sporadic cases 
when the repeat is newly expanded, as this individual may have no other affected family members. 
Repeat expansions cause disease through toxic gain of function. This gain of function can allow 
expanded proteins to avoid degradation, exhibit changes in expression, and influence function of 
other interacting genes [28–30]. Recently, it has been demonstrated in SCA8 and FXTAS,  
an X-linked ataxia, that RNA can be translated independent of a traditional ATG start site, in a 
process referred to as repeat-associated non-ATG translation, contributing to the harmful effects of 
aberrant proteins [31–33]. 
3.1.2. Other Mutations in AD Ataxias 
Several of the other more recently discovered dominant ataxias are caused by conventional 
mutations: SNVs, insertions, and deletions. Conventional mutations are much less common in AD 
ataxias than repeat expansions. Several mutations have only been reported in select populations or 
families, while others appear to exist worldwide. SCA28, for example, causes 1.5% of AD ataxia in 
Europeans, but has not been detected in other large populations such as Chinese [34,35]. Dominant 
mutations can result in disease through haploinsufficiency due to gene deletion or disruption of 
functionally important residues, or by dominant negative mechanisms. Although more rare than in 
repeat expansions, anticipation has been documented in cases of indel or SNV mutations. The 
mechanism behind anticipation in ataxia due to indel or SNV mutations is unknown. 
The variety of mutation types present in dominant ataxias illustrates the need for careful 
attention to molecular assays used to screen for new mutations. ITPR1 was initially discarded as a 
candidate gene but later reassessment of the same samples detected the disease-causing  
deletion [25,36]. The confirmation of ITPR1 as an ataxia causing gene in humans led to the careful 
screening and discovery of mutations in SCA16 and SCA29 patients [26,27]. 
3.2. Autosomal Recessive 
Autosomal recessive (AR) ataxias occur more frequently than AD ataxias. Known AR ataxia 
genes are reported in Table S2. Despite the greater frequency of AR ataxias, many of these cases 
go genetically undiagnosed. Often, only one individual in a family presents with recessive ataxia. 
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These cases may appear sporadic or idiopathic, making it difficult to distinguish AR from  
a de novo AD mutation or a new expansion event. In addition, the number of genes causing AR 
ataxia is large, and often mutations are family-specific or private variants, which appear most 
frequently under conditions of a suspected founder effect or consanguineous union. Recessive 
ataxias, more often than dominant, have symptom onset from birth or in early childhood, but this 
may be due to ascertainment, and later onset recessive ataxias certainly also exist. Unlike AD, early 
onset AR are typically non-progressive in their symptoms, with more multisystem involvement 
leading to other symptoms such as intellectual disability [37,38]. 
The most common autosomal recessive ataxia, and the most common early onset ataxia, is 
Friedreich’s ataxia (FRDA). FRDA is estimated to have a prevalence of 1 in 20–50,000. In certain 
regions of the world, carrier rates have been estimated to be as high as 1 in 11 [39]. It is most 
commonly seen in individuals of European ancestry but is present worldwide. FRDA is primarily 
caused by a GAA intronic repeat expansion of the frataxin gene, with rare conventional mutations 
also reported [40,41]. The intronic expansion interferes with transcription and results in suppression of 
gene expression [42,43]. FRDA is a prime example where understanding the cellular pathology has 
guided research towards treatment, with several groups exploring methods to therapeutically 
increase the expression of frataxin [44], some of which are in or nearing clinical trials 
Ataxia telangiectasia (A-T) is an early onset ataxia affecting 1 in 40–100,000. As mutations 
disrupt DNA repair, individuals with A-T are susceptible to radiation and oxidative stress. 
Heterozygous carriers for mutated ATM gene have a greater susceptibility to developing cancer. 
Mutations in ATM are highly variable, with over 600 unique variants reported. 
There are several other ataxias that exhibit clinical features and molecular pathology similar to 
A-T. A-T like disorder is caused by mutations in MRE11A, another DNA repair gene. Individuals 
with A-T like disorder share the same neurological defects, along with oculomotor apraxia, but lack 
the telangiectasia and other features. Four other genes have been identified to cause ataxia with 
oculomotor apraxia (AOA). AOA2 is caused by mutations in SETX and is predicted to be 
responsible for 8% of non-Friedreich recessive ataxias [45]. It is prevalent among French-Canadians, 
but also present in other populations [45]. AOA1 is common among Japanese and Portuguese, 
where it was additionally characterized with features of low serum albumin and high cholesterol 
levels [46]. Mutations in GRID2 and PIK3R5, which cause AOA and AOA3, are much less common. 
3.3. X-Linked 
In contrast to AD and AR ataxias, there are comparatively few known X-linked ataxias. The 
most common X-linked ataxia is fragile X-associated tremor ataxia syndrome (FXTAS). FXTAS is 
caused by a CGG repeat expansion in the 5' untranslated region of the FMR1 gene [47]. This 
ataxia-associated expansion is often referred to as a fragile X “premutation”. The normal length of 
the FMR1 repeat is less than 39 repeats, whereas 55 to 200 repeats are considered to be a 
premutation. Males with greater than 200 repeats have the full expansion mutation, which causes 
fragile X syndrome, a severe disease caused by expansion of the same repeat [48]. In the U.S., 
carrier rates for the FMR1 premutation are estimated at 1 in 209 for females and 1 in 430 for  
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males [49]. A study in a population from Quebec estimated premutation rates at 1 in 259 for 
females and 1 in 813 for males [50,51]. 
FXTAS is characterized by tremor and ataxia with late onset, usually past the fifth decade. As 
the gene is X-linked, males are far more commonly affected than females [52]. In female carriers, 
an estimated 20% experience symptoms of premature ovarian insufficiency, with onset of 
menopause before 40 and/or fertility issues [53]. Males with fragile X display a very different 
phenotype from FXTAS, with prominent intellectual disability and abnormal facial features. FMR1 
is a prime example of how subtle differences in mutations within the same gene can greatly impact 
the phenotype. 
Other X-linked ataxias are rare, often restricted to a single family. A mutation in ATP2B3, also 
known as PMCA3, was recently associated with spinocerebellar ataxia in an Italian family. 
Researchers found a single point mutation disrupted calcium transport in the cell, resulting in a 
“pure cerebellar” phenotype, with congenital onset ataxia, cerebellar atrophy, hypotonia, and slow 
eye movements [12,54]. Although the phenotype reported is similar to that seen in other families, 
this is the only reported ATP2B3 ataxia mutation to date. Sideroblastic anemia with ataxia (ASAT) 
is caused by mutations in ABCB7. 
3.4. Mitochondrial 
Mitochondrial DNA is maternally transmitted through mitochondria in the oocyte. Mutations in 
mitochondrial DNA genes tend to result in more multisystem diseases that can contain ataxia as a 
symptom. Neuropathy, ataxia, and retinitis pigmentosa (NARP) is caused by mutations in the 
mitochondrial DNA gene MTATP6 [55]. 
Mutations in nuclear genes that function primarily in the mitochondria can also cause ataxia. 
Despite their association to the mitochondria, these mutations are inherited in an AR pattern. 
Mutations in POLG, which is a subunit of mitochondrial DNA polymerase, are responsible for 
ataxia and other multisystem features [56]. C10orf2, or twinkle, is necessary for proper mtDNA 
replication and is responsible for a variety of neurological phenotypes including infantile onset 
ataxia [57–60]. 
3.5. Multiple Systems Atrophy and other Multisystem Diseases that Include Ataxia 
Multisystem diseases can be more difficult to diagnose due to the variability in presentation. 
More diverse neurological phenotypes, such as seizures and myopathy, and non-neurological 
symptoms such as hearing loss, cardiac problems, and diabetes can complicate these disorders. 
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder. Individuals may 
initially present with Parkinsonism or ataxia, and progress to more severe cerebellar atrophy and 
nervous system dysfunctions. Mutations in COQ2 shown to be responsible for MSA have been 
shown to be more common in the Japanese population [61]. Refsum disease can also cause 
cerebellar ataxia but ataxia is not present in all Refsum patients. Several members of the 
peroxisome biogenesis factor family are responsible for several peroxisome biogenesis disorders 
that can appear similar to Refsum. These diseases range in severity from resulting in early death to 
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survival and functional ability in adulthood. The broad phenotypes displayed in these diseases can 
make them difficult to diagnose and classify. 
4. Mutations in Conserved Pathways Cause Ataxia 
Despite the great advances made in sequencing technology and the discovery of new genes, 
there is still a gap in the full understanding of the function of these gene products. Many of the 
functions of ataxia genes have yet to be discovered, despite overwhelming evidence that they are 
responsible for causing disease. Discovery of genetic pathways involved in ataxia genes is 
important to our understanding of disease pathogenesis, and may also impact some treatments. 
Expression studies and protein interaction assays focused on known ataxia genes have helped 
identify pathways and protein interactions [62]. Researching expression and pathways can be 
difficult, primarily due to the low availability of relevant tissue, as brain donation and biopsy are 
delicate topics for those with ataxia and their families. Knowledge of these pathways will not only 
be important for efforts for treatment development but aid in the discovery of new ataxia genes 
through the identification of common pathways and interactions. A success story for this approach 
is the identification of a new EA candidate gene, UBR4, which was selected as a candidate gene 
due to its role in ubiquitination and localization with another ataxia gene, ITPR1 [63]. 
4.1. DNA Repair 
The ability of a cell to repair damage to DNA is important in order to maintain proper function 
and avoid deleterious mutations. DNA damage can result in cell death by apoptosis or the 
formation of cancerous cells. Several ataxia genes have roles in DNA repair, with many involved in 
ataxia with oculomotor apraxia. MRE11 acts in a complex to locate damaged DNA, where it 
recruits ATM to phosphorylate p53 and induce DNA repair [64]. In individuals with ataxia-causing 
MRE11 mutations, MRE11 fails to effectively form a complex and recruit ATM [65]. Mutations in 
SETX, responsible for ataxia with oculomotor apraxia, greatly decrease the ability of cells to repair 
double strand breaks caused by oxidative stress [66]. Single strand repair mechanisms are impaired 
by mutations in TDP1 and APTX [67–69]. 
4.2. Channelopathies 
Mutations in genes responsible for the transport of ions in and out of the cell result in 
channelopathies. Channelopathies have received the most attention as a common pathway in 
neurological disease, with several reviews focused on the role of channel genes in disease and 
neurological disorders. Defects in ion channel genes usually result in dominant negative 
mechanisms, as they can alter the current and exchange of ions across cell membranes, affecting 
cell signaling or causing intracellular accumulation. Ion voltage channels help to regulate the action 
potential of neurons and release neurotransmitters. EA1, EA2, and EA5 are all caused by mutations 
in channel genes, a potassium voltage gated channel and two calcium voltage dependent  
channels [24,70,71]. Two other potassium voltage gated channel genes, KCNC3 and KCND3, are 
responsible for SCA13 and SCA19/22 [13,14,72]. Inositol 1,4,5 triphosphate binding to ITPR1 
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mediates the release of calcium from intracellular stores in the endoplasmic reticulum [73,74]. 
Deletions in ITPR1 are hypothesized to cause adult onset ataxia through haploinsufficiency, and 
mutations in conserved domains affect channel function resulting in congenital ataxia [25–27]. 
4.3. Ubiquitination 
Ubiquitination serves multiple roles within the cell, including targeting proteins for degradation. 
Many ataxias result from a mutant protein escaping this degradation system. Disruption of 
ubiquitination systems can cause failures in many cellular processes, such as protein degradation 
pathways, membrane tracking, apoptosis, and immune system processes. 
Several ataxia genes are in or interact with ubiquitination system proteins. Mutations in 
RNF170, an E3 ubiquitin ligase, are responsible for AD sensory ataxia [75,76]. RNF170 was shown 
to associate with inositol 1,4,5-triphosphate receptors (IP3), while mutations in its receptor, IP3R1 
(ITPR1) also cause ataxia, providing a link between ubiquitination and ion channel signaling [76]. 
ATXN3 is a de-ubiquitinating enzyme that interacts with parkin, an E3 ubiquitin ligase, resulting in 
more de-ubiquitinated parkin in the presence of ATXN3 repeat expansion mutants [77]. Recently 
mutations in two different E3 ligases have been associated with ataxia and hypogonadism: RNF216 and 
STUB1 [78,79]. 
4.4. Transcription/Translation 
The ability to control gene expression and protein abundance is important for proper function in 
the cell and organism. Failure in proper transcriptional mechanism and regulation can result in a 
variety of diseases including cancer, autoimmune, and neurological [80] disorders. ATXN1 forms a 
complex with the transcriptional repressor capicua and may interact with the transcription factor 
ROR  [29,81]. Nemo-like kinase (NLK) has been shown to interact with ATXN1 transcriptional 
complex, and decreased expression of NLK positively modulates the phenotype in SCA1 models, 
providing another biological target for future treatments [82]. The transcription factor ROR  
exhibits decreased levels in SCA1 and SCA3, with null and mutant mice for Rora showing 
cerebellar defects and ataxia [81,83,84]. Along with DNA repair, mutations in SETX also interfere 
with transcription, highlighting interactions between senataxin and proteins involved in 
transcription and RNA processing [85]. 
5. Genetic Testing of Ataxias and Personalized Medicine 
5.1. Is Genetic Testing of Ataxia Useful? 
Rare forms of ataxia respond to Vitamin E or Coenzyme Q10 (AVED and SCAR9/ARCA2), but 
for most ataxias, only symptomatic treatment is available. Genetic testing for diseases with no 
treatment is controversial and in the U.S., is usually considered a personal choice, whereas 
developing countries do not routinely offer testing. Thus, what are the reasons to test a patient with 
ataxia for known genes? Indeed, some of those with ataxia have commented upon finding out that 
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they had e.g., SCA2, so now what? There is little difference in treatment or prognosis, so why all 
the expense of testing? 
One reason given for genetic testing is family planning. This most often arises in dominant 
ataxias where the disease is seen in prior generations, but can apply to recessive ataxias, especially 
in isolated populations where disease alleles may be at a higher frequency. Individuals who are 
carriers of a disease mutation may make different reproductive choices to avoid passing the disease 
on to the next generation. They may choose to avoid passing on genetic material by not having 
children, choosing adoption, or use of egg/sperm donors. Those wanting biological children may 
utilize pre-implantation screening with in vitro fertilization or termination of pregnancy after 
prenatal diagnosis [86]. Pre-implantation testing and testing of children have resulted in a new 
ethical conundrum of “genetic ignorance”, where parents may decide to remain ignorant about their 
own results, but wish to test offspring or embryos, possibly unnecessarily [87]. 
A more complex situation is that of FXTAS. This diagnosis in an older male with ataxia implies 
a very high risk of the more severe fragile X syndrome in any grandsons or nephews through his 
female relatives. Since the FMR1 expansion is on the X chromosome, females can be 
asymptomatic carriers. For example, a female with a male relative with FXTAS may be a carrier, 
and hence be at risk of having a son with fragile X syndrome. A survey on genetic screening for 
FMR1 mutations showed that while individuals are concerned about finding out they are carriers, 
and the emotional stress that may accompany that, many note the value in being able to make 
informed reproductive choices and possible benefits to other family members [88]. 
Genetic testing also will allow pre-symptomatic testing. One man, after finding out the genetic 
cause of his mother’s ataxia, decided to get tested himself before purchasing a house—he reasoned 
that if he had the mutation, the house should accommodate his future potential disability needs such 
as walker and wheel chair accessibility. Pre-symptomatic testing can result in unintended 
consequences for those tested, which may explain why for some neurodegenerative diseases, like 
Huntington’s, a minority of those at risk are tested [89,90]. There are reports of greater instances of 
depression in individuals with positive test results, possible stigmatization by peers or family 
members, or having difficulty obtaining life insurance. 
Genetic testing offers a definitive diagnostic confirmation for patients. Some individuals with 
ataxia are first diagnosed as having amyotrophic lateral sclerosis, multiple sclerosis, MSA, or 
Parkinson’s. Genetic testing will become an increasingly important part of differential diagnosis in 
these individuals. Desire for knowledge and closure about what is causing their symptoms can be 
comforting to affected individuals and family members. Genetic testing also has clear clinical 
ramifications for prognosis. As there are clinical differences in progression rates between different 
forms of ataxia [21], genetic testing can help patients and their physicians understand their own 
prognosis. For example, SCA7 leads to severe vision problems or blindness, and SCA6 also leads 
to some vision problems, whereas SCA2 symptoms also include neuropathy, tremors and cramps. 
Rarely, Vitamin-E responsive ataxia may be confused clinically with Friedreich’s ataxia, and hence 
this diagnosis will open up a new treatment with large doses of vitamin E. In turn, sometimes 




5.2. Genetic Testing Now and in the Future Era of Cheap Sequencing 
Currently, genetic testing is performed by a number of academic and commercial laboratories. 
For recessive ataxias, usually Friedreich’s ataxia is tested first, although depending on the 
symptoms, other ataxias are included. For dominant ataxias, the five most common SCAs are often 
tested first [92]. If these are negative, comprehensive panels for most known dominant or recessive 
ataxia genes, or all, are available from commercial sources [93]. Comprehensive panels are helpful 
when the mode of inheritance is not clear—e.g., if a parent died before symptom onset, or has some 
neurological symptoms that are not identical, or had been diagnosed with a different disorder. 
Next generation exome sequencing has shown some success in clinical environments, demonstrating 
that it may be more efficient than testing for mutations in ataxia genes individually [94–98]. 
Several academic clinical laboratories offer targeted sequencing of hundreds of genes, whereas 
others, such as Baylor and University of Chicago, offer exome sequencing, but may specifically 
evaluate ataxia genes [99,100]. At what point it is best to move from sequencing genes one at a 
time to large panels, and when from large panels to whole exome, is currently not clear. In 
addition, whole exome or genome sequencing can identify mutations in genes unrelated to ataxia, 
such as genes associated with early onset breast cancer. This is not unique to ataxia, and  
how to deal with such secondary or “incidental” findings is currently actively debated by ethicists 
and clinicians. 
In addition, there are current limitations to next generation sequencing technology. Currently 
large repeat expansions cannot be accurately sequenced or mapped to identify the common repeat 
expansion mutations. This is a limitation of the short reads captured by the sequencing technology; 
reads comprised of entirely repeats cannot be aligned to accurately determine placement or length. 
New computational methods are being developed in an attempt to tackle this problem. It is 
important for clinicians and genetic counselors to consider that next generation sequencing does 
not guarantee a diagnosis and should address this point with patients desiring sequencing. 
Hence, a fully comprehensive genome analysis that covers all ataxia gene mutations is not 
currently available. Given the heterogeneity of ataxias, and the large number of genes still being 
detected each year, a comprehensive genetic test will be a challenge for researchers and clinicians. 
6. Conclusions 
The variability in phenotypic symptoms and genetic causes provide a challenge for clinicians 
and geneticists in studying ataxia. Advancements in sequencing technology have greatly increased 
our rate of discovery of new ataxia genes and ability to screen for known genes. With the price of 
whole exome sequencing and soon whole genome sequencing falling below $1000 a sample, it has 
become the cost effective approach to screen multiple genes at the same time. Continuing 
expression studies and investigation into the role of genes will help identify shared pathways and 
functions. A challenge in this movement towards next generation sequencing technology is the 
discovery of new repeat expansions, which are difficult to detect using this new technology. The 
number of known genes mutations responsible for ataxia keeps growing every year; however we 
still do not have well defined functions or pathways for many of these genes. With greater 
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understanding of the pathways these genes are involved in and how each mutation causes disease, 
we may be able to generate more targeted and effective treatments in the future. 
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Functional Gene-Set Analysis Does Not Support a Major Role 
for Synaptic Function in Attention Deficit/Hyperactivity 
Disorder (ADHD) 
Anke R. Hammerschlag, Tinca J. C. Polderman, Christiaan de Leeuw, Henning Tiemeier, 
Tonya White, August B. Smit, Matthijs Verhage and Danielle Posthuma 
Abstract: Attention Deficit/Hyperactivity Disorder (ADHD) is one of the most common 
childhood-onset neuropsychiatric disorders. Despite high heritability estimates, genome-wide 
association studies (GWAS) have failed to find significant genetic associations, likely due to the 
polygenic character of ADHD. Nevertheless, genetic studies suggested the involvement of several 
processes important for synaptic function. Therefore, we applied a functional gene-set analysis to 
formally test whether synaptic functions are associated with ADHD. Gene-set analysis tests the 
joint effect of multiple genetic variants in groups of functionally related genes. This method 
provides increased statistical power compared to conventional GWAS. We used data from the 
Psychiatric Genomics Consortium including 896 ADHD cases and 2455 controls, and 2064  
parent-affected offspring trios, providing sufficient statistical power to detect gene sets representing 
a genotype relative risk of at least 1.17. Although all synaptic genes together showed a significant 
association with ADHD, this association was not stronger than that of randomly generated gene 
sets matched for same number of genes. Further analyses showed no association of specific 
synaptic function categories with ADHD after correction for multiple testing. Given current sample 
size and gene sets based on current knowledge of genes related to synaptic function, our results  
do not support a major role for common genetic variants in synaptic genes in the etiology of ADHD. 
Reprinted from Genes. Cite as: Hammerschlag, A.R.; Polderman, T.J.C.; de Leeuw, C.;  
Tiemeier, H.; White, T.; Smit, A.B.; Verhage, M.; Posthuma, D. Functional Gene-Set Analysis 
Does Not Support a Major Role for Synaptic Function in Attention Deficit/Hyperactivity Disorder 
(ADHD). Genes 2014, 5, 604-614. 
1. Introduction 
Attention Deficit/Hyperactivity Disorder (ADHD) is one of the most common childhood-onset 
neuropsychiatric disorders. The worldwide prevalence is estimated at ~5% [1], and remained 
relatively stable across the last three decades [2]. ADHD is characterized by a persistent pattern of 
inattention and/or impulsiveness and hyperactivity. Despite high heritability estimates for ADHD, 
averaging 70% [3], the identification of genes has been difficult. Most likely this is mainly due to 
the polygenic character of ADHD, similar to that of other complex traits, meaning that many 
genetic variants with small effects contribute to ADHD risk [4]. 
Genome-wide association studies (GWAS) of ADHD have yielded no significant single 
nucleotide polymorphism (SNP) associations thus far [5]. However, it has been reported that the 
top hits of GWAS point to the involvement of synaptic processes such as neurotransmission, cell-cell 
communication systems, potassium channel subunits and regulators, and more basic processes like 
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neuronal migration, neurite outgrowth, spine formation, neuronal plasticity, cell division, and 
adhesion [6–8]. Furthermore, many genes previously implicated in ADHD [9] are expressed in the 
synapse (i.e., DBH, SLC6A2, ADRA2A, HTR1B, HTR2A, TPH1/2, MAOA, CHRNA4, SNAP25, and 
BDNF), suggesting the involvement of synaptic function in the etiology of ADHD. 
In addition to common genetic variants, rare variants may contribute to ADHD risk. Increased 
structural variation burden has been reported, particularly in subjects with intellectual  
disability [10–13]. Interestingly, biological pathways enriched for GWAS SNP associations with low 
p-values overlap with pathways enriched for rare structural variants, including pathways important 
for synaptic function [12]. Of special interest are SNPs and duplications spanning the CHRNA7 
gene, which is primarily involved in modulation of rapid synaptic transmission and which has been 
associated with other neuropsychiatric phenotypes in addition to ADHD [12,13]. Furthermore, 
strong associations have been reported for structural variation affecting metabotropic glutamate 
receptor genes and genes that interact with them. Several of these genes are important modulators 
of synaptic transmission and neurogenesis [11]. 
Given the polygenic nature of ADHD, it is likely that non-random combinations of genetic 
variants are involved in the etiology of ADHD. Genes do not work in isolation; rather, they form 
complex molecular networks and cellular pathways. Therefore, it is plausible that the numerous 
genetic variants of small effect aggregate in genes that share a similar cellular function. Evaluating 
the joint effect of multiple SNPs in functionally related genes increases the statistical power to 
detect associations with ADHD compared to single SNP methods, as it reduces multiple testing. 
Moreover, single SNP associations do not necessarily lead to knowledge about underlying biological 
mechanisms, while a set of genes with the same function could result in more insight in the 
molecular or cellular mechanisms of ADHD [14]. 
Prior studies that tested the joint effect of genetic variants generally grouped genes based on 
biological pathways. However, grouping genes based on cellular function (“horizontal grouping”) 
instead of biological pathways (“vertical grouping”) may be especially powerful in synaptic protein 
networks [15,16]. Many different pathways regulate synaptic function, but act not independent,  
as many proteins act across pathways. For example, different neuromodulator pathways  
(e.g., dopamine or serotonin) include receptors that are activated by the specific neuromodulators, 
but are functionally and often structurally similar to each other. It may well be that genetic variants 
influencing complex traits like ADHD concentrate at similar cellular function, by which they 
influence different pathways leading to similar consequences in synaptic function. 
The majority of gene-set analyses that have been conducted have used publicly available gene 
sets. However, currently available public gene sets are generally incomplete and neither error-free 
nor unbiased, especially with regard to genes active in the brain [17,18]. Fortunately, expert-curated 
sets of genes are increasingly becoming available, such as the mir-137 gene set [19], specific synaptic 
gene sets [15], and gene sets for glial function [20]. 
As the results of previous GWAS and genes affected by structural variation suggested 
involvement of synaptic function, we hypothesized that synaptic processes play a role in the 
etiology of ADHD. Collective testing of genetic variants in genes grouped according to similar 
synaptic functions may be the most optimal way to test this. Therefore, we applied a functional 
21 
 
gene-set analysis for ADHD using 18 previously published, expert-curated pre- and postsynaptic 
gene sets [15]. To our knowledge, this is the first study to conduct hypothesis-driven gene-set 
analysis for ADHD by grouping synaptic genes according to cellular function. We used ADHD data 
from the Psychiatric Genomics Consortium (PGC) [5]. 
2. Methods 
2.1. Sample 
We used GWAS summary statistics from the currently largest publicly available ADHD data 
set, as provided by the PGC [5]. Details on the data set have been described previously [5]. In 
short, the data set consisted of four projects: the Children’s Hospital of Philadelphia (CHOP), phase I 
of the International Multicenter ADHD Genetics Project (IMAGE), phase II of IMAGE (IMAGE II), 
and the Pfizer-funded study from the University of California, Los Angeles, Washington University, 
and Massachusetts General Hospital (PUWMa). The total sample consisted of 896 unrelated cases 
and 2455 controls, and 2064 trio samples (alleles transmitted to offspring were considered as “trio 
cases”, and non-transmitted alleles as “pseudo-controls”). All samples were of European ancestry 
and met diagnostic criteria for ADHD as defined by the DSM-IV. All samples underwent the same 
quality control and analysis steps. The strongest single SNP association with ADHD in this data set 
was p = 1.10 × 10 6 [5]. 
2.2. Defining Functional Gene Sets 
Generation of the synaptic gene sets has been described previously [15]. Briefly, synaptic gene 
grouping was based on cellular function as determined by previous synaptic protein identification 
experiments and data mining for synaptic genes and gene function. This resulted in the inclusion  
of 1028 genes, expressed in either the pre- or postsynapse or in both, divided over 17 synaptic gene 
sets with a specific synaptic function, and one synaptic gene set with unassigned cellular function. 
The gene sets with gene IDs are available at the Complex Trait Genetics webpage [21]. 
2.3. Power Analysis 
The Genetic Power Calculator (GPC) [22,23] was used to define the minimal genotype relative 
risk that could reliably be detected for a gene set given the current sample size. Because the PGC 
data set consists of both case-control samples and trio samples, power was calculated using the 
weighted mean of the noncentrality parameters of the samples. To use the GPC for gene-set 
analysis, we assumed that the risk allele frequency represents the average allele frequency of all 
contributing risk variants in a gene set, and that the relative risk is representing the global effect of 
the gene set. We further used a disease prevalence of 5% (as estimated by Polanczyk et al. [1]), and 
a multiplicative model (power calculation based on the allelic test). Tests were corrected for the 




2.4. Gene-Set Analysis 
Gene-set analysis was conducted using JAG [24]. To test the hypothesis that synaptic function 
was associated with ADHD, we conducted self-contained tests for each gene set and one overall 
test including all synaptic gene sets. For each gene set, the test statistic was defined as the sum over  
the log10 of SNP p-values annotated to genes in that gene set. These SNP p-values were taken 
from the PGC association results. To allow for unbiased interpretation of the test statistic, 10,000 
permutations were conducted in which any relation between a genetic variant and affection status 
was disconnected. As such, linkage disequilibrium (LD), and number of SNPs and genes within 
each gene set stayed intact. For each permutation of the data set, the test statistics of the gene sets 
were computed. The self-contained p-value was calculated as the proportion of test statistics in the 
permuted data sets that was higher than the original test statistic. Bonferroni correction was applied 
to account for multiple testing with a corrected significance threshold of  = 0.05/18 = 2.8 × 10 3. 
For the permutations of the data set, we used the genotype data of the European ancestry 
samples from the 1000 Genomes project [25] with a simulated binary phenotype (as we had no 
access to raw data of the PGC). Using this as reference data, we could appropriately account for 
LD effects on correlations in SNP p-values in the PGC association data. For the test statistics of the 
original gene sets, only SNPs that were also available in the 1000 Genomes genotype data  
were used. 
Competitive tests were performed for gene sets found to be significant in the self-contained test. 
While self-contained tests evaluate whether a gene set is associated with ADHD under the null 
hypothesis of no association, a competitive test shows whether the observed (self-contained) 
association is stronger than expected by chance for gene sets with the same number of genes. To this 
end, 150 random gene sets were generated, matching for the same number of genes. JAG calculated 
a self-contained p-value for each of these random gene sets. The competitive p-value was then 
computed as the proportion of random gene sets with self-contained p-values lower than the  
self-contained p-value for the gene set itself. Only gene sets with a competitive p-value < 0.05 were 
considered to be significant. 
3. Results 
3.1. Power Analysis  
Power analyses showed that for gene sets containing on average SNPs with a risk allele 
frequency (RAF) of at least 0.1, our sample had sufficient power ( 0.80) to detect gene sets with a 
genotype relative risk (GRR) of 1.23 (Figure 1). For gene sets containing a mean RAF of at least 
0.2, we had sufficient power to detect gene sets with a GRR of 1.17. 
3.2. Gene-Set Analysis  
A total number of 1,206,461 SNPs were available for gene-set analysis. Of these, 61,413 SNPs 
mapped to 956 genes (out of 1028) within our gene sets. All 956 synaptic genes together were 
significantly associated with ADHD in the self-contained test (Table 1). However, the competitive 
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test showed that the synaptic genes were not more strongly associated with ADHD than randomly 
generated gene sets matched for same number of genes, suggesting that the self-contained p-value 
was significant merely due to a large number of SNPs being evaluated, which did not particularly 
aggregate in genes involved in synaptic function. 
Figure 1. Statistical power to detect gene sets in the Psychiatric Genomics Consortium 
(PGC) Attention Deficit/Hyperactivity Disorder (ADHD) sample. Power is displayed 
for different genotype relative risks (GRR), and risk allele frequencies (RAF) of 0.1 and 
0.2. The weighted mean of the noncentrality parameters of the case-control sample  
(896 cases and 2455 controls) and trio sample (2064 trios) was used to calculate power. 
Power analyses assume a disease prevalence of 5% and a multiplicative model. We 
assumed that gene sets behave as individual single nucleotide polymorphisms (SNPs). 
Tests are corrected for number of gene sets (  = 2.8 × 10 3). Dotted horizontal line 
represents power of 0.80. 
 










in GWAS Data 
Self-Contained  
p-Value  
(  = 2.8 × 10 3) 
Competitive 
p-Value  
(  = 0.05) 
All synaptic genes 1028 956 61413 0.0393 * 0.1733 
Ion balance/transport 43 40 1454 0.0118 NA 
Cell metabolism 57 51 1059 0.0429 NA 
Endocytosis 26 26 1075 0.0554 NA 
Cell adhesion and trans-synaptic signaling 81 76 13550 0.0709 NA 
Exocytosis 87 83 4855 0.0962 NA 
Protein cluster 47 42 4182 0.1491 NA 
Peptide/neurotrophin signals 28 25 1742 0.1659 NA 
Structural plasticity 98 90 4655 0.1764 NA 
Tyrosine kinase signaling 7 7 1281 0.2030 NA 
Neurotransmitter metabolism 29 27 1059 0.2959 NA 
RNA and protein synthesis, folding and breakdown 71 64 1152 0.4994 NA 
Ligand-gated ion channel signaling 36 32 2935 0.6500 NA 
G-protein-coupled receptor signaling 41 40 3129 0.6578 NA 
Unassigned 61 53 2258 0.6644 NA 
Intracellular signal transduction 150 145 9563 0.7001 NA 
G-protein relay 27 25 946 0.7047 NA 
Intracellular trafficking 80 75 2024 0.7334 NA 
Excitability 59 56 4508 0.7914 NA 
*  = 0.05. 
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Self-contained tests for the specific synaptic gene sets showed associations at nominal 
significance levels for the involvement of ion balance/transport and cell metabolism in ADHD 
(Table 1). However, these associations did not survive Bonferroni correction. All other  
self-contained p-values were >0.05. We thus conclude that no significant associations were found 
between any of the specific synaptic gene sets and ADHD. Consequently, no subsequent 
competitive tests were performed for the synaptic gene sets of specific functions. 
4. Discussion 
Results from previous GWAS have led to the conclusion that ADHD is a heritable, yet 
polygenic disorder influenced by many genetic variants of small effect. Top hits from previous 
studies have suggested a role for synaptic processes in the etiology of ADHD. In the current study, 
we tested the hypothesis that genetic variants that influence the risk for ADHD cluster in synaptic 
gene sets. We used expert-curated gene sets of pre- and postsynaptic genes. Using the largest 
public ADHD GWAS sample currently available, our study had sufficient statistical power to 
detect gene sets representing a GRR of at least 1.17 (or 1.23 for less common alleles) for the 
liability to develop ADHD. The self-contained test of all synaptic genes together showed a 
significant association with ADHD. However, for complex traits that are polygenic, any large 
group of genes is likely to be associated due to background polygenic effects. The competitive test 
showed that the association was not stronger compared to that of randomly generated gene sets 
with the same number of genes. This suggests that the association was not a result of the selection 
of synaptic genes, but merely because of the large number of genes. Hence, our results support the 
idea that ADHD is a polygenic disorder, and suggest that overall synaptic function does not play a 
major role in the etiology of ADHD, given current synaptic genes. 
In addition, no specific synaptic function categories were associated with ADHD after 
correction for multiple testing. These results suggest that if common genetic variants in the current 
synaptic gene sets with a specific function play a role in the etiology of ADHD, their effect is 
modest at most, even when considering the joint effect of multiple genetic variants. 
Although previous analyses suggested involvement of several synaptic processes in  
ADHD [6,7,11–13], it should be kept in mind that the majority of previous results reported  
non-significant, suggestive results, and hence no strong conclusions could be drawn regarding the 
impact of those processes on ADHD. For example, a recent study used a different type of 
categorization of gene sets: they constructed gene sets based on pathways and candidate genes, and 
did report significant associations of dopamine/norepinephrine and serotonin pathways, and genes 
involved in neuritic outgrowth, with the hyperactive/impulsive component of ADHD [26]. 
However, in this study competitive tests to investigate if reported associations were stronger than 
can be expected by the polygenic nature of ADHD were not performed. Consequently, it remains 
unclear whether the reported associations are due to the background polygenic effects like our 
apparent association of synaptic genes with ADHD. 
Synaptic function has been implicated and confirmed for other psychiatric disorders, especially 
schizophrenia [19,24] and bipolar disorder [27,28]. For example, gene sets of cell adhesion and  
trans-synaptic signaling and excitability showed replicated associations with schizophrenia [19,24]. 
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Recent cross-disorder analyses by the PGC reported overlap in genetic liability between psychiatric 
disorders (schizophrenia, bipolar disorder, major depressive disorder, autism spectrum disorder, and 
ADHD) [29,30]. However, of all five psychiatric disorders, ADHD showed the weakest genetic 
overlap with other psychiatric disorders, having only a moderate genetic correlation with major 
depressive disorder, and showing no overlap with schizophrenia, bipolar disorder, and autism 
spectrum disorder. Our current findings fit into this overall picture of a separate genetic etiology of 
ADHD, by showing no evidence for an association with common variants in the current curated list 
of synaptic genes. 
The list of genes involved in synaptic function is however a dynamic list: it depends on 
available experimental data and expert curation. When more experimental data is generated more 
genes may be included, which may have been missed in the current analyses. However, if genetic 
variants with an effect on ADHD risk aggregate in genes that are active in the synapse, it is 
expected that many genes within this gene set play a role in ADHD. Thus, an indication of 
association should be present if any of our current gene sets has a strong effect on ADHD risk, 
even when the current gene sets are not complete. Our results do not show any clear trends of 
association between the gene sets and ADHD.  
An alternative explanation for the lack of association in our study could be the heterogeneous 
nature of ADHD. It is known that ADHD is characterized by a heterogeneous manifestation of 
symptoms, possibly reflecting genetic heterogeneity [31]. Genetic heterogeneity makes it more 
challenging to detect genetic variation that plays a role in the etiology of ADHD, as the 
heterogeneity results in an apparent reduction of the effect sizes of true genetic variants. The 
current lack of association of synaptic functions with ADHD diagnosis together with previous 
reports that implicate a role of synaptic function based on smaller scaled samples, may reflect the 
involvement of synaptic function in only very specific sub-populations of ADHD symptoms. 
Future studies focusing on ADHD symptom profiles are needed to detect such specific associations 
between synaptic function and ADHD subtypes. 
5. Conclusions 
We find no evidence for involvement of specific synaptic functions in the etiology of ADHD, 
given current sample size and gene sets based on current knowledge of genes related to synaptic 
function. Our results suggest that if common genetic variants in the current synaptic gene sets play 
a role in the etiology of ADHD, their effect is modest at most, even when considering the joint 
effect of multiple genetic variants. 
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Discovery in Genetic Skin Disease: The Impact of High 
Throughput Genetic Technologies 
Thiviyani Maruthappu, Claire A. Scott and David P. Kelsell 
Abstract: The last decade has seen considerable advances in our understanding of the genetic basis 
of skin disease, as a consequence of high throughput sequencing technologies including next 
generation sequencing and whole exome sequencing. We have now determined the genes underlying 
several monogenic diseases, such as harlequin ichthyosis, Olmsted syndrome, and exfoliative 
ichthyosis, which have provided unique insights into the structure and function of the skin. In 
addition, through genome wide association studies we now have an understanding of how low 
penetrance variants contribute to inflammatory skin diseases such as psoriasis vulgaris and atopic 
dermatitis, and how they contribute to underlying pathophysiological disease processes. In this 
review we discuss strategies used to unravel the genes underlying both monogenic and complex 
trait skin diseases in the last 10 years and the implications on mechanistic studies, diagnostics,  
and therapeutics. 
Reprinted from Genes. Cite as: Maruthappu, T.; Scott, C.A.; Kelsell, D.P. Discovery in Genetic 
Skin Disease: The Impact of High Throughput Genetic Technologies. Genes 2014, 5, 615-634. 
1. Introduction 
The advent of high throughput single nucleotide polymorphism (SNP) genotyping  
and latterly, next generation sequencing (NGS) technology including whole exome sequencing 
(WES) have revolutionised our approach to genetic diagnostics and novel gene discovery in the 
genodermatoses—a group of inherited skin disorders. 
Prior to this, technologies including linkage analysis using genome wide microsatellite  
panels in combination with candidate gene screening by PCR and Sanger sequencing have been the 
primary method for discerning new skin disease-associated loci. Successes with this approach 
include Hailey-Hailey Disease (OMIM #169600) [1], Netherton Syndrome (OMIM #256500) [2], 
Darier-Disease (OMIM #124200) [3], and Dyschromatosis symmetrica hereditaria (OMIM 
#127400) [4]. Candidate gene screening approaches have also yielded success, particularly in 
deciphering the keratin disorders [5]. However, clinical and likely genetic heterogeneity of skin 
diseases and the availability of DNA from probands only, or from small families, have hindered 
disease gene discovery for many disorders [6]. This can now be surmounted with high-density SNP 
homozygosity mapping for consanguineous recessive disorders, and in particular NGS and WES 
for dominant and recessive disorders, which has facilitated our understanding of some of the 
genetic make up of common diseases. 
Skin diseases are ideal for determining genotype-phenotype correlations because of the relative 
ease with which clinical and histological examination can be made. In addition, inflammatory 
pathways involved in the pathogenesis of skin diseases such as psoriasis vulgaris (PV) are relevant 
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to a number of other immune-mediated diseases including inflammatory bowel disease and 
rheumatoid arthritis [7]. 
The genetic bases of many monogenic skin diseases have been unravelled and in this review  
we focus on examples of discoveries in cutaneous genetics, applying different strategies such as 
SNP microarray, microsatellite linkage analysis, targeted NGS and WES. Equally, it has also been 
informative in understanding the significance of de novo mutations including the unusual 
phenomenon of revertant mosaicism in the skin, where spontaneous correction of a disease-causing 
mutation in a somatic cell occurs [8]. We have also gained insights into complex trait diseases and 
will explore what contributions these have made to mechanistic insights, diagnosis and treatment of 
common skin diseases including psoriasis, atopic dermatitis (AD) (eczema), and skin cancer. 
2. Harlequin Ichthyosis 
The discovery that ABCA12 gene mutations are associated with the skin disease harlequin 
ichthyosis (HI) is an example of where SNP microarray technology was used successfully to 
elucidate the genetic locus associated with this disease [9]. 
The inherited ichthyoses are a heterogeneous group of disorders characterised by skin scaling,  
often of the whole surface, and hyperkeratosis [10]. Syndromic (affecting multiple tissues) as well 
as nonsyndromic forms of ichthyosis exist and mutations in multiple genes are associated with 
disease including TGM1 (OMIM *190195), NIPAL4 (OMIM *609383), STS (OMIM *300747), 
ALOX12B (OMIM *603741), ALOXE3 (OMIM *607206), CYP4F22 (OMIM *611495), and FLG 
(OMIM *135940) amongst others (reviewed in [10]). Autosomal recessive congenital ichthyosis 
(ARCI) is comprised of three main groups: congenital ichthyosiform erythroderma (CIE), lamellar 
ichthyosis (LI) and HI [10]. HI (OMIM #242500) is the most severe form of ichthyosis and has a 
high perinatal mortality, with babies presenting at birth with hard scale plates with deep fissures, 
eclabium, and bilateral ectropion (reviewed in [9,11]). 
The discovery of the genetic cause of HI was hampered by availability of DNA from only 
affected family members or from small families due to the severity of the condition, thus genetic 
linkage studies were unfeasible [9]. To investigate the genetic basis of HI, Kelsell et al. (2005) [9] 
used a SNP microarray to map a block of homozygosity on chromosome 2q35 and to identify a 
minimal region between HI patients from consanguineous parents, which contained the ABCA12 
gene. ABCA12 belongs to the ATP-binding cassette (ABC) A family of transporters, some 
members of which have been implicated in lipid transport (reviewed in [12]). 
ABCA12 was a promising gene candidate for HI because patient skin displayed aberrant lipid 
distribution [9] and missense mutations in ABCA12 were already known to be associated with 
another form of ARCI, LI [13]. PCR and Sanger sequencing of the ABCA12 gene in HI patients 
confirmed that recessive mutations were associated with HI [9,14]. Mutations in ABCA12 are now 
known to be associated with all three forms of ARCI (reviewed in [10]). However, unlike for LI 
and CIE, in which largely missense ABCA12 mutations are associated with disease [13,15,16], HI 
is usually associated with loss of function gene mutations including nonsense, frameshift, and 
splice site mutations, which severely disrupt the cellular functions of ABCA12 [9,17–19]. 




patients with homozygous loss of function mutations have an increased risk of mortality, indicating a 
survival advantage for patients with compound heterozygous mutations [11]. 
ABCA12 is thought to transport lipids via lamellar granules where they are processed and 
released to form lipid lamellae constituting the stratum corneum in the epidermis [14,23]. A 
reduction in the number, and structural abnormalities, of lamellar granules has been observed in HI 
patient skin [14,24,25]. In addition, characterisation of HI patient skin has shown a loss of nonpolar 
lipids [26] and abnormal glucosylceramide localization [14], and experiments with patient-derived 
keratinocytes showed aberrant glucosylceramide accumulation in lamellar granules [27], which is 
indicative of a lipid transport defect as a result of loss of ABCA12 function [14,26,27]. 
Similarly, Abca12 knockout mice models [28–30] and an abca12 knockout zebrafish model [31] 
showed features of aberrant lipid transport compared to controls (reviewed in [32]). HI skin also 
shows features of premature terminal differentiation and a decreased expression of certain 
proteases, which suggests that loss of ABCA12 disrupts keratinocyte differentiation and epidermal 
desquamation, resulting in the formation of an aberrant epidermal barrier [26]. 
Prior to the discovery of the genetic cause of HI, prenatal diagnostic investigations depended  
on obtaining a foetal biopsy for analysis by electron microscopy, and on sonography [33,34]  
(reviewed in [35]). The discovery of the genetic cause of different ichthyoses, including HI, 
represents a major milestone in the ability to perform genetic diagnosis, carrier screening, genetic 
counselling, and prenatal diagnosis. 
Current approaches to genetic screening for HI can involve screening specific exons, as there are 
some recurrent ethnic group mutations in ABCA12 [18,19] and using WES, circumventing the need 
for performing PCR and Sanger sequencing of all 53 coding exons of the ABCA12 gene. 
3. Exfoliative Ichthyosis 
The discovery of cystatin A (CSTA) gene mutations in association with exfoliative  
ichthyosis [36] is an example of the successful implementation of combining SNP microarray 
analysis with targeted NGS to determine the genetic cause of disease. 
Autosomal recessive exfoliative ichthyosis (OMIM #607936) is characterised by palmoplantar 
skin peeling and dry scaly skin, with trauma and moisture aggravating the condition [36]. 
Microsatellite linkage analysis of two related Bedouin families initially suggested linkage of the 
disease to chromosome 12q13, which contains the type II keratin cluster [37]. 
Blaydon et al. (2011) [36] revisited this family and applied whole genome homozygosity 
mapping which revealed a common block of homozygosity between affected Bedouin patients on 
chromosome 3q21 as the likely disease gene location. Sequence capture and NGS of this region 
was then performed and revealed a splice site mutation in CSTA, which was found to segregate 
with exfoliative ichthyosis in the Bedouin family. This locus was missed in the microsatellite 
genome scans performed by Hatsell et al. (2003) [37] due to markers for this region being 
uninformative. Sanger sequencing of CSTA in a different family with exfoliative ichthyosis 
revealed a homozygous nonsense mutation which also segregated with disease [36]. In a 
subsequent study, WES revealed a novel homozygous nonsense mutation in CSTA in a large family 
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with acral peeling skin syndrome [38] with similar clinical features to the patients reported in 
Blaydon et al. (2011) [36]. 
Cystatins are cysteine protease inhibitors which are thought to have a protective function against 
endogenous and external proteases, and to potentially modulate the degradation of intra- and 
extracellular proteins (reviewed in [39]). CSTA has been identified as a constituent of the cornified 
envelope [40] and is expressed in the suprabasal layers of the epidermis, the highest expression of 
which is in the granular layer [36,41]. CSTA is secreted by keratinocytes in vitro and has also been 
found in sweat, and is believed to have a protective role by inhibiting the proteolytic activity of 
dust mite allergens Der p 1 and Der f 1 [42]. CSTA levels have also been implicated as prognostic 
markers in different cancers [43–45]. 
Characterisation of skin from exfoliative ichthyosis patients with CSTA mutations revealed 
widened intercellular gaps in the lower epidermis, whereas the upper epidermal layers appeared 
normal with no evident barrier defect [36]. Experiments using an in vitro keratinocyte cell 
knockdown model showed an adhesion defect in response to mechanical stress, and an organotypic 
CSTA knockdown model showed similar abnormalities to the patient skin [36]. This finding is 
indicative of CSTA having a key role in keratinocyte adhesion in the basal epidermal layers and 
that loss of CSTA causes a predisposition to epidermal splitting. There were no obvious 
abnormalities in a murine model with a chromosomal deletion, which included the Csta gene [46], 
although investigation of a skin phenotype was not described. 
4. Olmsted Syndrome 
The genetic basis of various skin diseases (Table 1) has been determined using exome 
sequencing technology. One example where WES enabled the identification of the underlying 
causative genes is Olmsted syndrome (OS) [47,48]. OS (OMIM #614594) is a rare disorder 
characterised by mutilating palmoplantar keratoderma and periorificial keratosis. Additional 
clinical features include constriction of the digits, dystrophy of the nails, diffuse alopecia and a 
predisposition to infection and development of squamous cell carcinoma on keratotic lesions [47]. 
Different modes of inheritance have been hypothesised [47–50]. 
Table 1. Examples of genes associated with skin disease discovered using exome 
sequencing technology. 
Gene Disease Mode of Inheritance Reference 
AAGAB Punctate palmoplantar keratoderma Type I AD [51,52] 
ADAM10 Reticulate acropigmentation of Kitamura AD [53] 
AQP5 Nonepidermolytic palmoplantar keratoderma AD [54] 
ENPP1 Cole disease AD [55] 
EXPH5 Inherited skin fragility AR [56] 
HOXC13 Pure hair and nail ectodermal dysplasia AR [57] 
KANK2 Palmoplantar keratoderma and woolly hair AR [58] 
MBTPS2 Olmsted syndrome XLR [48] 
POFUT1 Dowling-Degos disease AD [59] 
POGLUT1 Dowling-Degos disease AD [60] 
SERPINB7 Nagashima-type palmoplantar keratosis AR [61] 
TRPV3 Olmsted syndrome AD/AR [47]/[62] 




WES was used successfully to identify mutations in the Transient Receptor Potential Cation 
Channel, Subfamily V, Member 3 (TRPV3) gene [47], and the Membrane-Bound Transcription 
Factor Protease, Site 2 (MBTPS2) gene [48] to be associated with OS. 
Lin et al. (2012) performed WES of an OS patient and her unaffected parents and identified a 
novel de novo heterozygous mutation p.G573S in TRPV3 [47]. Screening for TRPV3 mutations in 
five other OS patients revealed that three were heterozygous for p.G573S, one heterozygous for 
p.G573C and one heterozygous for p.W692G [47]. 
TRPV3 is a member of the TRPV cation channel family, and is known to be expressed in 
various tissue types including skin and hair follicles [63–65]. The murine TRPV3 mutants p.G573S 
and p.G573C were discovered in spontaneous hairless rodent strains that develop dermatitis, a trait 
inherited in an autosomal dominant manner [66]. Trpv3 knockout mice display wavy hair, curly 
whiskers and a defective skin barrier, and it is believed that TRPV3 associates with TGF- /EGFR in 
a signalling pathway to modulate keratinocyte differentiation and hair morphogenesis [67]. 
In vitro functional studies with the three OS-associated TRPV3 mutants indicated that they are 
gain of function mutants, creating constitutively open channels and causing increased cell death of 
cells expressing the mutants [47]. Similar results were obtained in in vitro expression studies with the 
murine TRPV3 mutants p.G573S and p.G573C [68]. It has been hypothesised that in vivo the 
mutants may cause apoptosis and subsequent keratoderma in patients, and could contribute to their 
pruritis [47]. 
A subsequent study using WES revealed the recurrent TRPV3 mutation p.G573S in sporadic  
OS [69]. Screening by Sanger sequencing has also revealed a homozygous mutation in an OS 
patient, indicating recessive inheritance [62]. Both recessive [70] and sporadic [71] TRPV3 
mutations have been associated with atypical OS with erythromelalgia. 
Exome sequencing of two affected males reported previously in a consanguineous pedigree [72]  
in which OS followed a suggested X-linked recessive inheritance pattern, revealed a novel 
MBTPS2 gene mutation which segregated with disease in the family [48]. This discovery expands 
the number of disorders attributed to MBTPS2 gene mutations, as other mutations in this gene are 
associated with ichthyosis follicularis with atrichia and photophobia (IFAP) syndrome [73–75], 
BRESEK/BRESHECK syndrome [76], and keratosis follicularis spinulosa decalvans (KFSD) [77]. 
MBTPS1 and MBTPS2 are involved in activating signalling proteins such as the transcription 
factors SREBPS, enabling cells to respond to sterols [78,79] and in the processing of ATF6,  
which is a component of the unfolded protein response (UPR) [80]. In vitro functional studies with 
IFAP and KFSD MBTPS2 mutants revealed decreased sterol responsiveness compared to  
wild-type [73,77], and mutants which caused the greatest impairment of enzyme activity seemed to 
be associated with increased disease severity in patients [73]. 
5. Complex Traits of the Skin 
In the last 10 years there have been landmark discoveries in our understanding of the genetic 
basis and pathophysiology of inflammatory skin diseases, most notably PV and AD. Both are 
common, complex diseases, in which a host of environmental factors can trigger disease in 
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genetically susceptible individuals [81,82]. Inflammatory dermatoses are associated with both a 
significant burden on healthcare resources and patients’ quality of life [83,84]. 
Identification of susceptibility loci for PV and AD have resulted from developments in genome 
wide association studies (GWAS), which have been applied to all common disorders. Information  
has been generated by the HapMap and 1000 Genomes projects, in parallel with the technology to 
genotype multiple individual DNA samples at one million or more loci, allowing SNPs to be 
reviewed and enabling comparisons of allele frequency between large numbers of cases and 
controls to identify those which confer risk of disease [85]. The development of DNA microarray 
based genotyping allows up to a million SNPs to be tested simultaneously. 
6. Psoriasis 
PV is a common and chronic inflammatory disease, which can affect the skin, nails and joints.  
It is characterised by immune-mediated epidermal hyperproliferation [86]. It is a highly heritable 
disease, with increased concordance in monozygotic versus dizygotic twins (65%–72% versus  
15%–30% respectively) [87]. During the last 10 years, almost 40 GWAS-identified novel  
psoriasis-susceptibility loci have been identified and more recently, the genes within these loci and 
their significance to the pathophysiology of PV are becoming clearer [88]. Interestingly, several 
show clustering to a distinct segment of the inflammatory cascade [89]. Psoriasis susceptibility 
locus 1 (PSORS1), located on the MHC region on chromosome 6p21, has been most consistently 
identified in GWAS with a significant odds ratio of 3.0 [90]. Genes implicated within this 250 kb 
interval include HLA-C (human leukocyte antigen C), CCHCR1 (coiled-coil -helical rod  
protein 1), and CDSN (corneodesmosin). These were considered as potential disease-associated 
genes due to their function and the presence of disease-associated SNPs within their coding  
sequence [91]. Identification of the causal disease susceptibility allele was extremely challenging, 
ultimately Nair et al. (2006) sequenced the entire PSORS1 region in individuals bearing different 
HLA-C alleles to identify SNPs unique to the PSORS1 haplotype. They indicated that HLA-Cw6 
was the major PSORS1 disease allele [92], reflecting the importance of antigen presentation in the 
pathophysiology of PV. 
Identification of susceptibility loci has contributed to our understanding of PV pathogenesis, 
which appears to involve the innate and adaptive immune responses. Pathways that have been 
identified in various studies include IL12/IL17 axis activation (IL23R, IL12B, IL23A, and TRAF31P2), 
type 1 interferon induction (IFIH1, RNF114, and TYK2) and NF- B signaling (CARD14, REL, 
NFKBIA, TNFAIP3, and TNF1P) [89,90,92–97]. Of particular interest is the Th1-Th17 axis, 
involving the recently described subset of IL17 expressing T cells (Th17) [98] which is thought to 
play a major role in the development and maintenance of psoriatic plaques [97]. 
IL12 and IL23 are cytokines that induce naïve CD4+ lymphocytes to differentiate into type 1 
helper cells and type 17 helper cells, both of which are key mediators of PV [97]. IL12 and IL23 share 
a common p40 subunit encoded by the IL12B gene. In mice, injection of IL23 results in epidermal 
hyperplasia, which is mediated by IL22 produced by Th17 cells. This shows similarities to 
phenomena observed in humans [99]. GWAS have identified three SNPs with strong evidence of 




(encoding a subunit of the IL23 receptor) [94] raising the possibility that dysregulated IL23 
signaling could lead to chronic immune responses within epithelial cells. Ustekinumab (Stelara®) is 
a human IgG1  monoclonal antibody against the p40 subunit of the IL12 and IL23 cytokines that 
has demonstrated significant improvement in outcome measures for the treatment of PV in Phase 
III clinical trials [100]. A significant proportion of patients had at least 90% improvement in their 
psoriasis area-and-severity index (PASI) score, with a proportion experiencing complete clearance 
by 12 weeks [100]. These findings also establish a central role for the IL12/IL23 p40 cytokines in 
the pathophysiology of PV. 
Another approach to utilise the discoveries gained from GWAS studies is personalised 
medicine. For example, patients with PV who carry risk variants in IL12B may benefit preferably 
from a monoclonal antibody targeting its p40 subunit, e.g., Ustekinumab. Studies using molecular 
profiling of PV and clinical phenotyping to predict treatment response have shown promise [101] 
and larger studies are underway. This is one example of how PV has been used as a paradigm for 
autoimmune disease and for proof-of-principle studies of targeted biologic therapies, because of the 
ease of accessing the skin and objectively measuring disease severity and responses to treatment. 
Rare variants with large effect have been observed in families where PV segregates as an 
apparent Mendelian trait. The psoriasis susceptibility locus 2 (PSORS2) was first mapped in 1994 
to human chromosomal region 17q25-qter in a large family of European ancestry [102]. More 
recently, it has been shown that PSORS2 is due to gain of function mutations in the caspase 
recruitment domain family member 14 (CARD14) [96] using linkage analysis, targeted and exome 
capture in combination with NGS. On the basis of these findings, further work has uncovered rare 
missense variations in CARD14 linked to PV using a large case-control study [95]. CARD14 
encodes a NF- B activator within the skin epidermis. The mutations identified lie within the 
coiled-coiled domain of CARD14 and result in enhanced NF- B activity compared with wild-type 
CARD14 [95]. 
Generalised pustular psoriasis (GPP) can present with an acute, widespread and life-threatening 
eruption associated with fever and leukocytosis. It has long been considered a variant of PV. 
Mutations in IL36RN, which encodes the IL36 receptor antagonist and abrogates downstream 
activation of NF- B signaling, have been shown to underlie GPP in consanguineous pedigrees of 
North African origin [103]. This mutation results in enhanced production of IL1, IL6, and IL8 
inflammatory cytokines, which may contribute to the profound systemic inflammatory response 
seen clinically in these patients [103]. Similar recessive mutations in IL36RN have not been 
observed in patients with PV alone [104]. Genetic studies suggest that in fact, PV and  
GPP are etiologically distinct clinical entities, which consequently have important therapeutic 
implications [105]. 
7. Atopic Dermatitis (Eczema) 
AD is a chronic inflammatory skin disease characterised by disturbed skin barrier function and  
dry, itchy skin. Its prevalence worldwide is increasing and in some countries affects almost 20% of  
children [106]. Like PV, concordance is observed in twin studies with rates of 0.72–0.86 in 
monozygotic and 0.21–0.23 in dizygotic twin pairs [107]. A complex interplay between 
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environmental, genetic and immunological factors, as for many common disorders, all contribute to 
susceptibility and severity. 
The filaggrin story is central to our understanding of AD and ichthyosis vulgaris (IV). It 
exemplifies how the study of a monogenic disorder can translate to a complex trait disease. In 
2006, null mutations in the filaggrin gene FLG were first identified in Irish families with IV, which 
often causes dry, scaly skin and is also a strong genetic risk factor for AD [108]. Histological 
evidence for the possible lack of filaggrin in IV dates back to 1985 [109] however these 
preliminary studies were hindered by the daunting size and repetitive nature of FLG, particularly 
exon 3. The McLean group developed a successful strategy to analyse this locus with the use of long 
range PCR to amplify exon 3 in combination with short specific PCRs to amplify remaining 
overlapping fragments that were then used to reconstruct the repetitive sequence [108]. Further 
research has identified significant associations of FLG mutations with atopic asthma, allergic 
rhinitis and peanut allergy [110], as well as early onset and increased severity of AD [111]. These 
studies have been reproduced in a variety of geographical populations, including European, 
Japanese, Taiwanese, Chinese, and Korean [112–114]. Indeed, the correlation between FLG 
mutations and AD is considered one of the most robust examples of genotype-phenotype 
relationship in complex trait disease with an odds ratio of up to 13.4 [115]. 
Filaggrin plays a key role in epidermal barrier function. Briefly, its degradation products act  
as “natural moisturising factors” in the skin and assist the formation of a flattened granular cell  
layer upon keratinocyte terminal differentiation [116]. Studies describing murine models of 
filaggrin haploinsufficiency have shown skin barrier impairment and enhanced sensitisation to 
percutaneous allergens [117,118]. The significant effect of FLG mutations on AD risk highlights the 
role of impaired skin barrier function in the pathogenesis of atopic diseases. Filaggrin replacement 
therapies could prove significant in the management of AD. Recently, Otsuka et al. (2014) [119] 
identified a novel compound JTC801, with potential therapeutic applicability. This has been shown 
to increase expression of filaggrin in both human and murine keratinocytes and, when administered 
orally, it can hinder the development of AD-like inflammation in the NC/nga AD mouse  
model [119]. 
Although the AD spotlight has focused largely on filaggrin, several other genes have been 
implicated in the pathogenesis of this disorder. To date, a total of 19 genome-wide significant  
(p < 5 × 10 8) susceptibility loci have been identified through GWAS [120]. The first GWAS data 
was published in 2009 and included 939 cases and 975 controls in addition to 270 complete nuclear 
families with two affected siblings [121]. It identified a novel susceptibility locus in 11q13.5, located 
38 kb downstream of C11orf30. The peak association was observed 68 kb upstream of the leucine 
rich repeat containing 32 gene (LRRC32) which has been shown to be expressed in activated 
human regulatory T cells [122]. Carriers have a risk of developing AD that is 1.47 times that of 
controls [121]. A 2011 Meta analysis of GWAS for AD included 5606 cases and 20565 controls and 
an additional 5419 cases and 19833 controls in a validation study [114]. Three novel risk loci reached 
genome-wide significance: rs479844 upstream of ovo-like zinc finger 1 (OVOL1), rs2164983 near 
actin-like 9 (ACTL9) and rs2897442 in kinesin family member 3A (KIF3A). They also confirmed 




and hair shaft abnormalities [93]. It is thought to play a role in regulating epidermal proliferation and 
loricrin expression, impairing premature terminal differentiation [123]. KIF3A associated SNPs map 
within a cluster of cytokine and immune mediated genes including Th2 cytokine genes: IL13 and 
IL4. These cytokines have been implicated in other autoimmune and inflammatory diseases 
including PV [124], Crohn’s Disease [125] and asthma [125]. Increased levels of Th2 cytokines 
such as these have been reported in AD as well as greater levels of mRNA expression in acute skin 
lesions compared with unaffected skin in patients [126–128]. These GWAS findings highlight the 
role of skin barrier function (FLG), epidermal proliferation and differentiation (OVOL1) and the 
adaptive immune system response (IL13-RAD50, LRRC32) in the pathophysiology of AD. 
Despite these promising discoveries, less than 20% of disease variance has been explained [129]. 
The phenomenon of “missing heritability” has been observed across other complex diseases and 
suggests that unmapped common and rare variants with small effect size in GWAS as well as genetic 
interactions may contribute to the remaining heritability [129]. Epigenetic studies focusing on the 
contribution of DNA and chromatin methylation may also explain the role that they play in the 
formation and progression of complex diseases by regulating gene expression [130]. Future work 
integrating GWAS and epigenetic data may provide insights into our understanding of complex trait 
disease. In summary, GWAS data reinforces the concept that multiple low risk variants are most 
likely to contribute to AD and PV, but that larger sample sizes may be necessary to identify them. 
8. Conclusions 
The post-Human Genome Project era has seen remarkable advances in our understanding of  
genes underlying both rare and common skin disease. Such insights have proved significant beyond 
the field of dermatology because of shared mechanisms of disease for example, PV and 
inflammatory bowel disease. The wider relevance of skin disease is highlighted by the fact that skin 
is frequently a marker of internal disease. For example, mutations in ADAM17 not only  
cause inflammatory skin and bowel disease but increased susceptibility to infection and 
cardiomyopathy [131]. Similarly, the study of tylosis with oesophageal cancer, an autosomal 
dominant cancer syndrome that presents with skin thickening of the palms and soles, has brought to 
light the role of the inactive rhomboid family member iRHOM2 in cancer pathophysiology [132] 
and wound healing [133]. This also highlights that mechanistic studies are facilitated by the relative 
ease with which patient material can be obtained by skin biopsy to derive cell lines for  
functional studies. 
Skin disease is particularly remarkable for its intragenic heterogeneity, for example distinct 
dominant and recessive mutations in the desmosomal Desmoplakin gene DSP can result in a 
spectrum of disease phenotypes ranging from arrhythmogenic right ventricular cardiomyopathy 
(ARVC) and striate palmoplantar keratoderma to palmoplantar keratoderma with woolly hair and 
ARVC (reviewed in [134]). 
GWAS, WES and whole genome sequencing (WGS) involving increasingly larger cohorts of 
ethnically diverse populations may also identify additional low and high penetrance variants that 
contribute to phenotypic variability. WGS is becoming increasingly affordable and offers scope to 
become the most cost-effective method for genetic diagnostics. In parallel, advances in 
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bioinformatics and statistics are necessary to analyse the vast quantity of data generated by these 
studies, and distinguish significant findings. We may also see a move towards re-classification of 
skin diseases and malignancies based on genome sequence and subsequently, a targeted therapeutic 
approach to optimise treatment outcome. 
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Epigenetic Control of the Genome—Lessons from  
Genomic Imprinting 
Bjorn T. Adalsteinsson and Anne C. Ferguson-Smith  
Abstract: Epigenetic mechanisms modulate genome function by writing, reading and erasing 
chromatin structural features. These have an impact on gene expression, contributing to the establishment, 
maintenance and dynamic changes in cellular properties in normal and abnormal situations. Great 
effort has recently been undertaken to catalogue the genome-wide patterns of epigenetic  
marks—creating reference epigenomes—which will deepen our understanding of their contributions to 
genome regulation and function with the promise of revealing further insights into disease etiology. 
The foundation for these global studies is the smaller scale experimentally-derived observations 
and questions that have arisen through the study of epigenetic mechanisms in model systems. One 
such system is genomic imprinting, a process causing the mono-allelic expression of genes in a 
parental-origin specific manner controlled by a hierarchy of epigenetic events that have taught us 
much about the dynamic interplay between key regulators of epigenetic control. Here, we 
summarize some of the most noteworthy lessons that studies on imprinting have revealed about 
epigenetic control on a wider scale. Specifically, we will consider what these studies have revealed 
about: the variety of relationships between DNA methylation and transcriptional control; the 
regulation of important protein-DNA interactions by DNA methylation; the interplay between 
DNA methylation and histone modifications; and the regulation and functions of long  
non-coding RNAs. 
Reprinted from Genes. Cite as: Adalsteinsson, B.T.; Ferguson-Smith, A.C. Epigenetic Control of 
the Genome—Lessons from Genomic Imprinting. Genes 2014, 5, 635-655. 
1. A Primer on Epigenetics, DNA Methylation and Histone Modifications  
Epigenetic modifications perform three main functions in mammalian cells: they contribute to 
the control of chromosome architecture ensuring stability and appropriate segregation of 
chromosomes during mitosis; they contribute to regulation of the silencing and inaccessibility of 
repetitive elements and endogenous retroelements; and they can initiate and maintain the activity 
and repression of individual genes or clusters of genes. Here we focus on the role of epigenetic 
modifications in the control of mammalian transcription and the contribution of genomic 
imprinting studies to our understanding of epigenetic mechanisms. 
In mammals, the different cells that make up an organism generally contain the same DNA yet 
their cellular morphology and function can vary greatly. This is largely a result of differential gene 
expression, which is developmentally regulated and can then be maintained after repeated cell 
divisions. The maintenance of expression states/levels requires heritable information to be passed 
through cell division to ensure propagation in each daughter cell, and it is this information that has 
been termed epigenetic. Further, cells are subject to dynamic changes in gene expression, 




processes. Epigenetic mechanisms include DNA methylation and post translational modifications 
to core histones. Other related components have been proposed as epigenetic such as non-coding 
RNAs (ncRNAs) and nucleosomal positioning, however these might also be considered mediators 
and/or facilitators of epigenetic states. The characterization and mapping of genome-wide 
epigenetic modifications represent an ever increasing field of research. These studies are revealing 
genome-wide patterns of epigenetic regulation that not only have confirmed many of the 
conclusions suggested from more traditional experimental approaches in model systems but also 
allow for the generation of new hypotheses that await experimental testing. One model system that 
contributed a foundation for these studies is the process of genomic imprinting. 
DNA methylation is a process whereby a methyl (CH3) group is added most commonly to a 
cytosine in DNA. In mammals it is generally found at CpG dinucleotides and can be correlated 
with gene repression in a variety of ways (discussed in more detail below). CpG sites are generally 
depleted in the genome, apart from stretches of DNA called CpG islands where CpG density is 
high. CpG islands can be concentrated at gene promoters and are generally unmethylated. CpG 
sites outside CpG islands are generally methylated (reviewed in [1,2])—resulting in a genome-wide 
methylation pattern that can be described as roughly bimodal. Acquisition of DNA methylation is 
catalyzed by a family of DNA methyltransferases (DNMTs, reviewed in [3]). DNMT1 has affinity 
for hemi-methylated DNA and is responsible for maintaining methylation after DNA replication 
and DNMT3A and DNMT3B catalyze de novo DNA methylation while the DNA methyltransferase 
homologue, DNMT3L acts as a cofactor and has no methyltransferase activity. 
Waves of DNA methylation loss and acquisition are orchestrated during embryonic 
development. After fertilization the two parental genomes are mostly stripped of their epigenetic 
marks, a process that presumably “resets” the genome to a naive state applicable for pluripotency 
(DNA methylation at certain sequences in imprinted loci are among few genomic regions to 
“escape” this demethylation, see details in Section 2). Around blastocyst implantation de novo 
methylation then occurs and, to our knowledge, no further genome wide erasure/acquisition waves 
occur in somatic cells. Another wave of genome-wide reprogramming occurs in primordial germ 
cells (this time DNA methylation at imprinted loci is also lost, see details in Section 2); erasure of 
DNA methylation commences in the embryonic germline after embryonic day 7.5 (E7.5) in the 
mouse and progressive de novo methylation follows at E12.5 in prospermatogonia of male 
embryos, but occurs after birth in oocytes of female embryos (reviewed in [4]). This germline 
epigenetic reprogramming is required for generating functional germ cells and failure to do this 
appropriately usually results in infertility or developmentally abnormal embryos that die during 
gestation [5,6]. 
Covalent post-translational modifications to core histones (histone modifications henceforth) 
can impact the conformation of the nucleosome-nucleosome architecture within chromatin and 
influence its function such that some modifications are associated with an active chromatin state 
and others with a repressive state (for extensive review refer to [7]). The full repertoire of histone 
modifications is unknown, but is complex, with some specific amino acid residues influencing the 
ability of others to be modified, and some sites having the potential to be modified in multiple 
different ways. It is currently unclear whether many of the modifications truly are epigenetically 
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heritable in a replication-dependent manner, like DNA methylation. Lysine methylation and lysine 
acetylation are among the best characterized histone modifications whose correlations with gene 
activity and repression have been extensively studied. Furthermore, enzymes involved in “writing” 
and “erasing” these epigenetic marks have been identified and characterized; histone lysine 
methyltransferases deposit methyl groups to lysine, and histone lysine demethylases remove them. 
Histone acetyltransferases (KATs) and histone deacetylases (HDACs) deposit and remove acetyl 
groups, respectively. Generally, regions with acetylated histones are associated with gene activity 
and regions devoid of acetylated histones are repressed, while associations between histone 
methylation and gene transcription are more site specific; histone 3 lysine 4 (H3K4) and H3K36 
methylation are for example found on expressed genes while H3K9 methylation is associated with 
repressed genes. Their distribution in the genome can be associated with certain genomic motifs, 
e.g., gene regions such as promoters or open reading frames (ORFs), or intergenic regions such as 
repeats. For example, H3K4me3 (me3 denotes tri-methylated) is found at the promoters of active 
genes, whilst H3K4me1 is associated with enhancers, H3K20me3 is found at repressed repeat 
regions, and H3K9me3 at promoters of repressed genes, retroelements, imprinted loci and at 
pericentromeric repeat regions.  
2. Genomic Imprinting and Targeting DNA Methylation 
Genomic imprinting is a process causing the mono-allelic expression of a specific subset of 
mammalian genes in a parental origin specific manner (reviewed in [8,9])—i.e., genes that are 
expressed either from the paternally inherited chromosome or from the maternally inherited 
chromosome (paternal allele and maternal allele henceforth) are imprinted. The non-equivalence of 
parental genomes in mammals was discovered in 1984 [10,11], and individual imprinted genes 
were first discovered in 1991 (reviewed in [8]). Today, over 100 imprinted genes have been 
identified, most of which are organized in clusters and are regulated in a coordinated manner by a 
single imprinting control region (ICR) [9]. Most clusters contain at least one non coding gene and 
multiple protein coding genes, whose functions regulate embryonic development, placentation and 
a range of post-natal processes. 
Epigenetic mechanisms allow the transcriptional machinery of the cell to distinguish the two 
parental chromosomes at imprinted loci and hence provide an important paradigm for 
understanding epigenetic control of gene activity and repression. Specifically, the discovery of 
differences in DNA methylation in the same place on the two parental chromosomes suggested the 
importance of epigenetic mechanisms in regulating imprinting [12,13] and the potential for 
epigenetic control in a wider context. The identification of imprinting control regions and their 
validation genetically as functional elements essential for the imprinting of multiple genes in cis, 
elucidated imprinting control. The loss of imprinting after targeted deletion of DNMT1 proved that 
DNA methylation was required for imprinting [14]. Importantly, in the absence of DNMT1, some 
imprinted genes were activated but others became repressed, an indication that methylation could 
impact activity as well as repression. 
The acquisition of methylation at ICRs occurs in the germ line de novo by DNMT3A and 




acquiring methylation in oocytes—paternal and maternal ICRs, respectively. It is of interest that 
paternal ICRs are always located in intergenic regions while maternal ICRs are located at promoter 
sequences. Importantly, erasure of imprints occurs in the wave of demethylation that occurs in the 
primordial germ cells. However, in order to retain the memory of the parental origin that is 
subsequently established after that reprogramming, imprints must be retained during the  
post-fertilization epigenetic reprogramming phase [4]. Interestingly, other regions of the genome 
seem refractory to zygotic reprogramming [15] though these are not necessarily parent-specific or 
retained like imprints during development. The relationship, if any, of these regions to ICRs remains 
unclear. In addition to the ICR, other differentially methylated regions (DMRs) are located at some 
imprinted clusters, but a notable difference between ICRs and these DMRs is that differential 
methylation of the latter is not germline established, but rather is acquired post-fertilization. In all 
cases, these so-called secondary DMRs—to distinguish them from regions such as ICRs that 
acquire differential methylation in the germline—require the ICR for their establishment. The 
mechanisms through which ICRs control gene expression in their respective clusters are diverse 
and remain the subject of active research, including analysis of regulation by ncRNAs and of the 
relationships between DNA methylation and histone and non-histone proteins. 
Both in imprinted and non-imprinted contexts, little is known about why certain DNA sequences 
become methylated and not others, or how this may change dynamically within a sequence such as 
a particular CpG island at a gene promoter. Most likely, it is a process that must be targeted in 
some manner. Targeting of the DNA methylation machinery has received much attention and 
efforts made to identify intrinsic sequence specificities of DNMTs and their cofactors. It has thus 
generally been assumed that the acquisition of methylation represents the “active” process in 
establishing differential methylation. However, recent studies on DMRs in the germlines and their 
propagation after fertilization suggest it might also be protection from DNA methylation and 
maintenance at methylated regions that determine differential methylation (Figure 1A, reviewed  
in [16]): Rather than appearing as discrete methylated sequences in otherwise unmethylated 
regions, maternal ICRs (which represent the vast majority of ICRs) are surrounded by methylation 
at both flanks. In contrast, these ICRs are unmethylated in sperm but are also flanked by 
methylation at surrounding sequences, suggesting that DNA methylation may be the “default” state 
and that it is protection from methylation at the ICRs, and perhaps other non-imprinted sequences 
as well, that establishes their differential methylation. Furthermore, in the germline, far more 
sequences are differentially methylated between oocytes and sperm than the ICRs; recent  
genome-wide studies suggest they are in the counts of thousands in oocytes and hundreds in  
sperm [15,17,18]. In contrast to ICRs these sequences generally lose methylation after fertilization, 
suggesting targeted maintenance of DNA methylation at specific sequences is essential for the 
germline-derived differential methylation of imprinted loci. Hence perhaps, loss of maintenance, in 
addition to active removal of DNA methylation at non-imprinted loci, contributes to the mechanism 
through which demethylation occurs in somatic cells. KRAB zinc finger proteins (ZFP) represent a 
family of over 350 tetrapod-specific genes whose functions remain poorly understood. They bind 
DNA and have previously been shown to recruit the repressive chromatin machinery in a  
site-specific manner. One of these KRAB-ZFPs, ZFP57, has been shown to be required to maintain 
the DNA methylation memory at imprints during post-fertilization reprogramming when the bulk 
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of the genome is changing its epigenetic state [19]. ZFP57 binds methylated DNA and is  
thought to recruit methyltransferases to imprinting control regions hence preventing them from loss 
of their imprints. 
3. DNA Methylation and Gene Repression—The Chicken or the Egg? 
3.1. DNA Methylation Correlates with Repression 
The correlation between DNA methylation and gene repression was noted in several 
experiments assaying viral and endogenous gene expression in mammalian, frog and sea urchin 
cells in the late 1970s and early 80s [20–30]. Experiments were conducted to determine whether 
the observed relationship was purely correlational, or whether DNA methylation functionally 
regulated gene expression. This was, however, challenging, but the strong evidence in many 
different contexts, showing that hypomethylated regions were associated with activity and 
hypermethylated regions refractory to transcription, suggested that absence of DNA methylation 
may be necessary though not sufficient for transcription. Vardimon et al. injected bacterial 
plasmids containing in vitro methylated or unmethylated DNA encoding a viral gene into frog 
oocyte nuclei [31]. They observed maintenance of the respective methylation states over a 24 h 
period, and expression of the gene in oocytes that were injected with unmethylated DNA but not in 
those that were injected with methylated DNA [31]. In a similar experiment, Stein et al.  
transfected in vitro methylated or unmethylated plasmids containing the Aprt (adenine 
phosphoribosiltransferase) gene into cultured Aprt null mouse cells. They observed maintenance of 
the respective Aprt methylation states after integration into the endogenous genome over several 
cell divisions for both unmethylated and methylated plasmids, and that integration of the 
unmethylated but not the methylated gene rescued the Aprt null phenotype, suggesting methylation 
of the gene was associated with inhibition of its transcription [32]. 
Correlations between gene expression and DNA methylation have been assessed at CpG sites 
across whole chromosomes or the whole genome. Consistent with the earlier studies, DNA 
methylation of promoter sequences, though rare at CpG island promoters, was observed to correlate 
with gene repression [33–35]. The functional role of DNA methylation in repressing gene 
expression is further suggested by results from studies in which the genes encoding the DNA 
methyltransferases are deleted conditionally in various cell lineages. Generally, the loss of DNMTs 
results in dysregulation of multiple genes, with a trend towards gene activation rather than 
silencing, again suggesting that DNA methylation represses gene expression (reviewed in [36]). 
Furthermore, treatment of cells in vivo with the DNA methyltransferase inhibitor 5-Azacytidine 
was shown to result in gene activation in several experiments in the 1980s, with concomitant loss 
of DNA methylation (reviewed in [37]). Together all these findings have led to the general 
assumption that loss and acquisition of DNA methylation at a gene promoter results in gene 
activation and silencing, respectively, but none actually proved that the acquisition of DNA 





3.2. DNA Methylation as a Consequence of Transcriptional Silencing 
Studies of the temporal onset of mono-allelic expression of imprinted genes and the acquisition 
of differential methylation at secondary DMRs during mouse development indicate that DNA 
methylation can be acquired after gene repression (Figure 1B). The imprinted genes Gtl2, Cdkn1C, 
H19 and Igf2r each contain a secondary DMR in their promoters, which become differentially 
methylated days after their mono-allelic expression is observed (summarized in [38]). Generally, 
mono-allelic expression of these genes is initiated around the morula or blastocyst stage (E3.5-4.5), 
while differential methylation of the respective secondary DMR occurs after E6.5 [13,38–42]. In 
the most extreme case, Igf2r is mono-allelically expressed from the maternal allele from E6.5 
onward but the silent paternal allele only becomes methylated at or after E15.5 [13,42]. It is 
reasonable to assume that this temporal relationship, where methylation is acquired as a 
consequence of gene repression, also applies to non-imprinted genes (Figure 1B). In particular, is 
has recently been shown that DNA methylation levels are secondary to the binding of transcription 
factors; Stadler et al. [43] identified multiple clusters of CpG sites that have low to intermediate 
levels of methylation, 10%–50%, in mouse embryonic stem (ES) cells. These low methylated 
regions (LMRs) are likely distal regulatory regions, and are bound by various transcription factors. 
Scrambling binding sites for the insulator protein CTCF or knocking out the transcription factor 
REST led to increased methylation at the LMRs. Furthermore, reintroduction of REST into the 
REST /  cells reverted the methylation status of the LMRs to the normal low levels [43]. These 
findings suggest DNA methylation may not have a direct role in silencing gene expression in all 
situations. In such cases DNA methylation might rather be acquired after gene silencing to 
maintain the repressed state or as a secondary readout of other mechanisms of genome control. 
Nonetheless, there are situations where acquisition of DNA methylation unquestionably does regulate 
gene expression, notably at the germline DMRs of imprinted genes [1,8,9,14–16]. 
4. How Does DNA Methylation Confer Effects on Gene Expression? 
4.1. Proteins Attracted and Repelled 
In situations where DNA methylation does indeed direct gene repression there are currently two 
model mechanisms that are generally acknowledged [1,44]: First, DNA methylation can attract 
proteins that bring about gene repression through recruitment of chromatin modifiers. A group of 
proteins, collectively referred to as methyl binding proteins (MBPs) have been characterized and 
shown to specifically bind to methylated, but not unmethylated, DNA [44–49]. MBPs are known to 
interact with histone modifiers such as HDACs, e.g., in forming complexes, such as the 
nucleosome remodeling deacetylase (NuRD) complex, which through their histone deacetylase 
activity and subsequent chromatin condensation bring about gene repression [50–55]. Secondly, 
certain proteins may interact with DNA in a methylation dependent manner. Here, DNA 
methylation may be refractory to the binding of proteins, such as transcription factors or other 
regulatory proteins [56–58], that are necessary for gene expression (Figure 1C). For this latter 
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model, the best characterized example is the regulation of CTCF binding at the imprinted H19/Igf2 
cluster via differential DNA methylation on the two parental alleles (reviewed in [1]). 
4.2. Regulation of CTCF Binding at the H19/Igf2 Imprinted Cluster; the Insulator Mechanism 
In the H19/Igf2 imprinted cluster, the protein coding gene Igf2 is expressed from the paternally 
inherited allele [59]. This expression pattern is dependent on the regional ICR [60], on its 
differential methylation [12,14,61] and on the insulator protein CTCF binding to the ICR. On the 
unmethylated maternal allele, CTCF can bind, while its binding is inhibited on the methylated 
paternally inherited chromosome [62–65]—thus CTCF binding to DNA is methylation-sensitive 
(Figure 1C). Igf2 and a downstream non-coding RNA gene, H19, share enhancers that are located 
at the 3' end of H19 [66,67] and the parental specific expression of Igf2 and H19 are ultimately 
determined by interaction with these sequences; on the paternally inherited chromosome,  
Igf2-enchancer interaction is possible and the gene is expressed. On the maternally inherited 
chromosome this contact is blocked by CTCF binding to the ICR and this facilitates enhancer 
interaction with a now active H19 instead, and also results in Igf2 repression. 
What is the mechanism of CTCF’s enhancer blocking activity? The current model (reviewed  
in [68]) suggests that in the H19/Igf2 cluster, chromatin loop formation on the maternal allele 
spatially inhibits enhancer interaction with Igf2. The process appears to depend on three elements; 
dimerization, CTCF binding to more than one region and physical contact between these 
neighboring sites via CTCF interaction [69–74]. The model suggests that on the unmethylated 
maternally inherited chromosome, CTCF binds to the ICR and also to an upstream somatic DMR 
located 5' of Igf2. Binding does not occur at the paternal allele where methylation inhibits the 
binding. On the maternal allele ICR-DMR contact is made possible by CTCF dimerization bringing 
together the two distinct loci, and because they flank Igf2, the gene is ‘looped out’ (Figure 1D). 
Further chromatin contacts within the cluster, some facilitated by CTCF, then result in physical 
separation between the Igf2 loop and the enhancers. Recently cohesins have been shown to bind to 
over half of CTCF binding sites in the genome, including in the H19/Igf2 cluster [75]. Given the 
ability of cohesins to tether DNA strands (i.e., sister chromatids after cell’s S-phase) it is possible 
that cohesins contribute mechanistically to these chromatin contacts on the maternal H19/Igf2 
locus. On the paternal allele, where CTCF cannot bind, long-range chromatin interactions are not 
observed within the cluster, suggesting a state that allows interaction between the 90 kb distant 
enhancers and Igf2 (Figure 1D) [73]. Similar interactions involving CTCF have been noted at other 
loci (Figure 1D). 
5. Relationship between DNA Methylation and Histone Modifications  
Similar to DNA methylation, correlation between multiple histone modifications in various 
genomic elements, including promoters, have been associated with gene activity and repression,  
and early studies illustrating this indeed investigated the relationship in the context of imprinted  
loci [76–82]. A functional relationship may therefore potentially exist between DNA methylation 




exclusive, with the other. Indeed, as noted above, MBPs can recruit histone modification enzymes. 
Well-defined examples of histone modifications that regulate de novo DNA methylation are 
however scarce [83,84]. One very compelling example again comes from the study of genomic 
imprinting, as discussed below. 
DNMT3L lacks a DNA methyltransferase activity, but it is necessary for methylation of DNA in 
certain situations [85,86] because it forms a complex with DNMT3A and DNMT3B, impacts their 
activity and contributes to their structural interaction with chromatin [87–90]. The ability is likely a 
result of a recently discovered affinity of DNMT3L to histone H3 [90] and this interaction is 
dependent on the methylation state of H3 at lysine K4—the binding only occurs when the histone is 
unmethylated hence H3 methylation might shield from DNA methylation [90]. A functional role 
for H3K4 methylation in modulating DNA methylation came from an imprinting study where 
Ciccone et al. showed that this interaction has important regulatory implications. The group 
generated mice deficient for a H3K4 demethylase enzyme, KDM1B, which resulted in increased 
H3K4 methylation in oocytes, where KDM1B is almost exclusively expressed. Consistent with 
inhibition of the DNMT3L-DNMT3A complex binding to methylated histone H3, DMRs at four 
imprinted regions that normally acquire DNA methylation in the female germ line were 
unmethylated in the Kdm1b null oocytes and imprinted expression of the corresponding genes was 
lost in embryos from Kdm1b null females (Figure 1E) [91]. These results strongly suggest a 
functional link between loss of H3K4 methylation and acquisition of DNA methylation, at least at 
imprinted regions (Figure 1E). 
Cedar and Bergman take this further proposing a model of how the bimodal methylation pattern 
of mammalian genomes may be dependent on this same relationship. They suggest that de novo 
DNA methylation at the blastocyst stage is prevented at particular loci by deposition of H3K4 
methylation. They further suggest that H3K4 methyltransferases may be targeted to CpG islands by 
RNA polymerase II and as a consequence, the DNA methyltransferase machinery containing 
DNMT3L, cannot access CpG sites in regulatory regions that are CpG islands [84]. 
H3K9 di- and trimethylation is associated with repressive DNA. DNA methylation is often 
found at such regions. Furthermore, DNA is globally hypomethylated in mouse ES cells carrying 
deletion of a H3K9 methyltransferase, G9a [92]. In this case the loss of DNA methylation is not a 
result of the aberrantly low levels of histone methylation, but rather due to loss of the histone 
methyltransferase enzyme itself; the DNA methyltransferase machinery interacts with G9a,  
and this interaction is mediated through a protein domain that is independent of the histone 
methyltransferase catalytic activity by a SET protein domain. Therefore, in G9a /  mouse ES cells 
carrying G9a transgenes that lack histone methyltransferase activity, e.g., due to a point mutation in 
the SET domain, DNA methylation levels are partially rescued [93,94]. Regulation of DNA 
methylation through interaction of the DNMTs with histone modifiers, rather than with the histone 
modifications themselves, seems to be common and is observed for multiple mammalian histone 
methyltransferases [95–97], as well as in plant [98] and fungal systems [99]. Interestingly, in 
G9a /  ES cells DNA methylation is lost at some imprinted loci [94,100], but where tested this is 
not observed in embryos [100,101]. This behaviour at imprints may suggest that ES cell culture is 
not a faithful model for assessing a requirement for histone modifying enzymes in DNA 
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methylation, but equally might also reflect different properties of imprint-specific maintenance in 
ES cells compared to in vivo.  
Figure 1. Regulatory epigenetic phenomena at imprinted loci. On the left are examples 
of various epigenetic mechanisms as observed in imprinted loci, and on the right 





(A) left: In the male germline (sperm), CpG dense regions are generally unmethylated and less dense 
regions are methylated. In the female germline (oocytes) CpG rich regions are more frequently 
methylated. This results in multiple differentially methylated regions between the male and female 
germlines. After fertilization only a small subset of these regions retain differential methylation. 
Retention of differential methylation at imprinting control regions (diamonds) post-fertilization may 
therefore be a targeted protection from either demethylation or de novo methylation; right: Model; 
Changes in DNA methylation may be mediated through loss and gain of such protection—when 
protection is lost (e.g., upper—as a result of factor (black triangle) binding or a histone modification that 
is non-permissive (red circle) for DNMT binding) CpGs become methylated by the methyltransferase 
machinery. If protection is gained (lower) the machinery cannot access the CpG sites to maintain 
methylation and after cell divisions methylation is therefore lost; (B) left: The secondary DMR located in 
the promoter region of the imprinted gene Gtl2 becomes methylated on the paternal allele after 
expression is silenced; right: Model; DNA methylation at CpG sites in promoter regions of  
non-imprinted genes may therefore, at least in some cases, occur after gene silencing; (C) left: In the 
H19/Igf2 imprinted locus, CTCF (red pentagon) binds the H19-ICR, on the unmethylated maternal allele, 
not the methylated paternal allele; right: Model; Methylation of CpG sites can inhibit protein binding 
(purple) to DNA; (D) left: In the H19-Igf2 imprinted locus CTCF (red pentagon) binds to regions 
flanking Igf2 and dimerizes, looping the gene and physically inhibiting its interaction with distal 
enhancers. On the paternally inherited allele, CTCF does not bind and enhancers are in contact with Igf2 
and the gene is expressed; right: Model; Looping of DNA sequences through the action of CTCF  
(red pentagon) can separate regions or bring them into contact; (E) left: In Kdm1b /  (histone 
methyltransferase) mouse oocytes, imprints are not established at multiple ICRs due to the inhibitory 
effect of H3K4 methylation on DNMT3L. Histone modification states in WT and Kdm1b /  mice are 
depicted as green and red circles to signify permissive and non-permissiveness to de novo DNA 
methylation, respectively. In embryos from Kdm1b /  mothers, imprinted expression is lost, and genes are 
biallelically expressed (Mest, depicted) or repressed; right: Model; Histone modifications (red and green 
circles) can regulate DNA methylation; (F) left: In the Igf2r imprinted locus Igf2r expression is inhibited 
by transcriptional interference from the Airn lncRNA transcript on the paternal allele. The lncRNA 
recruits histone modifiers such as G9a (blue) to proximal imprinted genes that contribute to silencing of 
the imprinted Slc22a3 in a lineage specific manner, e.g., through deposition of histone marks that are 
non-permissive for transcription (red circle); upper right: Model; lncRNAs may exert their effects in 
trans at proximal genes. As illustrated, a lncRNA is expressed and silences proximal genes, but not the 
more distal genes; lower right: Model; In the example provided a lncRNA and a coding gene are 
expressed from within the same ORF. Transcription of the lncRNA inhibits expression of the  
coding gene. 
6. lncRNAs 
6.1. lncRNAs, Definition, Characterization and Potential Functions 
In recent years the roles of long noncoding RNAs (lncRNAs) in regulating genome function 
have received considerable attention, and are now emerging as a large group of genes with 
potential functions of fundamental importance for cell biology (for review see [2,102–104]). 
lncRNAs are defined as noncoding RNA transcripts of >200 bp [104]. Transcription of lncRNAs 
resembles that of mRNA genes; they are transcribed by the same transcriptional machinery and by 
RNA polymerase II, the transcripts are 5' capped and can be spliced and shuttled to the  
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cytoplasm [102]. The lack of an open reading frame and their size are therefore the only criteria 
that currently define lncRNAs as a group [102,104]. On basis of high-throughput RNA sequencing 
experiments, the numbers of lncRNA transcripts have been suggested to range between  
5000–15,000 [105,106]. With higher sensitivity, targeted capture experiments have identified 
lncRNAs that are undetectable by high-throughput technology, suggesting that this range is an 
underestimate [107]. However, as a result of their loosely defined criteria, lncRNAs as a group may 
be very heterogeneous. Therefore, the functional roles discussed below may only apply to a subset 
of their estimated numbers. 
Despite the current excitement surrounding “new” roles for lncRNAs, they were shown to 
regulate genomic imprinting over a decade ago. Multiple potential functions of lncRNAs have been 
proposed whereby lncRNAs either exert their effects by acting in trans or by the act of their 
transcription in cis (transcriptional interference). Both effects have been shown to act at imprinted 
loci. Some trans acting lncRNAs, such as HOTAIR, have been suggested to exert their effects 
throughout the genome [108], while others, including most imprinted lncRNAs defined to date, act 
over a limited area surrounding or close to their transcriptional origin. Some lncRNAs may utilize 
both cis and trans acting mechanisms. An example is the imprinted Airn lncRNA whose 
transcription on the paternal chromosome represses Igf2r expression in cis by transcriptional 
interference [109], while the Airn RNA molecule itself is also necessary for regulating other genes 
in the cluster in a trans-targeted manner (see below, and Figure 1F [110]). Transcriptional 
interference is proposed to occur as a result of a collision between the transcriptional machineries 
of two adjacent or overlapping transcripts which might result in termination of one or both 
transcriptional events. Alternatively it may occur by promoter occlusion via inhibition of formation 
of a transcriptional initiation complex due to existing transcription of one transcript through the 
promoter of another [111]. 
Functions of trans acting lncRNAs have been proposed to fall into the following  
categories [112]: (1) Decoys: lncRNAs that bind to DNA binding proteins and prevent their 
interaction with DNA; (2) Scaffolds: lncRNA that function to join two or more proteins into an 
lncRNA-RNP (ribonucleoprotein) complex; (3) Guides: lncRNAs that bind proteins to guide them to 
certain genomic locations, e.g., by lending them specificity and/or binding capacity to certain DNA 
sequences or chromatin states.  
6.2. lncRNAs in the Epigenetic Control of Genome Function—Lessons from Imprinting 
Every cluster of imprinted genes contains at least one lncRNA and these lncRNAs are regulated 
by DNA methylation. This was demonstrated in experiments where the genes encoding DNA 
methyltransferases were deleted in mice to gauge effects on imprinting regulation. Promoters for 
the Airn, Nespas/Gnasxl, Snrpn and Kcnq1ot1 lncRNA genes lie within the ICR for their respective 
region and are differentially methylated on the two parental chromosomes. Upon loss of DNMT1, 
the maintenance methyltransferase, methylation is lost at these ICRs in E10.5 embryos (the genetic 
manipulation is lethal at later embryonic stages) and Airn, Nespas/Gnasxl, Snrpn and Kcnq1ot1 are 
biallelically expressed, with effects on neighboring imprinted protein coding genes, some of which 




promoters are located in the ICRs, exhibit differential methylation, and, importantly, are located 
within genes running antisense to them, hence these provide examples of critical regulatory DNA 
methylation at genomic regions considered by some to have little or no consequence, i.e., 
intragenic. The existence of other epigenetically regulated elements within genes and acting in this 
way to potentially regulate lncRNAs, may have very widespread effects on genome function. 
Furthermore, imprinted lncRNAs have been demonstrated to be necessary for epigenetic control 
of genome function, to guide chromatin modifying enzymes in trans to specific sites in the 
genome. This is thought to mediate changes in histone modifications and be associated with 
changes in transcriptional activity. Although challenging to address experimentally, this function 
for lncRNAs is currently the topic of much attention. It was studies on imprinted gene regulation at 
the Igf2r/Airn and Kcnq1/Kcnq1ot1 imprinted clusters that provided examples of this type of 
regulation [104]. Kcnq1ot1 and Airn are estimated as greater than 100 kb lncRNA transcripts, 
transcribed in an antisense orientation from within protein coding genes; Kcnq1ot1 from Kcnq1 in a 
1 Mb imprinted cluster that contains eight maternally expressed protein coding genes, and Airn 
from Igf2r in a 400 kb long imprinted cluster that contains three maternally expressed protein 
coding genes. Both transcripts generate unspliced lncRNAs that are localized in the  
nucleus [103,115,116]. The ICRs of both genes are methylated on the maternal, but not paternally 
inherited chromosome, and determine monoallelic expression of the lncRNAs from the paternal 
allele. In mouse genetic mutants, where the promoters of Airn and Kcnq1ot1 are deleted or their 
transcripts truncated by insertion of premature polyA sequence into the endogenous genes, biallelic 
expression of the imprinted protein coding genes occurs within their respective clusters [110,117–119]. 
These results suggested that the lncRNAs or the act of their transcription is necessary for silencing 
of genes in cis (Figure 1F). In addition, several lines of evidence further indicate that lncRNAs 
guide chromatin modifying enzymes in trans to establish repressive histone marks and gene 
silencing on the paternal allele (Figure 1F): In the Kcnq1 imprinted cluster Osbpl5, Cd81, Ascl2 
and Tscc4 are imprinted exclusively in the placenta [40] and so are Slc22a2 and Slc22a3 in the 
Igf2r/Airn cluster [120]. The paternal chromosomes are bound by the histone methyltransferases 
G9a and/or Ezh-Eed2 in the extraembryonic lineage [40,110], and both Airn and Kcnq1ot1 
lncRNAs associate with G9a histone methyltransferase in a lineage specific manner—in placenta 
but not embryo [110,115]. These results showed that lncRNAs may be a contributing factor for 
targeting epigenetic marks (Figure 1F) with genetic models being used alongside biochemical 
approaches to generate a more tractable and comparable experimental paradigm for added 
robustness. These studies have paved the way for explorations of the roles of multiple other 
lncRNAs which are found in association with different chromatin modifying enzymes [121,122]. 
Most recently, the imprinted lncRNA Gtl2/Meg3 has been shown to function in trans to target 
polycomb regulatory complexes in mouse and human stem cells in culture [123]. 
7. Conclusions 
The robust genetic approaches applied to the regulation of imprinting have allowed it to be an 
excellent hypothesis-driven model to investigate and understand the epigenetic control of genome 
regulation. One of its greatest strengths as a model is that it allows the comparison of differentially 
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expressed alleles of the two inherited copies of a gene with identical sequence within the same cell. 
Because these two parentally inherited alleles have well-defined different epigenetic states the 
contributions of these to gene expression can be determined. Since imprinted clusters employ 
multiple different epigenetic mechanisms, acting through various different mediators  
(long non-coding RNA, CTCF, etc.), this has enabled investigators to explore their hierarchical 
interactions and relationships with one another. As evidenced by the examples presented here, 
imprinting has provided insight into some of the most fundamental aspects of a range of epigenetic 
phenomena and their mediators.  
Nevertheless, many important aspects of imprinting and epigenetic control remain to be 
elucidated. These include: what allows epigenetic marks to be de novo targeted differently in the 
male and female germlines; whether they are modulated by extrinsic or intrinsic signals, for 
example in the context of development and disease; and how DNA methylation is actively removed 
during reprogramming and perhaps at other times in development. The mechanisms regulating 
some of these processes are beginning to emerge where the context of imprinting has contributed; 
the DNA binding proteins ZFP57 and PGC/Stella have been shown to target and maintain DNA 
methylation at imprinted clusters during postfertilisation epigenetic reprogramming [19,124] and 
selective loss of imprinting is necessary for stem cell regulation in the neurogenic niche of the 
developing mouse [125]. Whether we can apply more generally what we learn from these 
mechanisms—for example about the general targeting of epigenetic states or the dynamic changes 
in epigenetic state in specific cellular niches—remains to be determined. It is likely that future 
studies, addressing these and other similarly fundamental questions in the context of imprinting 
will continue to add new layers to our understanding of genome regulation and the epigenetic 
control of genome function more widely.  
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Abstract: Whole-exome sequencing (WES) is a new tool that allows the rapid, inexpensive and 
accurate exploration of Mendelian and complex diseases, such as obesity. To identify sequence 
variants associated with obesity, we performed WES of family trios of one male teenager and one 
female child with severe early-onset obesity. Additionally, the teenager patient had hypopituitarism 
and hyperprolactinaemia. A comprehensive bioinformatics analysis found de novo and compound 
heterozygote sequence variants with a damaging effect on genes previously associated with obesity 
in mice (LRP2) and humans (UCP2), among other intriguing mutations affecting ciliary function 
(DNAAF1). A gene ontology and pathway analysis of genes harbouring mutations resulted in the 
significant identification of overrepresented pathways related to ATP/ITP (adenosine/inosine 
triphosphate) metabolism and, in general, to the regulation of lipid metabolism. We discuss the 
clinical and physiological consequences of these mutations and the importance of these findings for 
either the clinical assessment or eventual treatment of morbid obesity. 
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1. Introduction  
Obesity is a global epidemic: the World Health Organization (WHO) estimates that half a billion 
people over the age of twenty worldwide are obese [1]. Global projections estimate that worldwide,  
1.2 billion individuals will be obese by 2030 [2]. 
Obesity and its related traits have high estimates of heritability (h2 between 40% and 70%) [3].  
The investigation of candidate genes and genome-wide association studies have identified more 
than 60 obesity susceptibility genes that predispose to increased body weight, waist circumference,  
waist-hip ratio, body mass index (BMI) and fat percentage or fat mass. However, mutations in 
these genes account for a very small fraction of the obesity phenotypic variance [4,5]. It has been 
estimated that at least 7% of children with severe early-onset obesity (defined by an onset before 
the age of 10 years and BMI over three standard deviations (SD) above normal) have a single locus 
sequence variant determining obesity [6]. Nine susceptibility genes, determinants of non-syndromic 
Mendelian forms of human obesity, are involved in the hypothalamic control of energy balance via 
the leptin-melanocortin pathway and/or in neural development [4]: brain-derived neurotrophic 
factor (BDNF), leptin (LEP), leptin receptor (LEPR), melanocortin-4 receptor (MC4R), 
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neurotrophic tyrosine kinase receptor type 2 (NTRK2), prohormone convertase 1 (PCSK1), 
proopiomelanocortin (POMC), single-minded homolog 1 (SIM1) and, more recently, melanocortin 
2 receptor accessory protein 2 (MRAP2) [7]. 
Exome sequencing is rapidly becoming the first-line approach for monogenic disorders [8]. The 
use of whole-exome capture and the complete sequencing of the coding genome of parent-child 
trios is a highly effective approach for identifying homozygous, compound heterozygous and de 
novo coding sequence variants, as multiple de novo sequence variants occurring within a specific 
gene (or within a gene family or pathway) are extremely implausible events [8]. Its rationale is 
based on the fact that gene variants located in exons are more likely to be pathogenic than those 
located in introns or between genes. The power of this strategy has increased with the access to 
large numbers of publicly available exome sequences that allow the controlled comparison of 
frequencies, as well as the identification of de novo variants and stratification by ethnicity. This 
strategy has been used to identify candidate genes for several Mendelian and complex traits [9–12]. 
In the assessment of obesity, whole-exome sequencing has identified sequence variants in the 
leptin receptor gene [13], in the ADCY3 gene [14] and in the BBIP1 gene in patients with  
Bardet–Biedl syndrome [15]. However, no novel pathogenic genes or pathways associated with 
obesity have been identified through this approach yet.  
In this study, by employing whole-exome capture and sequencing in the assessment of two 
patients with severe early-onset obesity (and their parents), we identified de novo mutations and the 
compound heterozygous status of several damaging variants. Intriguingly, some of these variants 
were harboured in genes involved in the pathophysiology of obesity (such as LRP2 and UCP2), 
providing the foundation for future research in this field. Thus far, we emphasize that the 
networking of clinical case-reports and genetic analyses would be crucial to finding the major loci 
underpinning complex disorders.  
2. Experimental 
Two family trios, the probands of which had severe early-onset obesity (onset before the age of  
10 years and BMI over three SD above normal) were included in this study. All parents and 
capable patients provided written informed consent for the genetic research studies, which were 
performed in accordance with the study protocol approved by the Australian National University 
Human Research Ethics Committee (Protocol 2011/108, approved on the 6 May, 2011) and in 
concordance with the Helsinki Declaration of 1975, as revised in 2008. DNA was extracted from 
peripheral blood from the patients and parents for genetic analysis. 
2.1. DNA Library Preparation, Exome Capture and Sequencing Protocol 
Libraries were constructed from 1 g of genomic DNA using an Illumina TruSeq genomic DNA 
library kit (Illumina Inc., San Diego, CA, USA). Libraries were multiplexed with 6 samples pooled 
together (500 ng of each library). Exons were enriched from the pooled 3 g of library DNA using 
an Illumina TruSeq Exome enrichment kit (Illumina Inc.). Each exome-enriched pool was run on a  
100-base-pair paired-end run on an Illumina HiSeq 2000 sequencer (Illumina Inc.). We surveyed 
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201,071 genomic regions in total using the exome capture platform. Ninety percent of the bases in 
approximately 197,000 of these targeted regions had at least one read coverage. All regions were 
sampled at approximately 50× coverage. 
2.2. Sequence Read Processing, Alignment, Bioinformatics and Genetic Analyses 
The sequencing image data were processed in real time using Illumina Real Time Analysis 
(RTA) software (Illumina Inc.) and converted to fastq files containing DNA base calls (A, C, G and T) 
and quality scores using the Illumina CASAVA pipeline (a software program that converts raw image 
data into sequences). The resulting fastq files were further processed for variant analysis. 
The entire workflow of data curation and analysis for variant-calling was developed by the 
Genome Discovery Unit (GDU) at The Australian National University. Key components of the 
workflow include: (i) quality assessment; (ii) read alignment; (iii) local realignment around the 
known and novel indel regions to refine indel boundaries; (iv) recalibration of base qualities;  
(v) variant calling; and (vi) assigning quality scores to variants (detailed workflow information is in 
the Supplemental Material).  
Subsequently, we included a filtering phase (using information from dbSNP and the 1K Exome 
Project), with the following sequential steps: (1) identification of rare or de novo variants (a lower 
minor allele frequency cut-off (MAF) in the window of 0.1%–1.0%); (2) filtering of variants to 
include those that are potentially pathogenic or are specific variants associated with disease 
susceptibility using several tools, namely, SIFT, PolyPhen2, Mutation Taster, Mutation Assessor 
and Functional Analysis through Hidden Markov Models (FATHMM), as implemented by the 
DNA-seq Analysis Package (SVS7.7.6, Golden Helix, Bozeman, MT, USA) (variants were not 
excluded if classified as potentially damaging by at least one of these filtering tools); (3) filtering of 
damaging variants based on genes known to be associated with human disease; and (4) independent 
confirmation of selected variants by Sanger sequencing (Supplemental Material). The definition of 
de novo sequence variants, compound heterozygous polymorphisms and rare recessive 
homozygous polymorphisms was performed with different modules of the DNA-seq Analysis 
Package (SVS7.7.6, Golden Helix, Bozeman, MT, USA). 
To identify potential enriched endocrine-physiological pathways, a genetic ontology pathway 
analysis was performed. For constructing the pathways, variants with potential functional changes 
detected by the de novo and the compound heterozygous analysis were examined with the set of 
algorithms implemented in MetaCore (Thomson Reuters, New York, NY, USA) for the heuristic 
interpretation of maps, networks and rich ontologies for diseases. 
3. Clinical Reports 
Patient 1: A Brazilian male teenager with a history of excessive weight gain starting at age 3, 
decelerated growth since age 11 and delayed puberty was first evaluated at age 14 y, 3 m. His body 
weight was 105.0 kg (+5.32 SD score), his height 152.5 cm ( 1.45 SD score) and his BMI  
45.2 kg/m2 (+11.03 SD score) (Figure 1). The patient had no complaints of hearing deficits or 
vision loss. Testicular volumes were <2 mL bilaterally, and he was at Tanner pubertal stage P2–P3. 
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He had cubitus valgus and round facies. During physical examination, profuse sweating was noted. 
Other physical signs were unremarkable. 
Obesity was a common finding in his family, but all individuals had normal height. His father is 
obese (BMI 36.7 kg/m2), as are his paternal grandfather (BMI 44.6 kg/m2) and paternal uncle  
(BMI 50.5 kg/m2). His mother’s BMI is 30.1 kg/m2, and two maternal aunts are also obese  
(BMI 31.6 and 30.1 kg/m2). His older brother is overweight (BMI 29 kg/m2). None of his family 
members have a history of severe early-onset obesity. There was no history of consanguinity in the 
family. Pregnancy was uneventful, and size at birth was 4.2 kg and 51.5 cm.  





Figure 1. Cont. 
 
Growth charts illustrating changes in height (A), weight (B) and BMI (C). M, maternal height; P, paternal 
height; TH, target height. From WHO Child Growth Standard: Methods and Developments. 
He had been previously diagnosed with central hypothyroidism at age 9, with thyroid-stimulating 
hormone (TSH) of 7.4 mU/L and free T4 of 9.5 pmol/L, with undetectable titres of antithyroglobulin 
and antithyroperoxidase antibodies and a normal thyroid ultrasound. He also had elevated serum 
prolactin levels of 2,908 pmol/L, measured for the first time at age 9. Magnetic resonance enhanced 
by the contrast gadolinium showed a pituitary gland of normal volume, with no evidence of 
pituitary adenoma and without any structural abnormalities in the brain. The search for 
macroprolactin was negative (71% recovery after polyethylene glycol precipitation). He had been 
on treatment with levothyroxine 88 g/day since age 9 y, 5 m, and cabergoline 0.5 mg every  
10–15 days since age 13 y, 2 m, which had normalized his serum TSH and prolactin levels. 
During the previous five years, he was treated with hypocaloric mixed diets, frequent physical 
activity, sibutramine 10 mg/day and orlistat 120 mg after meals. This approach resulted in only  
a 6-kg noncontinuous weight loss.  
The patient’s serum triglycerides and total cholesterol were elevated (3.11 and 4.84 mmol/L, 
respectively), with low HDL-cholesterol of 0.85 mmol/L and normal calculated LDL-cholesterol of 
1.99 mmol/L. Fasting plasma glucose and insulin were 5.33 mmol/L and 13 U/mL, respectively, 
with the homeostasis model assessment-estimated insulin resistance (HOMA-IR) index equal to 
3.07. His serum insulin-like growth factor 1 (IGF-1) level was below the age reference range 
(71.25 nmol/L; reference value 130–563 nmol/L). Growth hormone (GH) secretion was evaluated 
during a standard insulin provocative test, with no development of hypoglycaemia during the test 
(lowest glucose level of 3.55 mmol/L and respective GH level of 0.06 g/L). Morning cortisol and 
adrenocorticotropic hormone (ACTH) levels were normal (0.68 mol/L and 1.60 pmol/L, 
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respectively). His serum leptin levels were 8.1 and 18.0 g/L at age 9 and appropriately elevated at 
age 13 (69.7 g/L). At age 13, his total testosterone levels were pre-pubertal (0.90 nmol/L), and 
follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were undetectable. At age 13 y, 
9 m, his bone age was 15.6 years. Table 1 summarizes the laboratory test results and their 
respective reference range values.  
Table 1. Laboratory test results for Patient 1.  
Test Value Normal reference range 
Thyroid-stimulating hormone (TSH) * 7.4 mU/L 0.3–5.0 mU/L 
Free T4 * 9.5 pmol/L 10.3–25.7 pmol/L 
Antithyroglobulin (ATG) and 
antithyroperoxidase (ATPO) antibodies * 
Both negative 
<9.0 IU/mL (ATG) 
<116 IU/mL (ATPO) 
Prolactin * 2908 pmol/L 82–504 pmol/L 
Macroprolactin * Negative (71% recovery) >50% recovery 
Total cholesterol $ 4.84 mmol/L 4.4 mmol/L 
HDL cholesterol $ 0.85 mmol/L >1.16 mmol/L 
LDL cholesterol $ 1.99 mmol/L <2.84 mmol/L 
Triglycerides $ 3.11 mmol/L <1.02 mmol/L 
Fasting plasma glucose $ 5.33 mmol/L 3.89–5.5 mmol/L 
Fasting insulin $ 13 U/mL 1.8–4.6 U/mL 
Insulin-like growth factor 1 (IGF-1) & 71.25 nmol/L 130–563 nmol/L 
Growth hormone (GH)/glucose &# 0.06 g/L/3.55 mmol/L >5 g/L/<1.94 mmol/L 
Adrenocorticotropic hormone (ACTH) 
(morning) 
1.60 pmol/L 2.2–13.2 pmol/L 
Cortisol (morning) 0.68 mol/L 0.14–0.70 mol/L 
Leptin 8.1 * and 69.7 g/L & Detectable 
Total testosterone & 0.90 nmol/L 3.47–41.60 nmol/L 
Follicle-stimulating hormone (FSH) & Undetectable 0.5–10.5 IU/L 
Luteinizing hormone (LH) & Undetectable 0.5–7.9 IU/L 
Total calcium ^ 2.62 mmol/L 2.40–2.64 mmol/L 
Inorganic phosphate ^ 173.4 mmol/L 108.4–164.2 mmol/L 
Magnesium ^ 1.1 mmol/L 0.7–0.9 mmol/L 
Alkaline phosphatise ^ 114 U/L 66–571 U/L 
25-hydroxy vitamin D ^ 85 mmol/L >75 mmol/L 
Parathyroid hormone (PTH) ^ 2.6 pmol/L 1.0–5.5 pmol/L 
Selenium @ 0.03 mol/L 0.25–2.4 mol/L 
Total urinary protein @ 0.08 g/24 hours <0.15 g/24 hours 
* Measured at age 9, not treated with levothyroxine and cabergoline; $ measured at age 12; # GH and 
lowest glucose level measured during a standard insulin provocative test; & measured at age 13; ^ measured 
at age 14; @ measured at age 16. 
Radiographic studies showed lumbar scoliosis convex to the right, mild reduction of 
intervertebral spaces at L4-S1, mild shortening of L1, as well as a short fourth metacarpal. In order 
to exclude the diagnosis of Albright’s hereditary osteodystrophy, serum electrolytes, alkaline 
phosphatase, vitamin D and parathyroid hormone (PTH) were measured, which were all 
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unremarkable for Albright’s hereditary osteodystrophy (total calcium 2.62 mmol/L; inorganic 
phosphate 173.4 mmol/L; magnesium 1.1 mmol/L, alkaline phosphatase 114 U/L, 25-hydroxy 
vitamin D 85 mmol/L and PTH 2.6 pmol/L). His serum levels of selenium were 0.03 mol/L,  
10-fold lower than the lowest limit of the normal range (reference values 0.25–2.4 mol/L). Total 
urinary protein levels were 0.08 g/24 hours.  
Intramuscular injections of testosterone esters (70 mg every four weeks) were initiated for 
puberty induction. Biosynthetic GH was initiated in a dose of 0.33 mg/day and increased to  
0.66 mg/day according to IGF-1 levels. Four months after starting GH therapy, he developed 
episodes of fever of unexplained origin, which resolved spontaneously after six months. During 
that period, investigation for infection disease was negative, including a normal PET-scan, with 
leucocytosis as the only observed abnormality.  
Patient 2: A two year-old Brazilian girl was evaluated for severe early-onset obesity. Her body 
weight was 23 kg (+4.79 SD score), her height was 93 cm (+2.32 SD score) and her BMI  
was 26.6 kg/m2 (+4.49 SD score). She was born with 2.9 kg and 46 cm, from an uneventful 
pregnancy. Excessive weight gain was noted upon a few weeks after birth. Neurologic 
development was normal, with no evidence of Prader–Willi or Bardet–Biedl syndromes. She had 
normal serum leptin levels of 18 g/L. A history of recurrent bacterial and viral respiratory tract 
infections was noted, which warranted the need for antibiotic therapy almost every month.  
There was no significant familial history of obesity or consanguinity. The physical examination 
was unremarkable. 
4. Results 
We called a total of 455,342 variants, 336,652 of them polymorphic, 21,613 matched at the 
dbNSFP, 12,286 with potential pathogenic effects and 2,291 with a minor allele frequency <1% 
when compared to the 1 kG phase 1. Our filtering approach by de novo functional mutation 
screening reported three de novo sequence variants with a potential damaging effect (Table 2). 
These sequence variants were found in Patient 1 (UCP2) and in Patient 2 (AICDA and FAM71E2). 
The compound heterozygous analysis identified 20 variants with potential functional effects 
associated with eight genes, namely: LRP2, AMPD3, OR8U8-OR9G1 and SLC22A6 in Patient 1 
and TTN, APEH, DNAAF1 and KIR3DL3 in Patient 2 (Table 3). From a literature search on the 
compound heterozygous variants that were classified as damaging, we identified two sequence 
variants in the LRP2 gene that may potentially affect LRP2 protein function in Patient 1: a genomic 
variant G T (NC_000002.11:g.170009391G>T), resulting in a nonsynonymous substitution on 
codon 4127 (NM_004525.2:c.12379C>A; NP_004516.2:p.Arg4127Ser), and a genomic variant 
C T (NC_000002.11:g.170030506C>T), resulting in a nonsynonymous substitution on codon 
3646 (NM_004525.2:c.10937G>A; (NP_004516.2:p.Arg3646His). The LRP2 gene encodes a multi-
ligand endocytic receptor (also known as megalin or glycoprotein 330) involved in the regulation 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sanger sequencing of the two amplicons containing the two LRP2 sequence variants validated 
the findings obtained from the whole-exome capture and sequencing analysis (Figure 2). These 
results confirmed that each parent is heterozygous for one of the sequence variants (the mother is 
heterozygous for the mentioned sequence variant (g/t) (NC_000002.11:g.170009391G>T), and the 
father is heterozygous for the sequence variant (c/t) (NC_000002.11:g.170030506C>T), whereas  
the patient is heterozygous for both LRP2 sequence variants. Therefore, the patient is compound 
heterozygous for the LRP2 gene as initially described in the whole-exome capture and sequencing 
analysis (Figure 2). 
Figure 2. Sanger sequencing results from Patient 1 and parents. 
 
Sanger sequencing of the LRP2 gene shows that both parents are heterozygous for  
one of the mutations. The mother is heterozygous for the Chr2:170009391 sequence variant  
(g/t) (NC_000002.11:g.170009391G>T), and the father is heterozygous for the Chr2: 170030506 
variant (c/t) (NC_000002.11:g.170030506C>T). The patient is compound heterozygous and has both  
sequence variants. 
MetaCore analysis, including those genes harbouring functional mutations, namely UCP2, 
AICDA, FAM71E2, TTN, APEH, DNAAF1, KIR3DL3, LRP2, AMPD3, OR8U8-OR9G1 and 
SLC22A6, defined six pathways significantly overrepresented (after false discovery correction, 




metabolism/peroxisome proliferator-activated receptor (PPAR) regulation of lipid metabolism;  
(3) development of insulin, IGF-1 and TNF-alpha in brown adipocyte differentiation;  
(4) mitochondrial dysfunction in neurodegenerative diseases; (5) oxidative stress role of Sirtuin1 
and PGC1 alpha in the activation of the defence system; and (6) CTP/UTP (cytidine/uridine 
triphosphate) metabolism (Table 4). 
Table 4. Significant pathways from MetaCore analysis of candidate morbid  
obesity genes. 
Pathways of Candidate Morbid Obesity Genes 
Genes from Input 
List in Pathway 
p-Value FDR 
ATP, ITP metabolism AMPD3 1.107e-3 6.640e-3 
Regulation of lipid metabolism PPAR regulation of 
lipid metabolism 
UCP2 1.851e-2 3.164e-2 
Development of insulin, IGF-1 and TNF-alpha in 
brown adipocyte differentiation 
UCP2 2.332e-2 3.164e-2 
Mitochondrial dysfunction in  
neurodegenerative diseases 
UCP2 2.594e-2 3.164e-2 
Oxidative stress role of Sirtuin1 and PGC1 alpha in the 
activation of the defence system 
UCP2 2.637e-2 3.164e-2 
CTP UTP metabolism AICDA 4.709e-2 4.709e-2 
Note: p-values and false discovery (FDR) correction adjusting for multiple comparisons, representing the 
probability that these pathways generated from our candidate gene list would appear by coincidental 
chance from feeding a random set of genes.  
5. Conclusions 
In this study, by employing whole-exome capture and sequencing, we identified novel sequence 
variants in the LRP2 gene that might be associated with the phenotype of severe early-onset obesity 
in Patient 1. Similar to the other genes associated with monogenic forms of obesity, LRP2 is also 
involved in the regulation of the leptin-melanocortin pathway [16]. In addition, in Patient 1, we 
found a de novo sequence variant in the UCP2 gene, a transporter protein present in the 
mitochondrial inner membrane that is a key regulator of energy balance, the variants of which have 
already been associated with obesity [17]. In Patient 2, we identified sequence variants in the 
DNAAF1 gene, which might be related to the second patient’s phenotype. The DNAAF1 gene is 
required for the stability of the ciliary architecture, and it has been demonstrated that ciliary 
dysfunction is associated with the pathogenesis of obesity [18,19]. 
Recently, LRP2 has been nominated as a novel appetite regulator responsible for generating 
satiety signals in hypothalamic neurons [16]. It is a multiligand endocytic receptor, a member of 
the low density lipoprotein receptor gene family, which binds a large variety of ligands. Leptin is 
one of its ligands; LRP2 mediates its reuptake in renal tubules [20] and promotes leptin transport 
across the choroid plexus [21]. LRP2 also binds to the long-form leptin receptor (LepRb), forming 
a complex that is co-localized and subjected to endocytosis in the hypothalamic neurons. 




transducer and activator of transcription 3 (STAT3) signalling in hypothalamic neurons, including 
proopiomelanocortin (POMC)- and LepRb-expressing neurons. As a consequence, food intake and 
body weight are decreased. In the absence of functional LRP2, STAT3 signalling is decreased. 
Therefore, hunger is stimulated and satiety decreased [16]. 
The binding of LRP2 and LepRb is enhanced by clusterin, a sulphated glycoprotein  
widely expressed in hypothalamic areas involved in the regulation of food intake and energy 
metabolism [22]. Chronic intracerebroventricular (icv) administration of clusterin causes the 
reduction of food intake, body weight and epididymal fat mass [16]. LRP2 is expressed in rodent 
hypothalamus, and its inhibition by small interfering RNA significantly blunts the effects of 
clusterin icv injections on food intake and Stat3 activation [16]. Therefore, LRP2 acts as a key 
mediator of the food intake-suppressing effects of clusterin, and its absence can cause obesity in 
rodents (as previously demonstrated) [16].  
Sequence variants in the LRP2 gene have been previously associated with Donnai–Barrow/ 
facio-oculo-acoustico-renal (DB/FOAR) syndrome [23]. The phenotype of this syndrome includes 
agenesis of the corpus callosum, developmental delay, enlarged anterior fontanelle, high myopia, 
hypertelorism, proteinuria and sensorineural hearing loss, but not obesity. In a review by  
Pober et al., sensorineural hearing loss, high myopia and proteinuria were present in 100% of 
DB/FOAR syndrome cases. None of those features were present in Patient 1; therefore, we ruled 
this diagnosis out. Serum selenium levels in patients with DB/FOAR syndrome have not been 
reported, but it has been shown that LRP2 mediates the reuptake of selenoproteins in the kidney 
and that LRP2-mutant mice have low selenium serum levels due to the increased urinary excretion 
of selenoproteins [24]. Since the patient’s serum levels of selenium were 10-fold lower than those 
of the reference range, this finding supports the impairment of the biological function of LRP2.  
Besides suffering from severe early-onset obesity, Patient 1 also had pituitary dysfunction 
characterized by GH deficiency, central hypothyroidism and hypogonadotropic hypogonadism, with 
concomitant hyperprolactinaemia. It is unclear whether sequence variants in the LRP2 gene can 
directly affect pituitary development and function. LRP2 is essential for brain development [25], as 
knock-out mice exhibit holoprosencephaly [26] and Lrp2-mutant mice have abnormal cortical axon 
development [27]. Humans with DB/FOAR syndrome have structural brain abnormalities, mainly 
agenesis of the corpus callosum and, in one reported case, empty sella turcica [28]. These support 
the hypothesis that LRP2 sequence variants might lead to abnormalities in pituitary development 
and hypopituitarism.  
In addition, Patient 1 had a de novo variant in the UCP2 gene. As a transporter protein that is 
expressed in the mitochondrial inner membrane, UCP2 decreases mitochondrial ATP production 
by mediating H+ leak across the inner membrane [17]. Patient 1 has a G to A substitution at 
rs660339, resulting in an Ala55Val substitution, which has been associated with obesity in diverse 
settings [29,30]. Moreover, polymorphisms at rs660339 may also affect metabolic efficiency in 
terms of energy expenditure [31]. It is noteworthy to mention that this de novo variant has a 
reported minor allele frequency of about 0.5% and that it is a site that mutates recurrently.  
The other de novo sequence variants that we found in Patient 2 (AICDA, Activation-Induced 




coding genes for a RNA-editing deaminase and for a protein of unknown function, respectively.  
The variant rs5796316 in AICDA has been reported in one previous study. Whereas AICDA is 
possibly not implicated in the pathophysiology of obesity, the function of FAM71E2 is unknown to 
date. However, rs4252574 in FAM71E2 is quite common, and the variant A allele is the major 
allele reported at about 70%.  
In Patient 2, we did not find gene variants that would strongly explain the phenotype, as we did 
for Patient 1. However, we identified sequence variants harboured in the DNAAF1 that are possibly 
implicated in the patient’s history of recurrent infections and severe obesity. That gene is 
responsible for encoding a protein that is cilium-specific and is required for the stability of the 
ciliary architecture. DNAFF1 is one of the 21 genes in which mutations are associated with primary 
ciliary dyskinesia (PCD) [32]. It is unlikely that Patient 2 has PCD, given the absence of its clinical 
manifestations (bronchiectasis, defects in body situs and, later in life, infertility). However, it is 
possible that identified DNAAF1 sequence variants are causing a milder form of PCD with 
recurrent airway infections and severe obesity. Ciliary dysfunction has been associated with severe 
early-onset obesity, and currently, it is known that two obesity syndromes are caused by mutations 
in genes regulating ciliary function: Bardet–Biedl syndrome and Alström syndrome [19].  
It has been demonstrated that ciliary dysfunction leads to the development of obesity in  
animal models, due to diverse alterations in central and peripheral pathways regulating energy 
metabolism [18,33–38]. For Patient 2, electron microscopy would be useful in the assessment of the 
effect of the DNAAF1 gene variant on ciliary structure. Furthermore, as we have not confirmed the 
DNAAF1 variant by Sanger sequencing, we cannot confirm that it is in trans in the patient (i.e., each 
parent contributing one of the variants). 
It is unlikely that the other gene variants with potential damaging effect (Table 3) also play a role in  
the pathogenesis of obesity, since they are not related to the regulation of the leptin-melanocortin 
pathway. Particularly, TTN is a large gene, the variants of which are frequently unrelated to 
disease; and OR8U8-OR9G1, the variants of whichmost likely represent artefacts, possibly due to 
alignment problems.  
By performing MetaCore pathway analysis of the genes harbouring functional mutations, we 
observed that six pathways are significantly overrepresented, all of them involving energy or 
ATP/ITP/CTP/UCP metabolism. The importance of UCP2 on energy metabolism was further 
strengthened by the observation that four of these pathways were centred on the UCP2 gene.  
In whole-genome association studies (GWAS), the LRP2 and the DNAAF1 genes were 
previously associated with increased BMI in a British population, without reaching a level of 
significance that is relevant for GWAS [39]. Curiously, a higher significance level for a single 
nucleotide polymorphism (SNP) within the LRP2 gene (p = 8.68 × 10 6) was found in a GWAS of 
patients with anorexia nervosa [40]. Although variants at UCP2 rs660339 have been associated 
with increased BMI in Europeans [41], this finding was not replicated in a recent meta-analysis in 
populations representing four ethnicities [42].  
Whole-exome capture and sequencing can be used with family-based phenotype ascertainment 
strategies (nuclear and extended families) to exploit parent-child transmission and relative-relative 




increase efficiency. In an extreme phenotype study design, individuals who are at both ends of a 
phenotype distribution are selected for sequencing. It is assumed that alleles contributing to the trait 
in individuals who are at both ends of the phenotype distribution are enriched, and sequencing even 
a modest sample size can potentially identify novel candidate alleles. The same consideration is 
also applicable to additional alternatives aimed to identify de novo variants that involve the 
sequencing of parent-offspring trios in which only the offspring is affected. The clinical use of 
whole-exome capture and sequencing is promising, as demonstrated in a recent study that 
evaluated 250 patients with undiagnosed diseases: the success rate in obtaining a genetic diagnosis 
was as high as 25% in that study [12].  
Recently, guidelines for investigating and reporting the causality of sequence variants in human 
disease have been published, to avoid an acceleration of false-positive reports of causality [43]. In our 
study, we comply with those guidelines, but we acknowledge that our findings are not sufficient to 
implicate those gene variants as determinants of the obese phenotype. The significance of our results 
can be limited due to the fact that the number of probands is very small. However, a similar approach 
has already been validated and published by other studies, such as the Finding of Rare Disease Genes 
(FORGE) Canada Consortium [44]. In addition, WES has been applied for the diagnosis of several 
diseases, as observed in many case reports with very small sample sizes [45]. Furthermore, despite 
the fact that our results have not been replicated yet in other obese individuals, they are important to 
raise awareness of the LRP2 gene as a possible candidate as a novel monogenic cause of obesity. In 
addition, our results lack confirmation through functional data, which should be pursued  
in future studies.  
Whole-exome capture and sequencing analysis is a time- and resource-intense endeavour. 
Currently, we employ software that allows rapid selection of any genetic variant according to 
variant type, novelty (via screening public and private databases) and predicted protein effect. 
However, linking these results to phenotypic manifestations in a particular person is currently 
performed by a mixture of manual analysis using a number of additional databases (e.g., Human 
Genome Mutation Database, Online Mendelian Inheritance in Man (OMIM), PubMed and UCSC, 
among others). We built on existing analytic tools in order to rapidly detect and annotate genomic 
variants associated with human disease. We are aware that analytical criteria for filtering need to be 
flexible and up-to-date; therefore, we undertook a systematic upgrade and iterative processes of 
database evaluation by considering each filter. 
In conclusion, by employing a novel and unique strategy for whole-exome capture and 
sequencing analysis of two trios comprised of patients with severe early-onset obesity, we have 
identified sequence variants in the LRP2 and in the UCP2 genes that might explain the phenotype 
of a patient with severe early-onset obesity, central hypothyroidism, hypogonadotropic hypogonadism, 
growth hormone deficiency and idiopathic hyperprolactinaemia. In addition, we identified a 
sequence variant in the DNAAF1 gene that might be implicated in the development of severe 
obesity associated with ciliary dysfunction. Whereas de novo variants in the UCP2 gene have 
already been associated with obesity, the role of LRP2 and DNAAF1 sequence variants in human 
obesity needs to be further investigated by functional studies, and the frequency and distribution of 
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Open Access Data Sharing in Genomic Research 
Stacey Pereira, Richard A. Gibbs and Amy L. McGuire 
Abstract: The current emphasis on broad sharing of human genomic data generated in research in 
order to maximize utility and public benefit is a significant legacy of the Human Genome Project. 
Concerns about privacy and discrimination have led to policy responses that restrict access to 
genomic data as the means for protecting research participants. Our research and experience show, 
however, that a considerable number of research participants agree to open access sharing of their 
genomic data when given the choice. General policies that limit access to all genomic data fail to 
respect the autonomy of these participants and, at the same time, unnecessarily limit the utility of 
the data. We advocate instead a more balanced approach that allows for individual choice and 
encourages informed decision making, while protecting against the misuse of genomic data through 
enhanced legislation. 
Reprinted from Genes. Cite as: Pereira, S.; Gibbs, R.A.; McGuire, A.L. Open Access Data Sharing 
in Genomic Research. Genes 2014, 5, 739-747. 
1. Introduction 
Last year marked the 10th anniversary of the completion of the Human Genome Project  
(HGP) [1]. One of the many accomplishments of the HGP was the broad sharing of data generated 
by genomic research studies in order to maximize the utility of the data and the public benefit of 
such projects [2]. This helped to create a culture of openness in genomic research that was codified 
in a joint policy from the National Human Genome Research Institute (NHGRI) and the 
Department of Energy (DOE) in 1991 [3] that called for the rapid public release of data generated 
by the HGP and subsequent projects. Additional policies in the following years, both domestic and 
international, reaffirmed and expanded these recommendations for publicly sharing large-scale 
DNA sequence data [4–7]. 
Initially, the means for protecting participants’ privacy when these data were shared in open 
access (publicly accessible) databases rested upon the “de-identification” of the data by stripping 
them of all recognizable annotation before sharing. DNA has a very high information content, 
however, and in 2004, Lin et al. showed that it is possible to identify single individuals with as few 
as 30–80 single nucleotide polymorphisms (SNPs) [8,9], prompting new privacy concerns. In 2006, 
the U.S. National Institutes of Health (NIH) established the Database of Genotypes and Phenotypes 
(dbGaP) [10], which is a controlled access database, meaning that individual level genetic data are 
accessible only with approval from a Data Access Committee. The current NIH data sharing policy 
requires researchers to obtain approval from their institution before sharing genomic data in 
dbGaP, and provides guidance to institutions on how to review studies to ensure compliance with 
the policy, particularly with regard to the adequacy of informed consent documents. 
In 2008, Homer et al. revealed further complications by showing that it was possible to uniquely 
identify individuals in aggregated data sets [11]. This led to the implementation of additional 
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protections by restricting access to some aggregated data elements in dbGaP and other databases 
internationally [12]. Further, in early 2013, Gymrek et al. demonstrated that it was possible to 
identify individuals in the open access database of the 1000 Genomes Project by analysis of  
Y-chromosome short tandem repeats. They compared these data to genetic information available 
on a recreational genealogy website, and then used that information to link to additional publicly 
accessible data, such as obituaries and the National Institute of General Medical Sciences (NIGMS) 
Human Genetic Cell Repository, which banks samples from one of the same populations that took 
part in the 1000 Genomes Project [13]. This paper was the first to show unequivocally that 
individuals could be uniquely identified without first obtaining a reference sample. In response, the 
NIH worked with the NIGMS to move age information, which was previously publicly accessible, 
into the controlled-access part of the database [14]. 
Each successive policy decision to further restrict access to genomic data has received some 
pushback, with critics arguing that each was an overreaction and would unnecessarily impede 
science [12]. Nonetheless, limiting access to increasing amounts of data continues to be the 
primary policy response to mounting privacy concerns. Arguments against restricted access and for 
more open data sharing policies must balance the social and scientific benefits of unrestricted 
access to and use of data, with adequate protection of the rights and interests of individuals who 
contribute biological specimens and information to research. The almost exclusive focus on 
restricting access to genomic data as a matter of policy, however, impedes research and fails to 
respect the autonomy of those who choose to share their information openly. It has been observed 
that data in controlled access databases are used less frequently than data in open access databases, 
and as Rodriguez et al. [14] remind us, researchers and other custodians have an ethical 
responsibility not only to minimize the risk of harm to participants, but also to maximize the utility 
of generated data. These considerations have led some groups to advocate for a more balanced 
approach that expands options for open access genomic data release [15,16]. Providing research 
participants the opportunity to allow their data to be shared more broadly is consistent with the principle 
of respect for autonomy [9], and as we show below, at least among certain populations, there are a 
considerable number of “information altruists” [17] who would agree, if given the choice. 
2. Participant Perspective 
Although studies suggest that there is significant public concern about genetic privacy [18,19], 
in at least one study, the majority (60%) of more than 4600 U.S. adults surveyed reported 
willingness to participate in genomic research [20]. Likewise, we have found that a substantial 
number of research participants are even willing to consent to open access release of their genomic 
data. In a randomized trial of consent with 323 genomic research participants, the majority (84%) 
agreed to open access data release. Even after being debriefed, educated about all of the consent 
options, including the option to consent only to the release of data into controlled access databases 
like dbGaP, or not at all, and surveyed about their perspectives and concerns, the majority (53%) 
chose to allow their data to be shared in open access databases [21]. 
We found a similar response from participants in the Texas Cancer Research Biobank (TCRB), 
which aimed to establish a fully functional open access database incorporating cancer genomes and 
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other participant data. Controlled access data release was a condition of participation in the TCRB, 
but the informed consent process allowed participants to opt in to broader sharing of their genomic 
information via open access data release. Of the 194 participants who were offered this choice,  
122 (63%) agreed to open access data release. 
These studies present an encouraging picture of research participants’ altruistic motivations and 
lend support to the argument that restrictive data sharing policies fail to respect autonomy of 
participants who would choose to make their data more broadly available. However, they also raise 
two major challenges that deserve careful consideration: (1) genomic data sharing is a complex 
concept that can be difficult for participants to understand; and (2) there is a diversity of 
perspectives about open access data sharing and certain groups may be less willing to share their 
data publicly. 
2.1. Participant Understanding 
Autonomous decision-making requires adequate understanding of the options presented. Yet, 
ensuring adequate understanding is a challenge in all research involving human subjects. Studies 
suggest that research participants generally have difficulty understanding and remembering basic 
information described in research-informed consent documents (e.g., the purpose and risks of the 
research, as well as general concepts related to study design, like randomization) [22,23]. Genomic 
research and data sharing are complex concepts, so it is not surprising that participants also  
have difficulty understanding the differences between data sharing options. For example, in the 
randomized trial of consent mentioned above, a majority (54%) of participants who were surveyed 
either could not initially recall with whom they had agreed to share their data or did not understand 
that by agreeing to open access data sharing it meant that their data could be accessed and used by 
anyone on the internet without restriction [24]. One possible solution is to try to improve 
understanding with targeted educational interventions, such as brochures or videos. However, studies 
have shown that efforts to improve understanding have had only limited success, with the most 
effective intervention being on-on-one education [25,26]. 
Another approach to ensure participant awareness is to only release data into open access 
databases when participants can directly exhibit adequate understanding. For example, the Personal 
Genome Project, which aims to create a publicly available database of genomic and health 
information with no expectations of privacy, requires participants to correctly answer all questions 
in an enrollment examination prior to being allowed to participate, although they may retake the 
examination multiple times [27]. Similarly, in the TCRB, mentioned above, a subset (n = 37) of 
participants who had agreed to open access data sharing took part in an education session that 
described the difference between controlled and open access data release and the risks and benefits 
of each in a question and answer format with visual aids as appropriate. After completing the 
education session, participants were asked to take a survey, one aim of which was to assess 
understanding. We found that 73% of survey participants demonstrated adequate understanding, 
which we defined as (1) knowing that they agreed to open access data sharing; (2) knowing who 
could access data in an open access database; and (3) understanding the risk of discrimination 
associated with open access data sharing. Only data from those who had demonstrated adequate 
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understanding were eligible for open access data release. We also assessed participants’ risk 
tolerance and decisional conflict. Fifty-four percent of participants reported high risk tolerance, 
meaning that they (1) were comfortable sharing their genetic and health information with the 
general public; and (2) would still participate even if they knew someone would identify their 
genetic data. Using an adapted version of the decisional conflict scale [28], we found that 68% 
demonstrated low decisional conflict, meaning that they answered all six questions in a manner 
indicating that they had low decision uncertainty, no pressure from others, and high perceived 
effective decision making. Fourteen participants (38%) changed their consent and refused open 
access data sharing at the completion of the education session. Of the 23 participants (62%) who 
still agreed to open access data release, 19 had adequate understanding and were therefore eligible 
for participation. Data from those with high risk tolerance and low decisional conflict were 
prioritized for public release. 
There is considerable debate elsewhere concerning the definition of adequate understanding in 
research and how best to measure it [29]. Some have focused on developing educational 
interventions, such as those mentioned above, while others have proposed simplified consent 
documents as a way to improve understanding [30]. In the PGP and the TCRB, extensive measures 
were taken to assess understanding and to release data only from those who met a predefined 
threshold of comprehension. This is time consuming and resource intensive and may not be 
feasible in all genomic studies. Additional research is needed to identify methods of measuring and 
improving understanding that are not only effective, but are also efficient, especially in the context 
of genomic research involving open access data sharing. This is particularly important because 
participants’ right to withdraw from the research is necessarily limited by the inability to retrieve 
data that has been shared publicly. As these studies suggest, however, there is a subset of 
participants who understand the implications of open access data release and voluntarily agree to it. 
2.2. Diverse Viewpoints 
It is important to note that the participants in both the randomized trial of consent and the TCRB 
were primarily quite ill (sometimes with terminal disease), very trusting of their physicians, and 
highly motivated to participate in research. Even among this group, however, there was diversity of 
perspectives about open access data sharing. In the randomized trial of consent, for example, 
Hispanic, unmarried, and more educated participants were all less likely to choose public data 
release, as were parents who were making decisions about the release of their child’s data [21]. 
Other populations may exhibit even more variation in their perspectives on data sharing. For 
example, Lemke et al. [31] explored public and biobank participants’ attitudes toward genomic 
research and data sharing via focus groups. While different levels of data sharing (i.e., open versus 
controlled access) were not specifically examined in those studies, the investigators found more 
generally that there was wide variation in views on genomic data sharing, with some study 
participants more comfortable than others. Similarly, Trinidad et al. [32] conducted focus groups 
with research participants, surrogate decision-makers, and members of a health maintenance 
organization to investigate perspectives toward data sharing. They also found that perspectives 
varied, although they report that study participants were generally supportive of genomic data 
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sharing for scientific benefit. In a commentary on conducting research with tribal communities in 
the U.S., Harding et al. [33] argue that special considerations that take into account the 
populations’ perspectives are important when developing data sharing agreements with Native 
American tribes. 
Our focus in this paper is data sharing in the context of the United States. Research participants 
in other parts of the world may feel differently about their genomic data and whether or not it 
should be shared for research purposes [34]. Thus, although generally reported as positive, 
participant perspectives on data sharing vary between populations, as well as among individuals, 
based on context, clinical circumstances, and personal values and beliefs. 
3. Toward a More Balanced Approach 
The variation in individual and group preferences for and understanding about genomic data 
sharing suggests that both mandatory public data release, as well as blanket restriction of access to 
genomic research data as a matter of policy, are misguided. Regulatory bodies in general tend to 
address this “heterogeneity problem” by taking the most restrictive and risk averse approach [35], 
which, in this case, inhibits choice by prohibiting the broader release of data from those who 
understand and are comfortable with open access sharing. It also reportedly impedes research [14], 
although studies quantifying the added benefit of open access versus controlled access data sharing 
are required. We advocate instead for a more balanced approach that allows for individual choice, 
but provides protection to participants by supporting adequate understanding as part of the 
informed consent process, and by strengthening accountability and protections against the misuse 
of available data. 
Recent accounts demonstrate that some sophisticated patients are exercising their autonomy by 
sharing data themselves using existing platforms, such as social media, in order to facilitate 
discovery for rare and serious diseases [36]. If people are to share their own data, it is important 
that they are aware of the risk of identifiability and understand the challenge of obscuring segments 
of data in the context of public release [37]. For those whose data are shared within the research 
context, novel approaches have been suggested to give participants more control over decisions 
about who can access their data, as well as the ability to continue to manage such choices. For 
example, a relatively new platform called Reg4All [38] facilitates the sharing of health information 
in order to find relevant clinical trials, but also gives its users the ability to make finely-tuned 
choices about who can access their information or contact them. Others have introduced new 
approaches to consent that allow participants to be more nuanced in their choices, as well as change 
those choices over time [39], though, arguably, once data are released in an open access manner, 
there is no way to guarantee their removal from the public domain. 
Increased participant engagement and open access data sharing could both be accomplished with 
modifications to the existing dbGaP model. As it is currently designed, all individual level genomic 
data in dbGaP is accessible only via controlled access [10]. The NIH could support more broad 
sharing by creating a publicly accessible segment of dbGaP that includes data from those who 
agree to open access data release. Participants could also be provided the option for open access 
data sharing in the informed consent document when agreeing to participate in NIH-funded 
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genomic research. If a participant changes her consent over time, a request could be made to dbGaP 
to move the relevant data from the open access portion of the database to controlled access. 
Regardless of mechanism, if genomic data are made publicly available, then the individuals 
from whom those data originate ought to be protected against the misuse of that information. One 
way of providing some protection for these participants could be the use of “click-through” data 
use agreements. In this model, the person accessing the data would have to read and agree to a list 
of conditions of use of the data, including agreeing to not attempt to identify the individuals from 
whom the data came. However, while this may require those accessing the data to recognize that 
attempting identification would be a violation of the use of the data, such click-through data use 
agreements are not enforceable, and as such, may not provide adequate protection. 
There are existing laws in the United States that provide protection against misuse of genetic 
information. The vast majority of states have laws that govern the use of genetic information in 
health insurance and employment [40]. Likewise, the Genetic Information Nondiscrimination Act 
(GINA) [41], in effect as of 2009, makes it illegal for health insurers and employers with 15 or 
more employees to discriminate against people based on their genetic information. GINA has both 
corrective and monetary penalties that vary based on the intention and severity of the infraction. 
However, it does not protect against genetic discrimination in other types of insurance, such as 
long-term, disability, and life insurance, or any other realm outside of health insurance and 
employment. Additionally, some report not feeling fully protected by GINA, leading some to 
decline acceptance of DNA sequencing in both clinical and research-related contexts for fear of 
discrimination [42]. In contrast, the Human Tissue Act of the Parliament of the United  
Kingdom [43], which regulates activities with human bodies and tissues and also provides 
protection against the use of DNA without consent, is not limited to such contexts, and carries 
criminal penalties for violations that range from a fine to up to three years in prison. Though 
criminal law may not be the best approach to discourage the misuse of genetic data in the U.S., 
stricter penalties and broader protections against misuse of data by any third party may be needed 
to protect individuals who agree to share their data broadly for the public’s benefit. 
4. Conclusions 
In the context of research, investigators have a professional obligation to be good stewards of 
the data with which research participants have entrusted them. In order to fulfill this obligation, we 
need policies that respect participant autonomy and maximize the utility of the data, alongside 
strengthened legislation that protects those participants from the misuse of their genomic 
information. The field has made great progress in the 10 years since the completion of the Human 
Genome Project. We must find ways to protect participants, yet avoid unneeded hindrances of 
researchers’ access to genomic information. 
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A Balanced Look at the Implications of Genomic (and Other 
“Omics”) Testing for Disease Diagnosis and Clinical Care 
Scott D. Boyd, Stephen J. Galli, Iris Schrijver, James L. Zehnder, Euan A. Ashley and  
Jason D. Merker 
Abstract: The tremendous increase in DNA sequencing capacity arising from the 
commercialization of “next generation” instruments has opened the door to innumerable routes of 
investigation in basic and translational medical science. It enables very large data sets to be 
gathered, whose interpretation and conversion into useful knowledge is only beginning. A 
challenge for modern healthcare systems and academic medical centers is to apply these new 
methods for the diagnosis of disease and the management of patient care without unnecessary 
delay, but also with appropriate evaluation of the quality of data and interpretation, as well as the 
clinical value of the insights gained. Most critically, the standards applied for evaluating these new 
laboratory data and ensuring that the results and their significance are clearly communicated to 
patients and their caregivers should be at least as rigorous as those applied to other kinds of 
medical tests. Here, we present an overview of conceptual and practical issues to be considered in 
planning for the integration of genomic methods or, in principle, any other type of “omics” testing 
into clinical care. 
Reprinted from Genes. Cite as: Boyd, S.D.; Galli, S.J.; Schrijver, I.; Zehnder, J.L.; Ashley, E.A.; 
Merker, J.D. A Balanced Look at the Implications of Genomic (and Other “Omics”) Testing for 
Disease Diagnosis and Clinical Care. Genes 2014, 5, 748-766. 
1. Introduction 
Improvements in DNA sequencing technology in the past decade represent one of the most 
significant technological achievements in recent history, with far-reaching implications for 
medicine and society. Most human diseases have at least some genetic factors that contribute to 
their incidence, or course, either related to the germline genome inherited from an individual’s 
parents or the somatic genetic changes that can lead to the development of malignancies. The 
ability to read the DNA from an individual’s cells with next generation sequencing (NGS) should 
therefore offer insights relevant for medical care. However, there is a significant gap between our 
current ability to acquire sequence data and the ultimate goal of extracting all of the useful medical 
genetic knowledge from the sequences. In particular, societal expectations and ethical 
considerations require that any correlations between DNA sequences and predictions of disease 
risk, prognosis or optimal treatment choice should be held to higher standards of evidence than 
those that are typically applied in the peer review process for publication of a research article. In 
this overview, we initially highlight areas of recent progress and promise in clinical genomic 
testing (including whole genome sequence analysis, as well as analysis of selected fractions of the 
genome, such as the protein coding exome, or large panels of genes of clinical interest) and discuss 




framework governing such tests in the United States. The potential benefits of clinical genomic 
testing are tremendous, but devising appropriate systems for quality assurance, data sharing and 
validation, incorporation into clinical trials and cost-benefit analysis of this new diagnostic area 
will be an ongoing effort in the coming years. 
2. The Promise of Genomic Methods 
In the past decade, the quantity of DNA sequencing that can be performed per dollar spent has 
increased by several orders of magnitude, as a result of technological innovations enabling highly 
parallelized simultaneous sequencing of millions of spatially-separated template molecules, with 
optical or electronic readout of the sequencing reaction as it occurs [1,2]. With the latest generation 
of sequencing instruments, the cost for a whole human genome sequence with 30× coverage may 
approach $1,000 [3]. Although such estimates notably exclude the costs of interpreting the data, it 
is clear that genome sequencing is now within the range of costs for many other diagnostic 
methods, such as radiologic imaging studies or full evaluation of tissue biopsies by anatomic 
pathologists. As a result of painstaking earlier studies of the genetics of inherited diseases and the 
genetic changes that are found in cancer cells, there are already many known gene mutations whose 
significance in relation to particular diseases is described. For many of the most well-established 
variants, there are single-gene diagnostic sequencing tests already available, either from private 
companies or specialized, typically academic, diagnostic laboratories. The CDC estimates that 
genetic tests for use in the clinical setting have been developed for approximately 2,000 diseases [4]. 
The critical difference between current genome sequencing capabilities and these earlier test 
methods is that a significantly greater amount of data (whether genome, exome or gene panels) 
now can be gathered as readily and easily as the sequence from a single gene. Many medical 
centers and companies are hurrying to stake claims as the preferred destination for testing and 
interpretation of genomic sequence data for clinical purposes, as this methodology has begun to be 
adopted and standardized.  
Already, there are multiple published medical success stories using these methods. Sequencing 
of genomes or exomes (which includes the protein coding portions of the genome) for the diagnosis 
of patients with heritable syndromic disorders has resulted in a number of exciting case reports and 
studies of patients in whom likely causative mutations have been discovered, and in some cases, 
such findings have guided successful clinical treatment decisions [5–7]. Systematic efforts in the NIH 
Undiagnosed Diseases Program to apply genomic methods to arrive at diagnoses for patients with 
unusual or mysterious clinical presentations, particularly for cases where family history suggests a 
possible genetic cause, have also yielded new causative mutations and discoveries in human  
biology [8]. Likewise, clinical laboratories have used exome sequencing since 2011 to evaluate 
patients with suspected genetic disorders and have identified a molecular diagnostic yield of 
approximately 25% [9]. 
Sequencing of cancer genomes has revealed many new recurrent mutations that may  
contribute to the development of particular cancers, and has revealed new candidates for targeted 
therapies [10]. These new molecular insights into cancer are already beginning to influence the 
ways that cancers are classified and treated [11]. Similarly, sequencing of fetal DNA from the 
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plasma of a pregnant woman to screen for trisomies 18 and 21 demonstrates improved performance 
relative to prior aneuploidy screening methods [12]. Studies of viruses, bacteria and other microbes 
via sequencing of their small genomes is revolutionizing epidemiological tracking of infectious 
diseases and the rapid detection of new and emerging pathogens [13]. The most challenging area of 
all, predicting the risks of diseases in healthy human beings, has also show promise in particular 
disease categories, such as prediction of cancer risk in women having germline mutations in the 
BRCA1 or BRCA2 genes. More broadly, it is likely that only a fraction of potential  
disease-associated variants have been identified at present, and the cooperative or competitive 
relationships between the effects of different sequence variants are only beginning to be  
described [14]. Many common diseases (e.g., diabetes, schizophrenia and autism) do not appear to 
be the result of simple sequence alterations that could be easily diagnosed by DNA sequencing. In 
these diseases, there are many genes associated with increased risk, but the conditions may be 
caused by combinations of these genes acting together in association with environmental factors. In 
addition, while it is now possible to identify numerous variants in cancer genomes, the biological 
significance of many variants is unknown, and their annotation is not standardized. The number of 
clinically actionable variants, at present, is small. 
However, even given the above limitations, these advances herald the increasing importance that 
genome sequencing and related methods are likely to play in the diagnosis and management of 
diseases across all medical specialties. We are currently in a transition period in which methods 
initially applied in research settings and limited small clinical studies need to be adapted for 
application to large numbers of patients. With that transition comes a requirement for increased 
standardization, reliability and monitoring of experimental steps, as well as agreed-upon  
standards for data analysis, storage, clinical interpretation and communication with patients and/or 
their guardians. 
3. Research Experiments, Clinical Testing and Genomic Testing 
3.1. Research Assays and Methods 
The experimental methods used in medical testing typically originate in research laboratories in 
universities, government or private research institutes or corporations. However, there is a 
substantial difference between the assay performance characteristics needed for use in the 
published scientific literature, compared to those used for clinical diagnosis and guiding the 
treatment of patients. Authors using a new experimental method as part of a published  
peer-reviewed research study must convince the scientific reviewers selected by the journal that the 
assay is a valid method of measurement and has been appropriately applied to the research topic in 
question, but often, reviewers are not experts in all aspects of the experimental methodology and 
data analysis approaches used. The expectation in a research setting is that efforts by other 
researchers to replicate the results in question and to use the methods described will eventually test 
the reported results and reveal any limitations or errors. This approach has been the basis for 
essentially all scientific advances, despite the fact that very few published papers are entirely free from 




Recent studies have highlighted common problems with experimental design and statistical 
analysis that contribute disproportionately to preventable errors in the scientific literature, 
especially in attempting to identify genetic contributions to diseases [16,17]. These include choices 
in experimental design that can introduce biases favoring the discovery of apparently significant 
effects, even in randomized trials, where patient selection, problems with randomization, lack of 
blinded data analysis and changes in the plan for data analysis once a trial is underway can all have 
an impact. In case-control or retrospective studies, the potential for mistaken conclusions is even 
greater. Studies using large data sets are particularly vulnerable to errors from over-fitting a model to 
the data or insufficiently accounting for multiple hypothesis testing, especially if independent 
validation data sets are not used to test the robustness of initial conclusions. Other well-known 
factors that can distort the scientific literature are publication biases in favor of positive results and 
the competitive social and economic factors that disproportionately reward scientists publishing 
papers reporting apparently highly novel findings in prominent journals, while imposing minimal 
penalties for prior publications later found to be partly or completely in error. 
Several suggested improvements to the research methodology have been proposed, including 
advance registration of a wider range of clinical studies, better documentation of experimental 
protocols, results and data analysis approaches, more consistent involvement of statisticians and 
other experts in study design and analysis, full transparency and availability of experimental data 
and computer scripts used in data analysis and greater attention paid to research reproducibility in 
the professional evaluation of scientists [16]. In practice, an excessively regulated research 
environment would probably serve to stifle and limit some of the creative and perhaps poorly 
planned, but ultimately serendipitous efforts in science that can lead to unexpected insights, so a 
compromise between higher standards for clinical trial research and continued freedom of inquiry 
(subject to ethical and safety review by institutional review boards) in more exploratory areas of 
medical science would probably best serve the public and the ultimate goals of funding providers.  
3.2. Clinical Tests 
Clinical laboratory testing in the United States is regulated and subjected to greater 
methodological scrutiny than basic or clinical research. All clinical laboratory testing done for 
purposes of patient care (as opposed to research) must be performed in a CLIA (Clinical Laboratory 
Improvement Amendments of 1988)-certified laboratory. CLIA established key laboratory quality 
standards to ensure that test performance consistently meets patient care needs. CLIA certification 
may be achieved through the Centers for Medicare and Medicaid Services (CMS), which 
administers CLIA laboratory certification, or through CMS-approved accrediting organizations 
(e.g., the College of American Pathologists (CAP), or The Joint Commission). CLIA requirements 
are stratified according to the complexity of testing performed, with genomic testing generally 
falling into the highest level of complexity. Such high-complexity testing laboratories must meet 
specified quality standards, including those related to personnel qualifications and responsibilities, 
proficiency testing, facilities, general laboratory systems and quality management, as well as 
preanalytic, analytic and postanalytic systems. (CLIA Brochure, ICN #006270, May 2013). 
Laboratory compliance with CLIA regulations is evaluated by biennial on-site inspections. 
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Depending on the nature of the tests performed, additional requirements may need to be satisfied 
for such laboratories, including those of the AABB (formerly, the American Association of Blood 
Banks) (Bethesda, MD, USA), FDA (U.S. Food and Drug Administration, Silver Spring, MD, 
USA), ASHI (the American Society for Histocompatibility and Immunogenetics, Mt. Laurel,  
NJ, USA), FAA (Federal Aviation Administration, Washington, DC, USA) and state agencies.  
High-complexity testing must be done by or subject to the oversight of laboratory professionals 
with an advanced degree and with appropriate credentials in laboratory medicine.  
New types of laboratory tests, including most genomic tests, are not available in the form of 
FDA approved/cleared test kits, but rather are typically created within academic or commercial 
clinical laboratories as laboratory-developed tests (LDTs). Such development follows a strictly 
prescribed process of test validation prior to clinical implementation, which is when the test 
becomes orderable [18,19]. Recently, one high-throughput sequencing instrument and reagent kit 
system has received FDA clearance for use in clinical testing. In a recent position statement, the 
Association for Molecular Pathology (AMP) has introduced the term, laboratory-developed 
procedure, which is defined as “a professional service that encompasses and integrates the design, 
development, validation, verification, and quality systems used in laboratory testing and interpretative 
reporting in the context of clinical care” and which much more accurately reflects the highly 
complex nature of molecular laboratory testing, as well as the central contribution of highly trained 
and qualified laboratory professionals to the patient care process. AMP also concluded that CMS 
can ensure the effective oversight and validation of most molecular genetic laboratory tests [20]. 
3.3. Genomic Testing 
The nature of genomic testing, in which large data sets of DNA sequences can be conveniently 
gathered, but where only a fraction of the overall data can be interpreted at present, places these 
data sets at the interface between research and conventional clinical testing. Interpretation of 
genome sequence data is not unique in requiring sophisticated understanding, both of the methods 
used to gather the data, and the medical literature and body of prior investigation, to arrive at 
accurate conclusions. For example, histologic diagnosis of cancers in modern pathology practice 
depends on years of training in recognizing the visual characteristics of aberrant cell populations in 
tissue sections and selecting appropriate confirmatory tests. The history of revised and improved 
tumor classification systems in modern oncology reflects the increased understanding gained over 
decades by studying tumors with new experimental methods, revisiting prior data and correlating 
the features of each cancer with its response to treatment. Genomic sequence data are vast and 
complex in other ways, in that the data are generated as lists of nucleotide identities that require 
computational tools and comparison to sequences in reference databases for analysis, before the 
clinical significance of sequence variants can begin to be assessed.  
Despite amazing progress in the past decade, the technologies and analytical approaches for 
sequencing and interpreting genomes still have significant blind spots, such as the greater difficulty 
of detecting structural variants including insertions, deletions, inversions, and trinucleotide repeat 
expansions, compared to single nucleotide variants in sequences [21]. Reference databases of 




sequences derived from pseudogenes similar to the gene in question. It is likely to take many years 
to resolve such ambiguities or errors in prior gene sequencing work and to ensure that all sequence 
variants can be correctly annotated for medical applications. Judging from earlier work in human 
genetics, the interpretation of each patient’s genome sequence will require a personalized approach 
that takes into account the population group from which that person is derived. Even for the most 
extensively studied genes, such as the cystic fibrosis transmembrane conductance regulator 
(CFTR), the databases of mutations and their significance are quite limited, because functional 
studies have not been performed for most mutations and because mutations in population  
groups that have not been studied as extensively as European-derived groups are not well 
characterized [22]. 
In the near future, we should not necessarily expect that any given patient’s genome sequence, 
particularly if they are currently healthy, will reveal sequence features requiring any sort of 
response or clinical guidance beyond those that would already be provided by a physician in a 
routine checkup, such as advice about healthy diet, exercise, vaccinations and safety topics. A 
recent study of the potential and current limitations of whole genome sequence interpretation for 
clinical use in 12 healthy individuals highlighted the relatively small effects associated with most 
known disease-associated sequence variants, but also revealed that each individual had at least one 
gene variant from the Clinical Pharmacogenomics Implementation Consortium list of variants that 
can affect responses to drug therapies [14]. In addition, two of the 12 subjects studied received 
actionable information that could affect their future health, including one subject who underwent 
prophylactic surgery. Other studies have underlined the relatively small effect sizes of genetic 
variants for the most common and serious diseases, such as cardiovascular disease, but rare and 
highly deleterious variants can also be identified, such as those causing familial hypercholesterolemia, 
which would warrant immediate medical intervention, such as statin therapy [23,24]. Recently, 
standards of evidence for concluding that gene variants are associated with diseases have been 
proposed, taking into account the large amount of data gathered in genome or exome studies and 
the potential for false discoveries associated with such large numbers of observations of a sample; 
for example, in exome studies, p = 5 × 10 7 has been suggested as one threshold for claiming 
significance [25,26]. 
4. Quality Assurance in the Genome Sequencing Era 
Molecular diagnostic laboratories have provided innovative testing since the emergence of 
diagnostic methods applied to DNA or RNA molecules several decades ago. Clinical molecular 
laboratories are experienced in validating new methods for single gene testing and data analysis. In 
one sense, genomic testing is “just another” such innovation. However, it could be argued that the 
scale of data now obtainable represents a challenge for analysis that is not merely incremental, but is 
qualitatively different, as human beings cannot manually go through the sequences and interpret 
them visually in a practical amount of time. Instead, computational methods and bioinformatics 
tools are required to help carry out the analysis. This represents a significant break with prior 
traditions of medical training in all specialties, where, with rare exceptions, computer science and 
bioinformatics were not learned by the generations of physicians who are currently in practice and 
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in positions of authority. Physicians currently in training, particularly in laboratory medicine, now 
have the opportunity to learn and help to develop these new methods before they enter practice, and 
currently practicing physicians must at least learn how the results of genomic testing should be 
applied in their patient care decisions [27,28]. In spite of these challenges, the fundamental features 
required for reliable clinical laboratory tests based on genome sequencing are the same as those for 
other kinds of tests and are, in our view, compatible with current regulatory frameworks for 
ensuring the quality of medical laboratory testing. Some of the most critical initiatives underway in 
this area are as follows: 
(a) Guidelines for Clinical NGS Implementation 
 Initial laboratory guidelines for clinical diagnostic NGS testing have been established and 
published by several laboratory professional organizations. These include initiatives by 
professional organizations, such as the Association for Molecular Pathology (AMP) [29] and 
the American College of Medical Genetics and Genomics (ACMG) [30,31], as well as 
those by entities, such as the Clinical Laboratory Standards Institute (CLSI) and the 
Division of Laboratory Science and Standards at the Centers for Disease Control  
(CDC) [32]. These efforts are expected eventually to result in consistent recommendations for 
the clinical validation process of NGS testing, as well as for performance metrics and 
genomic reference materials for clinical use.  
(b) Checks and Balances: The College of American Pathologists Checklist for NGS Testing 
 The College of American Pathologists (CAP), a CMS-approved accrediting organization, 
has recently developed a new set of checklist requirements that are specific to NGS, which 
advances greater standardization in clinical NGS testing. CAP checklists are available to 
subscribing laboratories and cover key aspects of laboratory function: policies, procedures 
and pre-analytical, analytical and post-analytical aspects of clinical testing. There is a 
customized checklist for every section of a clinical laboratory, as well as a general checklist 
that applies to all sections. During a laboratory inspection, CAP inspectors use these 
checklists in their evaluation process, to assess whether laboratories follow regulations and 
practice guidelines and operate at a quality level that is worthy of CAP accreditation and 
CLIA certification. The NGS section of the molecular checklist contains a set of 
requirements for both the analytical wet bench processes, as well as for the various  
bio-informatics steps required for data analysis and annotation. Even though these 
requirements are not rigidly prescriptive, they highlight key points that must be considered 
when documenting the reliability and usefulness of clinical NGS testing methods. Many 
medical centers are within the second year or third of carrying out such testing and 
therefore have undergone inspection of their genomic or next-generation DNA sequencing 
assays by CAP or other groups that carry out inspections of CLIA-certified laboratories. 
Feedback from inspectors and participant laboratories will be very useful for identifying the 
areas in which checklists need to be revised or made more detailed, explicit or prescriptive, 
as well as for highlighting the more difficult or uncertain areas in genome sequence data 




in this new area and the knowledge and qualifications of the inspectors selected for this task 
will also be warranted as part of the laboratory medicine profession’s due diligence in 
incorporating these new testing methods into mainstream clinical testing. 
(c) Assay Validation Requirements  
 The assay validation conducted before a test is offered clinically documents that a test is 
consistently and accurately detecting what it claims to be able to identify. CLIA regulations 
(Code of Federal Regulations § 493.1253 (b) (2)) stipulate that certain core analytical 
characteristics must be assessed and documented. These include accuracy, precision, 
analytical sensitivity, analytical specificity, reportable range, reference intervals (normal 
values) and any other performance characteristic required for test performance (e.g., carryover, 
dilutions and calculations). The same parameters should be applied to NGS testing, which 
ranges in scope from single genes or mutation panels to genome sequencing. Limitations of 
sequence library generation and interpretation, including poorer quality analysis of 
repetitive sequence regions, less reliable detection or inability to detect certain categories of 
variation (e.g., insertions, deletions, and other structural variants), inadequately covered 
regions and similar problems should be reflected and noted in descriptions of the testing 
method. During the validation process, every single step of NGS must be evaluated, 
including sample library preparation, clonal fragment amplification, sequencing and all steps 
of the analysis. 
 A key need for NGS assay development and validation is the availability of well-
characterized “gold-standard” reference materials. Fortunately, there are several public efforts 
and commercial products that are beginning to meet this need. As an example, the National 
Institute of Standards and Technology (NIST), with the Genome in a Bottle Consortium, 
has developed well-characterized single genome reference material for SNVs and small 
insertions and deletions [33]. Continued support of these and related efforts are needed to 
generate additional reference genomes and other reference materials for additional 
applications (e.g., somatic variants). 
(d) Interpretation and Reporting of NGS Results 
 The ACMG has previously published recommendations for the interpretation and reporting 
of sequence variations for heritable disease, and updates to these recommendations that 
include interpretation and reporting of NGS-derived sequence changes are expected to be 
released soon [34]. Additional recommendations will likely be required for other 
applications (e.g., somatic mutation testing in cancer, pharmacogenetic variation). Despite 
the advances in sequencing technology, many of the key principles of interpretation still 
apply. SNP databases and disease-related collections of sequence variants are immensely 
helpful in variant annotation and interpretation, but there are significant issues that prevent 
them from being reliably used for clinical diagnostic purposes. Many population databases 
contain individuals that have developed or will develop disease, and many of the  
disease-specific databases include benign variants. This underscores the importance of 
centralized efforts to generate clinical-grade variant databases, such as ClinVar [35]. 
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 The final formal interpretation of NGS results, their official posting into the patient’s 
medical record and their translation into clinical care by the physicians responsible for 
doing that requires interdisciplinary collaboration, whereby pathologists, geneticists and 
other laboratory professionals become even more directly involved with others in the 
healthcare team, in order to ensure accurate diagnostic information for individual patients in 
the context of their disease phenotype. 
(e) Proficiency Testing for NGS Assays  
 Apart from the creation of NGS-specific checklist items, the CAP is in the process of 
developing NGS proficiency testing products, which are expected to become available in 
the near future. No other NGS proficiency testing is available in the U.S. from CMS or a  
CMS-approved accrediting organization. However, laboratories are required to participate in 
proficiency testing at least twice per year, and this requirement is currently met by 
alternative assessment. The purpose of such proficiency testing is to be a central quality 
assessment tool that is an integral component of laboratory inspections and regulatory 
requirements. To this end, laboratories commonly perform a blinded proficiency testing 
exchange with other laboratories. 
Assessing the Utility of Genomic Information in Clinical Patient Care 
We anticipate that NGS technologies will continuously improve in their ability to detect 
sequence changes and will increase their overall accuracy and ease of use. The increasing 
capabilities and enhancements to these instruments will facilitate the clinical use of genomic data. 
The information that is returned to the patient, however, reaches further than the technical and 
interpretational aspects alone and includes the perceived and, therefore, subjective value of the 
information. For individual patients, therefore, there is the aspect of personal usefulness (value 
from the patient’s perspective), as well as clinical utility, which constitutes the net health benefits 
or the balance of benefit versus harm. Clinical utility is a complex metric that includes a variety of 
aspects, such as the patient population tested, the clinical manifestations of the finding and the 
rationale for testing. Currently, some clinical questions that are explored with NGS can be 
addressed with considerable confidence, whereas others reach beyond established knowledge. This 
includes an assessment of the pathogenicity of some variants detected by NGS. Full disclosure of 
the level of confidence in the clinical meaning of confirmed results, careful patient selection and 
informed consenting, with a clear understanding of the context in which NGS testing is sought, and 
genetic counseling before and after testing are important quality measures for the clinical use of 
NGS testing. 
5. Physician Education and Training 
It seems certain that the incorporation of genomic methods into clinical patient care will 
significantly change some aspects of the practice of medicine, affecting not only those who are 
performing and interpreting genomic testing, but virtually all healthcare professionals. Efforts to 




microbiomes, etc., into clinical care need to be paralleled by the education of our medical students, 
residents, clinical fellows and faculty to provide a fund of knowledge and an understanding of the 
possibilities, strengths and limitations of these approaches when they are translated from research 
to the bedside. This can be accomplished through core efforts in medical school curriculum design, 
residency and fellowship training programs, as well as in the form of informal and formal 
continuing medical education (CME) for practicing physicians. Virtually every medical specialty 
will need to incorporate genomics aspects, as they pertain to that specialty, into their education. A 
concerted educational effort in medical schools will be critical to ensure the appropriate application 
of genomic testing, and resources are beginning to become available from professional and medical 
specialty organizations (for example, the Training Residents in Genomics Working Group, [36]).  
Recently, several pathology residency programs have introduced curriculum changes to include 
more genomic medicine teaching [27,28,37]. Admittedly, in the face of all the other knowledge that 
residents must acquire in the course of their training, these initial efforts will not produce 
pathologists who are equally expert in bioinformatics, histology and the wide scope of other 
laboratory testing methods, but they do represent a first step toward systematic training in the 
interpretation of large DNA sequence data sets.  
6. Ethical and Privacy Considerations 
Quality of Patient Information and Informed Consent 
Informed consent is the keystone of the ethical treatment of patients in clinical care settings. 
Patients must have the opportunity to learn about the benefits and limitations that may be 
associated with genomic testing and consider whether they wish to proceed with such tests. 
Especially because genomic methods (and other types of “omics” testing) can, in principle, provide 
magnitudes more information than those traditionally derived, the informed consent process can be 
more challenging. The level of that challenge depends on the scope of testing and is very different 
for single gene tests compared to the large net that can be cast with methods that determine the 
entire exome or genome of the patient. In the latter scenario, incidental findings may disclose 
medical or personal issues that the patient was not aware of and that were not part of the reason for 
the current care episode, but that may impact overall health and medical care. The process of 
returning incidental findings, especially when they may have direct medical ramifications, is an 
area of active discussion in the medical genetics community [38,39]. 
The ACMG has issued a policy statement emphasizing the need for informed consent and the 
content of such a process prior to exome or genome sequencing for germline conditions [40]. 
Additional recommendations by the ACMG addressing incidental findings have been released and 
updated [39]. The initial release of these recommendations gave rise to controversy about the 
informed consent process, and these issues are being considered by multiple additional medical 
specialties. Until community consensus is reached, individual institutions need to consider how to 
evaluate and communicate incidental findings of known significance, as well as those genome 
changes that are of, as yet, unknown clinical significance. What is reported, therefore, needs to be 
established upfront and clearly communicated to and meaningfully discussed with the patient or his 
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or her guardian, so that expectations are accurate. An informed consent process includes patient 
education and counseling prior to test ordering, with information addressing the results that will be 
included in the patient’s report, as well as a discussion of the limits of genomic testing and the 
interpretation of sequence variants. In addition, as with any other testing, patients need to be able to 
rely on the privacy and confidentiality of their data.  
7. Guiding Principles for Clinical Genomic and Other “Omic” Testing  
Any medical center or healthcare organization seeking to incorporate genomic or other “omic” 
testing into its system of patient care would be well served by: (1) ensuring that the testing is 
performed in a manner that is fully in accord with relevant legal and regulatory requirements and 
by personnel with the appropriate training and credentials to perform and interpret such testing; and  
(2) involving representatives of medical specialties, researchers in genetics, statisticians, computer 
scientists, bioethicists and hospital administrators in the planning, implementation and integration 
of this new kind of testing into clinical decision-making. Some key principles we recommend for 
consideration are listed in Box 1 and are described below:  
Box 1. Guiding principles for clinical genomic and other “omic” testing:  
(a) Clinical laboratory testing is an integral component of patient care and is held to different 
standards than research testing not used to guide clinical care. 
(b) Clinical genomic testing requires extra effort to be dedicated to designing the informed consent 
and patient education processes.  
(c) Education of physicians and other care-givers about genomic testing methods will be critical for 
appropriate use and maximal patient benefit.  
(d) The use of less-extensively validated genomic testing approaches for clinical care ordinarily 
should progress in a graded manner from use in “innovative care” settings, followed by use in 
clinical research settings, before being added to “standard” clinical laboratory testing.  
(e) Individual and institutional conflicts of interest in clinical genomic testing must be identified  
and managed.  
(f) These guiding principles also apply to efforts to introduce other clinical “omics” testing into 
clinical care (such as transcriptomes, proteomes, metabolomes and microbiomes). 
(g) Clinical genomic and other “omic” data and methodologies should, to the greatest extent 
possible, be shared openly with the wider medical and research communities, to accelerate the 






(a) Clinical Laboratory Testing Is an Integral Component of Patient Care and Is Held to 
Different Standards than Research Testing Not Used to Guide Clinical Care 
 Clinical laboratory testing, regardless of the assay methodology or test complexity, is done 
to guide patient care decisions, including making diagnoses, counseling patients regarding 
their prognosis or their future risk of developing disease, guiding management of the 
patient’s condition and making recommendations about reproductive or life style choices. 
Multidisciplinary committees of clinician specialists and clinical laboratory geneticists, guided 
by recommendations from medical specialty organizations, as well as other sources of 
information, may be best able to decide which new genomic tests or applications are sufficiently 
well-supported by evidence in the scientific literature to be adapted for clinical use.  
 Any implementation of clinical genomic testing must, of course, comply fully with all 
relevant laws and regulations governing laboratory tests and, in the United States of 
America, meet the standards of the professional bodies, such as the College of American 
Pathologists (CAP) and/or ASHI (the American Society for Histocompatibility and 
Immunogenetics) that, together with The Joint Commission, have been deemed the status to 
inspect clinical laboratories on behalf of the Centers for Medicare and Medicaid Services 
(CMS) to ensure that requirements for CLIA certification are met and all medical tests, 
including genomic tests, are being carried out responsibly.  
(b) Clinical Genomic Testing Requires Extra Effort to be Dedicated to Designing the Informed 
Consent and Patient Education Processes 
 Patients must be able to obtain sufficient information about the potential value, future 
implications and limitations of genomic testing so as to be able to give informed consent if 
they choose to “opt-in” to the use of such tests for their care. Patient education about 
genomic test results will help to ensure that any subsequent clinical decision-making is 
carried out as an informed collaborative process between the patient and their physician. In 
many cases, this may require additional time to be spent by hospital personnel with the 
patient to ensure that they understand what is measured and what is interpreted from 
genomic tests. It is likely that the development of additional educational resources for 
patients will be necessary for this process. As with almost any other clinical interaction with 
patients, the use of genomic testing should be done only on the basis of a patient decision to 
“opt-in”, rather than as a default pathway from which patients need to “opt-out”.  
(c) Education of Physicians and Other Care-Givers about Genomic Testing Methods will be 
Critical for Appropriate Use and Maximal Patient Benefit 
 Medical centers and healthcare organizations should consider establishing a set of 
resources, including a service staffed by individuals with training in molecular genetic 
pathology, medical genetics and genetic counseling, to educate and advise medical 
personnel about the proper selection of genetic tests and the appropriate interpretation of 
their results. The need for such a resource has been highlighted by a recent study performed 
at a large reference laboratory, which documented a strikingly high rate of inappropriate 
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selection of genetic tests (e.g., ordering the incorrect test, ordering tests that were not 
needed or ordering suboptimal tests given the clinical question being asked). Approximately 
26% of all requests for complex genetic testing for heritable disease were changed following 
review [41]. These misorders result in unnecessary costs to the healthcare system and, more 
importantly, may result in significant clinical consequences (e.g., failure or delays in 
receiving necessary testing, receiving incidental or secondary findings that were not 
requested or desired). 
 If clinical findings indicate that genomic tests could be helpful for the care of a particular 
patient, integrated “tumor board”-style meetings are particularly important in evaluating 
whether genomic sequencing methods should be applied for the care of that individual 
patient and for discussing the results and implications of the new genomic data for that 
patient’s care, particularly in challenging cases. It is still an open question as to how the 
cost of physician and other professional time and effort will be compensated for such 
diagnostic conferences, but the trend toward health system payments based on patient 
outcomes rather than the sheer volume of clinical work performed in a patient’s care may 
be compatible with such new efforts, if genomic testing contributes significantly to optimal 
diagnostic and management decisions and the cost-effectiveness of caring for individuals 
and populations in coming years.  
(d) The Use of Less-Extensively Validated Genomic Testing Approaches for Clinical Care 
Ordinarily Should Progress in a Graded Manner from Use in “Innovative Care” Settings, 
Followed by Use in Clinical Research Settings, before being Added to “Standard” Clinical 
Laboratory Testing 
 It is likely that a range of different approaches or applications of “genomic” testing will 
continue to be proposed by physician scientists and other medical investigators, spanning a 
wide range of different kinds of measurements and interpretations, with widely-varying 
levels of evidence for their actual clinical utility in different clinical contexts. There are 
preexisting good models for incorporating innovative clinical methods into practice, and 
these can be applied to the evaluation of genomic tests supported by various levels of prior 
evidence. For applications of “genomic” technology that measure already well-established 
genetic variants with clear clinical significance, typically by replacing older Sanger DNA 
sequencing assays, rapid incorporation into clinically and analytically validated molecular 
genetic pathology testing in the CLIA-certified clinical laboratories is advisable. The results 
of such sequence interpretation are applied for clinical decision-making in the same manner 
as equivalent results obtained using prior testing methods. 
 When the clinical value of genomic testing is not well established, but few or no other 
adequate diagnostic testing options exist, then, as with other types of “innovative clinical 
care” adopted by medical centers, the application of these tools on very limited numbers of 
patients for specific purposes at the discretion of the clinician can be considered. If genomic 
testing will be applied systematically on multiple subjects, without established evidence of 




accompanying human subject protections and regulations associated with this activity. This 
would, of course, include obtaining informed consent from the patient for the research, 
following an explicit and detailed discussion of the limitations of the novel test as a basis 
for making clinical decisions or healthcare recommendations, the kinds of unexpected (and 
in some cases, unwanted by the patient) test results that could be reported to the patient and 
their physician and additional confirmatory testing that would be required before making 
clinical decisions based on the results of the novel test. 
 As genomic testing and interpretation methods are validated by ongoing clinical research 
studies and evidence accumulates for the clinical utility of particular approaches in a given 
clinical context, some testing and interpretation methods would become sufficiently mature 
to join the list of “standard” laboratory tests that can be ordered for individual patients by 
clinicians without the additional safeguards and consultations described above. To the 
extent that patient informed consent permits, the data and interpreted results of genomic 
tests should be stored in databases that will permit additional research and discovery to 
proceed and derive additional clinical insights and knowledge from the testing process. 
(e) Individual and Institutional Conflicts of Interest in Clinical Genomic Testing must be 
Identified and Managed 
 Conflicts of interest are a serious concern for physicians and others responsible for patient 
care, and the current period of great discovery and commercial interest in clinical genomics 
has presented opportunities for physician-scientists and others to become involved in the 
commercialization of new genomic testing or interpretation methods. All physicians and 
healthcare institutions must be vigilant to ensure that such potential conflicts of interest do 
not lead to inappropriate decisions about the kinds of testing approaches to pursue or not to 
pursue. Individual conflicts of interest, where a faculty member or physician has a financial 
stake in a private company and/or intellectual property related to genomic testing and 
analysis methods, are similar to those that apply to the use of other medical technologies, 
pharmaceuticals and devices. Institutional conflicts of interest are those where the 
healthcare organization or those directing it could influence decisions about which kinds of 
diagnostic testing would be used for the care of patients, either to encourage the use of 
particular test methods, instruments, analytical systems or outsourcing to particular genomic 
testing to particular companies, or else the avoidance of particular tests or companies. 
Information about any such potential conflicts should be publicly available, as well as 
scrutinized and managed within the organization, to ensure and document the propriety and 
ethical behavior of all participants. 
(f) These Guiding Principles also Apply to Efforts to Introduce Other Clinical “Omics” Testing 
into Clinical Care (Such as Transcriptomes, Proteomes, Metabolomes and Microbiomes). 
 The improvement in NGS-based sequencing methods over the past five years has resulted in 
dramatic decreases in the cost per base of DNA sequence. Initially, these technologies 
revolutionized research endeavors, but clinical laboratories rapidly adopted these 
technologies. Other related complex testing using NGS or other technologies in the research 
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setting shows significant potential clinical utility. These methods and technologies include 
RNA sequencing (complementary DNA sequencing), proteomics, metabolomics and 
metagenomics, as well as functional genomic studies. We suggest that these guiding 
principles for genomic testing can also be applied to the incorporation of other complex 
clinical laboratory testing into patient care when sufficient evidence is available to support 
clinical utility. 
(g) Clinical Genomic and Other “Omic” Data and Methodologies Should, to the Greatest 
Extent Possible, be Shared Openly with the Wider Medical and Research Communities, to 
Accelerate the Pace of Medical Discovery and to Increase the Quality and Reproducibility of 
Clinical Genomic Data Analysis 
 With many technological advances, there are opportunities for private enrichment, as well 
as the creation of new public resources. The balance between these two components can 
shape the pace of adoption and the ultimate impact of the technology; the history of the 
development of the Internet and the role of “open source” contributions to it show the key 
impact that communities with some element of altruism or public spiritedness can have on 
the success of a technology. The recent U.S. Supreme Court ruling in AMP v. Myriad 
Genetics, Inc. [42], which determined that human genes themselves are not able to be 
patented, and the preceding ruling in Mayo Collaborative Services v. Prometheus 
Laboratories, Inc. [43], which found that correlations between measured analytes and 
medical interpretations of such data do not qualify as patentable inventions, may have 
somewhat decreased the likelihood that private companies will attempt to use litigation to 
deter testing for particular human gene mutations [44]. These rulings may increase the 
likelihood that individual companies may try to amass, and keep in private hands, human 
genetic information and clinical interpretations as trade secrets. In spite of this possibility, 
there is now an opportunity for medical centers and other healthcare institutions to cooperate 
in sharing data, interpretations and analysis methods, to speed the identification of 
correlations between genomic sequences and disease risks, prognosis and treatment 
outcomes. Currently, the initial frameworks for such data sharing and coordination efforts are 
promising, but medical organizations and, particularly, their patients will benefit from further 
joint activity in the public domain that advances clinical genomics [45] and that can serve as a 
counter-balance to siloed, competitive, inward-looking efforts (whether in academic or 
commercial settings).  
8. Conclusions 
We have entered a new era of clinical testing, in which genetic data and other types of “omics” 
data are much more easily obtained, but the challenges of their interpretation will likely continue 
for many years. A balance between efficient adoption of new genomic tests and careful 
consideration of the reliability and clinical value of the results derived from genomic sequence data 
is needed as these methods become more widely disseminated and utilized within healthcare 




experimentation compared to those that must be maintained for clinical testing, and these standards 
are under active development and refinement by laboratory professional organizations, as well as 
associations focusing on particular clinical conditions or specialties. We have outlined seven key 
principles for consideration in implementing clinical genomic testing, encompassing the technical, as 
well as the human elements that must be engaged and coordinated to enable optimal utilization of 
this new form of clinical care. Above all, we feel that this period of intense exploration and 
discovery in human genetics represents a major opportunity for cooperative and transparent work 
between different areas of laboratory and clinical medicine, for the ultimate benefit of the patients. 
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The Revolution in Human Monogenic Disease Mapping 
Emma Duncan, Matthew Brown and Eileen M. Shore 
Abstract: The successful completion of the Human Genome Project (HGP) was an unprecedented 
scientific advance that has become an invaluable resource in the search for genes that cause 
monogenic and common (polygenic) diseases. Prior to the HGP, linkage analysis had successfully 
mapped many disease genes for monogenic disorders; however, the limitations of this approach 
were particularly evident for identifying causative genes in rare genetic disorders affecting lifespan 
and/or reproductive fitness, such as skeletal dysplasias. In this review, we illustrate the challenges of 
mapping disease genes in such conditions through the ultra-rare disorder fibrodysplasia ossificans 
progressiva (FOP) and we discuss the advances that are being made through current massively 
parallel (“next generation”) sequencing (MPS) technologies. 
Reprinted from Genes. Cite as: Duncan, E.; Brown, M.; Shore, E.M. The Revolution in Human 
Monogenic Disease Mapping. Genes 2014, 5, 792-803. 
1. Introduction 
Until very recently, mapping the causative gene for monogenic diseases depended on finding 
families with demonstrable Mendelian inheritance of the disease, preferably in multiple 
generations. Linkage approaches in such families were successful in identifying mutations 
responsible for many of the more frequent monogenic diseases and traits [1]. However, identifying 
the underlying mutations in rare genetic diseases, especially those associated with low reproductive 
fitness, late onset diseases, or diseases with early lethality, proved much more challenging. 
The Human Genome Project (HGP) set the stage for success in meeting these challenges.  
The ultra-rare disorder fibrodysplasia ossificans progressiva (FOP), with a frequency of one in two 
million, is an example of such a success. Linkage in FOP families identified chromosomal regions 
of interest; Human Genome Project databases then facilitated the identification of candidate genes 
within the linkage region and permitted the efficient identification of altered DNA sequences. FOP 
was found to be caused by a recurrent single nucleotide substitution occurring in >95% of patients. 
Despite the ultimate success in mapping the FOP gene, this discovery took decades of effort to 
identify families with inheritance of the disease (linkage analysis was eventually accomplished 
with just five two-generation families) followed by the time-consuming tasks of conducting 
genome-wide linkage analysis, and subsequent identification and re-sequencing of candidate genes 
within the linkage intervals. Knowing the genetic mutation in FOP has led quickly to better 
understanding of the underlying pathology and directed strategies for treatments, neither of which 
were possible before molecular aetiology was determined. 
Building on the technology, computation, and scientific information generated through the HGP, 
the continued advances in mapping disease genes have been extraordinarily rapid. Faced today with 
the challenge of identifying a rare gene mutation in a disease like FOP, high-throughput exome 




gene identification may require sequencing of only a small number of unrelated cases, small 
families, or, in some cases, even a single proband. These breakthroughs are leading to an upsurge 
in disease gene discoveries with their associated benefits [2]. 
After mapping a disease-causing gene, many challenges remain in understanding additional 
genetic contributions to disease onset and progression. In FOP, for example, although the main 
disease characteristics are unique and readily recognized there is significant variability in the age of 
disease onset, the rate of disease progression, and the severity of disease, likely to arise from as yet 
un-identified genetic causes. Similar issues exist with many common heritable diseases such as 
osteogenesis imperfecta and Marfan’s syndrome. With further development of genome technologies, 
the ability to understand phenotypic variability and the participation of genetic modifiers is  
becoming a reality. 
2. Linkage Mapping 
2.1. History of Linkage Mapping 
At the turn of the twentieth century, Archibald Garrod coined the term “inborn errors of 
metabolism” to explain the increased incidence of alkaptonuria (and, subsequently, also cystinuria, 
pentosuria, and albinism) in consanguineous families compared with the general population, and 
suggested that these conditions were caused by transmissible elements within families [3]. Since 
this time, the challenge has been to identify these errors. 
For most of the twentieth century, linkage mapping was the standard means of identifying the 
gene/s underlying an inherited disorder. Linkage is the co-segregation of a genetic region with 
disease phenotype within a family. Markers, such as restriction fragment length polymorphisms, 
microsatellites, or single nucleotide polymorphisms (SNPs), are genotyped in family members. 
Markers close to a disease-causing mutation will be co-inherited with the disease-causing mutation, 
unless separated by a meiotic event—the closer the marker to the disease-causing gene,  
the less likely it will be separated at meiosis. An area of linkage within a family may thus extend a 
considerable genetic distance. Whole genome linkage scans, in which approximately  
300–400 microsatellite markers are genotyped in family members, usually result in identification of 
regions of linkage spanning 10–20 cM (on average ~10–20 million DNA bases). Such a region may 
harbor many hundreds of genes, and fine mapping (by further marker genotyping and/or 
sequencing of candidate genes) will usually be necessary to identify the exact causative gene. 
2.2. Weaknesses of the Linkage Approach 
Traditional “parametric” linkage analysis compares the likelihood of the observed transmission 
of genetic markers in relation to the trait or disease, in the context of a specified model of 
inheritance. Non-parametric methods not requiring knowledge of mode of inheritance can be used, 
though are less powerful when the correct mode of inheritance is known. Diseases with late onset 
of clinical features or with incomplete penetrance are harder to map by linkage due to possible 
incorrect attribution of disease status among family members. Diseases with significant 




same environmental stressors. The ability to map a gene also depends on the number of informative 
meioses within a pedigree. Thus, large families with many affected individuals—especially 
distantly-related individuals who will have a high number of meioses and recombination events 
between them—are the most useful for linkage mapping. Diseases that affect reproductive fitness 
(such as skeletal dysplasias) are less likely to have such large informative pedigrees. One solution 
to this problem is to use many families affected by the same condition in order to identify a 
common linkage region shared by affected persons within each family. This strategy requires that 
the disease be caused by mutations in the same single common locus in all families, although the 
causative mutation within this common locus may be unique in each individual family. The 
approach will, therefore, not be successful for diseases with “phenocopies”, in which a clinical 
phenotype may arise from mutations in more than one gene. (For example, phenocopies might 
result if mutations in various genes along a biological pathway resulted in a common phenotypic 
endpoint.) “Pooling” linkage information from families with disparate underlying causes would not 
be a successful strategy. Extremely rare diseases are, by definition, extremely rare; obtaining 
sufficient number of families to pool their linkage information will usually require international 
collaboration. Lastly, novel/spontaneous mutations (those newly occurring within an individual) 
cannot be mapped by linkage. 
2.3. Successes in Linkage Mapping: Monogenic vs. Complex Diseases 
Despite these limitations, mapping monogenic diseases by linkage has been quite successful, 
even for rare diseases, with well over 1000 monogenic (Mendelian) disorders mapped by the turn 
of the century [1]. Approximately two-thirds of the 400 or so recognized skeletal dysplasias were 
mapped by linkage or similar approaches by 2010 [4]. In contrast, mapping complex diseases by 
linkage was much less successful. Complex genetic diseases are typically polygenic in nature: 
affected individuals have different variants in multiple, but overlapping, sets of genes, with each 
variant contributing only a small part to the final overall phenotype. Before the era of high 
throughput microarray genotyping and the advent of genome-wide association studies (GWAS), 
only a handful of genes had been identified for complex diseases using linkage [5]. 
3. Mapping the FOP Gene Highlights the Challenges 
Fibrodysplasia ossificans progressiva (FOP; MIM 135100) is a severe disorder of progressive  
and extensive extra-skeletal ossification. Heterotopic ossification in FOP begins in childhood 
within connective tissues, such as skeletal muscle, tendon, and ligament. Onset of bone formation 
can be induced by trauma, or may occur spontaneously. Bone formation is episodic, leading to 
cumulative disability and shortened lifespan [6]. 
Reproductive fitness is low in FOP, resulting in infrequent inheritance and a population 
frequency (about one per two million) that reflects the rate of new mutations. When the search for 
the FOP gene began, only very few cases of familial inheritance of FOP had been reported, with 
most known cases occurring de novo in families (reviewed in [7,8]). Although these few family 




transmission of FOP made genome-wide linkage analysis, the state-of-the-art approach at the time, 
an impractical strategy for gene identification. 
Eventually, four small pedigrees with autosomal dominant inheritance of FOP were identified, 
although some had ambiguous clinical features. An initial genome-wide linkage analysis using  
240 microsatellite markers (spaced  25 cM) was conducted, although it was recognized that there  
was incomplete/uneven marker coverage across the genome and many markers lacked sufficient 
informativity [9]. Whilst the initial linkage analysis focused attention on a chromosome 4 locus [9], 
further analysis revealed additional linked loci on chromosomes 2 and 6. However, subsequent 
sequencing analysis of numerous candidate genes in the linkage regions revealed no identifiable 
mutations. The limited information available at this time about the human genome, including gene 
locations and sequence, made this process much more challenging. 
As genome analysis technologies continued to develop and additional families with autosomal 
dominant transmission of FOP were identified, further genome-wide linkage studies were 
performed. These used both a higher density SNP marker panel as well as more dense and 
informative microsatellite panels, which were combined in a single analysis. The international team 
involved focused their studies on five two-generation families with stringent and unambiguous 
phenotypic features of FOP in all affected family members (congenital malformation of the great 
toes and progressive heterotopic ossification in characteristic anatomic patterns). Consistent 
linkage was then demonstrated with the chromosome 2q23–24 interval in all five families (LOD 
score 2.3) [8], with no other locus segregating with the disease in all pedigrees. Using better 
characterized and annotated human DNA sequences generated through the Human Genome Project 
(HGP), we selected candidate genes within the 16.5 Mb linkage interval for sequencing and 
mutation identification. The interval contained more than 40 known genes, however, concurrent 
investigations had identified the BMP signaling pathway as altered in FOP [10–13], and genes in 
this pathway were given high priority. One such gene was the Activin A type I receptor gene 
(ACVR1; OMIM 102576; also known as Alk2 or ActRI), encoding a receptor for bone 
morphogenetic protein (BMP). 
DNA sequence analysis of all ACVR1 protein-coding exons and splice junctions identified a 
heterozygous c.617G>A (Arg206His; CGC  CAC) mutation present in all affected members in 
these FOP families, with the same mutation present in multiple sporadic cases of FOP [8]. 
Cumulative data over the past eight years shows that FOP is caused by this recurrent single 
nucleotide substitution in >95% of patients ([14–16]). In exceptional cases of FOP, mainly those 
whose phenotype varies slightly from the description above, affected individuals have mutations at 
other amino acid positions in ACVR1 in the glycine-serine (GS) or protein kinase domains [14,17]. 
Thus far, all patients clinically diagnosed with the “classical” FOP phenotype have ACVR1 
mutations, and these mutations are fully penetrant. 
4. Massive Parallel Sequencing: A New Era 
The mapping of rare monogenic disorders has been completely transformed by the advent of 
massive parallel sequencing (MPS), also known as “next-generation” sequencing. In the last few 




the rate of discovery has been exponential. To illustrate this latter point, we recently published a 
review of MPS in skeletal dysplasias; at the time of paper submission (April 2013) 26 papers had 
been published using MPS to identify the causative gene for 22 skeletal dysplasias; by the time of 
paper acceptance (July 2013) a further ten papers had added another six novel skeletal dysplasia 
genes to the list [2]. Since then, further causative genes for skeletal dysplasias, as well as a host of 
other Mendelian disorders, have been identified, and it is likely that many of the remaining 
unmapped monogenic diseases will prove tractable to mapping by MPS. 
4.1. MPS Technologies 
Disease gene identification by MPS became possible because of three main developments: the 
technology of sequencing multiple genetic regions simultaneously; the success of the Human 
Genome Project in providing a complete and reliable reference genome for comparison with the 
test sequence data; and the availability of large databases of genomic information from healthy 
individuals, and increasingly in patients with disease, to assist in assessment of variants observed. 
The pivotal technological breakthrough for MPS was the development of technologies and 
platforms for simultaneous sequencing of multiple regions of fragmented DNA or RNA in  
a single experiment. It is beyond the scope of this paper to provide a comprehensive discussion of 
these technologies. However, briefly: DNA is fragmented and common adapters are ligated  
to the fragment ends. The fragments are subsequently amplified by PCR, followed by  
sequencing-by-synthesis, the common adapters providing uniform starting templates for both the 
amplification and sequencing reactions for all fragments (more recent technological developments, 
so-called “third-generation” technologies, involve sequencing without this step of any preceding 
amplification, improving both accuracy and speed of MPS). Sequencing-by-synthesis involves 
addition of bases to a growing strand: as each base is added, a signal is generated and “read” by the 
software, thus generating the sequence of each fragment. The sequence of each fragment is then 
mapped against the human genome, allowing identification of genetic variants present in the 
sequenced individual(s). 
Large databases of genetic variation (such as The HapMap project, UK10K, 1000genomes, 
Human Variome Project, and NCBI dbSNP) are used in interpreting sequence data obtained through 
MPS: identified variants can be characterized as part of the “normal” variability seen in the 
population, or as novel or rare variants and thus more likely to be pathogenic. Of note, population 
genetic variability differs among populations of different ethnicities; the sequence data of an 
individual should be compared against an ethnically-matched reference genome sequence. Once the 
sequence data have been generated and compared with the appropriate reference human genome, the 
data can be analyzed empirically based on the observed inheritance and population prevalence of the 
condition under examination. 
Although MPS was developed for whole-genome sequencing (WGS), targeted sequencing proved 
more cost-effective and efficient initially. Thus, prior to amplification, a library of fragments 
containing regions of particular interest may be selected (for example, by using probes that anneal to 
specific regions of interest, allowing their subsequent identification and isolation for PCR 




to gene exons may be particularly suited for rare Mendelian disorders since prior to the  
advent of MPS 85% of monogenic diseases were predicted to arise from protein-coding  
mutations [18]—whether this will hold true as more causative mutations are identified is as  
of yet unknown. 
The power of MPS methodology is illustrated by the many causative genetic mutations 
identified since its advent, especially since they are frequently mapped through sequencing of 
remarkably few individuals. Indeed, some disease genes have been identified through sequencing of a 
single proband [2], although confirmation of pathogenicity requires subsequent validation, such as 
genetic evidence in other affected individuals and/or functional studies of the candidate gene. 
4.2. Mapping Strategies for Monogenic Diseases Using MPS 
The experimental design for mapping a monogenic disease by WES does not necessarily require 
any prior linkage or association data. Rather it depends on the population frequency of disease, the 
mode of inheritance (including penetrance), and the presence or absence of consanguinity of the 
affected individuals. These parameters then determine an appropriately parsimonious experimental 
design—how many and which individuals should be sequenced and what empirical approach 
should be adopted for analysis of the sequence data. For example, a rare autosomal recessive 
condition in a non-consanguineous family is likely to arise from compound heterozygosity; 
identification of two novel (or very rare) damaging variants in a single gene provides strong 
evidence of likely causality even if only a single affected individual from the family is sequenced. 
In contrast, mapping an autosomal recessive condition in a consanguineous family is more difficult. 
In this circumstance, the disease is more likely to arise from homozygous carriage of a novel  
(or rare) variant carried by both parents. However, a high number of homozygous rare variants 
would be expected due to consanguinity anyway; determining which of these is most likely 
pathogenic can be difficult. For an autosomal dominant condition, the most parsimonious 
experimental design is to sequence distantly-related affected individuals with a large number of 
meioses (and, by implication, recombination events) separating the affected cases—with n meioses 
between the individuals, the chance of a dominant variant segregating with affection status by 
chance is 1/2n. It is also possible to map de novo dominant conditions by sequencing unrelated 
individuals and analyzing the data either for a single variant carried by all affected individuals or for 
unique variants carried in a common gene by each individual [19]. These last analysis strategies 
depend crucially upon correct clinical phenotyping of the unrelated affected individuals. The 
inclusion of phenocopies in the analysis would decrease the success of mapping the causative 
gene—unless the stringent parameters of analysis are relaxed to allow for their possible presence. 
For example, one can search for a common shared gene amongst only a proportion of affected 
individuals rather than requiring a variant to be present in the same gene in every sequenced case. 
An alternative approach includes pathway analysis (searching for variants in a common pathway 
amongst individuals with a common phenotype). From a clinical viewpoint, large online databases 
cataloguing observed variants/mutations in patients with common conditions are also useful in 
identifying likely disease-causing mutation(s) (as examples, the Leiden Open Variation Database 




4.3. MPS Limitations 
Like all technologies, MPS has limitations. Good sequencing data depend upon sufficient 
capture of the causative gene by coverage of sufficient depth of sequencing to call homozygous or 
heterozygous variants (typically, 10-fold coverage is required for calling a homozygous variant and 
15-fold for a heterozygous variant). WES off-the-shelf target platforms vary in their coverage of 
the “whole exome” [20,21], which may result in a gene of interest failing to be sequenced. For 
example, we (and others) failed to identify the disease-causing mutation in OI type V despite 
sequencing several families with the condition; the causative mutation was identified in the 5' UTR 
of IFITM5 [22,23], a region not captured with the whole exome capture platform we had employed. 
Less-than-complete whole exome capture can arise for several additional reasons, including new 
gene annotation subsequent to platform development and production [24]; a manufacturing 
decision to target only the main transcript for a gene rather than all known transcripts of a gene; 
and the technical challenges of capturing GC-rich sequences (which are common in the first exons 
of many genes [25]). Conversely, there are some regions that amplify excessively: if duplicates are 
not removed, strand-specific PCR-introduced errors may result, skewing variant allele frequencies 
with consequent effects on variant detection sensitivity and specificity [26]. Regions of genomic 
sequence similarity may result in non-specificity of target fragment selection—for example, a 
probe may anneal not only to the desired target exon but also to an unwanted region of high 
homology which, when incidentally captured and sequenced, results in apparently novel 
heterozygous variants at those points of difference between the two selected regions (a 
phenomenon known as multi-mapping [27]). 
However, despite these limitations, faced today with the challenge of identifying a rare gene 
mutation in a disease like FOP, WES of a small number of FOP patients would likely rapidly reveal 
the recurrent c.617G>A (R206H) ACVR1 mutation, leading to quick recognition of ACVR1 as the 
disease-causing gene. If MPS technologies had been available when the search for the FOP gene 
began, the answer could have been found in 15 weeks, not 15 years. Certainly, this has proved to be 
the case in many other skeletal dysplasias where researchers are faced with similar issues of small 
families afflicted with diseases having a detrimental effect upon reproduction and lifespan [2,4]. 
4.4. Rare Variants as a Cause of Complex Diseases? 
Although we focused in this paper on the use of new mapping approaches for Mendelian 
disorders, MPS has also been used for mapping rare variants that contribute to the heritability of 
complex diseases. The contributions of rare variation in loci that also harbor common susceptibility 
alleles, or in genomic regions without common susceptibility alleles, are still the subject of active 
research. Whilst many examples exist of rare variants contributing to loci harboring common 
variant associations, these are few by comparison with the total number of common variant 
associations identified to date. Indeed, targeted sequencing of 25 loci associated with autoimmune 
disorders in nearly 25,000 individuals with six autoimmune phenotypes and just over 17,000 controls 
failed to identify any rare variants contributing significantly to immune-mediated disease 




identify a rare variant in LGR4 associated with both bone mineral density and fracture risk [29]. 
WES identified mutations in WNT1 as the cause of autosomal dominant early-onset osteoporosis in 
some families; however, as mutations in WNT1 were also identified in consanguineous families with 
autosomal recessive osteogenesis imperfecta it would perhaps be more correct to regard the families 
diagnosed with AD osteoporosis as having a subtle form of OI and/or a monogenic skeletal 
dysplasia rather than the common polygenic disease of osteoporosis [30,31]. Studies that conducted 
dense rare-variant genotyping, such as Immunochip-based analyses of immune-mediated diseases, 
have had little success in identifying novel rare variant associations, despite large sample  
sizes [29,32,33]. 
5. Conclusions and Challenges 
After mapping a disease-causing gene, many challenges remain, and many of these challenges 
are likely to be met through the resources and technologies that continue to build on the foundation 
of the Human Genome Project. 
One important consideration is in understanding the multiple genetic contributions to disease  
onset and progression in addition to the primary causative gene in monogenic disorders. In FOP,  
for example, although the main disease characteristics are unique and readily recognized, 
variability in the age of disease onset, the rate of disease progression, and the severity of disease 
can be high, even in the context of the same ACVR1 c.617G>A mutation. Such phenotypic 
variability is likely influenced by underlying genetic causes. Identification of genetic modifiers that 
“protect” an individual with an FOP mutation, for example by directing a late onset or less 
aggressive disease progression, would provide new therapeutic targets and strategies for treating 
the disease. Similar issues exist for many common heritable diseases, such as osteogenesis 
imperfecta and Marfan’s syndrome. With further development of genome technologies,  
the ability to understand phenotypic variability and the participation of genetic modifiers is 
becoming a reality. 
The ultimate challenge is to elucidate the functions of the target gene and the consequences of 
its mutant forms, and, most importantly, the translation of this knowledge to treatments. 
Identification of the specific mutation in ACVR1 has clear and important diagnostic value, 
providing a means to confirm suspicion of FOP based on toe malformations or, in cases of potential 
inheritance (and when sequencing in early life becomes more commonplace), a means to diagnose 
the condition before irreversible clinical manifestations occur allowing for early intervention. 
Identification of the target pathway and the specific mutation mechanism in FOP has opened up 
therapeutic strategies for this disease. Additionally, although the roles of BMP signaling in a wide 
range of tissue development and homeostasis functions had been well established and the signaling 
pathway and its components were well defined prior to identifying the FOP mutation, the roles of 
ACVR1/ALK2 in these processes were unrecognized and poorly understood. FOP identified 
ACVR1 as a key regulator of skeletal development and bone formation, providing an important new 
focus for skeletal biology and regenerative medicine. This has been the case for many skeletal 
dysplasias mapped to date, in which the causative gene was often not known to be involved in bone 




insights into musculoskeletal development and pathology, and many current treatments have been 
developed based on genetic discoveries—for example the development of anti-sclerostin antibodies 
based on the discovery that the high bone mass conditions of sclerosteosis and van Buchem’s 
disease arise from mutations in the gene for sclerostin [35,36]. The power of MPS to map  
disease-associated mutations will thus benefit not only affected individuals and families,  
but also lead to a dramatic expansion in our understanding of human diseases. This will inform 
development of new therapies not only for rare monogenic disorders but also for diseases common 
in the general population. 
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DNA Methylation Biomarkers: Cancer and Beyond 
Thomas Mikeska and Jeffrey M. Craig 
Abstract: Biomarkers are naturally-occurring characteristics by which a particular pathological 
process or disease can be identified or monitored. They can reflect past environmental exposures, 
predict disease onset or course, or determine a patient’s response to therapy. Epigenetic changes are 
such characteristics, with most epigenetic biomarkers discovered to date based on the epigenetic 
mark of DNA methylation. Many tissue types are suitable for the discovery of DNA methylation 
biomarkers including cell-based samples such as blood and tumor material and cell-free DNA 
samples such as plasma. DNA methylation biomarkers with diagnostic, prognostic and predictive 
power are already in clinical trials or in a clinical setting for cancer. Outside cancer, strong evidence 
that complex disease originates in early life is opening up exciting new avenues for the detection of 
DNA methylation biomarkers for adverse early life environment and for estimation of future disease 
risk. However, there are a number of limitations to overcome before such biomarkers reach the clinic. 
Nevertheless, DNA methylation biomarkers have great potential to contribute to personalized 
medicine throughout life. We review the current state of play for DNA methylation biomarkers, 
discuss the barriers that must be crossed on the way to implementation in a clinical setting, and 
predict their future use for human disease. 
Reprinted from Genes. Cite as: Mikeska, T.; Craig, J.M. DNA Methylation Biomarkers: Cancer and 
Beyond. Genes 2014, 5, 821-864. 
1. Introduction 
A biomarker is any biological characteristic that can be objectively measured and evaluated as  
an indicator of normal biological process, pathogenic process, or pharmacological response to a 
therapeutic intervention [1]. Biomarkers can be used at any stage of a disease and can be associated 
with its cause or latency (risk biomarkers), onset (diagnostic biomarkers), clinical course 
(prognostic biomarkers), or response to treatment (predictive biomarkers) ([2–4] and references 
therein). Biomarkers can also be associated with specific environments (exposure biomarkers). As 
almost all complex human diseases are caused by a mixture of genetic and environmental variation, 
biomarkers, especially those antecedent to disease, can be influenced by either of these factors. 
Biomarkers can also reflect the mechanisms by which exposure and disease are related. They can 
stratify individuals according to risk or prognosis and they can be used as targets or surrogate 
endpoints in clinical trials. An ideal biomarker must be able to provide clinically-relevant 
information, be accurately measurable in multiple individuals, ideally across multiple  
populations [2,4]. In this review we focus on DNA methylation biomarkers, review the current 
state of the field, and discuss limitations and our expectations for the future. 
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2. Epigenetics and Disease Latency 
Epigenetics refers to the molecular marks that influence gene function in a mitotically-heritable 
manner [5]. Epigenetic marks are themselves influenced by a mix of genetic and environmental 
variation [6]. A typical gene will be regulated by epigenetic marks present at one or more gene 
promoters, which are usually but not exclusively close to its transcriptional start site, and by one or 
more enhancers, which can be within the gene or a large distance away from the gene [7]. Such 
regions of transcriptional control exhibit molecular characteristics in the form of multiple, synergistic 
epigenetic marks.  
Epigenetic marks include methylation of DNA at the cytosine residue of cytosine-phosphate-guanine 
(CpG) dinucleotides and covalent modifications of amino acid residues within histone proteins that 
are responsible for the primary packaging of DNA. Other cellular components, such as those 
involved in writing, reading, and erasing epigenetic marks, determine the local chromatin structure, 
which at two extremes can be open and active or closed and inactive [8]. 
In the human genome, DNA methylation occurs almost exclusively at CpG dinucleotides.  
The cytosine residue of a CpG dinucleotide can be covalently modified by adding a methyl group  
to its carbon-5 atom resulting in 5-methylcytosine. The methyl group is transferred from  
S-adenosyl-L-methionine to a cytosine residue via DNA methyltransferases (reviewed in [9,10]). 
CpG dinucleotides are unevenly distributed throughout the genome and are generally  
methylated [11]. Some CpG dinucleotides are clustered in regions known as CpG-islands, which 
can span hundreds to thousands of base pairs and are generally unmethylated [11]. 
The definition of a CpG island has been quite arbitrary and two algorithms have found 
widespread use throughout the scientific community to identify CpG-islands in genomic DNA 
sequences [12,13]. However, genome-wide studies have vastly increased our understanding of the 
human genome over the last few years, and more sophisticated algorithms for the identification of 
CpG-islands have been developed [14–16]. 
CpG islands are often, but not exclusively, located at gene promoters, where the methylation 
status is generally correlated with transcriptional gene activity [11]. DNA methylation can have 
other (regulatory) functions outside promoter regions, for example in intragenic regions [17,18], 
intergenic regions [19] and in regions of low CpG density [20]. DNA methylation performs a 
regulatory role at local and global levels. Global methylation is mainly determined by methylated 
CpG dinucleotides in highly repeated DNA sequences, such as satellite DNAs, which play an 
important function in maintaining genome stability [21]. DNA methylation level changes, namely 
local hypermethylation (gain of DNA methylation) and global hypomethylation (loss of DNA 
methylation), are often associated with a diseased state. 
Most studies of the role of epigenetics in human disease have focused on investigating  
disease-associated DNA methylation changes and on determining the environmental influence on 
DNA methylation variations. Most of these have focused on cancer. It is now widely accepted that 
cancer results from a combination of genetic and epigenetic disruption or dysfunction (reviewed  




that certain environmental factors such as the exposure to certain chemicals, toxins or heavy metals 
are capable of altering the epigenome and ultimately increase the risk of developing cancer [23–25]. 
Outside cancer, environmental influences on DNA methylation are the centre of the 
developmental origins of health and disease (DOHaD) phenomenon [26,27]. In this phenomenon, 
which grew out of the “fetal origins” hypothesis [28], adverse environment, in utero or in early 
postnatal life, programs the body for complex, non-communicable diseases including diabetes, 
cardiovascular disease (CVD) and neurodevelopmental disorders. Central to this phenomenon is 
the hypothesis that disease predisposition results when postnatal environment is mismatched to 
prenatal environment [29]. 
The DOHaD phenomenon involves a period of disease latency between the early origins and the 
later clinical manifestation. This latency may be in the form of a few years, for example with 
obesity and autism, or many decades, in the case of CVD. Non-epigenetic biomarkers of latent 
conditions such as CVD are already being developed and these include plasma high sensitivity  
C-reactive peptide, blood pressure, body mass index and artery wall thickness [30,31]. We discuss 
below how epigenetic biomarkers, in particular DNA methylation biomarkers, are being identified 
within the context of cancer and DOHaD. 
3. Tissues and Bodily Fluids Suitable for Analysis of DNA Methylation Biomarkers 
Almost any biological tissue sample or bodily fluid can be used for DNA methylation analysis. 
DNA methylation is the most robust epigenetic mark and will survive most sample storage conditions 
including, in the case of Guthrie neonatal blood spots, long-term drying [32]. DNA methylation can 
also be studied in histological specimens such as formalin-fixed paraffin-embedded (FFPE)  
samples [33] and microscopic preparations [34]. The robustness of DNA methylation marks makes 
DNA methylation analysis very attractive in a clinical environment as the analysis of gene 
expression pattern and histone modifications require more careful storage conditions, either with an 
RNA-preserving agent, by snap-freezing, or by cryopreservation of viable cells. In most cancers, 
(primary) tumor biopsies can be sampled but for the early detection of cancer and most other non-
communicable diseases, only peripheral, easy-to-access tissues or bodily fluids can be collected. 
Such samples include venous peripheral blood, buccal epithelium or saliva, urine, stools, bronchial 
aspirates, and, even in some cases, muscle or adipose tissue [35–39] (Figure 1). At birth,  
placenta, umbilical cords and fetal membranes are also suitable tissues for analysis of DNA 
methylation [40–42]. 
It is important to note that even though it is desirable to measure disease-associated methylation 
biomarkers in a disease-relevant tissue, this condition does not always need to be met if a 
methylation biomarker is tightly associated with disease state. This is especially the case for tissues 
such as the brain and heart that can only be sampled post mortem. 
Cellular homogeneity within a tissue is also a desirable characteristic for a DNA methylation 
biomarker [43]. Tissues such as blood or even blood fractions such as mononuclear cells, exhibit 
cellular heterogeneity [44–46]. However, methods have been developed to control for such 
heterogeneity, using either differential cell counts [47] or post hoc in regression models [48–50]. 
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Figure 1. Illustration of the variety of tissues that can be used to investigate DNA 
methylation biomarkers. Note that tumor tissue is not listed individually as a cancer can 
affect any part of the body. 
 
4. Parameters for Developing DNA Methylation Biomarkers 
Before we go into more detail about specific DNA methylation biomarkers, we will review the 
measures of particular importance for assay performance and the barriers that must be breached in 
developing DNA methylation biomarkers. The nomenclature we use in this review is generally 
already in use, although it has not been previously summarized in such a way. It is as follows: 
single studies provide potential biomarkers, which could be validated using an independent 
technique and replicated in an independent cohort, also known as external validation. Following 
the systematic review and/or meta-analysis of a large number of independent studies, they become 
candidate clinical biomarkers that can enter clinical trials. Once approved, they become proven 
clinical biomarkers (Table 1). 
Table 1. Nomenclature used in this review for the stages of DNA methylation 
biomarker development. 
Nomenclature Description 
Potential biomarker Results of a single study 
Validated biomarker Same finding using an independent method 
Replicated biomarker Same finding in independent cohort(s) 
Candidate clinical 
biomarker 
Replicated in multiple cohorts and subjected to systematic review 
and meta-analysis; most likely undergoing clinical trials 
Proven clinical biomarker Used in clinical practice 
4.1. Methods for DNA Methylation Biomarker Discovery 
Genome-wide profiling of DNA methylation patterns of healthy and diseased individuals has 




in cancer but also other diseases such as metabolic or neurodevelopmental disorders. Following 
initial studies using pre-selected candidate gene approaches [51–53], many different genome-wide 
methods have been developed and used in the scientific community for DNA methylation 
biomarker discovery and good overviews are provided elsewhere [54–58]. Other scientific 
publications review such methods in the context of methylome-wide association studies (MWAS), 
which utilize a variety of platforms [59,60]. Typically, MWAS, as a subset of epigenome-wide 
association studies (EWAS), involves regression of DNA methylation at thousands to millions of 
CpG dinucleotides or CpG-rich regions on disease phenotype, outcomes or interventions. Such 
analyses usually adjust for multiple testing to produce potential methylation biomarkers in the form 
of differentially-methylated probes (DMPs) or regions (DMRs). Often, DMPs or DMRs are 
validated using locus-specific methods. The next stages of discovery following replication involve 
longitudinal analysis to resolve the issue of cause vs. effect in MWAS, and importantly to show 
whether replicated biomarkers can be used to predict a disease before its clinical onset or predict 
clinical outcomes after onset or after therapeutic intervention. Following discovery of such 
replicated biomarkers, further replication followed by meta-analysis and/or systematic review are 
required, at which stage these candidate clinical methylation biomarkers are ready for clinical trials 
leading to clinical proven methylation biomarkers. In this review we will focus on single locus 
DNA methylation biomarkers at all stages of discovery. 
4.2. DNA Methylation Assay Sensitivity and Specificity 
Assay sensitivity describes the proportion of patients with disease who have a positive test result 
(true positive rate), whereas the assay specificity describes the proportion of patients without 
disease who have a negative test result (true negative result) [61]. The ideal assay would show 
100% sensitivity and 100% specificity. In other words, the test is never positive for a disease-free 
patient and never negative for a patient with disease. However, this ideal scenario is rarely 
achieved. It is also important to note that an assay with a sensitivity of 50% and a specificity of 
50% is no better than tossing a coin to decide if the patient is harboring the disease or is  
disease-free [61]. 
The receiver operating characteristic (ROC) curve is a fundamental tool for diagnostic  
test or biomarker evaluation and visually displays the interdependency of specificity and  
sensitivity [62,63]. In a ROC curve the true positive rate (sensitivity; y-axis) is plotted in function 
of the false positive rate (1-specificity; x-axis). The area under the curve is equal to the probability 
that a classifier will rank a randomly chosen positive instance higher than a randomly chosen 
negative one. In other words, for a well performing diagnostic test or biomarker the curve is 
located towards the upper left corner. On the other hand a less well-performing diagnostic test or 
biomarker is characterized by a curve close to a diagonal line, representing a state in which 
sensitivity and specificity are similar. 
It is desirable to achieve values for sensitivity and specificity as high as possible. However,  
for some tests it might be acceptable to achieve a higher sensitivity by sacrificing assay specificity  
or vice versa. This could be the case in particular for diseases for which a misclassification would 
result in severe consequences for the patient [61]. Acceptable values for sensitivity and specificity 
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of a testing procedure can be determined by comparing to existing values of a test currently 
considered as gold standard. It is also important to consider that a diagnostic test is providing 
information independent of the experience of a clinician, which sometimes varies dramatically 
among hospitals and countries. However, it remains to be determined how easily the new testing 
procedure can be implemented in a clinical environment. 
4.3. Barriers to Developing, Testing and Using DNA Methylation Biomarkers 
Despite the promise of epigenetic biomarkers, so far only a few DNA methylation-based 
candidate biomarkers have reached the potential for use in a clinical setting, and all these are 
mainly related to the field of cancer. As with disease phenotypes, each clinical DNA methylation 
biomarker would need to be measured accurately and reproducibly. Differences in DNA 
methylation between cases and controls may be large (e.g., more than 50%) in cancer but in other 
non-communicable diseases may often be less than 5%. Methods used to measure methylation 
must be accurate to well below this level of resolution. The analytical sensitivity of specific 
methods is discussed below. Next, variability within the population needs to be small to maximize 
assay sensitivity and specificity. Predictive power also needs to be high. Positive predictive power 
is the percentage of people with a positive test who actually get the disease. These hurdles are all 
similar to those for any clinical trial. 
5. Methods Suitable for the Analysis of Locus-Specific DNA Methylation Biomarkers 
Many different methods have been described for the investigation of locus-specific DNA 
methylation (reviewed in [58,64–67]). Whereas some methods use genomic DNA for methylation 
analysis, the majority of methods require bisulfite-treated DNA as starting material [68,69]. 
Bisulfite treatment converts unmethylated cytosines to uracil, whereas 5-methylcytosines are 
relatively inert under reaction conditions. Subsequent use of bisulfite-treated DNA in PCR replaces 
the uracils with thymines and 5-methylcytosines with cytosines. Therefore, the methylation status 
of a particular CpG dinucleotide is detected indirectly [70]. 
The use of bisulfite-treated DNA has three important consequences for downstream applications  
for DNA methylation detection. Firstly, a considerable loss of initial input DNA can occur,  
due to extensive DNA degradation during the preparation and purification of bisulfite-treated  
DNA [71–74]. Loss of amplifiable DNA can be critical in particular for those samples where only a 
limited amount of genomic DNA is available, such as those from very small biopsies. Secondly, a 
poor bisulfite conversion rate can lead to false-positive results. This is of particular importance for 
very sensitive DNA methylation detection methods, such as those based on methylation-specific 
PCR (MSP) [75]. However, the use of a commercially-available bisulfite conversion kit can help to 
improve DNA recovery and to control for a proper bisulfite conversion rate [67,72]. Thirdly, PCR 
amplification may sometimes be biased towards unmethylated or methylated templates due to 
differences in CG content [76]. However, different approaches have been described in the literature 




Another problem for most downstream applications is the presence of heterogeneous DNA 
methylation patterns at many gene loci [81–83]. Heterogeneous methylation patterns are 
characterized by the presence of multiple epialleles (alleles which differ in the pattern of methylated 
and unmethylated CpG dinucleotides across the analyzed region). As every sample has its own set 
of epialleles, it can complicate quantification of methylation (reviewed in [84]) and cut-off value 
settings for when to call a sample unmethylated or methylated. The need for cut-off values also 
demands the use of quantitative DNA methylation detection methods, in particular for those gene 
loci, which are hypomethylated (loss of DNA methylation), or where already variable background 
methylation is present in healthy individuals [81,85]. 
Despite the many methodologies available for DNA methylation analysis the methodological 
considerations and requirements of a molecular diagnostics laboratory renders only a fraction of 
these methods suitable for DNA methylation analysis in a clinical setting. Such methods would 
need to use small quantities of DNA of varying quality. The latter is of particular importance for 
formalin-fixed paraffin-embedded (FFPE) specimens where the DNA is often degraded and 
chemically modified [86]. Ideally, DNA methylation detection methods for clinical settings should 
be low cost, easy to use, automatable, and capable of processing many samples in parallel in order 
to minimize costs of future tests. In the following sections we will discuss methods for DNA 
methylation detection suitable for use in clinical settings or in a molecular diagnostic laboratory. 
Bisulfite pyrosequencing (Qiagen, Hilden, Germany) is based on sequencing-by-synthesis 
methodology and uses bisulfite-treated DNA as starting material [87–89]. This method is relatively 
cost- and time-effective, and is suitable for DNA methylation analysis of single gene loci. DNA 
methylation can be determined at single CpG dinucleotide resolution but methylation levels are 
provided in a quantitative manner for each CpG site as an average across all epialleles amplified 
during PCR. The analytical sensitivity is about 5%–10% for individual CpG dinucleotides [90,91]. 
This approach has a high-throughput capacity and is well suited for the analysis of small PCR 
amplicons, such as those typically generated from FFPE specimens. Importantly, this approach 
allows to quality control for a sufficient bisulfite conversion rate. However, the downside of this 
approach is that the instrument required to perform DNA methylation analysis is rather costly. 
The MassARRAY EpiTYPER (Sequenom Inc., San Diego, CA, USA) also requires bisulfite-treated 
DNA as starting material and uses matrix-assisted laser desorption ionization time-of-flight  
(MALDI-TOF) mass spectrometry to extract (semi-) quantitative DNA methylation information 
from shifts and intensities of fragment signals after base-specific cleavage of PCR amplified 
epialleles present at single gene loci [92]. DNA methylation levels are determined as an average for 
a single CpG dinucleotide, or for multiple CpG dinucleotides, clusters of CpGs on the same fragment 
or  for multiple CpGs across all fragments of amplicons generated during PCR [93]. Nevertheless, 
this approach is suitable for providing an almost complete methylation profile across the  
region-of-interest [92]. The analytical sensitivity is similar to bisulfite pyrosequencing [93] and 
DNA methylation data obtained by both methods for the same set of CpG dinucleotides has been 
shown to be highly concordant [81]. Like bisulfite pyrosequencing, MassARRAY EpiTYPER is 
suitable for high sample throughput and also requires the purchase of an expensive instrument. 
134 
 
Methylation-sensitive high-resolution melting (MS-HRM) is an inexpensive, fast and medium to 
high throughput screening methodology for DNA methylation analysis at single gene loci [94,95].  
This approach requires bisulfite-treated DNA as starting material and exploits the differential 
melting behavior of PCR products generated from unmethylated and methylated epialleles. The 
melting profile of an unknown sample is compared to melting profiles of a DNA methylation 
standard series. This allows the reliably detection of homogeneous methylation levels down to  
1%–5%, and can detect the presence of heterogeneous methylation patterns. However, the presence 
of heterogeneous DNA methylation allows the estimation of methylation levels in a  
semi-quantitative or qualitative manner. This is because the presence of heterogeneous DNA 
methylation results in a complex melting profile that does not allow the ready estimation of the 
amount of methylated epialleles; the result is largely qualitative [84]. MS-HRM is quite  
attractive in a clinical environment as PCR amplification and subsequent DNA methylation 
analysis is performed in one tube, which minimizes the risk of sample mix-up and sample cross 
contamination [96]. However, MS-HRM is not suitable on its own for use in a clinical setting as 
this method is not capable to deliver quantitative methylation information. Nevertheless, MS-HRM 
PCR products can be further quantified for DNA methylation using bisulfite pyrosequencing [97]. 
Another group of important approaches for DNA methylation detection is based on  
methylation-specific PCR (MSP) [98]. The strength of MSP-based approaches comes from the high 
analytical sensitivity, which allows them to detect only few methylated epialleles in a large 
background of unmethylated epialleles. The high analytical sensitivity originates from PCR primers 
containing CpG dinucleotides that selectively amplify only methylated epialleles. However, 
conventional MSP is not suitable for use in clinical settings as this approach detects DNA 
methylation only in a qualitative manner [98]. This can result in an overestimation of methylation in 
particular for those samples where background methylation is already present in normal tissues [81]. 
Moreover, conventional MSP is difficult to standardize between different laboratories and is also well 
known to generate false-positive, as well false-negative results, especially when DNA of low 
quality is used as starting material, for example FFPE-derived DNA [99,100]. Nevertheless, 
quantitative offshoots of conventional MSP, such as MethyLight [101], ConLight-MSP [102],  
MS-FLAG [103], SMART-MSP [104] and HeavyMethyl [105] are potentially suitable approaches 
for use in a clinical environment. The latter approach has been already successfully applied for 
DNA methylation detection of SHOX2 and PITX2 (see below). 
Methylation-sensitive multiplex ligation-dependent probe amplification (MS-MLPA) plays a 
key role in the diagnosis of genomic imprinting disorders (see below) [106]. Different to the 
methods described above, this method uses genomic DNA as starting material to produce  
semi-quantitative DNA methylation information for single CpG dinucleotides. MS-MLPA relies on 
CpG dinucleotide-specific probes and a digestion step using the methylation-sensitive restriction 
endonuclease HhaI prior to PCR amplification to distinguish unmethylated from methylated 
epialleles. DNA methylation levels are determined by comparing peak sizes of patient samples 
with control samples and the analytical sensitivity is approximately 5%–20% [107–110].  




require non-standard laboratory instruments as the PCR amplification products are separated by 
capillary electrophoresis on a DNA analyzer instrument. 
The use of genomic DNA for methylation analysis is quite attractive as it avoids problems 
associated with bisulfite treatment. However, as MS-MLPA is based on a digestion step with a 
methylation-sensitive restriction endonuclease, false-positive results can occur as a result of 
incomplete digestion, in particular with DNA of poor quality. The use of the restriction 
endonuclease HhaI also limits the investigation of DNA methylation to HhaI recognition sites and 
therefore provides only a limited view of the DNA methylation landscape of any region of interest. 
However, MS-MLPA is capable of analyzing up to 50 CpG dinucleotides at any one time and 
allows the determination of DNA methylation levels at different gene loci simultaneously. 
Moreover, MS-MLPA can be combined with gene copy number and point mutation detection, 
which makes it a quite flexible methodology [110]. 
Lessons Learned from the DNA Methylation Biomarker MGMT  
The DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) was first 
characterized in the early 1990s [111,112] and its key role in the resistance of malignant glioma to 
alkylating drugs was proposed repeatedly [113–115]. Approximately ten years later, a first link was 
established between MGMT methylation and improved patient outcome in response of malignant 
gliomas to the alkylating drug carmustine [116]. However, the relatively small number of patients 
investigated as well as some flaws in study design raised concerns of the validity of the results and 
warranted confirmation of the potential predictive biomarker MGMT (see comments in [116,117]). 
Subsequently, MGMT methylation as a predictive biomarker of a patient’s response to 
alkylating drug regimens was replicated on different sample cohorts with mixed success. 
Methylation of MGMT was shown to serves as a predictive biomarker for determining response of 
glioma and glioblastoma patients treated with the alkylating agent Temozolomide [117,118]. 
Nevertheless, another study was not able to replicate MGMT methylation as a predictive biomarker 
in glioblastoma patients treated with alkylating drug regimens [119]. 
However, the seminal findings of a clinical trial reported in 2005, conducted by Hegi and 
colleagues, clearly showed that glioblastoma patients treated with Temozolomide showed a 
survival benefit if the promoter-associated CpG-island of the MGMT gene was methylated [120]. 
Since then, several clinical trials have confirmed MGMT methylation as a candidate clinical 
biomarker for determining patient response to Temozolomide treatment and it is now a proven 
clinical biomarker (reviewed in [121]). 
Since 2005, many research groups and commercial companies (Table 2) have spent much effort 
developing assays to investigate the methylation status of MGMT by using various methods  
and platforms [122–126]. However, these methods varied in analytical sensitivity and provided 
methylation information ranging from purely qualitative to quantitative. As consequence, the 
general lack of consensus for an agreed methodology and the widespread use of inappropriate 




Table 2. Commercially-available DNA methylation test kits for cancer. References are 
either systematic reviews/meta-analyses 1 or a set of corroborating references 2. This 






Diagnostic Test Kit: Brand Name 
(Manufacturer) 
References 
VIM diagnostic Colorectal Cologuard (Exact Sciences) [128] 1 
SEPT9 diagnostic Colorectal Epi proColon (Epigenomics)  
ColoVantage (Quest Diagnostics)  
RealTime mS9 (Abbott) 
[129] 1 
SHOX2 diagnostic Lung Epi prolong (Epigenomics) [130–135] 2 
GSTP1/APC/RASSF1A diagnostic Prostate ConfirmMDx (MDx Health) [136–138] 1 
MGMT predictive Glioblastoma PredictMDx Glioblastoma (MDx Health)  
SALSA MS-MLPA probemix ME011 
Mismatch Repair genes (MRC-Holland)  
PyroMark MGMT Kit (Qiagen) 
[121,139,140] 1 
Several recent studies assessing the clinical utility of different methodologies for MGMT 
methylation detection favor quantitative approaches such as bisulfite pyrosequencing [141,142]. 
Quantitative approaches are necessary to determine cut-off values for methylation ranges related  
to clinical information such as prognosis [143,144]. However, methylation cut-off values are not 
universal for a particular gene and strongly depend on the method used for DNA methylation 
analysis. Even by using the same methodology for methylation analysis requires determination of 
cut-off values for each assay as these values also depend on the region of the gene investigated, 
PCR primers and PCR conditions used as well as minimal tumor content required [143–145]. It has 
also been recognized that careful studies of the entire MGMT promoter-associated CpG-island are 
required to determine those CpG dinucleotides or CpG clusters suitable as a surrogate biomarker 
for biological or clinical relevant information [83,146]. 
Keeping in mind that MGMT methylation was one of the first DNA methylation biomarkers to 
be identified, it is not surprising that it took a considerable amount of time until it found its way 
into the clinic. Advancements in study and clinical trial design will certainly help to speed up 
replication and clinical implementation of new DNA methylation biomarker. However, the current 
lack of an agreed methodology as the gold standard for DNA methylation analysis is still a 
roadblock to overcome. For a more detailed view on which milestones need to be achieved in 
bringing a DNA methylation biomarker into clinical practice we refer the interested reader 
elsewhere [127]. 
6. DNA Methylation Biomarkers 
To date, the vast majority of replicated and candidate clinical DNA methylation biomarkers 
come from cancer research. Clinically-relevant DNA methylation biomarkers outside cancer exist 
for diseases originating from genomic imprinting disorders, such as Prader-Willi and Angelman 




and the chronic diseases to which they predispose. The following sections will give an overview of 
promising DNA methylation biomarkers for potential clinical use. 
6.1. Candidate Clinical DNA Methylation Biomarkers for Cancer 
A selection of candidate clinical DNA methylation biomarkers for cancer will be discussed 
below; many others have been described in greater detail elsewhere (e.g., [127,147–161]) or have 
been subject of systematic reviews and meta-analysis (e.g., [129,136–140,162]). Not surprisingly, 
much effort has been spent in identifying diagnostic DNA methylation biomarkers suitable for 
early detection and diagnosis of cancer. Early detection allows treatment of the cancer at a stage 
that is generally considered beneficial for disease outcome. Such tests could be blood-based or use 
other bodily fluids collected less invasively, which makes it very convenient to the patient. 
Prognostic biomarkers would provide information on a patient’s overall survival if the disease is 
left untreated, whereas predictive biomarkers would be suitable for determining a patient’s 
response to a certain drug regimen. The latter are of particular importance as they may help to 
minimize the health burden of patients, as well as to minimize costs for healthcare providers for 
unnecessary drug treatment. 
DNA methylation-based candidate clinical biomarker genes for the early detection include 
vimentin (VIM) [128,163], septin 9 (SEPT9) [129,164], and syndecan 2 (SDC2) [165,166] for 
colorectal cancer, glutathione S-transferase pi 1 (GSTP1) for prostate cancer [136,167,168], and 
cyclin-dependent kinase inhibitor 2A (CDKN2A) [169,170] and short stature homeobox 2 (SHOX2) 
(see below) for lung cancer. These have already reached clinical potential and for some diagnostic 
test kits are commercially-available (Table 2). In the next sections we will provide an overview of 
SHOX2, PITX2 and MGMT as good examples of diagnostic, prognostic and predictive biomarkers 
in cancer. 
6.1.1. SHOX2 
DNA methylation of the short stature homeobox 2 (SHOX2) gene was found to be a diagnostic 
clinical biomarker candidate for the detection of malignant lung disease even in patients where 
histology and cytology results are equivocal [135]. SHOX2 methylation allowed the specific 
detection of malignant lung disease with a sensitivity of 60% and a specificity of 90% in blood 
plasma using HeavyMethyl, a quantitative methylation-specific PCR-based approach [134]. The 
highest assay sensitivity was achieved for small cell lung cancer (SCLC) cases with 80% and 
squamous cell carcinoma (SCC) with 63%, respectively, when compared to adenocarcinomas (AC) 
cases with a sensitivity of only 39%. However, the poor sensitivity for detecting adenocarcinomas 
could be improved by the addition of a second (or more) adenocarcinoma-specific biomarker. Not 
surprisingly, the sensitivity values obtained of the blood-plasma-based assay were lower compared 
to sensitivities seen from bronchial aspirates (SCLC: 97% (80%), SCC: 82% (63%), and AC: 47% 
(39%)); overall sensitivity and specificity were 68% (60%) and 95% (90%), respectively) as the 
tumor-derived amount of DNA is expected to be lower in blood than a lung-specific  
analyte [134,135]. However, a blood-based assay has the advantage of using specimens which have 
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been collected with a far less invasive procedure compared to those obtained from bronchoscopy. 
Furthermore, a blood-based assay enables screening of asymptomatic patients whereas availability 
of bronchoscopy is limited to patients with suspected lung cancer. Noteworthy, elevated SHOX2 
methylation levels in pleural effusions do not only allow the detection of lung cancer but also the 
detection of other malignancies, such as breast cancer and gastrointestinal cancers [132,133]. 
However, assay sensitivity and specificity for these was not as good as for bronchial aspirates or 
blood. SHOX2 methylation level in lymph node tissue obtained by endobrochial ultrasound with 
transbronchial needle aspiration (EBUS-TBNA) improved endoscopic lung cancer staging with an 
assay sensitivity and specificity of 94% and 99%, respectively [130]. 
DNA methylation of SHOX2 not only provides diagnostic but also provides prognostic 
information for cancer patients [131,132]. Pleural effusion samples obtained from patients with 
different malignancies (including lung cancer) showed a shorter overall survival if elevated levels 
of SHOX2 methylation were detected [132]. Contrarily, gain of SHOX2 methylation in tumor 
tissues has been shown to be associated with good prognosis in lung cancer patients. The 
prognostic power of SHOX2 methylation was further improved when combined with DNA 
methylation analysis of PITX2 [131]. 
6.1.2. PITX2 
The paired-like homeodomain 2 (PITX2) gene encodes the PITX2 transcription factor. DNA 
methylation status of the PITX2 promoter has been identified as a candidate clinical biomarker in 
tumor tissues. This has provided prognostic information for breast cancer, prostate cancer, and lung 
cancer. PITX2 methylation in estrogen receptor alpha positive breast cancer patients without lymph 
node metastasis has been associated with poor prognosis when treated without any systemic 
adjuvant therapy [171] as well as a higher risk of disease recurrence after surgery when treated 
with the antiestrogen Tamoxifen only [172,173]. Furthermore, methylation of the PITX2  
promoter was also associated with poor patient outcome in estrogen receptor alpha positive,  
HER-2/neu-negative breast cancer patients positive for lymph node metastasis when treated with 
an anthracycline-based adjuvant chemotherapy [174]. Methylation of PITX2 in prostate cancer 
patients has also been shown to be a prognostic biomarker for an increased risk of biochemical 
recurrence after radical prostatectomy [175–177]. Importantly, the prognostic value of PITX2 
methylation was particularly high in tumor-enriched samples of patients at intermediate risk for 
whom further risk stratification is quite often challenging [176]. Interestingly, and different to 
breast and prostate cancer, increased DNA methylation levels of PITX2 were associated with 
prolonged survival in lung cancer patients and requires further investigation [131]. 
6.1.3. MGMT 
O6-methylguanine DNA methyltransferase is a DNA repair protein that is encoded by the 
MGMT gene and is capable of removing alkyl residues directly from the O6-position of guanines. 
However, if the DNA repair capacity of MGMT is impaired or inactivated, for example by DNA 




tumor MGMT promoter methylation renders cancer cells susceptible to the cell damaging effects of 
drug regimens utilizing alkylating agents [116,180] (see also Lessons learned from the DNA 
methylation biomarker MGMT). MGMT was one of the first predictive DNA methylation 
biomarkers to determine a patient’s response to alkylating chemotherapeutics and it was shown that 
glioblastoma patients with tumor MGMT promoter methylation have a survival benefit from 
Temozolomide chemotherapy [120,121]. 
The more frequent use of quantitative approaches such as bisulfite pyrosequencing to detect and 
measure MGMT methylation have revealed that the DNA methylation biomarker MGMT does not 
only have a predictive but also a prognostic clinical component (reviewed in [121,126]). 
Glioblastoma patients with more than 29% MGMT promoter methylation showed a longer 
progression-free and overall survival when treated with radiotherapy and Temozolomide [143]. A 
methylation cut-off value of 25% separated elderly glioblastoma patients into two groups with 
those having more than 25% of methylation had a better survival rate when treated with alkylating 
agents alone [144]. Tumor MGMT methylation status was also shown to have a prognostic value for 
progression-free survival of anaplastic glioma patients treated with radiotherapy alone [181,182]. 
7. DNA Methylation Biomarkers for Genomic Imprinting Disorders 
Whereas most genes are expressed from both the maternal and paternal allele, imprinted genes  
are monoallelically expressed in a parent-of-origin-specific manner either from the maternal or the 
paternal allele. Only a small proportion of all human genes are imprinted and are often found 
clustered in imprinted domains and mono-allelic gene expression is controlled by differentially 
methylated regions (DMRs) (reviewed in [183]). Disrupted or altered imprinting patterns have been 
linked to pathological conditions termed genomic imprinting disorders (reviewed in [184]). Examples 
of imprinting disorders include Prader-Willi syndrome (PWS), Angelman syndrome (AS),  
Beckwith-Wiedemann syndrome (BWS) and Silver-Russell syndrome (SRS), which will be 
discussed briefly below.  
PWS and AS are clinically distinct neurodevelopmental imprinting disorders, which have been 
linked to a region on the long arm of human chromosome 15 (15q11–q13; reviewed in [185]). This 
region consists of several imprinted genes and the absence of paternally expressed genes in this 
imprinting domain results in PWS, whereas the loss of maternally-expressed genes causes AS. 
Additionally, point mutations in the E6-AP ubiquitin-protein ligase (UBE3A) gene, which is also 
part of the imprinting domain account for approximately 10% of AS patients. In cases where PWS 
or AS is suspected, DNA methylation analysis of the PWS/AS critical region allows the reliable 
identification of more than 99% of PWS patients and about 80% of AS patients [186].  
Two approaches are commonly used in molecular diagnostics for DNA methylation analysis of 
the PWS/AS critical region [186,187]. The first approach determines the methylation status at a 
single gene locus, the small nuclear ribonucleoprotein polypeptide N (SNRPN) gene, whereas the 
second approach determines the methylation status and gene copy number changes at several sites 
across the region [186]. DNA methylation analysis of the SNRPN gene is frequently determined by 
MSP [188,189] whereas the simultaneous investigation of methylation levels and gene copy 
numbers is determined by methylation-sensitive multiplex ligation-dependent probe amplification 
140 
 
(MS-MLPA) [190]. Molecular diagnostics of PWS and AS is quite complex and challenging, and 
guidelines for molecular genetic testing and reporting PWS and AS have been developed [186]. 
Furthermore, a WHO international genetic reference panel for PWS and AS has been established 
and was successfully validated in an international multicentre study [187]. 
BWS and SRS are imprinting disorders, which have been associated with imprinted genes on 
chromosome region 11p15.5 [191–193]. This region is functionally divided into two domains: the 
first domain consists of the imprinted insulin-like growth factor gene 2 (IGF2) and the non-coding 
RNA H19 and is controlled by DMR1 whereas the second region contains several imprinted genes, 
including cyclin-dependent kinase inhibitor 1C (CDKN1C), potassium voltage-gated channel, 
KQT-like subfamily, member 1 (KCNQ1) and KCNQ1 opposite strand/antisense transcript 1 
(KCNQ1OT1), is controlled by DMR2. Loss of methylation at DMR2 (KCNQ1OT1 
hypomethylation), is the most frequent alteration, in around 50% of BWS patients [194] whereas 
loss of methylation at DMR1 (H19 hypomethylation) is typically observed in SRS is found in 
around 40% of SRS patients [192,195]. As mentioned before, MS-MLPA allows the simultaneous 
investigation of methylation levels and gene copy numbers and has thus been considered well 
suited for detecting the majority of (epi-) genetic alterations associated with BWS and SRS in 
region 11p15.5 [196–198]. 
Most approaches for routine clinical DNA methylation analysis at single-gene loci in genomic 
imprinting disorders rely, most probably for historical reasons, on qualitative methylation detection 
methods. However, the diagnostic advantages of quantitative DNA methylation detection 
methodologies, such as bisulfite pyrosequencing [191,199,200], are being increasingly  
recognized and will be probably the preferred methods of choice for analyzing single gene loci in 
the near future. 
8. DNA Methylation Biomarkers of Outcome in Chronic Diseases Other than Cancer 
Given the likely early life origins for non-communicable disease, there are plenty of 
opportunities in which DNA methylation biomarkers could be used. Biomarkers for intrauterine 
environmental exposures such as maternal alcohol consumption or smoking could provide a way to 
measure exposures without the need for time-consuming, hard-to-administer questionnaires and 
where access to mothers is not possible. DNA methylation risk biomarkers could be used to stratify 
risk for latent non-communicable disease before the onset of disease. They could also be used to 
monitor progression from first symptoms to full disease. After disease onset, they could be used for 
predicting survival and response to therapy as they are beginning to do with cancer. Below, we 
review data from the most promising studies of environmental, risk, diagnostic, prognostic, and 
predictive DNA methylation biomarkers. 
8.1. DNA Methylation Biomarkers for Adverse Environments 
There have been a large number of environmental agents linked to epigenetic change, including 
toxins, stress and nutrition, and these have been reviewed elsewhere [201–203]. Below, we focus 




8.1.1. AHRR Methylation and Smoking 
Exposure to adverse environments at all stages of life have been shown to influence the 
epigenome (reviewed in [39,42,204,205]). However, a replicated association has been found for 
only one: the effect of DNA methylation on the aryl hydrocarbon receptor repressor (AHRR) gene 
involved in the detoxification of chemicals found in tobacco smoke. As of June 2014, ten 
independent methylome-wide studies using Illumina Infinium HM450 arrays (containing probes for 
about 480,000 CpG dinucleotides located in functionally-relevant regions of the genome [206]) had 
all identified the same smoking-associated probe, cg05575921, located in a region of intermediate 
CpG density (CpG-island shore) 450 bp upstream of a CpG island in the third intron of the AHRR 
gene [207–216] (Table 3). Two studies focused on the effect of maternal smoking in umbilical cord 
blood [209,215], which they and others [217] replicated in independent sample cohorts. Others 
found an association of adult smoking with AHRR methylation in blood [207,208,210–212,214], 
lung tissue [211] or blood lymphoblastoid cell lines [213]. No effects were seen at birth in placenta 
or buccal epithelium [217] and effects were seen elsewhere in the AHRR gene in lung alveolar 
macrophage DNA but not at the cg05575921 probe [213]. Three studies performed within-cohort 
validation using locus-specific DNA methylation analysis [207,211,212] and six studies replicated 
their findings in adults in independent cohorts [208,209,211,212,214,215]. Two studies  
showed evidence of a role for the region surrounding probe cg05575921 in regulation of AHRR 
expression [211,213]. All found an inverse relationship between smoking and DNA methylation 
with an effect size ranging from 4% in neonates of mothers who smoked throughout  
pregnancy [215] to 24.4% in adult current smokers [212].  
Similar effects were seen in Europeans, African Americans [207], and South Asians [208]. The 
latter study found that current smokers were identified with 100% sensitivity and 97% specificity 
in Europeans and with 80% sensitivity and 95% specificity in South Asians. Timing-specific 
effects were also found; prenatal smoking only exerted an effect when mothers smoked during a 
significant part of gestation [217,218]. Furthermore, associations found at birth were also present at 
18 months of age [217] but in adulthood, DNA methylation levels were similar in never smokers 
and in former smokers [212]. Clearly, loss of methylation at and around the AHRR cg05575921 
probe is strongly associated with first or second hand exposure to smoking. Importantly, one study 
found an association in adults with smoking, but not tobacco snuff consumption, implicating that a 
product(s) of tobacco combustion is responsible for the loss of DNA methylation rather than 
tobacco itself. Further work is needed to link this loss to the timing of prenatal smoking, and 
postnatal passive and active smoking, and its relationship with downstream health outcomes 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In addition to probe cg05575921, a number of CpG dinucleotides have been significantly associated 
with prior smoking. Table 4 lists these probes, using a cut-off of those that have been identified by 
four or more studies. These include two further CpG dinucleotides from AHRR [207,209–213], one 
from the thrombin receptor-like 3 (F2RL3) gene [208,211,214,216], one from the growth factor 
independent 1 transcription repressor (GFI1) gene and two from the myosin 1G (MYO1G) gene. In 
addition, two intergenic smoking-associated CpG sites have been replicated across multiple  
studies [207–209,211–214], all coinciding with regions of DNAse hypersensitivity, suggesting 
functional significance. Potentially, one or more of these CpG dinucleotides could be used in 
combination with probe cg05575921 as DNA methylation biomarkers for smoking. 
Table 4. Other HM450 probes with significant correlations with smoking in at least 
four studies. Probes are included if found to be significantly associated with smoking in 
at least four independent studies. DHS, DNAse hypersensitive site, indicative of 
regulatory potential. 
Probe Gene References 
cg03991871 AHRR [209,212,213,215] 
cg21161138 AHRR [207,209–212,215] 
cg03636183 F2RL3 [208,211,214,216] 
cg09935388 GFI1 [208,209,212,214,215] 
cg22132788 MYO1G [208–210,214] 
cg12803068 MYO1G [210,212,215,218] 
cg21566642 Intergenic (CpG island, DHS) [207,208,211,212] 
cg06126421 Intergenic (enhancer, DHS) [207,208,211,212,214] 
8.1.2. NR3C1 Methylation and Stress 
Stress triggers the activation of the hypothalamus-pituitary-adrenal axis, resulting in the 
production of glucocorticoids by the adrenal glands. By binding to receptors in the brain, 
glucocorticoids induce changes in gene expression and in turn, health and behavior [223]. 
Landmark studies with rats have shown that lack of maternal licking and grooming at birth resulted 
in an increased level of DNA methylation within the exon 17 promoter of the glucocorticoid receptor 
gene Nr3c1 in rat hippocampus, in particular at a region that binds nerve growth factor-inducible 
protein-A (NGFI-A) [224,225]. Since then, studies of the equivalent region in humans (exon 1F of 
the NR3C1 gene) have found decreased DNA methylation in cord blood [226,227] and  
placenta [228] associated with maternal anxiety during pregnancy. Others have shown that violence 
towards women during pregnancy can have a similar effect [229,230]. Even extremes of stress 
experienced prior to conception, in the form of the holocaust, were also found to correlate with 
NR3C1 exon 1F methylation, albeit in opposite directions depending on the sex of the parent [231]. 
Methylation analysis of various tissues from adults, either alive or post mortem, have found  
long-lasting effects of abuse [232–235] or death of a parent [235,236] during childhood on NR3C1 
exon 1F. In addition, adults with post-traumatic stress disorder had decreased DNA methylation at 
the same [237] or alternate [238] NR3C1 promoters. Of further interest, three studies have shown 




movement and attention at birth [239], response to psychotherapy in adults with posttraumatic 
stress disorder [240] or response to threat-associated stress in adult females [241]. In the latter 
study, DNA methylation levels at NR3C1, the estrogen receptor alpha gene ESR1 and the serotonin 
transporter gene SL6A4 each had independent predictive power. Furthermore, a model containing 
data from all those genes accounted for half of the variance in total cortisol output. Rat studies 
showing that the adverse effects and DNA methylation changes associated with early neglect could 
be reversed in adulthood by methyl-donor rich diet [242] or the histone deacetylase inhibitor 
Trichostatin A [243], suggesting that NR3C1 methylation could be use to monitor response to 
future interventions in humans. 
Clearly, methylation at NR3C1 promoters has the potential to be developed into a variety of 
candidate biomarkers. In addition, despite yielding no replicated stress biomarkers to date, the 
small (typically 1%–2%) effect sizes for NR3C1 methylation would suggest that there may be 
better DNA methylation-based stress biomarkers out there, discoverable using epigenome-wide 
approaches [244–248]. 
8.2. DNA Methylation Risk Biomarkers at Birth 
Measuring DNA methylation in five candidate genes in DNA from umbilical cords, Godfrey 
and colleagues found that methylation of two genes correlated with childhood adiposity as 
measured by fat mass and trunk/limb fat ratio in 78 nine-year-olds [42]. Methylation of the retinoic 
acid X receptor alpha (RXRA) gene and the endothelial nitric oxide synthase (ENOS) gene, together 
with sex, explained 25% of the variance in adiposity at age nine. Data for RXRA were replicated in 
a second cohort of 239 six-year-olds [42]. Other studies have identified associations between RXRA 
methylation in cord blood at birth and bone mineral density at age four [249] and between 
methylation of the alkaline phosphatase ALPL and body mass index at nine years of age [250]. 
However, the first association could not be replicated in another sample cohort whereas for the 
second association no replication study was performed. 
8.3. DNA Methylation Biomarkers during Childhood 
Rakyan and colleagues identified 132 CpG dinucleotides whose methylation levels differed 
significantly in twin pairs discordant for type 1 diabetes and which were subsequently validated 
with an independent method and replicated in a further set of twin pairs [251]. Two-thirds of these 
CpG dinucleotides were also present in singletons prior to the onset of overt symptoms of type 1 
diabetes but positive for diabetes-associated autoantibodies. If those findings can be further 
replicated, this could provide single or panels of DNA methylation candidate clinical biomarkers 
predicting the onset of type 1 diabetes. A potential biomarker study found that DNA methylation 
within the promoter of the peroxisomal proliferator activated receptor gamma (PPARG) gene in 
blood at age five to seven years predicted obesity risk from nine to 14 years [252]. However, these 
results have yet to be replicated. 
Autism spectrum disorder (ASD) describes a related set of neurodevelopmental disorders of 




behaviors and interests, and in some cases, cognitive delays. To date, a small number of ASD 
MWAS have been performed, using a variety of platforms, on lymphoblastoid cell lines [253], 
peripheral blood [254,255], buccal epithelium [256], post mortem occipital cortex and  
cerebellum [257], and dorsolateral prefrontal cortex, temporal cortex and cerebellum [258].  
ASD-specific DNA methylation was found in all but one study [257] and in the rest, although 
ASD-specific methylation was often validated within the study, only one study attempted to 
replicate across cohorts and tissues [258]. In this study, three significant ASD-associated array 
probes discovered in temporal cortex were replicated in such a manner. ASD-specific DNA 
methylation found within the proline-rich transmembrane protein 1 (PRRT1) gene was replicated in 
prefrontal post mortem cortex and cerebellum, methylation of c11orf21 was replicated in prefrontal 
cortex and methylation at an intergenic site near the zinc finger gene ZFP37 was replicated in a 
sex-specific manner in cerebellum. The only differentially methylated gene replicated in two 
separate studies is the olfactory receptor gene OR2L13 found in buccal epithelium [256] and 
peripheral blood [254]. Further replication will be required to develop this potential biomarker  
for ASD. 
8.4. DNA Methylation Biomarkers in Adults 
Cardiovascular disease (CVD) and its precursors are receiving arguably the greatest attention in 
MWAS outside cancer [259–261]. DNA methylation biomarkers could help ascertain risk early in 
life, help with diagnosis and predict response to interventions. Below, we report some of the more 
advanced such studies.  
Levels of fasting glucose and insulin and measures of insulin resistance are used to test for early 
signs of diabetes and they have been subject to a recent MWAS [262]. This study divided up a 
cohort of 837 non-diabetic individuals at a median age of 48 years into discovery and replication 
subsets. Using HM450 arrays on DNA from CD4+ T cells, the investigators found significant 
associations between methylation of two CpG sites with the ATP-binding cassette gene ABCG1, 
involved in macrophage cholesterol and phospholipids transport, with insulin resistance, with one 
associated with insulin “of borderline significance”. The CpG site with the strongest association 
with insulin and insulin resistance was also strongly associated with nearby single-nucleotide 
polymorphisms, implying that differences in genetic sequence can alter the epigenetic functionality 
of a genomic region. Another recent study replicated across two cohorts a DNA methylation 
biomarker for triglyceride levels at the carnitine palmitoyltransferase gene CPT1A in the same cell 
type [263]. In this study, CPT1A methylation explained 11.6% and 5.5% of the variation in 
triglyceride levels in the discovery and replication cohorts, respectively. 
Although several studies have discovered associations between DNA methylation and  
obesity [264], few studies have searched for risk or predictive DNA methylation biomarkers in 
adulthood. In one study that did, males with a history of CVD had higher global DNA methylation 
than those without [57]. Those who went on to develop symptoms of CVD six years later had 
intermediate levels of global DNA methylation. In other study, a type 2 diabetes-specific CpG 




of symptoms between ages 30 and 43 in a cohort of initially asymptomatic adults [265]. 
Replication is required for both studies. 
Two unreplicated studies resulted in potential predictive DNA methylation biomarkers for 
response to weight loss programs in adults. In the first, obese women with better response to 
dietary intervention showed significantly lower levels of DNA methylation at promoters of the 
leptin (LEP) and TNF-alpha (TNF) genes than the non-responder group [266]. Although no 
differences were found between responder and non-responder groups in LEP and TNF gene 
expression, if replicated, the potential predictive methylation biomarker would still be valid on its 
own. In a similar study of obese men, DNA methylation levels in several CpG dinucleotides 
located in the ATPase ATP10A and the CD44 antigen (CD44) genes showed statistical  
baseline differences depending on the weight-loss outcome [266]. Again, these finding have not yet 
been replicated. 
In a search for potential DNA methylation biomarkers of postpartum depression using MWAS  
and a parallel study in mice, Guintivano and colleagues found that DNA methylation at the 
heterochromatin protein 1 binding protein 3 (HP1BP3), and tetratricopeptide repeat domain 9B 
(TTC9B) genes predicted postpartum depression in the original and replication cohorts [267]. 
Adjustment for blood cell heterogeneity resulted in a higher specificity (96%) in both cohorts 
compared to unadjusted values. 
Schizophrenia is a psychotic disorder, and bipolar disorder is a mood disorder but both have 
similar symptoms and they are often studied together. Many potential DNA methylation biomarker 
studies and MWAS have been conducted for these disorders ([268–274] and references therein). 
Despite the heterogeneity of platforms and tissues used in these studies, a small number of 
potential diagnostic schizophrenia- and/or bipolar disorder-associated biomarkers have been 
identified. The serotonin receptor 2A (HTR2A) gene was differentially methylated in both disorders 
in two brain regions (frontal cortex and the anterior cingulate) [270], replicating the findings of a 
previous study [275,276]. Similar results were also found in saliva of patients with these  
disorders [277]. Another gene differentially methylated in two brain regions in both disorders was 
the dystrobrevin binding protein gene DTNBP1, also found in an MWAS of frontal cortex of 
females with both disorders [278] and in all individuals with schizophrenia [268]. The reelin (RLN) 
gene was differentially methylated in individuals with schizophrenia using an MWAS [271], as it 
was for schizophrenia and bipolar disorder in a MWAS of brain regions [270], replicating previous 
findings [279,280]. Other potential DNA methylation biomarkers for psychoses include the human 
leukocyte antigen (HLA) gene HCG9 and the serotonin transported gene SCL6A4 (5HTT). HCG9 
was identified in patients with schizophrenia or bipolar disorder in an MWAS of frontal  
cortex [278] and in brain, blood and sperm in an MWAS for bipolar disorder [281]. SLC6A4 was 
differentially methylated in an MWAS of saliva and frontal cortex in individuals with 
schizophrenia [272], similar to previous findings in lymphoblastoid cell lines and brain tissue of 
individuals with bipolar disorder in a study that included cross-cohort replication [282]. No studies 
have investigated the possibility of using above associative biomarkers as potential risk biomarkers in 




medication for schizophrenia or bipolar disorder [273,276]. Clearly, there is much promise for future 
potential biomarkers of risk, diagnosis and prognosis in schizophrenia and bipolar disorder. 
More longitudinal studies at stages of life are required to generate DNA methylation biomarkers 
for exposure and outcome in chronic diseases other than cancer. Birth cohorts and the retrospective 
utility of birth dried blood spot Guthrie cards [283] will be essential for this search. 
8.5. DNA Methylation Biomarkers of Aging 
A number of individual MWAS have looked at the relationship of DNA methylation and aging, 
with the intention of developing age-specific biomarkers for forensic applications and for 
investigating premature cellular aging. Three independent meta-analyses have been performed on 
such datasets [284–286]. The first [284] reviewed six MWAS datasets from Infinium HM27 arrays 
containing probes for about 27,000 CpG sites [287] on a variety of cell types. None of the  
1,093 age-associated probe CpG dinucleotides replicated across all six studies. However, probes at 
two genes, neuronal pentraxin II (NPTX2) and phosphodiesterase 4C (PDE4C), did overlap in five 
of the six studies. The second study [285] performed an analysis of DNA methylation from whole 
blood from 575 individuals ranging from newborns to age 78 from published HM27 datasets and 
replicated with a further group of four similar datasets. This yielded 99 significantly age-associated 
probes including the same PDE4C CpG probe cg17861230 as the first study. An even more 
extensive study of 39 “training” and 32 “test” HM27 and HM450 datasets of more than  
7,000 samples from multiple tissues yielded 353 “age predictor” CpG dinucleotides, which 
included one (cg13899108) in PDE4C [286] just 420 bp from the CpG site identified in the first 
two studies. Although this locus is the most validated age-related CpG dinucleotide, these analyses 
show that sometimes, a combination of several CpG dinucleotides may be more accurate than a 
single CpG site. A recent large single analysis measured age-associated DNA methylation in whole 
blood DNA from 656 individuals using HM450 arrays [288]. In this tissue, investigators identified 
70,387 significant age-associated CpG dinucleotides, of which, 53,670 were replicated in an 
independent dataset. Data was not available to identify whether the PDE4C locus mentioned above 
was among this dataset. The study went on to develop a predictive model of aging that included 
methylation data and clinical parameters such as gender and body mass index. We predict that this 
is how most DNA methylation biomarkers will be used in the future. The model selected a set of 71 
age-associated methylation biomarkers that were highly predictive of age. Although PDE4C was 
not among this subset, another probe within the subset, cg09809672 associated with the  
EDAR-associated death domain (EDARADD) gene was also identified as age-associated in two of 
the other studies [285,286]. Importantly, this study also found evidence of an accelerated 
epigenetic aging in tumor tissue [288] and a further study has since identified epigenetic age 
acceleration as a risk factor for mortality [289]. Clearly, age-associated DNA methylation 




9. Integrating Epigenetic Data into Disease Risk Models 
Although DNA methylation biomarkers can be used by themselves, the emerging field of 
molecular pathological epidemiology proposes that they can be integrated into models of disease 
risk together with other factors [4,290,291]. Such factors include transcriptomic, proteomic, 
metabolomic, microbiome, and neuroimaging data. The logic is that combinations of risk 
biomarkers will provide more accurate estimation of disease risk, particularly when dealing with 
individuals, due to inter- and intra-individual biological variation. Based on principles similar to 
systems and network biology and a variety of modeling methods, this field is in its infancy but is 
the next logical step for DNA methylation biomarkers and is already yielding promising results for 
genetic biomarkers [292]. 
10. Future Prospects 
An increasing tendency to harmonize appropriate methods for DNA methylation detection and 
reference standards will accelerate the development of DNA methylation biomarkers for cancer 
and for other diseases. This tendency will be synergistically enhanced by next generation 
sequencing methodology, which has unlocked a new area of possibilities. This relatively new 
methodology opens the avenue for routine testing of DNA methylation biomarker panels rather 
than the selective choice of individual biomarkers. The use of appropriate DNA methylation 
biomarker panels will prove beneficial where the disease phenotype is quite heterogeneous. It is 
also expected that the genetic component of disease will be further revealed, which will 
subsequently allows the strengthening of biomarker panels by combining genetic and DNA 
methylation biomarker panels [293]. 
It is not only important to have appropriate epi(genetic) biomarker panels available for certain 
diseases or risk stratification but also to translate them into clinical actionable information. If no 
clinical action is available there is a risk of adverse psychological impacts among patients and a 
risk of those patients being disadvantaged by healthcare providers. However, there is also an 
enormous potential that affected patients can use the knowledge to their benefit allowing them to 
actively prevent or delay the early onset of certain diseases. 
11. Conclusions 
DNA methylation biomarkers are promising and valuable biomarkers which are heading for the 
molecular diagnostic laboratory. This is particular true for methylation biomarkers in cancer where 
the biomarkers are currently being used for early detection. However, the uptake of DNA 
methylation biomarkers is quite slow and will still require a considerable amount of time until the 
field reaches its full potential. The development of DNA methylation biomarkers for cancer and 
other diseases has also been slowed down by the lack of standardized methodologies and reference 
standards for use in DNA methylation detection. The still widespread use of inappropriate methods 
in combination with inappropriate controls still produces potential DNA methylation biomarkers, 
which may not be replicated. The need for methods of quantitative DNA methylation detection is 




values determine a diseased or disease-free state. Finally, the availability of DNA methylation 
biomarkers in diseases other than cancer is still in its very early steps but in time, their transition to 
a clinical setting will follow as it has for cancer. 
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Mouse ENU Mutagenesis to Understand Immunity to 
Infection: Methods, Selected Examples, and Perspectives 
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Guillaume Bourque, Danielle Malo, Philippe Gros and Silvia M. Vidal 
Abstract: Infectious diseases are responsible for over 25% of deaths globally, but many more 
individuals are exposed to deadly pathogens. The outcome of infection results from a set of diverse 
factors including pathogen virulence factors, the environment, and the genetic make-up of the host. 
The completion of the human reference genome sequence in 2004 along with technological 
advances have tremendously accelerated and renovated the tools to study the genetic etiology of 
infectious diseases in humans and its best characterized mammalian model, the mouse. 
Advancements in mouse genomic resources have accelerated genome-wide functional approaches, 
such as gene-driven and phenotype-driven mutagenesis, bringing to the fore the use of mouse models 
that reproduce accurately many aspects of the pathogenesis of human infectious diseases. Treatment 
with the mutagen N-ethyl-N-nitrosourea (ENU) has become the most popular phenotype-driven 
approach. Our team and others have employed mouse ENU mutagenesis to identify host genes that 
directly impact susceptibility to pathogens of global significance. In this review, we first describe 
the strategies and tools used in mouse genetics to understand immunity to infection with special 
emphasis on chemical mutagenesis of the mouse germ-line together with current strategies to 
efficiently identify functional mutations using next generation sequencing. Then, we highlight 
illustrative examples of genes, proteins, and cellular signatures that have been revealed by ENU 
screens and have been shown to be involved in susceptibility or resistance to infectious diseases 
caused by parasites, bacteria, and viruses. 
Reprinted from Genes. Cite as: Caignard, G.; Eva, M.M.; van Bruggen, R.; Eveleigh, R.;  
Bourque, G.; Malo, D.; Gros, P.; Vidal, S.M. Mouse ENU Mutagenesis to Understand Immunity to 
Infection: Methods, Selected Examples, and Perspectives. Genes 2014, 5, 887-925. 
1. Introduction 
The Neolithic Era, which began around 10,000 years B.C., constituted a turning point in human 
civilization. Its importance stems not only from the establishment of the first human settlements, 
but also from the development of farming activities involving the domestication of wild plants and 
animals. These changes in societal organization brought humans into close contact with animals 
and soil, exposing them to potential new pathogens, and with each other, allowing the spread of 
any new infection. It therefore comes as no surprise that the Neolithic Era saw the emergence of 
several human infectious diseases [1]. Indeed, given this close proximity, trans-species infections 
became more likely and ultimately resulted in the appearance of diseases such as measles and 
smallpox [2]. As a result, from the Neolithic Era until the Industrial Revolution, human life 
expectancy did not exceed 25 years of age [3]. Fortunately, life expectancy has been steadily 
increasing over the last 150 years for two main reasons. First, public hygiene measures 
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implemented in the mid-19th century reduced the transmission of infection. Additionally, the 
advent of vaccination and antimicrobial drugs in the late 19th and early 20th century meant that 
many deadly infections were now curable or preventable. On a larger scale, diseases such as polio 
and measles were drastically reduced, while the dreaded smallpox was completely eradicated. 
Nevertheless, infectious diseases remain directly responsible for close to 25% of all deaths 
globally and constitute a perpetual burden for humankind [4]. Numerous circumstances favor the 
emergence or reemergence of pathogens, or their spread to new ecological niches; these include 
pathogen virulence factors, as well as changing environmental conditions and host factors  
(e.g., aging populations, a heavier chronic disease burden, and therapeutic suppression of host 
defenses) (Figure 1). Of course, the eradication of most infectious diseases is highly unlikely. 
Instead, we are often involved in an unremitting struggle to control infection, for which a constant 
influx of novel countermeasure strategies is needed. 
Figure 1. Factors involved in susceptibility to infectious diseases. 
 
The development of these novel countermeasure strategies largely relies on a better 
understanding of the molecular mechanisms of disease pathogenesis. This requires not only basic 
research on the pathogen side but also on its interaction with the host. A possible approach is to 
exploit the observed variability in the outcome of infection, since at any given time, even during 
epidemics, clinical disease only develops in a subset of exposed persons. A large body of evidence 
indicates that the human genome is a major determinant of the variability in the onset, progression, 
and severity of infectious diseases [5–8]. In light of this evidence, research efforts aiming to better 
understand the pathogenesis of infectious diseases have shifted their focus from the pathogen to the 
host. Investigators are thus now attempting to identify host genes that are essential for successful 
pathogen infection, instead of focusing solely on pathogen genes. Candidate gene analysis studies 
have revealed a handful of single gene variants associated with increased susceptibility or 
resistance to specific infectious diseases (reviewed in [5]). Some remarkable examples identified in 
human populations include the malaria-protective effect of heterozygosity in the case of otherwise 
disease-causing hemoglobinopathies, such as sickle cell anemia and thalassemia [9], the protective 
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loss-of-function alleles of the FUT2 gene [11]. Further, the study of children with rare monogenic 
defects has revealed a considerable number of rare human genetic variations in innate immune 
pathways that underlie susceptibility to certain infectious diseases. For example, IRAK and MYD88 
deficiencies predispose to life-threatening infection by some bacterial species [12]. Another 
example is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a primary immunodeficiency 
characterized by genetic defects in the IFN  pathway, leading to susceptibility to Mycobacterium 
bovis (BCG) or other environmental mycobacteria species innocuous to the general population and 
to non-typhoidal, extra-intestinal salmonellosis (for review, see [5]). Thus, the fact that individuals 
exposed to life-threatening pathogens display differential susceptibility to infection and varying 
disease outcome not only reflects the genetic variability within the human population, but also the 
functional genetic diversity of the immune response itself. 
The growing awareness of the importance of host genetic makeup in infectious disease outcome 
has motivated large-scale investigations of the human genome, made possible by recent 
technological advances. Namely, sequencing of the human genome [13], the International HapMap 
project [14], and microarray-based high-throughput genotyping technology have paved the way to 
Genome Wide Association Studies (GWAS) of major infectious diseases. In these GWAS, millions 
of single nucleotide polymorphisms (SNPs) can be tested for association with major infectious 
diseases, and this can be done simultaneously in thousands of individuals (for review, see [5]). 
Results emanating from these large datasets are certainly improving our understanding of infectious 
disease pathogenesis. However, full interpretation of the genes and pathways identified by GWAS 
studies is complicated by several factors including the modest effect size of most signals and the 
fact that even together these signals can explain only a fraction of the genetic predisposition to 
disease. Furthermore, the SNPs showing the strongest association are usually found near  
gene-coding regions rather than within obvious structural or regulatory regions making it difficult 
to pinpoint the gene directly involved in the disease phenotype. Such results are not entirely 
surprising given the inherent genetic heterogeneity of the human population, the variable exposure 
to the microbe during natural infection, the inherent variation in the microbe itself, and the 
difficulty associated with assembling the large cohorts required for GWAS. Yet, another key 
roadblock of GWAS studies is the lack of functional annotation for the majority of genes and 
encoded proteins, which is often limited to general ontology terms but lacks experimental 
validation for a possible role in an infectious disease phenotype. 
2. Mice to the Rescue 
An alternative and successful approach to identifying and characterizing the genetic component 
of the host response to infection in human studies has been the use of the mouse model. Owing to 
their striking physiological and genetic similarity with humans, mice have become a prime model 
for the study of human diseases. Numerous inbred strains exist that display natural resistance or 
susceptibility to a similar range of fungal, viral, parasitic, and bacterial pathogens, as well as the 
disease phenotypes associated with these infections [15–18]. These inbred strains represent 
homogeneous populations that serve to test different routes of inoculation, and various pathogen 
doses, all in a controlled environment, thus lessening many of the confounding effects encountered 
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in human genetic studies. Due to its prominent role in biomedical research, the mouse was selected 
as the first non-human mammal to have its genome sequenced [19], revealing an astonishing 
genetic homology between the two species. The mouse and human genomes are approximately the 
same size, contain the same number of genes and show extensive conservation in gene order. 
Namely, 80% of human genes had 1:1 orthologous relationships with mouse genes, likely maintaining 
ancestral function in both species [20]. Mutations that cause diseases in humans often cause similar 
diseases in mice, including defects in the genes of the immune system [21]. Yet another advantage 
of the mouse is the string of unique technological advantages to manipulate the mouse genome.  
Using the mouse model, two major genetic approaches have been employed to dissect the 
genetic architecture of the host defense against pathogens. The first is the so-called reverse genetic or 
gene-driven approach. In this approach, the sequence or expression of a gene of interest is altered, 
the effects of which are then investigated. Genetic modification of the mouse genome can be 
undertaken in various ways: (1) transgenesis or the introduction of gene DNA sequences into 
oocytes; (2) targeted mutation using embryonic stem cells (ES) which are modified to create 
knock-out alleles, whereby the function of the gene is abolished and equivalent to a null allele, or 
knock-in alleles resulting from the introduction of putative mutations in a given gene. In addition, 
recently developed genomic resources have further facilitated the use of genetically modified mice 
by the scientific community. These include large libraries of knock-out and conditional knock-out 
mice produced by international consortia aiming to target every gene in the mouse genome [22] 
and their accompanying large-scale phenotyping initiatives [23]; (3) targeted mutation in zygotes 
using the Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR associated 
(Cas9) system [24]. With this approach it is possible to efficiently produce mice with mutations in 
both copies of multiple genes in a matter of weeks [25]. The phenotypes of these genetically 
modified mice can then be thoroughly scrutinized to determine the function of a gene in the context 
of the whole organism. These tools are dramatically improving our understanding of the genetic 
etiology of infectious diseases in both mice and humans. However, in many instances, these reverse 
genetics experiments can prove to be inconclusive. This is the case, for example, when the 
inactivation of a gene results in embryonic lethality or, conversely, when the resulting phenotypes 
are only slightly different from the wild-type or even undistinguishable because of gene 
redundancy. The reverse genetics approach also requires a preliminary hypothesis for gene 
function. Yet, as of 2014, less than 50% of about 34,000 known mouse genes (coding or not) have 
some form of functional annotation based on experimental evidence [26–28], which shows how our 
understanding of gene function still lags behind our knowledge of gene sequence. 
The second approach is known as forward genetics, sometimes called phenotype-driven. The 
forward genetics approach begins with an inherited phenotype, with the aim of identifying the 
genomic regions and variant(s) underlying it. This involves the production of segregating crosses of 
inbred mouse strains or panels of specialized strains that display varying responses to infection, 
followed by linkage or association analyses. This approach is unbiased and requires no prior 
knowledge of gene function, allowing the discovery of unsuspected mechanisms. Numerous 
laboratory mouse resources are readily accessible for use in these studies: homozygous inbred 
strains, panels of selectively bred strains, consomic strains [29], recombinant congenic strains [30–32] 
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or recombinant inbred strains from the collaborative cross [33]. A growing number of wild-derived 
inbred strains [34] or outbred crosses [35] can also be obtained, increasing the pool of genomic 
variation available for these studies. Whole genome sequencing has been performed on 18 of the 
most commonly used inbred mouse strains; the results are now public [36,37], facilitating the 
identification of candidate genes underlying a given phenotypic variation. Moreover, forward 
genetics studies in mice have already been shown to work; some elegant examples have allowed 
the identification of a number of genes and proteins that are essential for the early detection of and 
response to many invading pathogens (for review see [38]). In some cases, the human orthologues 
of these mouse genes (e.g., NRAMP1, TLR4, IRF8) have also been associated with predisposition 
to infection in humans, providing evidence of evolutionary conservation of immune defense 
mechanisms. However, there are limitations to this forward genetics strategy. Namely, a given 
genetic effect may be complex, making it difficult for investigators to determine the contribution of 
individual genes, as this requires subsequent breeding of congenic mice over several generations 
followed by positional cloning. Identifying the precise nature of a genetic lesion in a given 
candidate gene can also be complicated for other reasons, such as the presence of multigenic 
families or unrelated genes within the candidate interval bearing various coding polymorphisms, or 
predictive regulatory mutations or splicing variants rendering it difficult to identify the causative 
variant. Many of these drawbacks, however, can be overcome by the use of mutagens that 
introduce random mutations in the germ line. As presented later, in these models the causative 
mutation can be more easily identified by comparison with the parental non-mutagenized strain. 
This functional genomic strategy has successfully advanced our understanding of the intricate 
cellular and molecular cascades involved in immunodeficiency, autoimmunity, or behavioral 
disorders, which have already been well documented by others (see [39–42]). In the remainder of 
this review, we present the advantages and how-to of experiments using chemical mutagenesis of 
the mouse germ-line to dissect the genetic architecture of immunity to infection in mice. We also 
detail the procedures required to identify causal mutations underlying altered phenotypes using 
next generation sequencing. Finally, we highlight some of the most important findings from in vivo 
screens in the area of infectious disease research and discuss perspectives for mouse ENU approaches. 
3. Chemical Mutagenesis and Generation of Mice Carrying Homozygous  
ENU-Induced Mutations 
To better understand the link between genotypes and phenotypes, and ultimately gene function, 
mouse geneticists have elaborated upon several methods capable of introducing random mutations 
in the mouse germ-line, with the aim of expanding the phenotypic diversity in inbred mice and thus 
providing a wider range of research objects. These methods include the use of whole mouse  
radiation [43], infection of pre-implantation embryos with retroviruses [44], and injection with 
chemicals, such as procarbazine, methyl ethane sulfonate (MES), and N-ethyl-N-nitrosourea  
(ENU) [45]. ENU mutagenesis, however, has become the most popular technique to induce germ-line 
mutations due to its advantageous attributes: potency, preferential activity in spermatogonial stem 
cells, and a propensity to introduce point mutations. 
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As early as 1979, W. L. Russell demonstrated that a single dose of ENU was significantly more 
active than X-ray or procarbazine treatment, the most commonly used mouse mutagens at the time [46]. 
Later, studies showed that the mutation frequency could be increased if the ENU dose was 
fractionated and injected on a weekly schedule instead of being administered in one large dose, as 
this allowed a higher total dose to be tolerated [47]. In these conditions, the activity of ENU was  
12 times that of X-rays and 36 times that of procarbazine, as well as being over 200 times the rate 
of spontaneous mutation [48]. The rate of ENU mutation appears variable for each gene, ranging 
from 1.5 to 10 3 per locus, which is equivalent to obtaining a mutation in a gene of choice at a rate 
of one in every 200–700 gametes screened. Additionally, it was noted that compared to  
X-ray-generated deletions, ENU rarely induced mutations in closely linked loci, suggesting that 
mutations introduced by ENU are subtler. Finally, compared to procarbazine, which is more active 
in transient post-meiotic cells, ENU preferentially affects spermatogonial stem cells, which are 
multiplied and replenished during the mouse lifetime, allowing the genetic lesions to be  
recovered indefinitely. 
ENU is an alkylating agent that acts by preferential transfer of its ethyl group to O and N 
radicals in genomic DNA within mammalian cells [49,50]. Binding of the ethyl to the 
nucleoradicals creates DNA adducts that provoke mispairing, resulting mainly in base-pair 
substitutions if not restored by enzymatic DNA repair mechanisms during replication [51,52]. 
Systematic analysis of the type and frequency of ENU mutations was recently done using  
whole-exome and whole-genome sequencing [53–55]. Genome-wide, ENU has an average point 
mutation rate of 1.5 per Mb of genomic DNA [55], with a bias for AT to GC transitions (45%) 
compared to AT to TA transversions (28%). The size of a given target gene and its AT density can 
therefore explain, at least in part, the variable sensitivity to the mutagenic effects of ENU. With a 
mouse genome size of about 2.7 Mb including 1.5% of protein coding sequence, one can expect 
about 1,900 new sequence variants per genome of which about 30 are coding. 
With a few exceptions (microRNA and cis-elements) [56,57], to date most ENU-induced 
phenotypes, whose corresponding genotype has been identified, result from nucleotide  
changes that alter the coding sequencing. A current survey of the Mutagenix database 
(http://mutagenetix.utsouthwestern.edu/home.cfm) which contains the largest collection of  
ENU-induced phenotypic mutations (N = 185) [58], revealed that 61% were missense mutations, 19% 
nonsense alleles, 18% splicing defects, and 2% were frame-shift mutations. Therefore, while  
targeted mutations producing null alleles are necessary for genetic dissection of phenotypic traits, 
ENU-induced point mutations can also be used in parallel, revealing the multiple functions of a 
gene by altering individual protein domains and splicing products. Further, point mutations can 
produce various types of allelic series: (1) hypermorphic or hypomorphic alleles (increased or 
reduced activity of the gene product, respectively); (2) antimorphic alleles (the gene product is 
antagonistic to the wild-type allele); or (3) neomorphic alleles (new molecular function) [59] which 
can display a broad range of possible phenotypes.  
The phenotypes that arise following ENU mutagenesis segregate with different inheritance 
patterns. Autosomal recessive (68%) is the most commonly observed, followed by dominant  
or co-dominant segregation (23%); X-linked recessive (4%) or X-linked dominant (1%) are rare, 
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though 4% remain uncharacterized [58]. Once male mice have been treated with ENU, they are 
crossed to female mice. The resulting large cohorts of offspring are then tested to identify the 
phenotypically distinct mice most likely to bear a large-effect mutation; this is usually done with 
dominant or recessive screens. The above data illustrates how recessive screens, which require a 
three-generation breeding scheme (see below), constitute a more efficient and inclusive design than 
dominant screens, although the latter are logistically simpler and quicker to conduct since only the 
first generation offspring are analyzed. Using different breeding schemes, these recessive screens 
have successfully advanced our understanding of the intricate cellular and molecular cascades 
involved in immunodeficiency and autoimmunity, as well as in neurological or behavioral disorders, 
as already reviewed by others (see [39–42]). 
Methods for mutagenizing male mice and breeding protocols to recover homozygous mutations 
have been described previously [60–62]. In our laboratory, we use a recessive screen involving 
genetically related mouse strains to generate the collections of mutant mice (Figure 2). By using 
genetically related inbred strains, the number of animals used and the timeline of the experiment 
can be reduced, as the mice that are screened also serve for mapping of the ENU-induced 
phenotypes. Moreover, using closely related strains alleviates any possible second-site modifier 
gene effects that could be present in the mapping strain. Briefly, we use well-validated protocols to 
induce single nucleotide mutations in 129S1/SvImJ (129S1) and C57BL/6 (B6) mice. This is done 
using a single intraperitoneal (i.p.) injection of 150 mg/kg of ENU (129S1) or three weekly i.p. 
injections of 90 mg/kg (B6) [63]. Following treatment, spermatogenesis ceases transiently and 
fertility is then regained after 11–13 weeks. In a general breeding strategy (Figure 2A), generation 
0 (G0) males are then out-crossed with wild-type female mice to produce G1 offspring. These G1 
hybrids carry one full set of mutagenized chromosomes and one full set of wild-type chromosomes. 
Individual G1 males are bred as founders of separate pedigrees, with the aim of bringing B6 or 
129S1 sequence variants to homozygosity. To achieve it, G1 males are first crossed with 
genetically related wild-type females (129X1/SvJ (129X1) females for 129S1 males and C57BL/10 
(B10) females for B6 males) to distinguish mutation-bearing chromosomes while preventing the 
introduction of additional genetic modifiers. The mutations present in the G1 founders are thus 
propagated in the G2 progeny. Since each G2 offspring should inherit only 50% of sequence 
variants present in the G1 males, two G2 daughters are backcrossed to their G1 father. This 
produces G3 progeny, where 12.5% of the G1 sequence variants should come to homozygosity in 
any given G3 offspring. On average, each G3 offspring is thus expected to be homozygous for about 
four to five loss-of-function sequence variants of the 30 present in the G1. Therefore, if there is a 
recessive Mendelian immune variant segregating within a pedigree, researchers can expect to 
identify 25% of individuals with the same trait or a cluster of two to four deviants by initially 
screening about 16 G3 offspring in that pedigree. The clustering of heritable variants within a 
pedigree filters out unavoidable false positives, which occur at a low rate (~5%) in screens for host 
susceptibility to infection; typically only one individual constitutes a false positive in a given 
pedigree. Variations of this breeding strategy have been used (Figure 2B) and will be described in 
the corresponding sections. 
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Figure 2. Breeding strategies used in our program to produce mice carrying homozygous  
N-ethyl-N-nitrosourea (ENU) mutations. (A) Treatment with ENU introduces mutations 
(indicated by a black or gray square) in the germ-line of males of generation 0 (G0). The 
mutagenized G0 male is out-crossed to a wild-type female to produce first generation (G1) 
animals. First generation G1 mice are carriers of ENU-induced mutations (indicated by  
half-filled black squares). G1 males are mated to wild-type females, to produce second 
generation (G2) animals, which carry about half of the mutation load present in the  
parental G1. Two G2 daughters are backcrossed to their G1 father to yield  
third-generation (G3) mice, where the original mutations have been brought to 
homozygosity (filled black squares). About 25% G3 progeny are expected to present a 
deviant phenotype in pedigrees that bear a given relevant recessive mutations; (B) In this 
strategy, the G1 progeny of two independent G0 males are intercrossed to produce G2 
animals, which in turn are intercrossed to produce G3 mice. 
 
(A) (B) 
This pedigree structure allows early mapping of heritable variants. At this point, breeding and 
screening of additional G3 siblings confirm the inheritance of Mendelian recessive infectious traits 
in one quarter of the offspring. If eight to ten G3 animals displaying a new recessive immune trait 
are obtained out of 40–50 G3 mice in the pedigree, a genome-wide scan can be performed to 
establish linkage of the variant to a large initial segment. Before the advent of next generation 
sequencing (NGS), a time consuming and labor intensive positional cloning approach had to be 
undertaken to identify candidate genes bearing new genetic variants. The use of NGS techniques 
has dramatically increased the pace of mutation identification. 
4. Gene Identification 
The materials and methods underlying phenotype-driven or forward genetics approaches have 
become considerably more powerful over the years. Traditionally, these approaches required 
laborious genetic and fine mapping procedures in order to refine regions of interest to large 
megabase (Mb) chromosomal loci for subsequent PCR amplification and direct sequencing. 
Nonetheless, they were the methods of choice for the discovery of novel genes and/or novel gene 














approaches, as it allowed the elaboration of robust methods of systematic mutation discovery, thus 
further closing the gap between phenotype and genotype. However, the sequencing and analysis of 
whole mammalian genomes remain a substantial bottleneck for many laboratories, both financially 
and computationally. Instead, inexpensive alternatives have been favored in order to sequence 
mouse mutations, namely targeting approaches using minimal mapping data. Moreover, targeted 
sequencing of coding regions of the genomes, or exomes, are particularly relevant for large 
mutational collections and have become the standard in cases where high-throughput gene mutation 
discovery methods are needed [64–66]. We describe below some of the standard techniques for 
sequencing and analysis of de novo mutations generated within ENU mouse models in a rapid and 
unbiased fashion. 
Currently, the most widely used commercial mouse exome capture panels (Agilent and NimbleGen) 
target approximately 37 Mb of the sequences contained within the consensus coding sequence 
(CCDS) database of the genome, as well as other genomic features (e.g., microRNAs) [53,67]  
(see Table 1). The protocols contained in each of these kits are very similar. First, labeled DNA  
(or RNA) baits ranging from 55 to 120 bases are hybridized to fragmented genomic DNA. The 
baits are pulled down using magnetic beads, and the “captured” genomic fragments are then 
sequenced using NGS instruments such as SOLiD, Illumina or Roche 454.  
Table 1. Comparison between two standard whole exome mouse capture kits. 
 Agilent Sureselect Mouse All Exon Nimblegen SeqCap Ez 
Probe size 120 bases 55–105 bases 
Target Region size 49.6 Mb 54.3 Mb 
Probe Type RNA DNA 
Number of Targeted Exons 221,784 203,225 
Mutation identification and ultimately gene discovery in the context of ENU-designed projects 
require significant computational analyses, where sequenced DNA fragments are mapped to a 
mouse reference sequence (C57BL/6J) [68] or to that of a specific mouse strain when  
available [36], followed by post alignment and variant calling procedures. For a given mouse 
sample, these procedures typically produce a large amount of single nucleotide variants (SNVs) 
and insertion/deletions (INDELs), which, depending on the sample’s genetic background and 
coverage, can range from a few thousand to hundreds of thousands in more divergent strains. 
Further steps are required to filter the strain specific variants if the reference sequence of the mouse 
background is not used. This can be accomplished, for example, by adding more controls.  
Numerous workflows (e.g., Genome Analysis Toolkit (GATK) best practices [69] and McGill 
University and Genome Quebec Innovation Centre (MUQGIC) [70]) have been designed for 
mutation discovery. Although each design may vary with regards to the steps and computational 
programs utilized, the underlying principle of these workflows remains the same. Each one divides 
the processing and analysis of sequencing data into three key steps: (1) data processing for quality 
control and filtering of sequenced reads; (2) variant discovery through alignment of filtered reads to 
known reference genomes; and (3) variant refinement leading to variant calling to identify 
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mutations of interest. A flow diagram similar to GATK best practices [71] but with subdivided 
steps in file format is shown (Figure 3). 
Figure 3. A typical workflow to identify causative mutations in genomic data. The 
procedures are separated into three general processes: (1) data processing, where raw 
sequencing data (fastq format) is aligned (sam/bam file format) to a known genome 
reference followed by alignment improvement steps (i.e., indel realignment, mark 
duplicates and base recalibration); (2) a variant discovery step in which single 
nucleotide variants (SNVs) are called from aligned data followed by subsequent 
filtering (using variant quality thresholds; hard filtering, or Genome Analysis Toolkit 
(GATK) variant recalibration; and soft filtering); (3) and a variant refinement step to 
reduce the number of candidate mutations to a manageable number for further 
validation using Integrative Genomics Viewer (IGV) and/or Sanger sequencing [71].  
 
The sequenced reads (in fastq file format) are usually derived from the instrument specific  
base-calling algorithm (or subsequent steps therein) and contain an identifier for each raw DNA 
fragment, as well as a phred quality score for each base in the fragment. The raw reads are aligned 
to a reference genome following a quality control step or “trimmed” to obtain a high quality set of 
reads for sequence alignment file (sam/bam) generation. The trimming step removes adaptor 
sequences from the raw reads and optionally removes bases at the 3' end using a specified phred 
quality threshold, and/or performs a size selection filtering step (e.g., trimmomatic [72]; Figure 3). 
The trimmed reads are aligned by using either a “hashing” or an effective data compression 
algorithm called the “Burrows-Wheeler transform” (BWT). Fast, memory-efficient BWT-based 
aligners, such as BWA [73], are often used in NGS studies. However, these aligners tend to be less 
sensitive than recent hash-based aligners, such as Novoalign [74], which conversely tend to require 
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Numerous software packages such as GATK [69], samtools [76], and Picard [77] have been 
developed to attempt to correct for biases incorporated at the sequencing and alignment phases, 
thus improving variant detection (Figure 3). During library construction and sequencing, duplicated 
DNA fragments produced by polymerase chain reaction (PCR) amplification and optical duplicates 
can occur. Software package such as Picard markDup and Samtools rmdup remove or flag  
potential PCR duplicates if both mates (in the case of paired-end reads) contain the same 5' 
alignment positions.  
At the alignment phase, due in part to the heuristics of the alignment algorithm and the 
alignment scoring procedure, refinement of mapped reads near indels (GATK indel realigner [69]) 
and quality scores (GATK base recalibration [69]) are typically required to help reduce false 
positive variants in downstream analysis. Utilizing these two post-alignment programs, GATK 
indel realigner transforms regions with misalignments generally introduced by indels into clean reads 
containing fewer mismatches, whereas base recalibration improves the quality score to better reflect 
the true base-calling error rates by correcting for variation in quality with respect to machine cycle, 
sequence context, and other attributes. 
To identify the protein-encoding mutations induced by ENU, numerous variant-calling 
procedures can be employed to convert base calls and quality scores into a set of genotypes on a 
per sample basis. The most recent variant callers, such as GATK [69], Samtools [75], and 
FreeBayes [78], use sophisticated statistical models that can be extended to incorporate additional 
information regarding allele frequencies and/or linkage disequilibrium (LD) patterns. Furthermore, 
joint analysis of multiple individuals can further improve genotype calling for single samples by 
taking into account allele frequencies or genotype frequencies [79]. 
Variant detection programs convert the refined base-calls and quality scores resulting from the  
post-alignment process and generate variant data containing information regarding the genomic 
position, SNV quality, etc., of each variant. Generally, thousands of SNVs are generated by the 
detection protocol. Further annotations and filtering procedures are thus required to identify the 
expected 50–100 ENU-induced mutations [80]. The use of functional annotation programs such as 
snpEff [81] and VEP [82], coupled with the exclusion of known variants (for example, on the basis 
of SNP data from the dbSNP database [83]) and of variants falling below acceptable quality 
metrics (QUAL, genotype quality (GQ), strand bias, etc.), can help to preferentially identify protein 
coding mutations. However, despite rigorous post-alignment refinement and variant exclusion 
criteria, recurrent false positive SNVs remain. By comparing a set of ENU samples to unrelated 
genome or exome sequencing data sets, as well as to mouse genomes data from the Sanger  
Institute [68] generated using the same analysis workflow, variants commonly shared between 
related strains or systematic false positives arising from mapping issues related to genome structure 
(e.g., repetitive or paralogous sequences) or errors (e.g., miss-annotated reference allele) can be 
flagged for removal. In numerous studies this procedure has proven successful in prioritizing 
candidate mutations and decreasing their numbers [54,80], and has helped reduce the time 
requirements and cost of visual inspection (e.g., Integrative Genomics Viewer (IGV) [84]), of 
Sanger sequencing [85], of validation, and ultimately of novel mutation/gene discovery. 
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ENU experiments have successfully identified candidate causative mutations residing in protein 
coding sequences, splice sites or UTRs. However, these causative mutations are not always 
successfully identified due to either the fact that they may reside in uncaptured regions (i.e., non-coding 
regions, regulatory regions or un-annotated coding sequences that are not captured by the capture 
design) or to biases in standard mapping and variant calling procedures. Therefore, further 
improvements are required in the development of software tools in order to better deal with regions 
of the genome that are difficult to map (e.g., paralogous sequences and GC-rich regions). The 
design of exome capture kits must also be improved to extend the set of captured regions. 
Alternatively, whole genome sequencing may also be a way to identify mutations in regions not 
captured by whole exome sequencing. 
5. Infectious Screens 
Establishing an ENU mutagenesis program with the aim of identifying genes involved in the 
host response to pathogens presents particular challenges. The first is the choice of a pathogen 
relevant to human health. Mouse models of infection with this pathogen must be available and 
representative of the corresponding human pathology. Also, the contribution of genetic factors in 
human and/or mouse response to this pathogen must be proven to support the feasibility of a 
genetic screen. The second challenge is the choice of the inbred mouse strain to be used for 
mutagenesis. There is ample evidence that the ENU sensitivity of inbred mice is genetically 
controlled and thus widely variable across strains [63]. This must be balanced with the varying 
susceptibility or resistance of inbred strains to infection with specific pathogens. The third challenge 
is the choice of the screening phenotype. Cell-based phenotypes have been used successfully to 
identify fundamental mechanisms of innate and acquired immunity [36,37]. The findings, however, 
require further validation in mouse models to determine a possible role in the infectious process. A 
clinically relevant, robust, and unequivocal in vivo phenotype is also attractive, as it will lead to the 
identification of the most important molecular determinants for a given infection; it will also 
minimize the appearance of false positives. Such phenotypes include severe disease (in terms of 
clinical evaluation or pathogen load) or death, when the mutagenized strain is resistant, or survival, 
when the mutagenized strain is innately susceptible, following infection. As presented below both 
screening approaches have led to the identification of key molecules involved in susceptibility or 
resistance to infectious diseases caused by parasites, bacteria, and viruses. 
6. Malaria Parasites 
Infecting hundreds of thousands of people every year, malaria is a significant cause of morbidity 
and mortality in developing countries (www.who.org). Having co-existed with humans for 
centuries, malaria has exerted a significant selective pressure on the human genome [16,86]. Likely the 
best-known selection has been the retention of deleterious hemoglobinopathies, such as sickle cell 
anemia, in malaria endemic regions [87,88]. Other variants associated with reduced susceptibility 
to malaria infections include those affecting erythrocyte proteins [89–94], the scavanger receptor 
CD36 [95,96], and elements of the host immune response, including human leukocyte antigen  
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(HLA) [97] and tomor necrosis factor-alpha (TNF- ) [98], among others [99,100]. Despite these clear 
examples, the genetic component influencing the human response to malarial parasites is complex, 
multigenic, and influenced by various environmental factors, including parasite virulence [101–103].  
Cerebral malaria (CM) is the most severe and lethal complication of Plasmodium falciparum 
infection in humans [104,105]. Prevalent in immunologically naïve children, CM is characterized 
by high fever and a rapid progression to severe cerebral symptoms including impaired consciousness, 
seizures, and coma [106,107], resulting in death in about 20% of all cases [16,107]. During CM, 
parasitized erythrocytes (pRBCs) become trapped within the brain microvasculature [103], 
triggering a strong pro-inflammatory response [104,105] leading to the activation of the vascular 
endothelium [106], as well as the recruitment of immune cells and activated platelets [108–110]. 
This host-directed immune response results in the disruption of blood-brain barrier integrity [111], 
suggesting that CM pathogenesis is at least partially caused by over-activation of the inflammatory 
response [16,106,107]. By gaining a more thorough understanding of this disease, including of the 
host genetic factors affecting differences in susceptibility, novel and more effective prophylactic and 
therapeutic interventions can be developed. 
Mice infected with Plasmodium berghei ANKA (PbA) have been used as a model of CM 
(experimental cerebral malaria, ECM). Mice susceptible to ECM develop neurological symptoms 
between days five to eight post-infection, including ataxia, hind limb paralysis, coma, and  
death [112]. ECM-resistant mice survive the cerebral malaria phase, but subsequently succumb to 
hyperparasitemia and resultanting anemia within three weeks post-infection [16]. Informative 
crosses between mouse strains of varying degrees of susceptibility to PbA have revealed at least 
nine quantitative trait loci (QTL) that modulate the host response to ECM [113–118]. However, 
these methods have failed to identify the causative genes, due in part to the large size of the 
genomic region and to the high number of positional candidates under the QTL peaks [119]. By 
introducing random point-mutations and small deletions within a susceptible genetic background, 
such as B6, B10, or 129S1, ENU-mutagenesis allows for the interrogation and determination of 
genes that are involved in resistance to ECM. 
6.1. Screening for Acquired Resistance to Cerebral Malaria 
We have successfully utilized ENU-mutagenesis to identify genes responsible for controlling 
susceptibility to ECM [119]. Male B6 mice (G0) were mutagenized with the administration of three 
consecutive i.p. injections of ENU. These G0 males were then bred to wild-type B10, 129S1, or B6 
females to establish heterozygous G1 offspring. G1 males were out-crossed a second time to  
wild-type susceptible females to form the G2 generation. One to two G2 females per pedigree were 
backcrossed to the paternal G1 to produce G3 offspring, fixing mutations to homozygousity in 
approximately 25% of all animals (Figure 2A). G3 mice were infected with 106 Plasmodium 
berghei ANKA-parasitized RBCs by intravenous injection. The appearance of neurological 
symptoms and survival time were used as phenotypic markers of ECM disease [119]. Phenodeviant 
pedigrees were defined as those exhibiting >17% resistant pups in at least three litters or 10 
offspring, whichever came first. 
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Enhanced laboratory resources and technological advances have allowed us to implement three 
variations of the general protocol outlined above. The first screen out-crossed mutagenized G0 
males to the B10 genetic background. G3 animals from this cross were phenotyped for  
ECM-resistance. To facilitate linkage mapping, G1 males identified as segregating an  
ECM-resistant phenotype were out-crossed to 129S1 wild-type females. The resulting F1s were 
intercrossed randomly to generate F2 offspring, which were then phenotyped. Pedigrees identified 
as resistant were then analyzed for linkage analysis using a genome scan. A total of 6062 G3 mice 
from 244 G1 males were screened, generating nine phenodeviant pedigrees, with a background 
survival of approximately 2.8%. From this screen, we have identified an ECM protective mutation 
in Jak3 (Jak3W81R) [119]. A cytosolic tyrosine kinase that interacts with the common c chain of 
cytokine receptors (IL-2, -4, -7, -9, -15, -21), JAK3 is required for STAT family members 
dependent transcriptional development and activation of inflammatory pathways in NK, T, and B 
cells [120]. Jak3W81R mutants exhibit reduced numbers of NK cells, CD8+ T cells, and B cells, as 
well as severely reduced production levels of IFN  by CD4+ T cells. We also demonstrated that 
tasocitinib, a JAK3 inhibitor used clinically to treat rheumatoid arthritis (RA) and Crohn’s disease 
(CD), can reduce neuroinflammation and increase survival of Jak3 /+ heterozygotes in the ECM 
model [119]. Genetic variants in JAK and STAT family proteins have been identified as causing 
certain primary immunodeficiencies and are also associated with chronic inflammatory diseases, 
such as inflammatory bowel disease (IBD), multiple sclerosis (MS), and systemic lupus 
erythematosus (SLE) in humans [121–123]. 
With respect to the second screen, we have out-crossed the mutagenized G0 males to the 129S1 
genetic background. The 129S1 strain produces larger litters, allowing for the generation of larger 
numbers of G3 animals. Additionally, out-crossing directly to the 129S1 background eliminated  
the requirement to complete additional out-crossing of phenodeviant animals. Twenty-eight 
phenodeviant pedigrees were identified following the screening of 7705 G3 animals in 220 
pedigrees, with a background survival of almost 8%. An epistatic interaction between the B6 and 
129S1 genetic backgrounds on Chromosomes 4 and 1 was identified in 10 of the 28 phenodeviant 
pedigrees, potentially masking the effect of ENU-mutagenesis [124]. However, several mutations 
were identified in this screen, including an abrogated splicing mutation of Exon 6 in the  
winged-helix transcriptional regulator Foxn1 gene [125] Foxn1 mouse mutants are athymic and 
severely immuno-compromised, while human FOXN1 mutations cause T-cell immunodeficiency [126]. 
Heterozygosity for the Foxn1 mutant allele confers partial protection against ECM, suggesting that 
FOXN1 transcriptional targets may be relevant to reducing neuroinflammation. 
The epistatic interaction between the B6 and 129S1 genetic backgrounds highlights both the 
limitations and advantages of different variations of the ENU-mutagenesis screen. Both the B6 and 
129S1 strains are susceptible to Plasmodium berghei ANKA infection, developing neurological 
symptoms between Days 5 and 10 post-infection. However, in over a third of the phenodeviant 
pedigrees identified in the mixed background screen, an enrichment of B6 alleles on distal 
chromosome 4 was associated with resistance to ECM. With such a high percentage of 
phenodeviant pedigrees mapping to the same locus, we hypothesized that the likelihood of this 
effect being caused by a single causative ENU-induced mutation was minimal, and that this effect 
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was due to genetic background rearrangements. Additional analysis revealed that ECM resistance 
on Chromosome 4 (Berghei resistance locus 8, named Berr8,) was being modulated by a second 
locus on Chromosome 1 (named Berr7). Although we had expected to discover single point mutations 
due to ENU-mutagenesis, these results highlight the complex nature of cerebral malaria, as well as 
the difficulty inherent to finding point mutations that are solely responsible for trait modulation. 
Due to improvements in technology and the resulting cost reduction, we switched from linkage 
analysis to exome sequencing analysis for the identification of ENU-induced mutations, removing 
the requirement for genetic background variations. Hence, the third and final screen was executed 
on a pure B6 genetic background, wherein the mutagenized G0 males were outcrossed to wild-type 
B6 females. Switching to the pure genetic background eliminated the likelihood of epistatic 
interactions between genetic backgrounds, as exhibited in the reduction of background survival rate 
from almost 8% in the B6x129S1 screen to less than 5% in the pure B6 screen. However, due to 
smaller litter sizes, almost 40% fewer G3 animals were produced from the 109 screened pedigrees. 
Even so, eight phenodeviant pedigrees were identified and are currently being investigated. 
6.2. Screening for Acquired Resistance to Blood-Stage Malaria 
ENU-mutagenesis has also been used to identify genes implicated in host resistance to  
blood-stage malaria. A dominant ENU-mutagenesis screen for erythrocyte production and 
maturation defects linked to malaria resistance identified two mutations in the Ank1 gene: an 
alternative splice acceptor mutation resulting in a frameshift mutation and premature stop codon 
was identified in Mpl /  mice mutagenized on a BALB/c background [127], and a single nonsense 
mutation was identified in mutagenized SJL/J mice [128]. Both mutations result in early truncation 
of the ANK1 protein, encoded by Ank1. Implicated in hereditary spherocytosis, an inherited form 
of hemolytic anemia, mouse erythrocytes harboring mutations in Ank1 exhibit increased  
resistance to P. chabaudi, a model of blood stage malaria, potentially due to parasite maturation 
impairment [127,128]. 
6.3. Conclusion  
ENU-mutagenesis has enabled the identification of individual genes involved in modulating the 
host response to both cerebral and blood-stage malaria. We have identified mutations in host 
inflammatory genes involved in T cell development and/or function (Jak3 and Foxn1), thymus 
development, and immune cell function [119,125]. These results are consistent with the current 
understanding of the role of T cells in cerebral malaria pathogenesis [129–132]. Additionally, these 
genes have been associated with the modulation of other models of acute inflammation as well as 
of chronic inflammatory conditions [99]. Other labs have identified mutations in the erythrocyte 
protein ANK1, an important factor in the erythrocyte cytoskeleton [127,128]. Mutations in 
erythrocytic proteins, including the cell surface Duffy antigen [92] and structural component  
Band 3 [89–91], have been associated with increased resistance to malaria in humans for several 
years. Together, these findings advance our understanding of the host response to malaria, and may 
aid in the discovery of novel drug targets against this devastating disease. 
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7. Salmonella Bacteria Infections 
Salmonella enterica infections in humans represent an increasingly significant economic and 
public health challenge that is associated with high morbidity and mortality in both developing and 
industrialized countries [133]. In fact, the increase in global population, the emergence of 
antimicrobial resistance in bacteria, and the prevalence of co-infections (e.g., Plasmodium, HIV) 
exacerbate the burden of this infectious disease [38]. Salmonella infection in humans can  
cause a range of food and waterborne illnesses, from a localized diarrheal disease to the more 
severe systemic disease, typhoid fever. In fact, nontyphoidal Salmonella enterica serovars  
(e.g., S. typhimurium, S. enteritidis) are the second leading cause of bacterial food poisoning in the 
United States. Importantly, about 1%–4% of these Salmonella-infected individuals are at an 
increased risk of developing sepsis, chronic infection or clinical sequelae (ex. chronic arthritis) [134–136]. 
Salmonella enterica Typhi is the etiologic agent of typhoid fever, which is endemic primarily in 
areas with poor sanitation and a lack of clean drinking water. Salmonella typhi causes twenty-one 
million infections annually, with 220,000 deaths [133]. The outcome of infection depends on the 
activation of early innate functions, neutrophilic infiltration, phagocytosis by tissue macrophages, 
and inflammatory cytokine/chemokine secretion (e.g., IFN , IL-12, IL-18, TNF , and IL-6). 
However, ultimately, the resolution of systemic infection is dependent on both humoral and  
cell-mediated immune responses [137,138]. 
In humans, the contribution of host genetics to Salmonella infection has been proven by the 
candidate gene approach and by exome sequencing in patients. Individuals with defects in the  
IL-12/IL-23 (IL-12 , IL-12R 1) and IFN  (IFN R1, IFN R2, STAT1) pathways are in fact 
predisposed to Mendelian susceptibility to mycobacterial disease (MSMD) and/or disseminated 
Salmonella infection [139–144]. Furthermore, major histocompatabilty complex (MHC) class II 
and III loci, as well as the TNF haplotype, were significantly associated with typhoid fever in a 
Vietnamese cohort [145]. Although clinical evidence supports a strong role for host genetics, 
susceptibility to Salmonella-related infections is complex and also influenced by environmental 
factors and bacterial serotype. 
Salmonella typhimurium infection is a recognized experimental model for studying systemic 
typhoid-like disease in mice [146,147]. Various classical inbred strains of mice demonstrate 
differential susceptibility/survival following sub-lethal intravenous infection with S. typhimurium 
strain Keller [148]. In particular, the 129 substrains (129S1, 129X1) of mice are highly resistant to 
virulent infection, compared to DBA/2J mice, which display intermediate mortality, and to the 
highly susceptible B6 strain. Although the genetic and molecular basis of several mutations 
important in resistance to Salmonella infection in mice have been identified, namely 
Nramp1/Slc11a1, Tlr4, and Pklr, the low frequency of naturally occurring spontaneous mutations 
has prompted the use of novel genomic approaches like ENU mutagenesis to identify novel host 




7.1. Screening for Acquired Susceptibility to Salmonella typhimurium 
We used ENU mutagenesis to further decipher the host genetic component of susceptibility to 
Salmonella infection in vivo. In the screen, G3 ENU-mutagenized mice between 7 and 9 weeks of 
age were challenged intravenously through the caudal vein with an infectious dose of virulent 
Salmonella typhimurium strain Keller, varying between 1000 to 10,000 colony forming units 
(CFUs), depending on the background strains used for breeding. Over the course of 14 days, 
infected mice were monitored for clinical manifestations of illness including a body score index of 
less than two, muscle wasting, fur ruffling (fever), inactivity, twirling, and shaking. Susceptible 
mutants were defined as those presenting severe clinical signs between Days 3 to 7 post-infection 
(prior to background control mice). On average, a minimum of six to eight G3 mice per G2 female 
were infected with the expectation of identifying two to five heritable deviant pedigrees following 
the screening of G3 mice derived from roughly 100 G1 males. 
Two prototype breeding schemes differing in the genetic contribution of background strains  
(B6, 129S1, 129X1, and DBA/2J) have been used in five rounds of screening for Salmonella 
susceptibility. Male 129S1 (G0) mice were mutagenized using a single i.p. injection of 150mg/kg 
of ENU at 8–10 weeks of age. The first breeding scheme involved the generation of G1 mice 
produced by two independent G0 males (Figure 2B). The G0 males were crossed to B6 females. 
For each G1 pedigree, four G2 brother-sister pairs were bred to produce G3 progeny. Using this 
breeding scheme, the Salmonella susceptibility allele Slc11a1Asp169 from B6 mice was segregated 
into the G2 population. G2 animals carrying the wild-type Slc11a1 alleles were then selected for 
further breeding. As the introduction of susceptibility to the B6 background was interfering with 
our capacity to capture recessive alleles acting in later infection stages (past Day 4), we 
subsequently modified the breeding scheme as in Figure 2A. Hence in the second round of 
screening, G0 males were out-crossed to wild-type 129X1 females to generate G1 heterozygote 
offspring. G1 males were further backcrossed to 129X1 females to generate G2 mice. G2 females 
were then backcrossed to the G1 male to give rise to G3 progeny, which were then used for primary 
phenotyping of susceptibility to infection using survival analysis with 10,000 CFUs. Using the 
following scheme, 643 G3 mice derived from 39 G1 males were screened and two deviant 
pedigrees were identified: Oxie & Celie (Ity14) (Immunity to Typhimurium locus 14) and Jody & 
Cloe (Ity15). In this particular case, we used a strain that was closely related to the mutagenized 
males to prevent or minimize the impact of the genetic background on the expressivity of the 
phenotype while allowing mapping in the G3 animals. We identified 105 SNPs between 129S1 and 
129X1. However, their clustering in the genome did not allow the mapping of some pedigrees. 
Variations of these protocols (Figure 2) were used to facilitate mapping resolution using SNPs 
between 129S1 and DBA/2J directly in the G3 population. In the third round of screening, G1 
males were out-crossed to DBA/2J, and the resulting G2 mice were randomly intercrossed to 
generate G3 progeny. G3 mice were then screened with an infectious dose of 5000 CFUs. Using 
this scheme, 1570 G3 mice derived from 65 G1 males were screened, and one deviant pedigree, 
Ity16, was identified, validated, and cloned [154]. In the fourth round of screening, G0 males were 
out-crossed directly to DBA/2J in order to introduce genetic variability as early as possible in the 
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breeding scheme, thus facilitating mapping (Figure 2B). In this round, 3,348 G3 mice derived from 
208 G1 males were screened and four deviant pedigrees were identified: Cherrie & Walter (Ity17), 
Jeanine & Harman (Ity18), Lexie & Leona, and Philippe & Desiree. Lastly, with the onset of 
whole-exome sequencing as an alternative to mapping using genetic variation between parental 
strains, the breeding scheme shown in Figure 2B was carried out on an 129S1 background. From the 
following screen we have infected 580 G3 mice derived from 41 G1 males, and two deviant pedigrees, 
Rakeem & Athena and Lessie & Virgie, were identified. 
In summary, 8,389 G3 mice derived from 491 G1 males were screened for increased 
susceptibility to Salmonella typhimurium infection as measured by survival analysis. A total of 10 
deviant pedigrees have been identified (Table 2). From this screen, we have to date identified, 
cloned, and characterized Salmonella susceptible mutations in Usp18 (Usp18L361F), Ank1 
(Ank1Gln1357Ter), and Stat4 (Stat4G418_E445) [154–156]. USP18 (Ubiquitin Specific Peptidase 18) both 
regulates type I IFN signaling and functions as a protease to remove ISG15 adducts from substrate 
proteins [157,158]. We have reported that decreased survival in mice that carry the Usp18L361F 
mutation results from increased bacterial loads in the spleen and liver, as well as increased 
inflammatory response leading to septic shock [156,159]. In more recent studies, we have shown 
that regulation of type I IFN signaling is the predominant mechanism affecting the susceptibility of 
Usp18L361F mice to bacterial infection. Also, we have found that hyperactivation of type I IFN 
signaling leads to increased ISGylation and IL-10 production, as well as decreased expression of 
markers of autophagy [160]. Additionally, we have shown that Usp18L361F mice are more 
susceptible to infection with Mycobacterium tuberculosis (same as above). 
Table 2. Summary of the three ENU-mutagenesis screens for experimental cerebral 
malaria, Salmonella, and herpes simplex virus (HSV)-1. 
 Malaria Salmonella HSV-1 
G1 males 573 491 265 
G3 mice 16,411 8,415 7,802 
Deviant pedigrees (in progress) 45 16 11 
Confirmed pedigrees 5 3 2 
The transcription factor STAT4 (Signal Transducer and Activator of Transcription Factor 4) is a 
critical mediator of IL-12 signaling. It plays an important role in both innate and adaptive immunity 
by regulating the transcription of target genes such as Ifng and those mediating NK cell 
cytotoxicity, T helper 1 cell differentiation, and immunoglobulin isotype switching to IgG1. The 
Stat4G418_E445 mutation results in impaired innate IFN  secretion, primarily from splenic NK and 
NKT cells, contributing to increased hepatosplenic bacterial loads. These findings support the 
importance of the IL-12/IFN  axis in resistance to Salmonella infection. 
ANK1 is a structural protein of the erythrocyte membrane, which plays an important role in 
membrane stability by mediating the attachment of band 3 (SLC4A1) and protein 4.2 (EPB4.2) to 
the spectrin-based membrane cytoskeleton [161]. Mice homozygous for the Ank1Gln1357Ter mutation 
develop hemolytic anemia and present clinicopathological features of human hereditary 
spherocytosis, the most common form of congenital chronic hemolysis in Europe and North 
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America [162]. On one hand, as observed with other mutations affecting red blood cell  
turnover [163], Ank1 deficits protect mice against malaria [128]. On the other hand, normal ANK1 
function is critical for an effective host response against infection with Salmonella. Salmonella 
susceptibility in Ank1Gln1357Ter mutant mice is the result of a combination of factors, namely the 
concomitant deposition of iron in tissues, which favors bacterial growth, and low levels of the iron 
regulatory hormone hepcidin [154]. In addition, the strong induction of heme oxygenase 1 (Hmox1) 
expression observed during malaria infection and in Ank1Gln1357Ter mutant results in impaired 
oxidative burst function, which favors the intracellular replication of bacteria [154,164]. 
7.2. Ex Vivo and in Vivo ENU Screens for Susceptibility to Bacteria Infections 
Additional ENU initiatives have uncovered novel genetic determinants of resistance to bacterial 
infections. Different primary screens in G3 offspring were used, including: (1) measurement of 
TNF bioactivity after ex vivo challenge of thioglycolate-induced peritoneal macrophages with 
various pathogen-associated molecular patterns (PAMPs) (Cd36, Tnf, Map3k8) [165–167];  
(2) measurement of type I IFN bioactivity after ex vivo challenge of thioglycolate-induced 
peritoneal macrophages with Listeria monocytogenes (Tmem173/Sting) [168]; (3) in vivo screen for 
other classes of pathogens (Slfn2) [169]; (4) mutations affecting hematopoetic cell development 
(Genista-Gfi1) [170]; and (5) visible phenodeviants presenting inflammatory lesions of the skin 
(Scd1) [171] or of the feet (Ptpn6/Shp1) [172]. For example, a TLR2 agonist screen in 
macrophages identified the Oblivious pedigree, which possesses a mutation in Cd36 resulting in 
increased susceptibility to infection with Gram positive bacterium Staphylococcus aureus [165]. In 
addition, the Sluggish pedigree, which carries a mutation in the Map3k8 kinase, has impaired type I 
IFN production downstream of TLR7 and TLR9 signaling, rendering it susceptible to Group B 
streptococcus infection in vivo [166]. Another example is the ENU-induced mutation in Gfi1 within 
the Genista pedigree, wherein depletion of PMNs confers resistance to Brucella abortus  
infection [173,174] and increased susceptibility to oral infection with Salmonella typhimurium 
sfiA  [170]. Moreover, the ex vivo ENU screen using Listeria monocytogenes identified the 
Goldenticket pedigree as carrying a mutation in Tmem173/Sting, further demonstrating the 
importance of type I IFN signaling during bacterial infection [168]. 
7.3. Conclusion 
ENU-mutagenesis identified single gene effects (novel allele and novel function) within critical 
pathways involved in immunity to bacterial infection that could potentially be translatable to 
infection with other classes of pathogens and/or to chronic inflammatory diseases. The findings 
have emphasized the importance of IFN signaling (Usp18, Stat4, Sting, Map3k8) during bacterial  
infections [155,156,166,168], as well as erythropoeisis and iron metabolism, (Ank1) in the case of 




8. Herpes Viruses 
The Herpesviridae family is a large ancient family with a long history of coevolution with their 
hosts probably predating the origin of the primate lineage. Altogether the nine human herpesviruses 
infect 90% of the world population causing different types of pathologies that vary considerably 
according to the immune status of the infected individual. These ubiquitous viruses constitute a 
striking example of the intricate interplay that can be gradually established between host and 
pathogen, and show that important information can be gleaned from the study of host-pathogen 
interactions, namely the contribution of both viral immune evasion and host resistance genes to the 
outcome of infection. 
8.1. Cytomegaloviruses 
Human cytomegaly virus (HCMV) is the most frequent congenital viral infection in developing 
countries, potentially leading to blindness, deafness or mental retardation in affected infants. 
Primary infection or reactivation of the virus can result in severe morbidity and mortality, 
especially in immune-compromised individuals such as transplant recipients, leukemia or 
lymphoma patients and AIDS patients. Fortunately, HCMV is closely related to its murine homologue, 
mouse cytomegalovirus and both cause death in immunocompromised individuals [175,176]. Thus, 
infection of mice with MCMV represents an excellent model for the study of HCMV pathology 
and indeed it is an important tool for virologists, immunologists, and geneticists, all of whom have 
benefited from the well-developed state of the model. Forward genetic studies in inbred mouse 
strains identified major epistatic (Klra16/H2k) or single gene effects (Klra7, Klra8) demonstrating 
the crucial role that natural killer (NK) cell specific activating (Ly49H, Ly49P) and inhibitory 
(Ly49G) receptors play in response to virus infections (reviewed in [177]).  
8.2. Screening for Altered Immune Responses to MCMV 
Beutler and colleagues were the ones to initiate the ENU screen for MCMV susceptibility (for 
the latest review, see [178]). With this strategy, over 20,000 G3 B6 mice carrying ENU mutations 
were infected i.p. with 105 plaque forming units (pfu) of MCMV. This viral dose was chosen because 
wild-type B6 mice are uniformly resistant in this infectious experimental situation. However, the 
pheno-deviant offspring that exhibited clinical signs of disease or/and high viral titers in the spleen 
were considered susceptible. Several mice with immunodeficiency phenotypes identified from 
other screens made by Beulter’s group, such as defects in toll-like receptor (TLR) signaling or 
adaptive immunity, were also tested for their potential MCMV susceptibility. Here, we highlight 
some of the most important findings that have been made using ENU-mutagenesis to test 
susceptibility to MCMV infection. 
Dendritic cells (DCs) are specialized cells of the hematopoietic system that alert the immune 
system to the presence of infection. Therefore, they generally represent the first line of defense 
against pathogens. In the context of MCMV infection, DCs recognize the virus through TLR3 and 
TLR9, which are able to respectively detect double-stranded RNA (an intermediate product of viral 
replication) and viral double stranded DNA. Following MCMV recognition, DCs and plasmacytoid 
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DCs (pDCs) in particular, produce large amounts of antiviral type I IFN cytokines (IFN- / ), 
which are essential mediators of the innate and adaptive immune responses. Thus, loss-of-function 
mutations in genes that encode components necessary for the expression of IFN- /  (such as Tlr9, 
Tlr3, Myd88, Trif, and Unc93b1), or that are involved in the IFN- /  signaling pathway  
(ie, downstream of IFN- /  receptor), like Stat1, have been shown to increase susceptibility to 
MCMV infection [179–182]. It should be noted that among all of these ENU mutations, only the 
one in Stat1 was initially identified from the MCMV screen, the others being deduced from 
immune screens. The NF- B signaling pathway is also essential for survival to MCMV infection. 
This is attested by the identification of a loss-of-function mutation in the Ikbkg gene encoding 
NEMO, a regulatory subunit of the IKK complex responsible for the nuclear translocation of  
NF- B [183]. Ex vivo screens for increased susceptibility to MCMV infection have been performed 
on peritoneal macrophages isolated from ENU-mutagenized mice, and revealed a missense 
mutation in the Eif2ak4 gene encoding GCN2 [184]. This protein is related to PKR, an effector 
known to inhibit viral replication via phosphorylation of the alpha subunit of eukaryotic initiation 
factor 2 (eIF2 ). The loss-of-function mutation identified in Eif2ak4 affects the phosphorylation of 
eIF2  in response to MCMV infection and was therefore associated with an increased susceptibility 
to MCMV. The MCMV screen, together with the immune screens, led to the identification of 
several phenodeviants with mutations in genes that contribute to the establishment of an efficient 
immune response against pathogens, as they act at different levels of IFN- /  production (TLR9, 
TRIF and UNC93B1), of IFN- /  signaling (STAT1), and of the antiviral response (GCN2). 
DCs are not the only sites of MCMV recognition. Natural killer (NK) cells are also  
important responders to MCMV infection, playing a crucial role in containing it at early times  
post-infection [185,186]. This was initially demonstrated by in vivo depletion studies, in which 
specific antibodies were used to transiently eliminate NK cells before infection with the  
virus [186–188]. Then, the differential susceptibility of the BALB/c and B6 strains was shown to 
be due to the presence of the NK-activating receptor Ly49H in the latter [189,190]. This receptor 
engages the MCMV viral protein m157 [191,192], leading to NK cell proliferation and target cell 
killing [193]. ENU studies allowed the initial discovery of mutations in the Gimap5 and Unc13d 
genes, in the context of two screens that had been designed to detect in vivo defective NK cells and 
cytotoxic T lymphocyte (CTL) responses [194] and MCMV susceptibility [195], respectively. In 
both cases, Gimap5G38C and Unc13djinx/jinx were shown to be associated with defects in NK cell 
activity and impaired resistance to MCMV infection, which are consistent with the crucial function 
of NK cells in the early control of MCMV replication. Gimap5G38C affects NK cell development, 
whereas Unc13djinx/jinx NK cells fail to degranulate, a deficit also observed in activated CD8+ T 
cells. Individuals carrying another deleterious mutation, this time in the Itgb2 gene encoding the 
integrin 2 CD18, which partially affects NK cell development, are, however, fully resistant to 
MCMV [196]. In this case, it suggests that even if the 2 integrins are required for optimal NK cell 
maturation, their partial deficiency could be overcome during MCMV infection, highlighting the 
robustness of antiviral protective responses. 
Other ENU mutations revealed from the screen for host survival against MCMV infection were 
independently identified in the Flt3 [197] and Slfn2 [169] genes. Flt3wmfl/wmfl mice have been shown 
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to have impaired DC development, making these cells incapable of supporting the effector function 
of NK cells [197]. In contrast to Flt3wmfl/wmfl, neither DCs, nor NK cells are impaired in Slfn2I135N  
mice [169]. However, both bacterial and viral infections trigger death by apoptosis of peripheral T 
cells and inflammatory monocytes in Slfn2I135N mice, indicating the crucial role of Slfn2 in 
maintaining quiescence in some immune cells. In addition to these ENU mutants recovered from 
the MCMV screen, four unrelated mutants, called Mayday, Solitaire, Goodnight, and Slumber, 
were shown to die very early post-infection (i.e., D2-D3 p.i.) before high viral titers could be 
observed in the spleen and the liver [198]. Their abrupt death was probably not caused by the direct 
lytic effects of the virus, but mostly by collateral damage, such as the accompanying inflammatory 
reaction in response to MCMV infection, since this phenotype was also observed after 
lipopolysaccharides (LPS) or CpG administration. Based on the comparative sequence analysis of 
these four mutants, their MCMV susceptibility has been shown to be due to a genetic 
rearrangement of the Kcnj8 locus that is likely to have occurred in B6 mice prior to ENU treatment. 
Kcnj8 encodes the potassium channel Kir6.1, which maintains the host homeostatic state during the 
innate immune response. Altogether, these mutations highlight genes that are directly involved in 
the immune system, but also show the importance of other non-immune signaling pathways, such 
as homoestasis, in host survival. 
8.3. Herpes Simplex Virus 1 
HSV-1 is the causative agent of herpes simplex encephalitis (HSE), a lethal neurological 
disease. It is acknowledged that environmental factors have no effect on the pathogenesis of  
“HSE, and no geographical or seasonal patterns in the distribution of the disease have been 
observed [199,200]. Despite the high seroprevalence of HSV-1 (up to 90%) [201], HSE pathology 
is rare and affects only a small proportion of otherwise healthy individuals. Therefore, in addition 
to HSV-1 infection, the second major cause of the disease is the presence of rare host genetic 
factors, which play a large part in determining the susceptibility of an individual to HSE. Loss-of-
function mutations in the UNC93B1, TLR3, TRIF, TRAF3, and TBK1 genes have been associated 
with a human genetic predisposition to HSE [202–207], illustrating the critical role of the 
UNC93B-TLR3-type I IFN pathway in protection against HSV-1. However, these mutations 
exhibit incomplete penetrance and represent only a minority of HSE cases. This indicates the likely 
existence of other anti-HSE pathways and may reflect the effects of additional host genetics factors. 
8.4. Screening for Acquired Susceptibility to HSE 
Two breeding schemes have been used in the mutagenesis screen to identify host susceptibility 
genes to HSV-1 infection. We started with the B6/B10 screen, where mutagenized B6 G0 males 
were out-crossed to B10. This allowed linkage mapping with the use of a panel of 255 B6/B10 
polymorphic markers (SNPs) distributed across the genome [208]. We then switched to a pure B6 
genetic background to eliminate the likelihood of epistatic interactions between the B6 and B10 
genetic backgrounds. In total (Table 2), 7,802 G3 B6 mice carrying ENU mutations derived from 
265 G1 males were infected i.p. with 104 pfu of HSV-1 strain 17. This dose led to lethal 
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encephalitis in susceptible A/J mice, whereas wild-type B6 mice remained unaffected. Following 
infection, the ENU-mutagenized mice were monitored for two weeks. The phenodeviant offsprings 
that exhibited clinical signs of disease or succumbed to the infection were considered susceptible. 
Using this strategy, we revealed eleven deviant pedigrees. One of these led to the identification of a 
premature stop codon (L3X) in the Ptprc gene, which encodes the leukocyte common antigen 
CD45. PtprcL3X mutant mice showed reduced numbers of CD3+ T and mature follicular B cells, 
suggesting defects in T and B cell development [209]. In this report, we also demonstrated that 
CD4+ Th1 cells, by producing IFN , help CD8+ T cell recruitment to prevent the dissemination of 
HSV-1 into the central nervous system, thus protecting mice from lethal HSV-1 infection. 
Altogether, our data point to CD45 as the first host component involved in the adaptive immune 
response that directly contributes to susceptibility to HSV-1 and HSE pathology. We are currently 
investigating the 10 other deviant pedigrees, which have, once again, shown the crucial role of T 
cells in host survival, but have also revealed that anti-inflammatory factors are critical to protection 
against HSV-1-induced encephalitis [210]. 
9. Conclusions and Perspectives 
ENU-mutagenesis constitutes an inherently unbiased and powerful approach to the production 
of new alleles. Technological improvements in high-throughput DNA sequencing, combined with 
the completion of the mouse genome project [68], have greatly facilitated their identification. The 
recent introduction of NGS has led to a faster and more efficient identification of ENU mutations, 
which is particularly helpful for analyzing large mutant collections, especially when mapping data 
are not available to guide an analysis. New variants generated by ENU-mutagenesis mirror those 
existing in the human population and also represent a natural complement to null alleles being 
produced by gene targeting. Finding new ENU-induced alleles will also benefit from the new 
CRISPR/Cas9 technology. ENU variants, although easier to pinpoint by sequencing, need to be 
validated experimentally as in any forward genetic approach of gene identification. The 
CRISPR/Cas9 system appears to be an excellent complement to ENU mutagenesis, allowing 
candidate point mutations identified by NGS to be efficiently confirmed as causative mutations. 
The ENU mutagenesis approach has proven to be extremely useful in dissecting the genetic 
architecture of host defenses against infectious diseases. The approach promises to remain current 
in the field, being constantly renewed by technological advances such as NGS or genome editing. 
As summarized in Table 2, over 30,000 G3 mice were screened by our group for either 
resistance to Plasmodium berghei or susceptibility to Salmonella typhimurium and HSV-1 
infection. In total, 72 deviant pedigrees have been identified and we have to date confirmed  
ENU-induced mutations for 10 pedigrees. These mutations highlight gene functions that are 
directly involved in the immune system (Foxn1, Jak3, Stat4, Usp18 and Ptprc), but also show the 
importance of other non-immune pathways, such as erythropoeisis and iron metabolism (Ank1), in 
host survival (Table 3). Beutler and colleagues also used the ENU mutagenesis approach, and over 
20,000 G3 mice were screened for their susceptibility to MCMV. In parallel, they also developed 
several “immune” ENU screens, where some phenodeviant pedigrees, characterized by defects in 
the TLR signaling pathway and/or in T/NK cells functions, were then tested for their potential 
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MCMV susceptibility. Of these, it should be noted that among the ENU mutations identified by  
the group of Beutler, only few were initially revealed by the MCMV in vivo screen (Stat1, Unc13d, 
Flt3 and Slfn2), the others being deduced from other screens (Tlr9, Trif, Unc93b1, Ikbkg, Eif2ak4, 
Gimap5) [178]. This observation can be explained by the fact that in vivo models are more complex 
than in vitro systems. Indeed, deficiencies in one particular immune cell or signaling pathway can 
be compensated by the presence of other competent immune cells, making the identification of 
defective alleles more difficult in vivo. 
The ENU mutations identified in Jak3 (Jak3W81R) and Ptprc (PtprcL3X) highlighted the critical 
nature of T cell function for CM pathogenesis and protection against HSV1 infection, respectively. 
The robustness of these mouse models of neuroinflammation and their ability to detect genetic 
effects regulating common pathways critical for neuroinflammation are highlighted by the 
complementary observations that the Jak3W81R mutant allele (protective in the ECM screen) confers 
susceptibility to HSV encephalitis (HSE), while the PtprcL3X (causing susceptibility to HSE screen) 
is protective in the ECM model [211]. This approach could be generalized to other interesting 
pedigrees, where the role of the ENU mutations could be assessed in these different mouse models 
of infectious diseases. By cross-testing these mutant pedigrees, it should be possible to reveal 
common and specific pathways, as well as cells and proteins, that are crucial in the protection against 
malaria and Salmonella or viral infections. Moreover, the role of ENU mutations identified in the 
neuroinflammatory models of ECM and HSE could also be tested in other models of inflammation, 
such as the model of experimental encephalitis (EAE) that mimics MS, or DSS colitis that models 
IBD. Preliminary experiments using the EAE model have already suggested that PtprcL3X mice are 
more resistant to EAE symptoms than wild-type and heterozygous littermate controls [210]. Thus, 
the cross-testing of these mutant pedigrees in different models of inflammation may provide 
additional information on the gene function, including its role in the pro- and anti-inflammatory 
balance. It can also provide novel targets for the development of new drugs that could be used in 
therapy for acute and chronic inflammatory diseases. As an example, a JAK3 inhibitor, currently in 
clinical use for the treatment of RA and CD (tasocitinib; Pfizer, New York, NY, USA), has been 
shown to reduce neuroinflammation and increase survival of Jak3 /+ heterozygotes in our ECM 
model [119]. Therefore, pharmacological modulation of JAK3 mimics the effect of its genetic 
inactivation, indicating that the ECM screen can identify novel pharmacological targets  
for drug discovery. 
One objective of the ENU-mutagenesis approach is to translate and validate knowledge obtained 
in the mouse infectious context to an improved understanding of human immunity and 
susceptibility to infection. As a starting point, mouse studies are fundamental for exploring  
host-pathogen interactions, especially when orthologous human genes exist. One striking example 
came from the discovery of the ENU-induced mutation in the mouse Unc93b1 gene that causes 
susceptibility to MCMV [181]. Based on this finding, the group of JL Casanova identified an 
autosomal recessive UNC93B deficiency in two human patients with HSE [202]. Furthermore, a 
survey of the literature has shown that human variants identified in our ECM and HSE screens are 
risk factors for inflammatory diseases. For example, genetic variants in JAK and STAT family 
members have been associated with IBD, MS, RA, and SLE [121,122]. PTPRC polymorphisms are 
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associated with autoimmune and inflammatory conditions including MS, SLE, and myasthenia 
gravis [212]. Thus, the ENU-mutagenesis approach should be continued in combination with 
GWAS studies, thus providing important insights into the pathways, cells, and proteins that directly 
impact susceptibility to pathogens, as it constitutes an invaluable resource for identifying novel 
therapeutic treatments. 
Table 3. Genes and pathways identified in ENU screens described in this review. 
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Homeostasis Kcnj8 MCMV Susceptible [198] 
Lipid metabolism Scd1 Immunity S. Pyogenes Susceptible [171] 
Acknowledgments 
This work was support by a Team grant (Danielle Malo, Philippe Gros, Silvia M. Vidal) from 
the Canadian Institutes of Health Research (CTP-87520). Grégory Caignard is supported by the 
Canadian Institutes of Health Research. Megan M. Eva is supported by the McGill University 
Health Centre. Silvia M. Vidal is supported by the Canada Research Chairs Program. We thank 
Eve-Marie Gendron-Pontbriand for proofreading the manuscript. 
Author Contributions 
Robert Eveleigh and Guillaume Bourque contributed to the section on gene identification 
(section 4); Rebekah van Bruggen and Philippe Gros contributed to the section about Malarial 
parasites infection and screen (section 6); Megan M. Eva and Danielle Malo contributed to the 
198 
 
section about Salmonella infection and secreen (section 7), Grégory Caignard and Silvia M. Vidal 
contributed to the sections about herpes virus infection and screen (section 8) as well as the 
introductory sections (sections 1, 2, 3 and 5) and the conclusions (section 9). 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Brussow, H. Europe, the bull and the Minotaur: The biological legacy of a Neolithic love 
story. Environ. Microbiol. 2009, 11, 2778–2788. 
2. McMichael, A.J. Environmental and social influences on emerging infectious diseases: Past, 
present and future. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2004, 359, 1049–1058. 
3. Casanova, J.L.; Abel, L. Inborn errors of immunity to infection: The rule rather than the 
exception. J. Exp. Med. 2005, 202, 197–201. 
4. Fauci, A.S.; Morens, D.M. The perpetual challenge of infectious diseases. N. Engl. J. Med. 
2012, 366, 454–461. 
5. Chapman, S.J.; Hill, A.V. Human genetic susceptibility to infectious disease. Nat. Rev. Genet. 
2012, 13, 175–188. 
6. Cobat, A.; Orlova, M.; Barrera, L.F.; Schurr, E. Host genomics and control of tuberculosis 
infection. Publ. Health Genet. 2013, 16, 44–49. 
7. Plantinga, T.S.; Johnson, M.D.; Scott, W.K.; Joosten, L.A.; van der Meer, J.W.; Perfect, J.R.; 
Kullberg, B.J.; Netea, M.G. Human genetic susceptibility to Candida infections. Med. Mycol. 
2012, 50, 785–794. 
8. Keynan, Y.; Malik, S.; Fowke, K.R. The role of polymorphisms in host immune genes in 
determining the severity of respiratory illness caused by pandemic H1N1 influenza.  
Publ. Health Genet. 2013, 16, 9–16. 
9. Min-Oo, G.; Gros, P. Erythrocyte variants and the nature of their malaria protective effect.  
Cell Microbiol. 2005, 7, 753–763. 
10. Lederman, M.M.; Penn-Nicholson, A.; Cho, M.; Mosier, D. Biology of CCR5 and its role in 
HIV infection and treatment. JAMA 2006, 296, 815–826. 
11. Lindesmith, L.; Moe, C.; Marionneau, S.; Ruvoen, N.; Jiang, X.; Lindblad, L.; Stewart, P.; 
LePendu, J.; Baric, R. Human susceptibility and resistance to Norwalk virus infection.  
Nat. Med. 2003, 9, 548–553. 
12. Von Bernuth, H.; Picard, C.; Puel, A.; Casanova, J.L. Experimental and natural infections in 
MyD88- and IRAK-4-deficient mice and humans. Eur. J. Immunol. 2012, 42, 3126–3135. 
13. International Human Genome Sequencing. Finishing the euchromatic sequence of the human 
genome. Nature 2004, 431, 931–945.  
14. The International HapMap Consortium. A haplotype map of the human genome. Nature 
2005, 437, 1299–1320. 
199 
 
15. Hohl, T.M. Overview of vertebrate animal models of fungal infection. J. Immunol. Methods 
2014, doi:10.1016/j.jim.2014.03.022. 
16. Longley, R.; Smith, C.; Fortin, A.; Berghout, J.; McMorran, B.; Burgio, G.; Foote, S.; Gros, 
P. Host resistance to malaria: Using mouse models to explore the host response. Mamm. 
Genet. 2011, 22, 32–42. 
17. Sancho-Shimizu, V.; Zhang, S.Y.; Abel, L.; Tardieu, M.; Rozenberg, F.; Jouanguy, E.; 
Casanova, J.L. Genetic susceptibility to herpes simplex virus 1 encephalitis in mice and 
humans. Curr. Opin. Allergy Clin. Immunol. 2007, 7, 495–505. 
18. Wick, M.J. Innate immune control of Salmonella enterica serovar Typhimurium: Mechanisms 
contributing to combating systemic Salmonella infection. J. Innate Immun. 2011, 3, 543–549. 
19. Waterston, R.H.; Lindblad-Toh, K.; Birney, E.; Rogers, J.; Abril, J.F.; Agarwal, P.; Agarwala, R.; 
Ainscough, R.; Alexandersson, M.; An, P.; et al. Initial sequencing and comparative analysis 
of the mouse genome. Nature 2002, 420, 520–562. 
20. Church, D.M.; Goodstadt, L.; Hillier, L.W.; Zody, M.C.; Goldstein, S.; She, X.; Bult, C.J.; 
Agarwala, R.; Cherry, J.L.; DiCuccio, M.; et al. Lineage-specific biology revealed by a 
finished genome assembly of the mouse. PLoS Biol. 2009, 7, e1000112. 
21. Guenet, J.L. Animal models of human genetic diseases: Do they need to be faithful to be 
useful? Mol. Genet. Genet. 2011, 286, 1–20. 
22. Guan, C.; Ye, C.; Yang, X.; Gao, J. A review of current large-scale mouse knockout efforts. 
Genesis 2010, 48, 73–85. 
23. Ayadi, A.; Birling, M.C.; Bottomley, J.; Bussell, J.; Fuchs, H.; Fray, M.; Gailus-Durner, V.; 
Greenaway, S.; Houghton, R.; Karp, N.; et al. Mouse large-scale phenotyping initiatives: 
Overview of the European Mouse Disease Clinic (EUMODIC) and of the Wellcome Trust 
Sanger Institute Mouse Genetics Project. Mamm. Genome 2012, 23, 600–610. 
24. Gaj, T.; Gersbach, C.A.; Barbas, C.F., 3rd. ZFN, TALEN, and CRISPR/Cas-based methods 
for genome engineering. Trends Biotechnol. 2013, 31, 397–405. 
25. Wang, H.; Yang, H.; Shivalila, C.S.; Dawlaty, M.M.; Cheng, A.W.; Zhang, F.; Jaenisch, R.  
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated 
genome engineering. Cell 2013, 153, 910–918. 
26. Blake, J.A.; Bult, C.J.; Eppig, J.T.; Kadin, J.A.; Richardson, J.E. The Mouse Genome 
Database: Integration of and access to knowledge about the laboratory mouse. Nucl. Acids 
Res. 2014, 42, D810–D817. 
27. Smith, C.M.; Finger, J.H.; Hayamizu, T.F.; McCright, I.J.; Xu, J.; Berghout, J.; Campbell, J.; 
Corbani, L.E.; Forthofer, K.L.; Frost, J,P. The mouse Gene Expression Database (GXD): 
2014 update. Nucl. Acids Res. 2014, 42, D818–D824. 
28. Begley, D.A.; Krupke, D.M.; Neuhauser, S.B.; Richardson, J.E.; Bult, C.J.; Eppig, J.T.; 
Sundberg, J.P. The Mouse Tumor Biology Database (MTB): A central electronic resource for 
locating and integrating mouse tumor pathology data. Vet. Pathol. 2012, 49, 218–223. 
29. Wiltshire, S.A.; Leiva-Torres, G.A.; Vidal, S.M. Quantitative trait locus analysis, pathway 
analysis, and consomic mapping show genetic variants of Tnni3k, Fpgt, or H28 control 
susceptibility to viral myocarditis. J. Immunol. 2011, 186, 6398–6405. 
200 
 
30. Di Pietrantonio, T.; Hernandez, C.; Girard, M.; Verville, A.; Orlova, M.; Belley, A.;  
Behr, M.A.; Loredo-Osti, J.C.; Schurr, E. Strain-specific differences in the genetic control of 
two closely related mycobacteria. PLoS Pathog. 2010, 6, e1001169. 
31. Toth, L.A.; Trammell, R.A.; Williams, R.W. Mapping complex traits using families of 
recombinant inbred strains: An overview and example of mapping susceptibility to Candida 
albicans induced illness phenotypes. Pathog. Dis. 2014, 71, 232–246. 
32. Boivin, G.A.; Pothlichet, J.; Skamene, E.; Brown, E.G.; Loredo-Osti, J.C.; Sladek, R.; Vidal, 
S.M. Mapping of clinical and expression quantitative trait loci in a sex-dependent effect of 
host susceptibility to mouse-adapted influenza H3N2/HK/1/68. J. Immunol. 2012, 188,  
3949–3960. 
33. Ferris, M.T.; Aylor, D.L.; Bottomly, D.; Whitmore, A.C.; Aicher, L.D.; Bell, T.A.;  
Bradel-Tretheway, B.; Bryan, J.T.; Buus, R.J.; Gralinski, L.E.; et al. Modeling host genetic 
regulation of influenza pathogenesis in the collaborative cross. PLoS Pathog. 2013, 9, e1003196. 
34. Guenet, J.L.; Bonhomme, F. Wild mice: An ever-increasing contribution to a popular 
mammalian model. Trends Genet. 2003, 19, 24–31. 
35. Chia, R.; Achilli, F.; Festing, M.F.; Fisher, E.M. The origins and uses of mouse outbred 
stocks. Nat. Genet. 2005, 37, 1181–1186. 
36. Keane, T.M.; Goodstadt, L.; Danecek, P.; White, M.A.; Wong, K.; Yalcin, B.; Heger, A.;  
Agam, A.; Slater, G.; Goodson, M.; et al. Mouse genomic variation and its effect on 
phenotypes and gene regulation. Nature 2011, 477, 289–294. 
37. Simon, M.M.; Greenaway, S.; White, J.K.; Fuchs, H.; Gailus-Durner, V.; Wells, S.; Sorg, T.; 
Wong, K.; Bedu, E.; Cartwright, E.J.; et al. A comparative phenotypic and genomic analysis 
of C57BL/6J and C57BL/6N mouse strains. Genet. Biol. 2013, 14, R82. 
38. Vidal, S.M.; Malo, D.; Marquis, J.F.; Gros, P. Forward genetic dissection of immunity to 
infection in the mouse. Annu. Rev. Immunol. 2008, 26, 81–132. 
39. Cook, M.C.; Vinuesa, C.G.; Goodnow, C.C. ENU-mutagenesis: Insight into immune function 
and pathology. Curr. Opin. Immunol. 2006, 18, 627–633. 
40. Hoebe, K.; Beutler, B. Forward genetic analysis of TLR-signaling pathways: An evaluation.  
Adv. Drug Deliv. Rev. 2008, 60, 824–829. 
41. Hoyne, G.F.; Goodnow, C.C. The use of genomewide ENU mutagenesis screens to unravel 
complex mammalian traits: Identifying genes that regulate organ-specific and systemic 
autoimmunity. Immunol. Rev. 2006, 210, 27–39. 
42. Oliver, P.L.; Davies, K.E. New insights into behaviour using mouse ENU mutagenesis.  
Hum. Mol. Genet. 2012, 21, R72–R81. 
43. Russell, W.L. Radiation and chemical mutagenesis and repair in mice. Johns Hopkins Med. J. 
Suppl. 1972, 1, 239–247. 
44. Jaenisch, R. Germ line integration and Mendelian transmission of the exogenous Moloney 
leukemia virus. Proc. Natl. Acad. Sci. USA 1976, 73, 1260–1264. 
45. Russell, L.B.; Russell, W.L. Frequency and nature of specific-locus mutations induced in 
female mice by radiations and chemicals: A review. Mutat. Res. 1992, 296, 107–127. 
201 
 
46. Russell, W.L.; Kelly, E.M.; Hunsicker, P.R.; Bangham, J.W.; Maddux, S.C.; Phipps, E.L. 
Specific-locus test shows ethylnitrosourea to be the most potent mutagen in the mouse.  
Proc. Natl. Acad. Sci. USA 1979, 76, 5818–5819. 
47. Russell, W.L.; Hunsicker, P.R.; Carpenter, D.A.; Cornett, C.V.; Guinn, G.M. Effect of dose 
fractionation on the ethylnitrosourea induction of specific-locus mutations in mouse 
spermatogonia. Proc. Natl. Acad. Sci. USA 1982, 79, 3592–3593. 
48. Hitotsumachi, S.; Carpenter, D.A.; Russell, W.L. Dose-repetition increases the mutagenic 
effectiveness of N-ethyl-N-nitrosourea in mouse spermatogonia. Proc. Natl. Acad. Sci. USA 
1985, 82, 6619–6621. 
49. Singer, B. All oxygens in nucleic acids react with carcinogenic ethylating agents. Nature 
1976, 264, 333–339. 
50. Bignami, M.; Vitelli, A.; di Muccio, A.; Terlizzese, M.; Calcagnile, A.; Zapponi, G.A.;  
Lohman, P.H.M.; den Engelse, L.; Dogliotti1, E. Relationship between specific alkylated 
bases and mutations at two gene loci induced by ethylnitrosourea and diethyl sulfate in CHO 
cells. Mutat. Res. 1988, 193, 43–51. 
51. Van Zeeland, A.A. Molecular dosimetry of alkylating agents: Quantitative comparison of 
genetic effects on the basis of DNA adduct formation. Mutagenesis 1988, 3, 179–191. 
52. Vogel, E.W.; Natarajan, A.T. DNA damage and repair in somatic and germ cells in vivo.  
Mutat. Res. 1995, 330, 183–208. 
53. Fairfield, H.; Gilbert, G.J.; Barter, M.; Corrigan, R.R.; Curtain, M.; Ding, Y.M.;  
Ascenzo, M.D.; Gerhardt, D.J.; He, C.; Huang, W.H.; et al. Mutation discovery in mice by 
whole exome sequencing. Genet. Biol. 2011, 12, R86. 
54. Andrews, T.D.; Whittle, B.; Field, M.A.; Balakishnan, B.; Zhang, Y.; Shao, Y.; Cho, V.;  
Kirk, M.; Singh, M.; Xia, Y.; et al. Massively parallel sequencing of the mouse exome to 
accurately identify rare, induced mutations: An immediate source for thousands of new 
mouse models. Open Biol. 2012, 2, 120061. 
55. Bull, K.R.; Rimmer, A.J.; Siggs, O.M.; Miosge, L.A.; Roots, C.M.; Enders, A.;  
Bertram, E.M.; Crockford, T.L.; Whittle, B.; Potter, P.K.; et al. Unlocking the bottleneck in 
forward genetics using whole-genome sequencing and identity by descent to isolate causative 
mutations. PLoS Genet. 2013, 9, e1003219. 
56. Lewis, M.A.; Quint, E.; Glazier, A.M.; Fuchs, H.; de Angelis, M.H.; Langford, C.;  
van Dongen, S.; Abreu-Goodger, C.; Piipari, M.; Redshaw, N.; et al. An ENU-induced 
mutation of miR-96 associated with progressive hearing loss in mice. Nat. Genet. 2009, 41,  
614–618. 
57. Masuya, H.; Sezutsu, H.; Sakuraba, Y.; Sagai, T.; Hosoya, M.; Kanedaa, H.; Miuraa, I.; 
Kobayashia, K.; Sumiyamad, K.; Shimizu, A.; et al. A series of ENU-induced single-base 
substitutions in a long-range cis-element altering sonic hedgehog expression in the 
developing mouse limb bud. Genomics 2007, 89, 207–214. 
58. Arnold, C.N.; Barnes, M.J.; Berger, M.; Blasius, A.L.; Brandl, K.; Croker, B.; Crozat, K.;  
Du, X.; Eidenschenk, C.; Georgel, P.; et al. ENU-induced phenovariance in mice: Inferences 
from 587 mutations. BMC Res. Notes 2012, 5, 577. 
202 
 
59. Puk, O.; Moller, G.; Geerlof, A.; Krowiorz, K.; Ahmad, N.; Wagner, S.; Adamski, J.;  
de Angelis, M.H.; Graw, J. The pathologic effect of a novel neomorphic Fgf9(Y162C) allele 
is restricted to decreased vision and retarded lens growth. PLoS ONE 2011, 6, e23678. 
60. Caspary, T. Phenotype-driven mouse ENU mutagenesis screens. Methods Enzymol. 2010, 
477, 313–327. 
61. Probst, F.J.; Justice, M.J. Mouse mutagenesis with the chemical supermutagen ENU.  
Methods Enzymol. 2010, 477, 297–312. 
62. Georgel, P.; Du, X.; Hoebe, K.; Beutler, B. ENU mutagenesis in mice. Methods Mol. Biol. 
2008, 415, 1–16. 
63. Justice, M.J.; Carpenter, D.A.; Favor, J.; Neuhauser-Klaus, A.; de Angelis, M.H.;  
Soewarto, D.; Moser, A.; Cordes, S.; Miller, D.; Chapman, V.; et al. Effects of ENU dosage 
on mouse strains. Mamm. Genet. 2000, 11, 484–488. 
64. Bainbridge, M.N.; Wang, M.; Burgess, D.L.; Kovar, C.; Rodesch, M.J.; D’Ascenzo, M.; 
Kitzman, J.; Wu, Y.-Q.; Newsham, I.; Richmond, T.A.; et al. Whole exome capture in 
solution with 3 Gbp of data. Genet. Biol. 2010, 11, R62. 
65. Choi, M.; Scholl, U.I.; Ji, W.; Liu, T.; Tikhonova, I.R.; Zumbob, P.; Nayirc, A.;  
Bakkalo lud, A.; Özend, S.; Sanjad, S.; et al. Genetic diagnosis by whole exome capture and 
massively parallel DNA sequencing. Proc. Natl. Acad. Sci. USA 2009, 106, 19096–19101. 
66. Ng, S.B.; Buckingham, K.J.; Lee, C.; Bigham, A.W.; Tabor, H.K.; Dent, K.M.; Huff, C.D.; 
Shannon, P.T.; Jabs, E.W.; Nickerson, D.A.; et al. Exome sequencing identifies the cause of a 
mendelian disorder. Nat. Genet. 2010, 42, 30–35. 
67. Pruitt, K.D.; Harrow, J.; Harte, R.A.; Wallin, C.; Diekhans, M.; Maglott, D.R.; Searle, S.;  
Farrell, C.M.; Loveland, J.E.; Ruef, B.J.; et al. The consensus coding sequence (CCDS) 
project: Identifying a common protein-coding gene set for the human and mouse genomes. 
Genet. Res. 2009, 19, 1316–1323. 
68. Mouse Genome Project. Available online: http://www.sanger.ac.uk/resources/mouse/genomes/ 
(accessed on 28 August 2014). 
69. DePristo, M.A.; Banks, E.; Poplin, R.; Garimella, K.V.; Maguire, J.R.; Hartl, C.;  
Philippakis, A.A.; del Angel, G.; Rivas, M.A.; Hanna, M.; et al. A framework for variation 
discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 2011, 43, 
491–498. 
70. Pipeline Space Home. Available online: https://biowiki.atlassian.net/wiki/display/ 
PS/Pipeline+Space+Home (accessed on 28 August 2014). 
71. GATK Best Practices. Available online: http://www.broadinstitute.org/gatk/guide/ 
best-practices (accessed on 8 August 2014).  
72. Lohse, M.; Bolger, A.M.; Nagel, A.; Fernie, A.R.; Lunn, J.E.; Stitt, M.; Usadel, B.  
RobiNA: A user-friendly, integrated software solution for RNA-Seq-based transcriptomics. 
Nucl. Acids Res. 2012, 40, W622–W627. 
73. Li, H.; Durbin, R. Fast and accurate long-read alignment with Burrows—Wheeler transform. 
Bioinformatics 2010, 26, 589–595. 
203 
 
74. Li, H.; Homer, N. A survey of sequence alignment algorithms for next-generation 
sequencing. Br. Bioinform. 2010, 11, 473–483. 
75. Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.;  
Abecasis, G.; Durbin, R. The Sequence Alignment/Map format and SAMtools. 
Bioinformatics 2009, 25, 2078–2079. 
76. Skliris, G.P.; Rowan, B.G.; Al-Dhaheri, M.; Williams, C.; Troup, S.; Begic, S.; Parisien, M.; 
Watson, P.H.; Murphy, L.C. Immunohistochemical validation of multiple phospho-specific 
epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive 
human breast carcinomas. Breast Cancer Res. Treat 2009, 118, 443–453. 
77. Picard. Available online: http://picard.sourceforge.net (accessed on 28 August 2014). 
78. Garrison, E.; Marth, G. Haplotype-based variant detection from short-read sequencing. 
Available online: http://arxiv.org/abs/1207.3907 (accessed on 28 August 2014).  
79. Nielsen, R.; Paul, J.S.; Albrechtsen, A.; Song, Y.S. Genotype and SNP calling from  
next-generation sequencing data. Nat. Rev. Genet. 2011, 12, 443–451. 
80. Moresco, E.M.; Li, X.; Beutler, B. Going forward with genetics: Recent technological 
advances and forward genetics in mice. Am. J. Pathol. 2013, 182, 1462–1473. 
81. Cingolani, P.; Platts, A.; Wang le, L.; Coon, M.; Nguyen, T.; Land, S.J.; Lu, X.; Ruden, D.M.  
A program for annotating and predicting the effects of single nucleotide polymorphisms,  
SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3.  
Fly (Austin) 2012, 6, 80–92. 
82. McLaren, W.; Pritchard, B.; Rios, D.; Chen, Y.; Flicek, P.; Cunningham, F. Deriving the 
consequences of genomic variants with the Ensembl API and SNP Effect Predictor. 
Bioinformatics 2010, 26, 2069–2070. 
83. Sherry, S.T.; Ward, M.H.; Kholodov, M.; Baker, J.; Phan, L.; Smigielski, E.M.; Sirotkin, K. 
DbSNP: The NCBI database of genetic variation. Nucl. Acids Res. 2001, 29, 308–311. 
84. Robinson, J.T.; Thorvaldsdottir, H.; Winckler, W.; Guttman, M.; Lander, E.S.; Getz, G.; 
Mesirov, J.P. Integrative genomics viewer. Nat. Biotechnol. 2011, 29, 24–26. 
85. Sanger, F.; Nicklen, S.; Coulson, A.R. DNA sequencing with chain-terminating inhibitors.  
Proc. Natl. Acad. Sci. USA 1977, 74, 5463–5467. 
86. Kwiatkowski, D.P. How malaria has affected the human genome and what human genetics 
can teach us about malaria. Am. J. Hum. Genet. 2005, 77, 171–192. 
87. Ayi, K.; Turrini, F.; Piga, A.; Arese, P. Enhanced phagocytosis of ring-parasitized mutant 
erythrocytes: A common mechanism that may explain protection against falciparum malaria 
in sickle trait and beta-thalassemia trait. Blood 2004, 104, 3364–3371. 
88. Friedman, M.J. Erythrocytic mechanism of sickle cell resistance to malaria. Proc. Natl. Acad. 
Sci. USA 1978, 75, 1994–1997. 
89. Allen, S.J.; O’Donnell, A.; Alexander, N.D.; Mgone, C.S.; Peto, T.E.; Clegg, J.B.;  
Alpers, M.P.; Weatherall, D.J. Prevention of cerebral malaria in children in Papua New 




90. Foo, L.C.; Rekhraj, V.; Chiang, G.L.; Mak, J.W. Ovalocytosis protects against severe malaria 
parasitemia in the Malayan aborigines. Am. J. Trop. Med. Hyg. 1992, 47, 271–275. 
91. Genton, B.; al-Yaman, F.; Mgone, C.S.; Alexander, N.; Paniu, M.M.; Alpers, M.P.;  
Mokela, D. Ovalocytosis and cerebral malaria. Nature 1995, 378, 564–565. 
92. Miller, L.H.; Mason, S.J.; Clyde, D.F.; McGinniss, M.H. The resistance factor to Plasmodium 
vivax in blacks. The Duffy-blood-group genotype, FyFy. N. Engl. J. Med. 1976, 295,  
302–304. 
93. Ruwende, C.; Khoo, S.C.; Snow, R.W.; Yates, S.N.; Kwiatkowski, D.; Gupta, S.; Warn, P.; 
Allsopp, C.E.; Gilbert, S.C.; Peschu, N.; et al. Natural selection of hemi- and heterozygotes 
for G6PD deficiency in Africa by resistance to severe malaria. Nature 1995, 376, 246–249. 
94. Tishkoff, S.A.; Varkonyi, R.; Cahinhinan, N.; Abbes, S.; Argyropoulos, G.; Destro-Bisol, G.; 
Drousiotou, A.; Dangerfield, B.; Lefranc, G.; Loiselet, J.; et al. Haplotype diversity and 
linkage disequilibrium at human G6PD: Recent origin of alleles that confer malarial 
resistance. Science 2001, 293, 455–462. 
95. Aitman, T.J.; Cooper, L.D.; Norsworthy, P.J.; Wahid, F.N.; Gray, J.K.; Curtis, B.R.;  
McKeigue, P.M.; Kwiatkowski, D.; Greenwood, B.M.; Snow, R.W.; et al. Malaria 
susceptibility and CD36 mutation. Nature 2000, 405, 1015–1016. 
96. Omi, K.; Ohashi, J.; Patarapotikul, J.; Hananantachai, H.; Naka, I.; Pottere, S.; Medanad, I.M.; 
Miua, J.; Ball, H.J. CD36 polymorphism is associated with protection from cerebral malaria.  
Am. J. Hum. Genet. 2003, 72, 364–374. 
97. Hill, A.V.; Allsopp, C.E.; Kwiatkowski, D.; Anstey, N.M.; Twumasi, P.; Rowe, P.A.; Bennett, S.; 
Brewster, D.; McMichael, A.J.; Greenwood, B.M. Common west African HLA antigens are 
associated with protection from severe malaria. Nature 1991, 352, 595–600. 
98. McGuire, W.; Hill, A.V.; Allsopp, C.E.; Greenwood, B.M.; Kwiatkowski, D. Variation in the 
TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994, 
371, 508–510. 
99. Bongfen, S.E.; Laroque, A.; Berghout, J.; Gros, P. Genetic and genomic analyses of  
host-pathogen interactions in malaria. Trends Parasitol. 2009, 25, 417–422. 
100. Verra, F.; Mangano, V.D.; Modiano, D. Genetics of susceptibility to Plasmodium  
falciparum: From classical malaria resistance genes towards genome-wide association studies. 
Parasit. Immunol. 2009, 31, 234–253. 
101. Fortin, A.; Stevenson, M.M.; Gros, P. Complex genetic control of susceptibility to malaria in 
mice. Genes Immun. 2002, 3, 177–186. 
102. Hunt, N.H.; Golenser, J.; Chan-Ling, T.; Parekh, S.; Rae, C.; Pottere, S.; Medanad, I.M.; 
Miua, J.; Ball, H.J. Immunopathogenesis of cerebral malaria. Int. J. Parasitol. 2006, 36,  
569–582. 
103. Miller, L.H.; Baruch, D.I.; Marsh, K.; Doumbo, O.K. The pathogenic basis of malaria. Nature 
2002, 415, 673–679. 
104. Newton, C.R.; Hien, T.T.; White, N. Cerebral malaria. J. Neurol. Neurosurg. Psychiatry 
2000, 69, 433–441. 
205 
 
105. Tripathi, A.K.; Sha, W.; Shulaev, V.; Stins, M.F.; Sullivan, D.J., Jr. Plasmodium  
falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human 
cerebral endothelium. Blood 2009, 114, 4243–4252. 
106. Brown, H.; Hien, T.T.; Day, N.; Mai, N.T.; Chuong, L.V.; Chau, T.T.; Loc, P.P.; Phu, N.H.; 
Bethell, D.; Farrar, J.; et al. Evidence of blood-brain barrier dysfunction in human cerebral 
malaria. Neuropathol. Appl. Neurobiol. 1999, 25, 331–340. 
107. Mishra, S.K.; Newton, C.R. Diagnosis and management of the neurological complications of 
falciparum malaria. Nat. Rev. Neurol. 2009, 5, 189–198. 
108. Hafalla, J.C.; Claser, C.; Couper, K.N.; Grau, G.E.; Renia, L.; de Souza, J.B.; Riley, E.M.  
The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to 
Plasmodium-induced acute immune pathology. PLoS Pathog. 2012, 8, e1002504. 
109. Lacerda-Queiroz, N.; Rodrigues, D.H.; Vilela, M.C.; Rachid, M.A.; Soriani, F.M.; Sousa, L.P.; 
Campos, R.D.; Quesniaux, V.F.; Teixeira, M.M.; Teixeira, A.L. Platelet-activating factor 
receptor is essential for the development of experimental cerebral malaria. Am. J. Pathol. 
2012, 180, 246–255. 
110. Lou, J.; Lucas, R.; Grau, G.E. Pathogenesis of cerebral malaria: Recent experimental data and 
possible applications for humans. Clin. Microbiol. Rev. 2001, 14, 810–820. 
111. De Souza, J.B.; Riley, E.M. Cerebral malaria: The contribution of studies in animal models to 
our understanding of immunopathogenesis. Microbes Infect. 2002, 4, 291–300. 
112. Senaldi, G.; Vesin, C.; Chang, R.; Grau, G.E.; Piguet, P.F. Role of polymorphonuclear 
neutrophil leukocytes and their integrin CD11a (LFA-1) in the pathogenesis of severe murine 
malaria. Infect. Immun. 1994, 62, 1144–1149. 
113. Bagot, S.; Idrissa Boubou, M.; Campinom, S.; Behrschmidt, C.; Gorgette, O.; Guénet, J.L.; 
Penha-Gonçalves, C.; Mazier, D.; Pied, S.; Cazenave, P.A. Susceptibility to experimental 
cerebral malaria induced by Plasmodium berghei ANKA in inbred mouse strains recently 
derived from wild stock. Infect. Immun. 2002, 70, 2049–2056. 
114. Berghout, J.; Min-Oo, G.; Tam, M.; Gauthier, S.; Stevenson, M.M.; Gros, P. Identification of 
a novel cerebral malaria susceptibility locus (Berr5) on mouse chromosome 19. Genes 
Immun. 2010, 11, 310–318. 
115. Bopp, S.E.; Rodrigo, E.; Gonzalez-Paez, G.E.; Frazer, M.; Barnes, S.W.; Valim, C.;  
Watson, J.; Walker, J.R.; Schmedt, C.; Winzeler, E.A. Identification of the Plasmodium 
berghei resistance locus 9 linked to survival on chromosome 9. Malar. J. 2013, 12, 316. 
116. Campino, S.; Bagot, S.; Bergman, M.L.; Almeida, P.; Sepulveda, N.; Pied, S.;  
Penha-Gonçalves, C.; Holmberg, D.; Cazenave, P.-A. Genetic control of parasite clearance 
leads to resistance to Plasmodium berghei ANKA infection and confers immunity.  
Genes Immun. 2005, 6, 416–421. 
117. Ohno, T.; Nishimura, M. Detection of a new cerebral malaria susceptibility locus, using CBA 




118. Bopp, S.E.; Ramachandran, V.; Henson, K.; Luzader, A.; Lindstrom, M.; Spooner, M.;  
Steffy, B.M.; Suzuki, O.; Janse, C.; Waters, A.P.; et al. Genome wide analysis of inbred 
mouse lines identifies a locus containing Ppar-gamma as contributing to enhanced malaria 
survival. PLoS ONE 2010, 5, e10903. 
119. Bongfen, S.E.; Rodrigue-Gervais, I.G.; Berghout, J.; Torre, S.; Cingolani, P.; Wiltshire, S.A.;  
Leiva-Torres, G.A.; Letourneau, L.; Sladek, R.; Blanchette, M.; et al. An N-ethyl-N-nitrosourea 
(ENU)-induced dominant negative mutation in the JAK3 kinase protects against cerebral 
malaria. PLoS ONE 2012, 7, e31012. 
120. Nosaka, T.; van Deursen, J.M.; Tripp, R.A.; Thierfelder, W.E.; Witthuhn, B.A.;  
McMickle, A.P.; Doherty, P.C.; Grosveld, G.C.; Ihle, J.N. Defective lymphoid development 
in mice lacking Jak3. Science 1995, 270, 800–802. 
121. Jostins, L.; Ripke, S.; Weersma, R.K.; Duerr, R.H.; McGovern, D.P.; Hui, K.Y.; Lee, J.C.; 
Schumm, L.P.; Sharma, Y.; Anderson, C.A.; et al. Host-microbe interactions have shaped the 
genetic architecture of inflammatory bowel disease. Nature 2012, 491, 119–124. 
122. International Multiple Sclerosis Genetics Consortium. The genetic association of variants in CD6, 
TNFRSF1A and IRF8 to multiple sclerosis: A multicenter case-control study. PLoS ONE 2011,  
6, e18813. 
123. Jakkula, E.; Leppa, V.; Sulonen, A.M.; Varilo, T.; Kallio, S.; Kemppinen, A.; Purcell, S.; 
Koivisto, K.; Tienari, P.; Sumelahti, M.; et al. Genome-wide association study in a high-risk 
isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am. J. Hum. Genet. 
2010, 86, 285–291. 
124. Torre, S.; van Bruggen, R.; Kennedy, J.M.; Berghout, J.; Bongfen, S.E.; Langat, P.;  
Lathrop, M.; Vidal, S.M.; Gros, P. Susceptibility to lethal cerebral malaria is regulated by 
epistatic interaction between chromosome 4 (Berr6) and chromosome 1 (Berr7) loci in mice. 
Genes Immun. 2013, 14, 470. 
125. Torre, S.; Gros, P. Department of Human Genetics, Department of Biochemistry, and Complex 
Traits Group, McGill University, Montréal, QC, Canada. Unpublished data, 2014.  
126. Pignata, C.; Fusco, A.; Amorosi, S. Human clinical phenotype associated with FOXN1 
mutations. Adv. Exp. Med. Biol. 2009, 665, 195–206. 
127. Rank, G.; Sutton, R.; Marshall, V.; Lundie, R.J.; Caddy, J.; Romeo, T.; Fernandez, K.; 
Mccormack, M.P.; Cooke, B.M.; Foote, S.J.; et al. Novel roles for erythroid Ankyrin-1 
revealed through an ENU-induced null mouse mutant. Blood 2009, 113, 3352–3362. 
128. Greth, A.; Lampkin, S.; Mayura-Guru, P.; Rodda, F.; Drysdale, K.; Roberts-Thomson, M.; 
McMorran, B.J.; Foote, S.J.; Burgio, G. A novel ENU-mutation in ankyrin-1 disrupts malaria 
parasite maturation in red blood cells of mice. PLoS One 2012, 7, e38999. 
129. Belnoue, E.; Kayibanda, M.; Vigario, A.M.; Deschemin, J.C.; van Rooijen, N.; Viguier, M.; 
Snounou, G.; Rénia, L. On the pathogenic role of brain-sequestered alphabeta CD8+ T cells 
in experimental cerebral malaria. J. Immunol. 2002, 169, 6369–6375. 
130. Finley, R.W.; Mackey, L.J.; Lambert, P.H.; Virulent, P. berghei malaria: Prolonged  




131. Renia, L.; Potter, S.M.; Mauduit, M.; Rosa, D.S.; Kayibanda, M.; Deschemina, J.;  
Snounoub, G.; Grüner, A.C. Pathogenic T cells in cerebral malaria. Int. J. Parasitol. 2006, 
36, 547–554. 
132. Grau, G.E.; Piguet, P.F.; Engers, H.D.; Louis, J.A.; Vassalli, P.; Lambert, P.H. L3T4+ T 
lymphocytes play a major role in the pathogenesis of murine cerebral malaria. J. Immunol. 
1986, 137, 2348–2354. 
133. Crump, J.A.; Luby, S.P.; Mintz, E.D. The global burden of typhoid fever. Bull. World Health 
Organ. 2004, 82, 346–353. 
134. Mastroeni, P.; Maskell, D. Salmonella Infections: Clinical, Immunological, and Molecular 
Aspects; Cambridge University Press: Cambridge, UK, 2006; Volume 13, p. 381. 
135. Gordon, M.A.; Banda, H.T.; Gondwe, M.; Gordon, S.B.; Boeree, M.J.; Walsh, A.L.; Corkill, J.E.; 
Hart, C.A.; Gilks, C.F.; Molyneux, M.E. Non-typhoidal Salmonella bacteraemia among  
HIV-infected Malawian adults: High mortality and frequent recrudescence. AIDS 2002, 16,  
1633–1641. 
136. Majowicz, S.E.; Musto, J.; Scallan, E.; Angulo, F.J.; Kirk, M.; O’Brien, S.J.; Jones, T.F.;  
Fazil, A.; Hoekstra, R.M. The global burden of nontyphoidal Salmonella gastroenteritis. Clin. 
Infect. Dis. 2010, 50, 882–889. 
137. Mittrucker, H.W.; Kaufmann, S.H. Immune response to infection with Salmonella 
typhimurium in mice. J. Leukoc. Biol. 2000, 67, 457–463. 
138. Dougan, G.; John, V.; Palmer, S.; Mastroeni, P. Immunity to salmonellosis. Immunol. Rev. 
2011, 240, 196–210. 
139. Alcais, A.; Abel, L.; Casanova, J.L. Human genetics of infectious diseases: Between proof of 
principle and paradigm. J. Clin. Invest. 2009, 119, 2506–2514. 
140. Bustamante, J.; Zhang, S.Y.; von Bernuth, H.; Abel, L.; Casanova, J.L. From infectious diseases 
to primary immunodeficiencies. Immunol. Allergy Clin. North Am. 2008, 28, 235–258. 
141. Casanova, J.L.; Fieschi, C.; Zhang, S.Y.; Abel, L. Revisiting human primary 
immunodeficiencies. J. Intern. Med. 2008, 264, 115–127. 
142. De Beaucoudrey, L.; Samarina, A.; Bustamante, J.; Cobat, A.; Boisson-Dupuis, S.;  
Feinberg, J.; Al-Muhsen, S.; Jannière, L.; Rose, Y.; Desurenaim, M.; et al. Revisiting human 
IL-12Rbeta1 deficiency: A survey of 141 patients from 30 countries. Med. (Baltim.) 2010, 89, 
381–402. 
143. Gordon, M. Salmonella infections in immunocompromised adults. J. Infect. 2008, 56,  
413–422. 
144. Lammas, D.A.; Casanova, J.L.; Kumararatne, D.S. Clinical consequences of defects in the  
IL-12-dependent interferon-gamma (IFN-gamma) pathway. Clin. Exp. Immunol. 2000, 121,  
417–425. 
145. Dunstan, S.J.; Stephens, H.A.; Blackwell, J.M.; Duc, C.M.; Lanh, M.N.; Dudbridge, F.;  
Phuong, C.X.; Luxemburger, C.; Wain, J.; Ho, V.A.; et al. Genes of the class II and class III 
major histocompatibility complex are associated with typhoid fever in Vietnam. J. Infect. Dis. 
2001, 183, 261–268. 
208 
 
146. House, D.; Bishop, A.; Parry, C.; Dougan, G.; Wain, J. Typhoid fever: Pathogenesis and 
disease. Curr. Opin. Infect. Dis. 2001, 14, 573–578. 
147. Santos, R.L.; Zhang, S.; Tsolis, R.M.; Kingsley, R.A.; Adams, L.G.; Bäumler, A.J. Animal 
models of Salmonella infections: Enteritis versus typhoid fever. Microbes Infect. 2001, 3,  
1335–1344. 
148. Roy, M.F.; Malo, D. Genetic regulation of host responses to Salmonella infection in mice.  
Genes Immun. 2002, 3, 381–393. 
149. Malo, D.; Vogan, K.; Vidal, S.; Hu, J.; Cellier, M.; Schurr, E.; Fuks, A.; Bumstead, N.;  
Morgan, K.; Gros, P. Haplotype mapping and sequence analysis of the mouse Nramp gene 
predict susceptibility to infection with intracellular parasites. Genomics 1994, 23, 51–61. 
150. Qureshi, S.T.; Lariviere, L.; Leveque, G.; Clermont, S.; Moore, K.J.; Gros, P.; Malo, D. 
Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 1999, 
189, 615–625. 
151. Poltorak, A.; He, X.; Smirnova, I.; Liu, M.Y.; van Huffel, C.; Du, X.; Birdwell, D.; Alejos, E.; 
Silva, M.; Galanos, C.; et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: 
Mutations in Tlr4 gene. Science 1998, 282, 2085–2088. 
152. Vidal, S.M.; Malo, D.; Vogan, K.; Skamene, E.; Gros, P. Natural resistance to infection with 
intracellular parasites: Isolation of a candidate for Bcg. Cell 1993, 73, 469–485. 
153. Roy, M.F.; Riendeau, N.; Bedard, C.; Helie, P.; Min-Oo, G.; Turcotte, K.; Gros, P.;  
Canonne-Hergaux, F.; Malo, D. Pyruvate kinase deficiency confers susceptibility to 
Salmonella typhimurium infection in mice. J. Exp. Med. 2007, 204, 2949–2961. 
154. Yuki, K.E.; Eva, M.M.; Richer, E.; Chung, D.; Paquet, M.; Cellier, M.; Canonne-Hergaux, F.; 
Vaulont, S.; Vidal, S.M.; Malo, D.; et al. Suppression of hepcidin expression and iron 
overload mediate Salmonella susceptibility in ankyrin 1 ENU-induced mutant. PLoS One 
2013, 8, e55331. 
155. Eva, M.M.; Yuki, K.E.; Dauphinee, S.M.; Schwartzentruber, J.A.; Pyzik, M.; Paquet, M.; 
Lathrop, M.; Majewski, J.; Vidal, S.M.; Malo, D.; et al. Altered IFN-gamma-mediated 
immunity and transcriptional expression patterns in N-Ethyl-N-nitrosourea-induced STAT4 
mutants confer susceptibility to acute typhoid-like disease. J. Immunol. 2014, 192, 259–270. 
156. Richer, E.; Prendergast, C.; Zhang, D.E.; Qureshi, S.T.; Vidal, S.M.; Malo, D.  
N-ethyl-N-nitrosourea-induced mutation in ubiquitin-specific peptidase 18 causes 
hyperactivation of IFN-alphass signaling and suppresses STAT4-induced IFN-gamma 
production, resulting in increased susceptibility to Salmonella typhimurium. J. Immunol. 
2010, 185, 3593–3601. 
157. Malakhova, O.; Malakhov, M.; Hetherington, C.; Zhang, D.E. Lipopolysaccharide activates 
the expression of ISG15-specific protease UBP43 via interferon regulatory factor 3. J. Biol. 
Chem. 2002, 277, 14703–14711. 
158. Kim, K.I.; Yan, M.; Malakhova, O.; Luo, J.K.; Shen, M.F.; Zou, W.; de la Torre, J.C.;  
Zhang, D. Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. 
Mol. Cell. Biol. 2006, 26, 472–479. 
209 
 
159. Richer, E.; Yuki, K.E.; Dauphinee, S.M.; Lariviere, L.; Paquet, M.; Malo, D. Impact of 
Usp18 and IFN signaling in Salmonella-induced typhlitis. Genes Immun. 2011, 12, 531–543. 
160. Dauphinee, S.M.; Richer, E.; Eva, M.M.; McIntosh, F.; Paquet, M.; Dangoor, D.; Burkart, C.; 
Zhang, D.E.; Gruenheid, S.; Gros, P.; et al. Contribution of increased ISG15, ISGylation and 
deregulated type I IFN signaling in Usp18 mutant mice during the course of bacterial 
infections. Genes Immun. 2014, 15, 282–292. 
161. Perrotta, S.; Gallagher, P.G.; Mohandas, N. Hereditary spherocytosis. Lancet 2008, 372,  
1411–1426. 
162. Eber, S.W.; Gonzalez, J.M.; Lux, M.L.; Scarpa, A.L.; Tse, W.T.; Dornwell, M.; Herbers, J.; 
Kugler, W.; Ozcan, R.; Pekrun, A.; et al. Ankyrin-1 mutations are a major cause of dominant 
and recessive hereditary spherocytosis. Nat. Genet. 1996, 13, 214–218. 
163. Min-Oo, G.; Fortin, A.; Tam, M.F.; Nantel, A.; Stevenson, M.M.; Gros, P. Pyruvate kinase 
deficiency in mice protects against malaria. Nat. Genet. 2003, 35, 357–362. 
164. Cunnington, A.J.; de Souza, J.B.; Walther, M.; Riley, E.M. Malaria impairs resistance to 
Salmonella through heme- and heme oxygenase-dependent dysfunctional granulocyte 
mobilization. Nat. Med. 2012, 18, 120–127. 
165. Hoebe, K.; Georgel, P.; Rutschmann, S.; Du, X.; Mudd, S.; Crozat, K.; Sovath, S.; Shame, L.; 
Hartung, T.; Zähringer, U.; et al. CD36 is a sensor of diacylglycerides. Nature 2005, 433,  
523–527. 
166. Xiao, N.; Eidenschenk, C.; Krebs, P.; Brandl, K.; Blasius, A.L.; Xia, Y.; Khovananth, K.;  
Smart, N.G.; Beutler, B. The Tpl2 mutation Sluggish impairs type I IFN production and 
increases susceptibility to group B streptococcal disease. J. Immunol. 2009, 183, 7975–7983. 
167. Rutschmann, S.; Hoebe, K.; Zalevsky, J.; Du, X.; Mann, N.; Dahiyat, B.I.; Steed, P.;  
Beutler, B. PanR1, a dominant negative missense allele of the gene encoding TNF-alpha 
(Tnf), does not impair lymphoid development. J. Immunol. 2006, 176, 7525–7532. 
168. Sauer, J.D.; Sotelo-Troha, K.; von Moltke, J.; Monroe, K.M.; Rae, C.S.; Brubaker, S.W.; Hyodo, M.; 
Hayakawa, Y.; Woodward, J.J.; Portnoy, D.A.; et al. The N-ethyl-N-nitrosourea-induced 
Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon 
response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 2011, 79,  
688–694. 
169. Berger, M.; Krebs, P.; Crozat, K.; Li, X.; Croker, B.A.; Siggs, O.M.; Popkin, D.; Du, X.;  
Lawson, B.R.; Theofilopoulos, A.N.; et al. An Slfn2 mutation causes lymphoid and myeloid 
immunodeficiency due to loss of immune cell quiescence. Nat. Immunol. 2010, 11, 335–343. 
170. Ordonez-Rueda, D.; Jonsson, F.; Mancardi, D.A.; Zhao, W.; Malzac, A.; Liang, Y.; Bertosio, E.; 
Grenot, P.; Blanquet, V.; Sabrautzki, S.; et al. A hypomorphic mutation in the Gfi1 transcriptional 
repressor results in a novel form of neutropenia. Eur. J. Immunol. 2012, 42, 2395–2408. 
171. Georgel, P.; Crozat, K.; Lauth, X.; Makrantonaki, E.; Seltmann, H.; Sovath, S.; Hoebe, K.;  
Du, X.; Rutschmann, S.; Jiang, Z.; et al. A toll-like receptor 2-responsive lipid effector pathway 




172. Croker, B.A.; Lawson, B.R.; Rutschmann, S.; Berger, M.; Eidenschenk, C.; Blasius, A.L.; 
Moresco, E.M.Y.; Sovath, S.; Cengia, L.; Shultz, L.D.; et al. Inflammation and autoimmunity 
caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc. Natl. 
Acad. Sci. USA 2008, 105, 15028–15033. 
173. Jaeger, B.N.; Donadieu, J.; Cognet, C.; Bernat, C.; Ordonez-Rueda, D.; Barlogis, V.;  
Mahlaoui, N.; Fenis, A.; Narni-Mancinelli, E.; Beaupain, B.; et al. Neutrophil depletion 
impairs natural killer cell maturation, function, and homeostasis. J. Exp. Med. 2012, 209, 
565–580. 
174. Barquero-Calvo, E.; Martirosyan, A.; Ordonez-Rueda, D.; Arce-Gorvel, V.; Alfaro-Alarcon, A.; 
Lepidi, H.; Malissen, B.; Malissen, M.; Gorvel, J.; Moreno, E. Neutrophils exert a 
suppressive effect on Th1 responses to intracellular pathogen Brucella abortus. PLoS Pathog. 
2013, 9, e1003167. 
175. Krmpotic, A.; Bubic, I.; Polic, B.; Lucin, P.; Jonjic, S. Pathogenesis of murine 
cytomegalovirus infection. Microbes Infect. 2003, 5, 1263–1277. 
176. Rawlinson, W.D.; Farrell, H.E.; Barrell, B.G. Analysis of the complete DNA sequence of 
murine cytomegalovirus. J. Virol. 1996, 70, 8833–8849. 
177. Pyzik, M.; Gendron-Pontbriand, E.M.; Vidal, S.M. The impact of Ly49-NK cell-dependent 
recognition of MCMV infection on innate and adaptive immune responses. J. Biomed. 
Biotechnol. 2011, 2011, 641702. 
178. Moresco, E.M.; Beutler, B. Resisting viral infection: The gene by gene approach. Curr. Opin. 
Virol. 2011, 1, 513–518. 
179. Tabeta, K.; Georgel, P.; Janssen, E.; Du, X.; Hoebe, K.; Crozat, K.; Mudd, S.; Shamel, L.;  
Sovath, S.; Goode, J.; et al. Toll-like receptors 9 and 3 as essential components of innate 
immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 2004, 
101, 3516–3521. 
180. Hoebe, K.; Du, X.; Georgel, P.; Janssen, E.; Tabeta, K.; Kim, S.O.; Goode, J.; Lin, P.;  
Mann, N.; Mudd, S.; et al. Identification of Lps2 as a key transducer of MyD88-independent 
TIR signalling. Nature 2003, 424, 743–748. 
181. Tabeta, K.; Hoebe, K.; Janssen, E.M.; Du, X.; George, P.; Crozat, K.; Mudd, S.; Mann, N.; 
Sovath, S.; Goode, J.; et al. The Unc93b1 mutation 3d disrupts exogenous antigen 
presentation and signaling via Toll-like receptors 3, 7 and 9. Nat. Immunol. 2006, 7, 156–164. 
182. Crozat, K.; Georgel, P.; Rutschmann, S.; Mann, N.; Du, X.; Hoebe, K.; Beutlerm, B. Analysis 
of the MCMV resistome by ENU mutagenesis. Mamm. Genome 2006, 17, 398–406. 
183. Siggs, O.M.; Berger, M.; Krebs, P.; Arnold, C.N.; Eidenschenk, C.; Huberb, C.; Piriea, E.; 
Smarta, N.G.; Khovanantha, K.; Xia, Y.; et al. A mutation of Ikbkg causes immune deficiency 
without impairing degradation of IkappaB alpha. Proc. Natl. Acad. Sci. USA 2010, 107,  
3046–3051. 
184. Won, S.; Eidenschenk, C.; Arnold, C.N.; Siggs, O.M.; Sun, L.; Brandla, K.; Mullenb, T.; 
Nemerowb, G.R.; Morescoa, E.M.Y.; Beutler, B. Increased susceptibility to DNA virus 
infection in mice with a GCN2 mutation. J. Virol. 2012, 86, 1802–1808. 
211 
 
185. Biron, C.A. Initial and innate responses to viral infections—Pattern setting in immunity or 
disease. Curr. Opin. Microbiol. 1999, 2, 374–381. 
186. Bukowski, J.F.; Woda, B.A.; Habu, S.; Okumura, K.; Welsh, R.M. Natural killer cell 
depletion enhances virus synthesis and virus-induced hepatitis in vivo. J. Immunol. 1983, 131, 
1531–1538. 
187. Bukowski, J.F.; Woda, B.A.; Welsh, R.M. Pathogenesis of murine cytomegalovirus infection 
in natural killer cell-depleted mice. J. Virol. 1984, 52, 119–128. 
188. Welsh, R.M.; Dundon, P.L.; Eynon, E.E.; Brubaker, J.O.; Koo, G.C.; O’Donnell, C.L. 
Demonstration of the antiviral role of natural killer cells in vivo with a natural killer  
cell-specific monoclonal antibody (NK 1.1). Nat. Immun. Cell Growth Regul. 1990, 9,  
112–120. 
189. Brown, M.G.; Dokun, A.O.; Heusel, J.W.; Smith, H.R.; Beckman, D.L.; Blattenberger, E.A.; 
Dubbelde, C.E.; Stone, L.R.; Scalzo, A.A.; Yokoyama, W.M. Vital involvement of a natural 
killer cell activation receptor in resistance to viral infection. Science 2001, 292, 934–937. 
190. Lee, S.H.; Girard, S.; Macina, D.; Busa, M.; Zafer, A.; Belouchi, A.; Gros, P.; Vidal, S.M. 
Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural 
killer cell receptor of the C-type lectin superfamily. Nat. Genet. 2001, 28, 42–45. 
191. Arase, H.; Mocarski, E.S.; Campbell, A.E.; Hill, A.B.; Lanier, L.L. Direct recognition of 
cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002, 296,  
1323–1326. 
192. Smith, H.R.; Heusel, J.W.; Mehta, I.K.; Kim, S.; Dorner, B.G.; Naidenko, O.V.; Iizuka, K.; 
Furukawa, H.; Beckman, D.L.; Pingel, J.T.; et al. Recognition of a virus-encoded ligand by a 
natural killer cell activation receptor. Proc. Natl. Acad. Sci. USA 2002, 99, 8826–8831. 
193. Dokun, A.O.; Kim, S.; Smith, H.R.; Kang, H.S.; Chu, D.T.; Yokoyama, W.M. Specific and 
nonspecific NK cell activation during virus infection. Nat. Immunol. 2001, 2, 951–956. 
194. Barnes, M.J.; Aksoylar, H.; Krebs, P.; Bourdeau, T.; Arnold, C.N.; Xia, Y.; Khovananth, K.; 
Engel, I.; Sovath, S.; Lampe, K.; et al. Loss of T cell and B cell quiescence precedes the onset 
of microbial flora-dependent wasting disease and intestinal inflammation in Gimap5-deficient 
mice. J. Immunol. 2010, 184, 3743–3754. 
195. Crozat, K.; Hoebe, K.; Ugolini, S.; Hong, N.A.; Janssen, E.; Rutschmann, S.; Mudd, S.;  
Sovath, S.; Vivier, E.; Beutler, B. Jinx, an MCMV susceptibility phenotype caused by 
disruption of Unc13d: A mouse model of type 3 familial hemophagocytic lymphohistiocytosis.  
J. Exp. Med. 2007, 204, 853–863. 
196. Crozat, K.; Eidenschenk, C.; Jaeger, B.N.; Krebs, P.; Guia, S.; Beutler, B.; Vivier, E.;  
Ugolini, S. Impact of beta2 integrin deficiency on mouse natural killer cell development and 
function. Blood 2011, 117, 2874–2882. 
197. Eidenschenk, C.; Crozat, K.; Krebs, P.; Arens, R.; Popkin, D.; Arnolda, C.N.; Blasiusa, A.L.; 
Benedictb, C.A.; Morescoa, E.M.Y.; Xiaa, Y.; et al. Flt3 permits survival during infection by 




198. Croker, B.; Crozat, K.; Berger, M.; Xia, Y.; Sovath, S.; Schaffer, L.; Eleftherianos, I.;  
Imler, J.; Beutler, B. ATP-sensitive potassium channels mediate survival during infection in 
mammals and insects. Nat. Genet. 2007, 39, 1453–1460. 
199. Abel, L.; Plancoulaine, S.; Jouanguy, E.; Zhang, S.Y.; Mahfoufi, N.; Nicolas, N.;  
Sancho-Shimizu, V.; Alcaïs, A.; Guo, Y.; Cardon, A.; et al. Age-dependent Mendelian 
predisposition to herpes simplex virus type 1 encephalitis in childhood. J. Pediatr. 2010, 157, 
623–629. 
200. Yao, H.W.; Ling, P.; Chen, S.H.; Tung, Y.Y.; Chen, S.H. Factors affecting herpes simplex 
virus reactivation from the explanted mouse brain. Virology 2012, 433, 116–123. 
201. Kennedy, P.G.; Chaudhuri, A. Herpes simplex encephalitis. J. Neurol. Neurosurg. Psychiatry 
2002, 73, 237–238. 
202. Casrouge, A.; Zhang, S.Y.; Eidenschenk, C.; Jouanguy, E.; Puel, A.; Yang, K.; Alcais, A.;  
Picard, C.; Mahfoufi, N.; Nicolas, N.; et al. Herpes simplex virus encephalitis in human  
UNC-93B deficiency. Science 2006, 314, 308–312. 
203. Zhang, S.Y.; Jouanguy, E.; Ugolini, S.; Smahi, A.; Elain, G.; Romero, P.; Segal, D.;  
Sancho-Shimizu, V.; Lorenzo, L.; Puel, A.; et al. TLR3 deficiency in patients with herpes 
simplex encephalitis. Science 2007, 317, 1522–1527. 
204. Sancho-Shimizu, V.; Perez de Diego, R.; Lorenzo, L.; Halwani, R.; Alangari, A.;  
Israelsson, E.; Fabrega, S.; Cardon, A.; Maluenda, J.; Tatematsu, M.; et al. Herpes simplex 
encephalitis in children with autosomal recessive and dominant TRIF deficiency. J. Clin. 
Invest. 2011, 121, 4889–4902. 
205. Perez de Diego, R.; Sancho-Shimizu, V.; Lorenzo, L.; Puel, A.; Plancoulaine, S.; Picard, C.; 
Herman, M.; Cardon, A.; Durandy, A.; Bustamante, J.; et al. Human TRAF3 adaptor 
molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to 
herpes simplex encephalitis. Immunity 2010, 33, 400–411. 
206. Guo, Y.; Audry, M.; Ciancanelli, M.; Alsina, L.; Azevedo, J.; Herman, M.; Anguiano, E.; 
Sancho-Shimizu, V.; Lorenzo, L.; Pauwels, E.; et al. Herpes simplex virus encephalitis in a 
patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity.  
J. Exp. Med. 2011, 208, 2083–2098. 
207. Herman, M.; Ciancanelli, M.; Ou, Y.H.; Lorenzo, L.; Klaudel-Dreszler, M.; Pauwels, E.;  
Sancho-Shimizu, V.; de Diego, R.P.; Abhyankar, A.; Israelsson, E.; et al. Heterozygous 
TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of 
childhood. J. Exp. Med. 2012, 209, 1567–1582. 
208. Xia, Y.; Won, S.; Du, X.; Lin, P.; Ross, C.; la Vine, D.; Wiltshire, S.; Leiva, G.; Vidal, S.M.; 
Whittle, B.; et al. Bulk segregation mapping of mutations in closely related strains of mice. 
Genetics 2010, 186, 1139–1146. 
209. Caignard, G.; Leiva-Torres, G.A.; Leney-Greene, M.; Charbonneau, B.; Dumaine, A.;  
Fodil-Cornu, N.; Pyzik, M.; Cingolani, P.; Schwartzentruber, J.; Dupaul-Chicoine, J.; et al. 
Genome-wide mouse mutagenesis reveals CD45-mediated T cell function as critical in 
protective immunity to HSV-1. PLoS Pathog. 2013, 9, e1003637. 
213 
 
210. Caignard, G.; Vidal, S.M. Department of Human Genetics and Complex Traits Group, 
McGill University, Montréal, QC, Canada. Unpublished data, 2014.  
211. Caignard, G.; Gros, P.; Vidal, S.M. Department of Human Genetics, Department of 
Biochemistry, and Complex Traits Group, McGill University, Montréal, QC, Canada. 
Unpublished data, 2014.  




Delivery of a Clinical Genomics Service 
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Abstract: Over the past five years, next generation sequencing has revolutionised the discovery of 
genes responsible for rare inherited diseases previously resistant to traditional discovery techniques. 
This review considers how this new technology is being introduced into clinical practice to aid 
diagnosis and improve the clinical management of individuals and families affected by rare diseases 
where access to genetic testing was previously limited. We compare and contrast the different 
approaches that have been adopted including panel based tests, exome and genome sequencing. We 
provide insights from our own clinical practice demonstrating the challenges and benefits of  
this new technology. 
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1. Clinical Genetic Testing for Inherited Disorders 
Rare diseases are individually rare but affect a large number of individuals—for example, it is 
estimated that collectively they affect around 1 in 17 individuals in Western populations [1]. The 
identification of a specific genetic variant, in a patient DNA sample, that is responsible for a rare 
inherited disease can establish or confirm a clinical diagnosis, inform screening programmes and the 
implementation of personalised approaches to medical management. The information also facilitates 
risk assessment for affected families and enables reproductive decision-making. 
Molecular genetic testing for rare diseases has been managed by a small number of expert 
clinicians, Clinical geneticists, over the past three to four decades, but is now becoming relevant to 
more patients seen across all clinical specialties. However, for clinicians within such so-called 
“mainstream” specialties (i.e., outside of clinical genetics) it is often difficult to know how to access 
genetic testing for their patients. Over the past thirty years, Medical Genetics laboratories have been 
providing mutation testing for a relatively small number of inherited disorders due to variants in 
single genes. Of the approximately 7000 rare inherited disorders that have been defined, 3500 have 
so far been characterized at a molecular level [2]. The Genetic Testing Registry has collated the 
details on 16,000 tests for 4200 conditions analysing 2800 different genes [3]. The majority of these 
tests are still undertaken on a research basis. Clinically accredited testing provided by diagnostic 
laboratories is often limited. 
The traditional testing model has been driven by clinical hypotheses (Figure 1, using congenital 
cataract, a genetically heterogeneous condition, as an exemplar). A clinician usually defines, through 
detailed clinical investigation, a specific phenotype and subsequently develops a testable clinical 
hypothesis. The resulting clinical question leads to the request of a specific (usually single gene) test 
or at most the testing of a very small number of potentially relevant genes. This aims to confirm or 
refute the clinician’s suspicions and historically has been limited in great part by the technological 
limitations of nucleic acid sequencing. The pick up rate of such a testing approach varies considerably 
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from approximately 0.6% for Fragile X syndrome [4] to over 40% for CHARGE syndrome [5]. In 
general, this has been a highly targeted approach, that is expensive, iterative and inefficient because 
of the limited number of target genes that can be tested and by the tendency to institute a large number 
of simultaneous investigations. By its very nature, it has also been limited to patients, and their 
relatives, with clinical features indicative of a specific genetic disease. Even where genetic testing is 
well established in familial breast cancer, genetic testing for BRCA1 and BRCA2 mutations has been 
limited to those with a very strong family history of the condition. Genetic molecular analysis has 
been especially challenging for genetically heterogeneous conditions, that is those conditions of 
identical phenotype cause by mutations in a wide range of genes, including intellectual and 
developmental delay, deafness, retinal dystrophies, congenital cataract, neuropathies and  
cerebellar ataxias. 
Figure 1. Classical clinical hypothesis-driven diagnostic approach. Traditional 
investigation of genetically and clinically heterogeneous conditions, such as congenital 
cataract, require an inefficient and iterative process based upon the development and 
testing of multiple clinical hypotheses, which leads to testing of many genes in series. 
 
2. Next Generation Sequencing as a Diagnostic Tool 
In 2009, the first proof of principle studies were published exploring the application of massively 
paralleled or so called “next generation” sequencing (NGS) to identify the novel causes of rare 
inherited diseases [6,7]. These conditions had previously not been amenable to standard gene 
discovery approaches, e.g., de novo autosomal dominant disorders could not be refined by  
linkage analysis and/or candidate gene approaches had proved unsuccessful. The technology and 
bioinformatic approach demonstrated an extremely powerful ability to identify disease-causing genes 
from large genomic regions using small patient cohorts. This technology has led to the molecular 
characterization of numerous rare disorders and has been hailed as a revolution in medical research 
and practice [8]. NGS has already been applied in many disciplines across medicine, including in 
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microbiology, virology, transplantation medicine and in the identification of acquired (somatic) 
mutations in tumours. However, this paper considers the use of clinical application of NGS in the 
molecular diagnosis of rare diseases. 
NGS, when first applied to Mendelian disorders focussed on gene discovery where the majority 
of studies used either approaches focussing of targeted sequencing of genomic regions or most 
commonly on whole exome sequencing (WES). The WES approach is focused on approximately 1% 
of the genome, which includes coding and non-coding exons, some intronic and untranslated regions 
and promoters. It is important to note that the terms whole exome and whole genome sequencing are 
misnomers as the entire sequence of the exome or genome is not covered using the currently available 
techniques [9]. Focussing on the protein-coding DNA sequence such an approach generates 
manageable datasets; although large when compared to conventional sequencing, these are 
comparatively small when compared to the data from complete genomes. These present challenging, 
but surmountable, computing challenges [8]. 
In the clinical setting, the commonest initial approach—that has been introduced by many clinical 
laboratories—is the targeted sequencing of a panel of genes relevant to a specific disease indication 
(Figure 2). Here, NGS has already had a major impact. Our own experience with testing of a panel 
of 105 inherited retinal dystrophy (IRD) genes has seen an increase in detection of the causal variant 
from 14% to 60% over the past two years of providing this service, allowing earlier implementation 
of genetic diagnosis and a reduction in the use of other diagnostic options [10]. More recently an 
“exome” approach to clinical diagnostic NGS sequencing has been adopted due to considerable 
practical advantages from the ability to develop a single diagnostic pathway for a huge range of 
clinical indications [11]. Please provide the original file (in ppt or other format) or a copy in tiff 
format of Figure 2 with high resolution. 
Figure 2. Genomic diagnostic approach Genomic technologies allow early genetic 
investigation of heterogeneous disorders, allowing much improved diagnostic pick-up, 




2.1. Targeted Next Generation Sequencing for Diagnostic Molecular Testing 
To sequence relatively small numbers of genes many approaches have been introduced to harness 
the power of NGS to improve throughput, reduce costs and improve turnaround times. For example, 
long range PCR has been used in our laboratory for BRCA1 and BRCA2 mutation analysis to generate 
large overlapping amplicons, which can then be sequenced. For panels of genes many technologies 
have been used to target the specific sequences, e.g., amplicon generation, Haloplex and 
hybridisation capture. Each of these methods has advantages and disadvantages in terms of labor 
intensity, cost and the specificity of the sequence generated. Further, each method has some 
limitations when identifying small insertion/deletion mutations has meant that, when using it as a 
replacement for Sanger-based diagnosis, care needs to be taken in using it as an equally effective 
diagnostic mechanism of excluding mutations in given genes [12]. 
Testing of panels of genes sequenced by NGS has been introduced with considerable success. The 
capture of selected sequences has been employed on both a research and diagnostic basis to study 
groups of genes—focused around biochemical pathways or those known to cause specific phenotypes, 
usually to analyse 20–200 genes in genetically heterogeneous disorders, such as IRD [10]. 
Such panels have many advantages over exome-based approaches: since they sequence fewer 
targets than genome-wide approaches they currently remain cheaper in absolute cost terms, although 
not when cost per base is used as the basis for evaluation. Panel-based approaches can now achieve 
even and very high levels of coverage of the targets selected, 99% coverage, allowing considerable 
clarity in diagnostic reporting. Importantly, many of the methodologies for capture-based exome 
sequencing, in particular at lower levels of overall coverage, have resulted in patchy coverage with 
a significant dropout of many, in particular GC-rich exons [13]. From a diagnostic viewpoint this 
dropout has been seen as challenging as it hinders the ability of the clinical scientist to deliver a 
report that provides a confident definition that a comprehensive screening of the selected genes has 
been undertaken and that, for exonic and flanking sequences, it is unlikely that a given individual 
carries a pathogenic variant. Such clarity is important as there are increasing numbers of clinicians, 
who are unfamiliar with complex genetic terminology and mechanisms, requesting genetic testing to 
inform their clinical practice. 
Gene panel testing has other attractions when applied in the diagnostic sphere. The ability to 
define the genes that are screened lowers the likelihood that unexpected and potentially actionable 
findings may be encountered. However, it should be recognised that even amongst panel testing 
unexpected findings will nonetheless be found: for example, for two panels designed for ophthalmic 
disorders by our group [10,14], a wide range of conditions are covered by approximately  
100–200 genes, many of broad pleiotropic effect [15]. Taking the example of retinal disease,  
it should be remembered that the ability to diagnose, in those with apparently isolated retinal 
dystrophy, syndromic conditions such as Senior-Loken and Bardet-Biedl syndromes can be—for the 
patient—unexpected and can result in altered management. When compared to single gene  




When compared to exome (WES) or whole genome (WGS) sequencing, gene panel testing thus 
offers apparent simplicity and has consequently been employed to improve diagnosis of genetically 
heterogeneous monogenic diseases (e.g., retinitis pigmentosa, congenital deafness, cardiomyopathy). 
The relatively small numbers of potentially novel or pathogenic variants identified enable a detailed 
and focussed approach to variant interpretation that is more manageable for clinical scientists 
analysing and interpreting variants discovered through WES. However, even at this level of 
complexity, there are challenges presented in patient reporting. For example, in a series of 700 
patients with IRD that has been evaluated for variation in 105 genes, in 40 (approximately 12%) of 
those for whom a molecular cause for their condition was found were shown to be heterozygous 
carriers of a pathogenic variant in another gene known to cause autosomal recessive IRD  
(Black; personal communication [16]). Here, the issue of disclosure is not straightforward and 
requires clear policy decisions by the diagnostic team delivering NGS [17]. Furthermore, it is 
essential that these policies are complementary to, and understood by, the clinicians consenting to 
testing. Since families with higher levels of consanguinity may not be identified to clinical scientists, 
it may be necessary to report all incidental carriers in such circumstances. Such an approach may 
differ from WES, where the numbers of heterozygous recessive variants present in each individual 
is high and the identification of carrier status relating to conditions not similar to the primary 
indication for testing is potentially more complex. 
As gene panels are adopted for clinically and phenotypically heterogeneous disorders, it becomes 
possible for gene testing to be employed earlier in the diagnostic pathway (Figure 2). The breadth of 
variants that are identified—even in small gene panels—means that interpretation is highly context 
dependent and in our experience this has led to the development of dialogue between the clinical 
reporting scientist and the diagnostic clinician. The development of multidisciplinary reporting 
processes allows sharing of complex phenotypic, family, clinical and genomic data. For example, 
amongst the multi-systemic diseases that cause congenital cataract, such as cerebroteninous 
xanthomatosis, Stickler or Cockayne syndromes, genomic discoveries may uncover unexpected or 
overlooked clinical features that require re-evaluation in the clinic. In addition, genomic discoveries 
in conditions such as inborn errors of metabolism may define a range of secondary clinical 
investigations that support genomic findings and facilitate precise diagnosis [18]. In delivering NGS 
multi-gene panels, the identification of variants of uncertain significance is common. While, from a 
clinician’s viewpoint these cannot necessarily be acted upon, they represent a considerable workload 
for the team reporting genomic sequencing. At the current time the laboratory methodologies for 
NGS and the informatics tools to process the data have been honed substantially and have reached a 
point where this can be relatively easily automated. However, variant interpretation is both gene and 
phenotype specific. While there may well be certain guiding principles that are generally applicable, 
nonetheless this remains a labour intensive and complex aspect of NGS panel testing that must be 
factored into the costs of delivering testing in a healthcare setting. The diagnostic power of gene 
panel testing via NGS is remarkable and, alongside research developments, has allowed NGS very 
rapidly to contribute to clinical care. However, in planning the adoption of such processes, the hidden 
costs of testing are easily overlooked including the need for segregation studies, increased uptake of 
cascade testing and the need to evaluate the increasing demand for testing. These may be offset, 
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potentially, by reduced adoption of clinical investigations that are superseded by NGS testing, but in 
many circumstances the costs of such tests are held in separate budgets to other aspects of clinical 
care. Finally, when considering multigene panels it is important to realise that, while compared to 
genome-wide approaches there is less data generated and analysed, there is nonetheless a 
considerable need for IT support, including sufficient computing hardware for data analysis and 
storage. Ensuring that data governance—in the diagnostic setting—fulfils those required in a 
healthcare setting immediately places a significant extra financial burden. 
2.2. The Use of Genome-Wide NGS Approaches as a Diagnostic Tool 
The speed of technological advance in NGS is remarkable, and has led to the technology being 
described as “disruptive” [19]. Recapitalisation and standardisation of approaches that are key to 
secure delivery of accredited diagnostics remain challenging in an environment that is yet to fully 
mature. The panel-based approaches, discussed above, are inherently prone to redundancy as new 
genes relevant to a particular condition are discovered. As wet lab sequencing and bioinformatic 
processing and analysis become standardized and provided by increasing numbers of diagnostic 
laboratories, a single test and pipeline that leads to rapid diagnosis is appealing, with economies of 
scale and resultant rapid turnaround. Consequently genome-wide approaches, which facilitate 
sequencing of all known genes, are increasingly seen to be an important step in the delivery of 
genomic medicine—and we will now consider both exome-based and genome based approaches 
(Figure 3). 
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2.2.1. Clinical Exome Sequencing 
The ability of NGS to sequencing the entire exome—that is all of the coding exons of the 
expressed component of the genome, has fuelled gene discovery and accelerated the understanding 
of the pathogenesis of many monogenic diseases. As a result, clinical exome sequencing has been 
launched at a number of Centres in the United States [5], Australia and Europe and is being actively 
developed by clinical laboratories across the world [20]. Interestingly, in order to develop workable 
pipelines and a cost effective manner, at present in most clinical centres clinical reports are generated 
providing genetic sequencing data that is directly related to the specific phenotype of the tested 
individual—that is such an approach is based upon an in silico panel of genes that are analysed 
bioinformatically and reported (Figure 3). Such a targeted approach to analysis reduces substantially 
the cost of analysis, validation and variant interpretation. However, as discussed above, it is 
important in the consent process that patients and their families understand such focused  
analytical approaches. 
In addition to a focussed approach, extended clinical reports may also be delivered that can 
provide information about:  
(i) Carrier status for a range of recessive disorders to inform future reproductive risks. 
(ii) Inherited disorders that are not predicted on the basis of family history or clinical 
presentation and for which treatment or preventive screening may be appropriate—so-called 
actionable variants. An example would be the detection of a variant in the low density 
lipoprotein receptor (LDLR) that would consistent with a diagnosis of familial 
hypercholesterolemia for which dietary intervention and statin treatment can reduce the risk 
of cardiovascular disease. 
(iii) Pharmacogenetic data that may reduce the risk of adverse drug reactions, e.g., detection of 
variants in thiopurine methyl transferase that predict adverse response to thiopurines,  
e.g., azathiopurine. 
There has been, and remains, extensive debate about the optimal approach to clinical exome 
sequencing, including uncertainty in defining the optimal population who should be tested and what 
information should be reported back to health care professionals and tested individuals. In one recent 
study of 250 cases referred for clinical exome sequencing, 80% of referrals were of children with 
neurological problems. In this group molecular diagnoses were confirmed in 62 (25%) with analysis 
confined to genes known to cause inherited disorders [5]. Of note, demonstrating the power of this 
approach, a significant number of the causative genes defined in this cohort had been discovered in 
the previous twelve months. The utility of exome testing has been explored in a number of other 
clinical settings, including improving diagnosis of children on intensive care units [21] or in children 
affected by likely recessive disorders when born to consanguineous parents [22]. 
Overall, exome sequencing lends itself to a high diagnostic yield in a range of clinical scenarios, 
including the molecular diagnosis of heterogeneous disorders, including primary immunodeficiencies 
and metabolic disorders. This precise diagnosis will result in reduced expenditure on alternative 
diagnostic tests and importantly provide patients and parents of affected children with diagnostic 
certainty. In addition to providing diagnostic information, reports are emerging of exome sequencing 
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that has led to successful changes in clinical management—for example in the diagnosis and 
treatment of early onset inflammatory bowel disease [23] and in sepiapterin reductase deficiency in 
twins leading to supplementation of L-dopa therapy with 5-hydroxytryptophan [24]. 
2.2.2. Whole Genome Sequencing 
Whole genome sequencing (WGS) is considered to be the most comprehensive form of genetic 
test currently available [25]. In contrast to exome sequencing relatively few studies have used (WGS) 
in rare disease gene discovery. Initially successes have mainly been confined to use of WGS in 
combination with other sequencing approaches [26] or to identify non-coding mutations that have an 
effect on genes known previously to cause the specific phenotype [27]. Combination approaches 
allow refinement of the data analysis from tens of gigabytes to megabyte levels. The control datasets 
for non-coding variants are less mature and the functional assays to determine the potential 
phenotypic effects of non-coding variants are challenging to undertake and interpret, such that 
confident identification of pathogeneic mutations in the non-coding genome for rare diseases remains 
a formidable challenge. However, WGS presents considerable technological advantages over exome 
sequencing in that, because it is not based around biased capture-based enrichment approaches, it 
generates data on an entire genome, often with a consistent average coverage. Consequently, 
coverage of GC rich regions is improved and there is a considerably improved ability to determine 
rearrangements and copy number variants. Most recently this has been applied to a cohort  
of 50 individuals with a diagnosis of severe learning disability (LD) [28], a series of conditions that 
are associated with extraordinary genetic heterogeneity that are frequently undiagnosed. The 
conditions can be associated with macroscopic and/or submicroscopic chromosomal rearrangements 
as well as de novo copy number variations (CNVs) and single-nucleotide variations (SNVs). These 
are currently diagnosed using combined microarray/NGS (targeted panel or exome) sequencing 
approaches and has been demonstrated that WGS represents a single genetic test that can characterize 
the full range of genetic variants and enable a clinician to reach a genetic diagnosis in the majority 
of patients with severe LD. 
However, WGS is yet to be introduced widely into routine clinical practice due in large part to 
the technological and practical hurdles presented by the technology. The generation of terabytes of 
sequence data that require massive computing capacity to analyse means that WGS is mainly confined 
to large-scale research or commercial laboratories where it has been applied in disease gene discovery 
studies. Advances in computing will ensure that WGS will be introduced rapidly over the coming 
years to supercede both gene panel and WES. 
2.2.3. Methodological Considerations of Different NGS Approaches 
In adopting genomic technologies—from panel-based testing to WGA—the standardisation and 
full clinical validation of downstream processing will be essential. Here, a challenge is in ensuring 
that clinicians and clinical scientists are fully aware of the capabilities, limitations and overall design 
of analysis pipelines. For example, for WES we currently use a library preparation that results in, an 
average read depth of 140× across the exome which results in 94% coverage of the reference exome 
222 
 
at 30× depth and generates approximately 13 Gb of data. Consequently, there is somewhat uneven 
coverage across many genes, a limitation that is important to stress to clinicians who may need to 
understand why a negative test may be received. For many capture technologies—that are used for 
both panel-based NGS approaches and for WES—the ability to assess dosage is limited and means 
that CNV analysis remains very challenging, potentially requiring reflex dosage testing. This is likely 
to be a limitation that WGS overcomes. 
Analyses of raw data include data generation, collection and processing, followed by  
application-specific clustering, parsing and visualisation. Here there has been a pragmatic need to 
adopt research-designed bioinformatic analyses, which are often performed “in-house” using custom 
freeware designed pipelines for variant calling. Standardisation and full clinical stress testing will be 
key to ensuring that testing is of high quality, is reliably adopted and also to enabling effective data 
sharing across different diagnostic centres and platforms. 
Variant interpretation remains extremely time-consuming and highly specialised. The process 
currently relies—in a diagnostic setting—on trained clinical scientists and has, to date, been far less 
automated than other areas of the NGS pipeline. In silico analyses determine whether sequence 
alterations are predicted to cause disruption of conserved residues. In diagnostic laboratories 
potential causal variants are often confirmed (currently, at least) by Sanger sequencing and 
segregation analyses, where possible, are undertaken to provide further evidence of pathogenicity. 
The definition of novel and pathogenic variants use sequence comparisons of sequences with  
(i) published data (themselves of highly variable reliability) (ii) databases of known mutations such 
as the Human Gene Mutation Database or publically available exome data resources such as Exome 
Variant Server [29] and (iii) the use of in-house databases of exome data. Such a labour intensive 
process remains important since a trained understanding of the technology and a high index of 
clinical suspicion can lead to re-evaluation of sequence data to define a causative mutation. For 
example, in a young child with severe triglyceridemia in whom a heterozygous, previously reported, 
mutation in LPL was identified. There was no sequence variant evident on the second allele to support 
a diagnosis of the autosomal recessive condition, lipoprotein lipase deficiency. However, the number 
of sequence reads was diminished across exons 4 and 5 of LPL (Figure 4) in comparison with an 
exome on the same sequence run. Subsequent, cDNA sequencing confirmed a heterozygous deletion 
of exons 4 and 5, confirming the diagnosis of lipoprotein lipase deficiency. 
The limitations of current databasing are well understood amongst bioinformaticians and many 
clinical geneticists but will need to be more widely understood to enable secure variant interpretation 
across the clinical spectrum [30]. Of course, such resources are becoming more mature and 
informative as additional data is deposited and the ability to interpret exome-derived data is 
improving rapidly. By contrast, WGS will generate significant numbers of novel variants which will 
be difficult to interpret for pathogenicity and indeed it is likely that most early clinical analyses of 
WGS data will be focused on the in silico exome. For a thorough understanding of variant 
pathogenicity, high throughput functional studies including reporter assays, expression analyses, 
biochemical tests or in vivo assays will need to be developed to complement the emergent sequence 
data to allow full interpretation. Finally, the strategy around testing only the affected individual or in 
some scenarios WES or WGS of parents or other relatives (affected/unaffected) may be informative 
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to refine the bioinformatics analysis and reduce the number of potential candidate causative gene 
variants. A successful example has been the application of a trio sequencing approach of affected 
child and unaffected parents to identify de novo pathogenic mutations, especially for severe 
congenital/developmental disorders [31]. 
Figure 4. Copy number variation detected by exome sequencing. Decreased numbers of 
sequence reads are present in exons 4 (e.g., see arrow) and 5 of LPL in the individual with 
lipoprotein lipase deficiency (top panel) compare to exons 3 and 6 (similar number of reads in 
patient DNA sequence and that of a control individual below). This indicates a heterozygous 
deletion of exons 4 and 5 of LPL, which is confirmed in the bottom panel by sequencing of 
cDNA generated from RNA extracted from lymphocytes from the affected individual. 
 
3. Adoption of Clinical Genomics into Routine Clinical Practice 
Next generation sequencing presents an exciting opportunity to revolutionise the diagnosis of rare 
disease and improve the effectiveness of healthcare delivery across all specialties. A number of 
specific areas will require focus if this is to be realised in a safe and effective manner: 
3.1. Training 
NGS is applicable across the healthcare spectrum—that is, it has been shown to be  
disease-agnostic. It is already proven to be a fundamental tool both clinical and research spheres and 
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also—as recent studies have shown—relevant to both rare and common diseases. For example the 
next generation sequencing era introduces exciting new possibilities for singling out genetic variants 
of large effect that contribute to common disease in individuals as demonstrated for age-related 
macular degeneration [32]. A consequence of this broad relevance will be the opportunity to introduce 
NGS testing into the mainstream medical disciplines, including cardiology, neurology, and 
gastroenterology where to date genetic testing has been used less extensively and where the 
experience in delivering it remains more limited. 
A recent survey of over 130 physicians at our Hospital across a number of specialties, including 
medicine (21%), surgery (13%), paediatrics (18%), anaesthetics (16%), and ophthalmology (7.5%) 
indicated enthusiasm for exome testing as a diagnostic aid. Over 11% of respondents had already 
requested an exome and over 53% envisaged requesting a test within the next five years. Limitations 
of current testing were availability (23%), difficulty with interpretation (47%) and concerns 
regarding identification of unexpected complex predictive data on cancer or neurodegenerative 
disease (23%). Such concerns emphasize the importance of clear guidance being established by 
national professional organisations in concert with patient support groups and other relevant 
stakeholders. However, experience from the practice of genetic medicine suggests that there is a need 
for an understanding of genetics, such as mutational mechanism and of genomic architecture and that 
this is aligned to experience in working closely with families and in delivering the counselling 
required to ensure effective and safe adoption of testing. Overall, therefore there is an urgent need 
for training to facilitate the adoption of the types of genomic technologies discussed above. This will 
need to be applied across all aspects of healthcare, including subspecialty clinicians and 
counsellors—potentially including those in primary care—who will need to be comfortable in 
understanding the nature and capability of the tests they order. Furthermore, this creates pressure to 
increase the numbers of scientists and bioinformatics experts who will be required to process the 
increasing number of tests. 
The comparative youth of NGS is itself an inhibitor to widespread adoption in the clinical arena. 
In such a rapidly changing environment, the choices of technology and approach are fluid; exome 
capture technologies continue to improve, WGA costs are reducing and platforms rapidly 
maturing/becoming obsolete. Many healthcare-facing laboratories have until now been exercised 
with the decision to invest in the development of panel-based NGS tests or genome based (exome) 
approaches which are already considered by some to be out-dated. It is likely that the high cost of 
computing and of capitalisation/recapitalisation will either favour the larger healthcare organisations, 
or even lead to widespread outsourcing of sequencing. This is exemplified by the move by the 100000 
Genome Project to a centralised and homogenised sequencing approach [33]. Both approaches will 
have a significant impact on how the technologies are introduced. 
3.2. Standardised Phenotyping 
The power of new genetic testing technologies to define the causes of rare inherited disorders has 
been remarkable. However, a limitation to further discovery has been the ability to share data 
generated on independent families with variants in the same gene with similar or different clinical 
phenotypes. Such data sharing will facilitate the definition of the ultra-rare conditions which, to date 
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have remained undiagnosed [30]. Many research groups have identified potential causative genetic 
variants in single families where the burden of proof has not been satisfied to confirm causation as a 
mutation(s) in a second unrelated family has not been demonstrated. Many international efforts have 
been initiated to address this issue, including The Human Phenotype Ontology project [34] and 
databases that allow sharing of clinical and sequence data between clinical research groups,  
e.g., PhenomeCentral. 
3.3. Ethical Issues 
A range of complex ethical issues will influence a generalised introduction of genome-wide NGS. 
At present, clinical reports from such genomic testing are generated to provide feedback relevant 
to the presentation of the tested individual. Thus, despite the breadth of genetic information available 
many centres, including our own, have decided initially to apply a bioinformatic filter based on the 
phenotypic features of the patient that predefines the panel of genes that will be analysed [21]. Such 
an approach significantly reduces, but does not abolish, the likelihood of identifying co-incidental 
genetic variants and speeds up the data analysis. 
However, the potential to generate data that identify predisposition to conditions that are not 
predicted from family history or current health is significant. The American College of Medical 
Genetics [35] and European Society of Human Genetics [36] have considered how extra information 
potentially generated from genome analysis should be fed back to individuals. Information about 
increased risks of cardiac disease, cancer and rare inherited disorders (such as Marfan syndrome) 
potentially lend themselves to targeted interventions with improved outcomes. However, concerns 
have been raised about individual autonomy, inappropriate use of this information to discriminate in 
terms of employment and insurance and the burden placed upon health professionals to feedback 
accurate information that can have a measurable benefit [35–37]. 
A key area of future debate will be whether only those genes that are relevant to a specific patient 
phenotype are assessed and information relating to these fed back to the patient from their clinical 
exome—and if not, then precisely which so-called “actionable variants” are reported. The use of 
WES and WGS is a rapidly evolving area of medicine with different views emerging as to how this 
should be delivered. Our local patient advocate group has indicated that patients are keen for 
supplemental information that is derived from such testing to be used for patient advantage. 
However, the anecdotal feedback from patients interviewed in a clinic setting where exome testing 
has been offered, has suggested more reluctance in this regard. 
Lastly, it is important to note the cautionary tales from newborn screening programmes. Tandem 
mass spectrometry has revolutionized the number of inborn errors of metabolism that can potentially 
be identified in the newborn period from blood spot analysis. However, results should only be fed 
back to parents where there is clear evidence of benefit for the newborn child through treatment or 
altered clinical management, or information that may influence future parental reproductive choices. 
The natural history of the metabolic disorder should be known, reference should be made to 
histidinemia and the inappropriate adoption of newborn screening when some children were exposed 
the risk of liver biopsy despite the condition having a benign natural history [38]. The results of any 
genome test should be societally and individually acceptable and understandable. 
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3.4. Economic and Societal Issues 
The adoption of NGS—and ultimately WGS—will happen only if the diagnostic yield is sufficient 
to offset the costs of adoption. The 100000 Genome Project in the UK and similar initiatives across 
the world will start to address the technical and interpretative challenges posed by WGS and allow 
comparison with WES. However, it is challenging to measure the benefit of NGS as introduced 
across a population. Many groups, including our own, have numerous case reports of benefit through 
the identification of a previously unknown diagnosis. Clinical testing has already been introduced 
and so undertaking studies to establish improvements in outcome is difficult in this context. 
Randomized control trials will potentially provide the most compelling evidence of benefit and may 
be possible for defined groups of conditions, but it will be very challenging to interpret the benefits 
across heterogeneous groups of rare disorders. Such studies will be increasingly difficult to conduct 
if genome testing becomes the standard of care. Furthermore there are no universally agreed outcome 
measures in Genetic Medicine. Standard outcome measures such as the EQ-5D are not likely to 
capture the potential benefit of genetic testing, as they do not often result in an alteration in any of 
the measured parameters, e.g., mobility [39]. An alternative to randomized trials will be to make 
comparisons against historical data to determine potential benefit, but such analyses are beset by 
potential bias. 
The point at which a genome test should be used in the diagnostic pathway is yet to be defined.  
Should a standard suite of diagnostic tests be used initially and sequencing applied as a second line 
or for certain clinical indications? Should the NGS test be the first line investigation? Studies to 
define these pathways are urgently required to ensure appropriate use of resources and to maximise 
patient benefit. At present genomic tests are used with rather limited scope within medical practice. 
This may reflect limited education of health care professionals about their utility, a lack of a robust 
evidence base for their routine adoption into clinical practice; and limited evidence that some genetic 
tests alter the clinical management. 
4. Conclusions 
NGS has already transformed the landscape for individuals and families with rare inherited 
disorders. Conditions previously resistant to research or accurate diagnosis are now the focus of study 
and amenable to routine diagnosis through panel based approaches or clinical exomes. The advances 
in genomic sequencing technology and computing will mean that such sophisticated tests will 
become the standard of care for individuals with rare inherited disorders. The obligation for 
geneticists and healthcare professionals to harness this genomic revolution for maximum patient 
benefit is a real one. The ethical, legal and social implications are complex and require an open 
vibrant dialogue and engagement from all members of society. 
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Somatic Mosaicism in the Human Genome 
Donald Freed, Eric L. Stevens and Jonathan Pevsner 
Abstract: Somatic mosaicism refers to the occurrence of two genetically distinct populations of cells 
within an individual, derived from a postzygotic mutation. In contrast to inherited mutations, somatic 
mosaic mutations may affect only a portion of the body and are not transmitted to progeny. These 
mutations affect varying genomic sizes ranging from single nucleotides to entire chromosomes and 
have been implicated in disease, most prominently cancer. The phenotypic consequences of somatic 
mosaicism are dependent upon many factors including the developmental time at which the mutation 
occurs, the areas of the body that are affected, and the pathophysiological effect(s) of the mutation. 
The advent of second-generation sequencing technologies has augmented existing array-based and 
cytogenetic approaches for the identification of somatic mutations. We outline the strengths and 
weaknesses of these techniques and highlight recent insights into the role of somatic mosaicism in 
causing cancer, neurodegenerative, monogenic, and complex disease. 
Reprinted from Genes. Cite as: Freed, D.; Stevens, E.L.; Pevsner, J. Somatic Mosaicism in the Human 
Genome. Genes 2014, 5, 1064-1094. 
1. Introduction to Somatic Mosaicism 
1.1. Early Studies of Mosaicism 
Somatic mosaic mutations are defined as mutations that occur in some cells of the soma of a single 
individual (Figure 1) [1,2]. The mixture of mutation-positive cells with non-mutated cells results in 
an individual who is a mosaic, or contains different DNA within different cells of his or her body. 
Mosaic mutations may be present in the germline or soma; however, typically only mutations in the 
soma have phenotypic consequences or are detectable by current genotyping methods. Mosaic 
mutations in germ cells are usually only discovered when they lead to inherited conditions in multiple 
progeny. De novo mutations are operationally defined as mutations found in all cells of an individual 
but not detected in that individual’s parents (Figure 1d,e) [3]. De novo mutations only present  
in the offspring may occur very early in development; however, this is rare and increasingly  
sensitive genetic assays are discovering low-level parental mosaicism in supposedly de novo cases 
(Figure 1b) [4,5]. 
The role of somatic genetic changes in human health has been considered at least since 1914 when 
Theodor Boveri recognized that cancers frequently have abnormal karyotypes [6]. Alfred Knudson 
built upon the work of Boveri and others and in 1971 described a two-hit model of cancer resulting 
from both an inherited germline mutation and a later somatic mutation [7]. The model of metastatic 
cancer occurring as a result of multiple mutations in a single cell lineage has remained largely 





Figure 1. Overview of categories of variation including inherited (panels A–C), de novo 
(panels D,E), and somatic variation (panels F,G). Inherited mutations are always 
transmitted through the germline (A); although a parent may also have a mosaic mutation 
(this combination of somatic and germline mosaicism is occasionally termed gonadal 
mosaicism) (B); In such cases, a child may inherit the variant as a heterozygous mutation 
with a more severe clinical phenotype. A parent may also have germline mosaicism that 
may be inherited by progeny (C); De novo mutations are operationally defined as 
genotypes observed in a child but not in either parent. They may originate in a parental 
germ cell (as may be inferred in a pedigree having multiple affected offspring) (D) or 
postzygotically (E); Somatic mutation may occur relatively early in development (F) or 
at any later time throughout the lifespan (G), generally affecting fewer cells. 
 
The scientific community was slower to realize the importance of postzygotic mutational events 
outside of cancer. In the early 1950s, Barbara McClintock demonstrated the phenotypic importance 
of somatic transposition in Zea mays, and in 1959 Sir Macfarlane Burnet proposed a role for somatic 
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mutation in disease [10,11]. Nonetheless, few studies indicated a role for somatic mosaicism in 
human health. This changed in the 1970s with the discovery that somatic gene rearrangement creates 
functional diversity of immunoglobulin and T-cell receptor genes [12–14]. Today, it is known that 
somatic mutations are ubiquitous [15] and have important roles in cancer [9], aging [16,17], 
neurodegeneration [18], monogenic disease [19–21], reversion of inherited disease [22–25], and 
numerous neurocutaneous disorders [26]. 
1.2. Categories of Somatic Variation 
Somatic variation has been observed at all genomic scales from point mutations to aneuploidies.  
At the level of whole chromosomes and large chromosomal segments, complex genomic 
rearrangements occur somatically (as well as in the germline). The loss or gain of entire 
chromosomes is thought to be caused by errors in chromosomal segregation during anaphase, while 
non-allelic homologous recombination may cause the loss, gain, or rearrangement of large genomic 
regions [27,28]. The phenotypic consequences of these events vary considerably based on the size 
of the event and the genomic region involved. 
In many instances, both copies of a chromosome pair (or of a chromosomal segment) are inherited 
from one parent, a phenomenon termed uniparental disomy (UPD) [29,30]. UPD may involve two 
copies from a parent that are identical (uniparental isodisomy) or different (uniparental 
heterodisomy). Either form may disrupt epigenetically imprinted regions (defined as undergoing 
differential expression depending on the parent of origin), while uniparental isodisomy may also 
expose two copies of a recessive mutation. One mechanism for the occurrence of UPD involves 
trisomic rescue in which an extra (third) copy of a chromosome is rejected, producing a diploid cell 
line in which one parent’s monoploid copy is lost [31]. Frequently, the trisomic rescue is restricted 
to a fraction of cells in an individual resulting in mosaic trisomy/UPD [32]. UPD may also result 
from somatic recombination occurring from a reciprocal exchange during mitosis, leading to  
loss of heterozygosity. 
RNA-templated DNA polymerases are another cause of genomic instability. While numerous 
types of repetitive elements are present in human genomes, only non-long terminal repeat 
retrotransposons are currently competent for retrotransposition [33]. Successful retrotransposition of 
these elements is dependent upon functional protein products from long interspersed elements 
(LINEs). In most somatic tissues, LINEs are epigenetically suppressed; however, these elements 
escape epigenetic repression during early embryonic development, and their integration into other 
functional genomic elements occasionally results in disease such as choroideremia (Online 
Mendelian Inheritance in Man [OMIM] #303100) [34]. Retrotransposition may also occur in somatic 
tissues with unusual epigenetic states [35]. 
Low complexity regions, including trinucleotide repeats, are scattered throughout the mammalian 
genome. Trinucleotide repeats can be hypervariable and expansions of some trinucleotide repeats are 
the causes of nearly 30 disorders [36,37]. The molecular mechanisms underlying expansion or 
contraction of these regions are complex and cause these regions to have variable length throughout 




Small genetic aberrations may be caused by a number of mechanisms. Polymerase errors may 
result in nucleotide misincorporation or small insertions or deletions in the germline or soma. Over 
time, DNA will accumulate numerous lesions and DNA polymerization across these lesions is 
especially error-prone. DNA lesions may be detected and repaired prior to DNA polymerization, but 
lesion repair may also create single nucleotide variants, or small insertions or deletions [45,46]. 
In linear mammalian genomes, DNA replication starts at multiple origins with DNA polymerases 
 and  [47,48]. Polymerase  moves with high processivity 5'–3' along the genome on the leading 
strand, moving in the same direction as the replication fork. On the lagging strand replication by 
polymerase  also proceeds 5'–3' but in the opposite direction as the replication fork, causing 
replication of that strand to be iterative. This process works well for the majority of the genome, but 
replication of the lagging strand leads to loss of genetic information at the ends of the chromosome 
during every replication [49]. This end replication problem is solved in the germline because the ends 
of chromosomes, telomeres, are protected by repetitive DNA which is synthesized by a dedicated 
RNA-templated DNA polymerase called telomerase [49]. However, telomerase is not usually 
expressed in somatic tissues, likely as a method of protection against malignant transformation, and 
decreased telomere length is a form of somatic variation. 
1.3. Mosaicism during Development 
A defining characteristic of mosaic mutations is that they occur postzygotically and are inherited 
by all subsequent cells in their lineage (Figure 1). Somatic errors in chromosomal segregation in 
early development induce an extraordinarily high rate of aneuploidy. Fifteen to 20% of  
clinically recognized pregnancies result in spontaneous abortion, and half of these are attributed to 
aneuploidy [29]. A review of 36 published studies showed that of 815 human preimplantation 
embryos, only 177 (22%) were diploid while 73% were mosaic [50]. In most cases, these were 
diploid-aneuploid mosaic embryos, having one or more diploid cells as well as other cells that were 
haploid or polyploid for a particular chromosome. Mitotic errors could account for the high rate of 
chromosomal mosaicism. 
Due to the exponential rate of growth during development, somatic mutations must occur early in 
development to have phenotypic effects over large portions of the body. Severe somatic mutations, 
which would be embryonic lethal if inherited, have a short window during development in which 
they must occur to be observed in adults [19]. If these severe mutations occur early in development, 
they will be embryonically or prenatally lethal; occurring later in development they may have little 
or no obvious phenotypic effect. 
Mutations that alter cellular growth do not necessarily have to occur within such a short 
developmental window. Inactivating mutations in genes encoding tumor suppressors or activating 
mutations in oncogenes may have functional consequences regardless of when they occur, as evident 
from their known roles in cancer. On the other hand, somatic growth-retarding mutations, such as 
inactivating mutations in oncogenes or certain cyclins, are unlikely to have phenotypic effect in 
adults regardless of when they occur in development as the total number of cells containing the 
mutation is likely to be small. 
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Somatic mutations are thought to occur in all cells during replication. On average, 50 mutations 
occur in microsatellite regions during every mitotic division of a given cell [15]. Mutations in 
microsatellites and other regions of the genome, assessed by either single-cell or deep sequencing, 
can then be used to infer cell lineage trees [51]. To date, the most successful lineage tracing 
experiments have made use of increasingly sophisticated microscopy techniques [52]. However, 
microscopy-based approaches have practical and technological barriers such as the requirement that 
non-transgenic cells must be monitored over time. Recent advances in whole genome amplification 
(WGA) and second-generation sequencing offer genetic-based approaches that do not have the same 
limitations. Already, these techniques have been used to provide a detailed view of the genetics of 
cancer metastasis [53,54]. 
1.4. Mosaicism across the Body 
By definition, somatic mosaic mutations affect only a subset of cells within an individual  
(Figure 1). This is most easily visible in monogenic mutations affecting pigmentation patterns. While 
such patterns may be mistaken for stochastic X chromosome inactivation or autoimmune response, 
somatic mutation is generally localized over a small portion of the body and in many cases occurs along 
lines of Blaschko [55]. To date, almost all non-cancerous somatic mutations characterized at the 
molecular level result in visible abnormalities, usually involving hypertrophy (cellular overgrowth) 
or abnormal pigmentation [26,55]. Some of our inability to identify mutations that do not result in 
visible phenotypes is practical; during dissection it is difficult to distinguish affected from unaffected 
tissue. However, due to the current emphasis on visible phenotypes, few data are available on the 
extent to which non-visible somatic mutations influence important biological processes. 
An important consideration is that somatic mutations occur in varying cell types and tissues as 
well as different developmental stages. This raises the possibility that a specific mutation may vary 
in its clinical importance depending on where the mutation occurs across the body. Mutations in 
GNAQ provide an example. We identified p.Arg183Gln mutations in GNAQ, encoding the G protein 
alpha subunit G q, as the cause of both Sturge-Weber syndrome (OMIM #185300) and port-wine 
stain birthmarks (OMIM #163000) [56]. Port-wine stains are non-syndromic vascular abnormalities, 
while the Sturge-Weber syndrome is a severe neurocutaneous disorder, although both conditions 
likely affect some of the same cell types (e.g., endothelial cells). The milder phenotype of the 
birthmarks could result from a later developmental origin of the mutation during fetal development. 
The identical p.Arg183Gln mutation in GNAQ, when occurring in melanocytes later in life, is a 
frequent driver mutation in uveal melanoma (OMIM #155720), highlighting the importance of both 
the location and timing of the mutation. p.Arg183Gln mutations in different cell types and 
developmental stages could have different phenotypic consequences, if any [57]. 
Other mosaic mutations also differ in their clinical importance based on cell or tissue-specific 
involvement. McCune-Albright syndrome (OMIM #174800) is characterized by increased function 
of endocrine glands, sexual precocity, café-au-lait macules, and fibrous dysplasia. These symptoms 
can vary considerably based, in part, on the bodily extent of the mutation [58]. Like Sturge-Weber 
syndrome, this disorder is caused by somatic activating mutations in a gene encoding a G protein 




mosaicism. GNAS is expressed biallelically through most of the body, but the maternal allele is 
imprinted in particular tissues such as the pituitary. The disorders progressive osseous heteroplasia 
(OMIM #166350) and pseudopseudohypoparathyroidism (OMIM #612463) result from loss of 
function mutations in the paternal allele of GNAS [59]. 
Somatic mutations in three AKT genes also have cell-specific effects [60–62]. Somatic AKT1 
mutations are associated with somatic breast cancer, colorectal cancer, and ovarian cancer  
as well as the Proteus syndrome. The AKT2 gene is expressed selectively in insulin-responsive  
tissues and mutations are associated with diabetes. Somatic mutations in AKT3 cause 
Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2 (OMIM *615937). Given 
the localized nature of somatic mutations in AKT discovered to date, it is likely that mutations in 
these genes occurring outside of vulnerable cell types have few effects. These examples highlight 
the complex interaction of localized somatic mutation with tissue or cell-specific gene expression 
and signaling pathways (Figure 2). 
Numerous studies have aimed to assess the prevalence of mosaic alterations in tissues of 
apparently normal individuals. Reanalysis of data from multiple large genome-wide association 
studies have determined that the number of detectable mosaic events rises sharply after age 50. 
Furthermore, individuals with increased numbers of mosaic events have higher risk for developing 
cancer [63,64]. While this measured increase of mosaicism may be due to increased rates mutation 
rates in elderly individuals, it is much more likely that these events are the result of clonal expansion 
and positive selection within the stem cell niche or decline in the total number of hematopoietic stem 
cell progenitors later in life. Notably, increased rates of mosaicism in apparently normal tissues have 
been linked to poorer prognosis in individuals with ovarian cancer [65]. 
Figure 2. Tissue-specific effects of mutations in GNAQ (A); GNAS (B); and AKT1, 
AKT2, and AKT3 (C). Constitutively activating mutations in GNAQ may lead to either 
Sturge-Weber syndrome, nonsyndromic port-wine stains, or uveal melanoma (A). Somatic 
activating mutations in GNAS lead to McCune-Albright syndrome, which may involve 
variable hyperthyroidism, café au lait macules and sexual precocity (B). Activating 
mutations in all three of the AKT genes cause cellular overgrowth phenotypes with 
mutations in AKT2 also implicated in abnormal insulin signaling (C). 
 
Studies of twins have demonstrated that post-zygotic mutations may be phenotypically important. 
Notable examples are monozygotic twins who are discordant for phenotypic sex due to mosaic loss 
of chromosome Y [66,67]. Numerous examples of monozygotic twins exist where either the  
presence [68,69] or severity [70] of disease is discordant between twin pairs due to variable proportions 
of mosaic cells. 
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Studies of multiple tissues of apparently normal individuals have also found evidence for mosaic 
events. Analysis of CNVs using hybridization of DNA from multiple tissues of three apparently normal 
individuals to bacterial artifical chromosome arrays found evidence for six somatic CNVs [71]. 
Higher resolution examination of a total 33 tissues from six individuals using array comparative 
genomic hybridization found evidence for 73 high-confidence mosaic CNVs, although a majority of 
high-confidence events (54/73) were found in one of two particular tissues [72]. It has been noted 
that induced pluripotent stem cells (iPSC) frequently contain CNVs which may cause genomic 
instability inheritent to the process of immortalization. Abyzov et al. performed a detailed study of 
this phenomenon and concluded that almost half of CNVs present in iPSC lines can be found in the 
parental fibroblasts. Furthermore, they conclude that approximately 30% of all fibroblasts in their 
sample contain some mosaic CNVs [73]. 
While experimentation with bulk tissues has shown that somatic mosaicism occurs frequently in 
normal populations, the combination of DNA from many cells limits the ability of an assay to detect 
mosaic events unique to single or few cells. As a result, sequencing of single-cells has been recently 
used to assay mosaicism in normal tissues. These methods have been used to sensitively reexamine 
conclusions regarding the extent of mosaicism in the brain. Previous reports had indicated that up to 
33% of neuroblasts were aneuploid while up 80 retrotransposon insertions occur per neuron [74–77]. 
Single-cell experiments of the same phenomena have shown that large copy-number variants occur 
in over 14% of neurons but whole chromosome aneuplodies and retrotransposition events are 
relatively rare [78–80]. 
Single-cell studies have also been used to investigate the extent to which mosaicism occurs in 
early development. It has been known since 1983 that chorionic villus sampling may indicate the 
presence of a trisomy, while the fetus is diploid without the presence of mosaicism, a condition 
termed confined placental mosaicism [81–83]. Single-cell studies of young embryos cultured in vitro 
also demonstrate that chromosomal aneuploidies are common and were found in 83% of tested 
embryos [84]. While it is likely that many aneuploid embryos are unlikley to result in viable 
pregnancies, recent advances in prenatal testing allow for the sensitive and specific detection of 
numerous trisomies by sequencing of circulating fetal DNA from maternal plasma [85]. 
2. Detection of Somatic Mosaicism 
2.1. Technical Considerations 
Almost every type of genetic variation has been implicated as a source of somatic variation 
including expansion of trinucleotide repeats, point mutation, copy-number loss/gain, uniparental disomy, 
mitotic recombination, aneuploidy, translocation, and retrotransposition [39–41,43,44,69,77,79,86–94]. 
The techniques summarized below vary widely in their ability to detect specific types of somatic 
variation and more specialized techniques exist for the sensitive detection of some types of variation. 
A primary consideration during the analysis of mosaic samples is the purity of the dissection from 
tissue samples. The presence of normal cells in affected tissue significantly decreases the ability of 
downstream analyses to detect mosaic alterations. This problem can be compounded by the 




somatic mutation, two neighboring cells may both be affected if they share a common  
lineage from the mutated cell. Alternatively, cellular migration could cause neighboring cells to 
originate from distinct precursors with only one cell affected. Cellular migration can place an 
important biological constraint on the visible frequency of driver somatic mutations in affected 
tissues (e.g., in the brain) [3,95,96]. 
While contamination of normal cells is known to decrease the observed frequency of mosaic 
mutations, other mechanisms may decrease the detectable fraction of mosaic cells within a sample. 
Two possibilities are cell-type specific lethality and mosaic absence of essential juxtacrine or 
paracrine signaling factors. Cellular signaling pathways are known to have cell-type specific effects 
raising the possibility that a mosaic mutation may be lethal in only one type of cell within a tissue 
(Figure 3a). Furthermore, some paracrine or juxtacrine signaling factors are essential for cell  
viability [97–99]. Mosaic loss of these factors could result in affected tissue that is dependent upon 
surrounding normal tissue for survival, reducing the total number of mutant cells (Figure 3b). 
In Sturge-Weber affected tissues, we detected GNAQ mutant allele frequencies between 1% and  
18% [56]. Other studies using similar techniques have detected mutant allele frequencies of  
1%–47% [61], 3%–30% [100], and 3%–35% [60] for causative mutations in individuals with Proteus 
syndrome (OMIM #176920), CLOVE (Congenital Lipomatous Overgrowth, Vascular anomalies, 
and Epidermal nevi) syndrome (OMIM #612918), and hemimegalencephaly (e.g., OMIM #615937), 
respectively. Such relatively low allele frequencies are likely explained by the presence of low 
proportions of affected cells in a given tissue due to cellular migration or impure dissection. 
However, the occurrence of mosaic cell death due to either cell-specific lethality or loss of essential 
signaling factors should be considered. 
Figure 3. Cell death may reduce the total number of cells harboring somatic mutation. 
Mosaic mutations may cause cell-type-specific lethality (A); Mosaic loss of an essential 
juxtacrine signaling factor may cause localized death of cells that are not adjacent to 
unaffected tissues (B). 
 
In second-generation sequencing experiments, sequencing and mapping errors are a major 
concern, as some portions of the genome are known to be prone to false-positive variant calls [101]. 
Recent improvements in sequencing chemistry have lowered the frequency of sequencing errors. 
However, biased errors in sequencing are still problematic for the detection of somatic variation, 
especially when the mutant allele frequency may be close to the technology’s inherent error rate. 
Generally, ultra-high depth sequencing (>500 reads) of normal and affected tissues will permit 
detection of these errors. However, exploratory studies generally do not reach this level of depth. It is 
likely that without validation, these errors are a source of false positives in somatic variation 
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databases. Comparing suspected somatic mutations across multiple tissue types from multiple 
individuals to estimate local error profiles may be a possible solution to this problem [102]. 
2.2. Cytogenetics 
Microscopy-based methods allow for the detection of large mosaic events in single cells. Early 
cytogenetic methods for identifying extra or fewer chromosomes involved counting condensed 
metaphase chromosomes under a microscope [103]. Later methods using Giemsa staining and other 
dyes produced unique chromosomal bands allowing for the identification of intra- and 
interchromosomal translocations, duplications, deletions, and large structural rearrangements. 
However, banding techniques can only resolve aberrations larger than 3–10 Mb [104]. Other methods, 
such as fluorescent in situ hybridization (FISH), label a specific region of the genome by hybridization 
of a fluorescent probe allowing for the detection of deletions and some duplications [105]. Variations 
in this methodology exist using multiple probes of different color to detect several unique fragments at 
a time (e.g., multicolor FISH). These methods are able to achieve resolutions below 100 kilobases or, 
in some cases, as few as several kilobases [106]. Potential probe binding to off-target regions is a 
major consideration in most FISH experiments and adequate controls are required to confirm locus 
specificity [106]. Variants on classical FISH methods continue to be developed which promise to 
increase the ability of fluorescent probes to detect small chromosomal abnormalities across 
increasingly large portions of the genome [106,107]. In combination with high-throughput 
techniques, these approaches may be used to screen large numbers of cells from a single individual 
allowing for the detection of low levels of mosaicism. 
2.3. Genome-Wide Arrays 
Comparative genomic hybridization (CGH) is a technique in which fluorophore-labeled DNA 
from a control and test individual are hybridized to a metaphase reference chromosome [108]. The 
ratio of fluorescence emission is then measured to allow for the detection of duplication or deletions. A 
ratio of 1:1 indicates that both samples of DNA carry the same copy number while deviations from 
this ratio indicate a copy number variant [109]. 
Two principal array-based techniques that have emerged as alternatives to CGH are array CGH 
(aCGH) and single nucleotide polymorphism microarrays (SNP microarrays) [110–112]. Similar to 
CGH, both aCGH and SNP microarrays have the ability to detect changes in copy number over  
large regions of the genome. SNP microarrays further have the ability to genotype individuals  
at the probed sites, which may be useful in the detection of low-level somatic events [113].  
Array-based approaches offer increased sensitivity over the entire genome for small CNVs relative 
to genome-wide microscopy-based approaches. aCGH and SNP microarray analysis can resolve 
regions less than 100 kb in size. However, the sensitivity of array-based approaches for somatic 
CNVs is dependent on having at least 5%–10% of the cells assayed containing the genetic  
variant. For larger CNVs affecting a smaller fraction of cells, microscopy-based approaches  




In both aCGH and SNP microarrays, deviations in relative probe intensities indicate deletion or 
insertion events. Normalized probe intensities are commonly reported as log-R ratios, with higher 
intensities indicating insertions while lower intensities indicate deletions. For SNP microarrays,  
the relative intensities of the two probes (one specific to each allele) at a locus is informative,  
and normalization of these intensities is measured as a B-allele frequency. For normal diploid tissues, 
B-allele frequencies approximate 0.0, 0.5, and 1.0 for AA, AB, and BB genotypes, respectively, 
while log-R ratios approximate 0 indicating no copy number change. 
The hybridization of genomic DNA to microarrays is inherently noisy and can be subject to large 
batch effects [114]. Furthermore, individual probes or even whole arrays may have errors caused by 
faulty manufacture. Together these artifacts make the detection of statistically significant mosaic 
CNVs difficult, but many software packages detect these events. Numerous tools use hidden Markov 
Models (HMMs) to integrate B-allele frequency and log-R ratio information for the detection of 
mosaic events, including PennCNV-2, GPHMM and MixHMM [115–117]. gBPCR uses an approach 
similar to the Bayesian Piecewise Constant Regression for the detection of mosaic abnormalities but 
has a long runtime per sample [118]. We developed triPOD which uses multiple algorithms for the 
detection of mosaic events and is unique in that it utilizes parental genotypes allowing for more 
sensitive detection of haplotype-specific mosaic abnormalities [113]. 
2.4. Second-Generation Sequencing 
Second-generation sequencing techniques have revolutionized human genetics in the last decade. 
Sequencing is performed either on single cells, a discrete number of cells, or bulk tissue. In the typical 
sequencing experiment, DNA is extracted from the input material and is fragmented, size-selected, 
and sequenced to produce strings of inferred nucleotides and their respective quality scores [119]. 
This information is used to align the sequencing reads to a reference genome. Differences between 
the aligned reads and the reference can be used to infer genetic variants including single-nucleotide 
variants or polymorphisms (SNVs or SNPs), insertions, deletions, translocations, and retrotransposition 
events. Furthermore, the total number of reads aligned to certain regions of the genome can be used 
to infer copy-number changes [120,121]. Numerous variations on this basic approach exist and here 
we will discuss the methods most applicable for the detection of mosaic events. 
Somatic genetic variants have been discovered via whole-exome or whole-genome sequencing of 
bulk tissue from paired affected and unaffected portions of the body [56,60,61,100]. Whole-exome 
sequencing relies upon an oligonucleotide bead or array-based enrichment of DNA fragments 
corresponding to exonic regions to reduce the representation of sequence from noncoding regions of  
the genome [122–124]. At similar depth, exome and whole-genome sequencing are considered to  
have similar sensitivity for most pathogenic SNVs and small insertions or deletions. Whole-exome 
sequencing is considered less sensitive for the identification of medium to large insertions or 
deletions or the detection of copy-number changes by analysis of read depth due to introduced biases. 
However, exome sequencing experiments are typically performed at higher depth due to the lower 
cost of the method. 
Numerous software packages allow the identification of somatic variants from these data. Somatic 
variant callers typically evaluate second-generation sequence data from paired tumor/normal  
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(or other affected/unaffected) samples. Examples include VarScan2 [121], SomaticSniper [125], 
JointSNVMix [126], Strelka [127], and MuTect [128]. After removal of low-quality reads, sequences 
are aligned to a reference genome to generate aligned binary sequence alignment/map (BAM)  
files [129]. At least three approaches have been employed for the detection of somatic SNVs and 
small insertions or deletions. (1) Allele frequencies can be compared. For example, VarScan2 
performs pairwise comparisons of base calls and normalized sequence depth at each position, 
accounting for factors such base quality scores, coverage and variant allele frequencies; (2) Bayesian 
comparison of joint diploid genotype likelihood can be estimated for both samples. The 
SomaticSniper algorithm calculates the statistical significance of all somatic variants at positions 
above a minimum threshold of coverage using this method; (3) Other Bayesian approaches have been 
applied. For example, Strelka models the normal sample as germline variation plus noise, while the 
affected sample includes noise along with germline and somatic variation. Other types  
of somatic variation may be detected from bulk sequencing. Tools such as VarScan2, ADTeX, 
Control-FREEC, SomatiCA, and LUMPY may be used for the detection of somatic CNVs or 
structural variants [121,130–133]. 
Besides variant identification, quantification of the fraction of cells affected by particular somatic 
changes provides a better understanding of the extent of the mosaic mutation and the period during 
development at which it occurred. Several tools have been developed to deconvolute somatic 
mutations into distinct populations as reviewed by Yadav and De and Ding et al. [134,135]. 
An alternative approach to sequencing bulk tissue is sequencing single cells or small numbers of 
cells. As single or hundreds of cells contain very little DNA, most experiments utilize multiple 
displacement amplification (MDA) or PCR based methods to amplify genomic DNA. Amplification 
can greatly increase the total amount of available DNA for sequencing at the expense of introduced 
biases such as allele dropout and chimeric amplification of genomic fragments [79,136–138]. Despite 
these introduced biases, amplification and subsequent second-generation sequencing or array-based 
analysis of single cells has been used to reliably find somatic copy number variation and 
retrotransposition events within the human brain as well as to map cell lineage within a bulk tumor 
dissection [53,54,79,139]. Numerous groups have also used single-cell techniques to discover SNVs 
or indels in single cells, however, allelic dropout and chimeric amplification are more problematic 
for these analyses as biases can be reduced for analysis of CNVs by increasing bin sizes but are more 
difficult to account for in analysis of SNVs [140–142]. 
3. Somatic Mosaicism in Disease 
3.1. Cancer and Aging 
The relationship between somatic mutation and cancer has been extensively reviewed  
elsewhere [9,17,87,143–145] and comprehensive lists of known oncogenes or tumor suppressors or 
genes significantly and recurrently mutated in cancer have been previously described [9,87]. Cancer 
has been described as having six hallmarks: proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, induction of angiogenesis, and inactivating 




advantage in tumor cells [9]. This may be achieved by elevating the activity of growth factors and/or 
their receptors, but more commonly driver mutations constitutively activate intracellular signal 
transduction cascades. Three of these are depicted in Figure 4 (in simplified form): 
Ras/Raf/MEK/ERK, Ras/PI3K/PTEN/Akt/mTOR [147], and GNAQ. These pathways contain both 
oncogenes (RAS, RAF, MEK, PIK3CA, AKT, GNAQ) and tumor suppressor genes (NF1, PTEN, 
TSC1, TSC2). For example the RAS family of oncogenes were the first oncogenes to be identified in 
cancer. Comprised of HRAS, KRAS and NRAS, activating mutations in these genes occur in 
approximately 20% of all cancers [148]. Germline variants are also well known to contribute to 
cancer morbidity [149–151]. Frequently, these variants affect proteins involved in DNA repair, 
highlighting the role of somatic mutations in tumorigenesis [152–155]. 
In common solid tumors, ~95% of protein altering mutations consist of single base substitutions, 
>90% of which are missense mutations, <8% are nonsense mutations, and <2% affect splice sites or 
untranslated regions [9]. Relatively large numbers of somatic mutations occur in tumors that are 
associated with mutagens such as ultraviolet light and cigarette smoke. For example, in non-small 
cell lung carcinomas the average mutation frequency is greater than ten-fold higher in smokers 
compared to those who never smoke [156]. 
Large-scale projects and databases have been developed to provide comprehensive catalogues of 
somatic mutations found in cancer [157,158]. COSMIC (Catalogue Of Somatic Mutations In Cancer) 
includes information on more than 1.6 million mutations from nearly 1 million cancer samples and 
includes various types of mutations (fusions, genomic rearrangements, whole genomes, and copy 
number variants) [157]. 
The combination of well-characterized somatic mutation databases and low-cost sequencing 
technologies may lead to improved patient outcomes in the near future. Biopsied tumors may be 
screened rapidly for putative driver mutations based on cancer type, informing treatment. Furthermore, 
once a cancer is in remission, tumor-specific DNA may be assayed at low cost with ultra-sensitive 
second-generation sequencing-based techniques [159]. These advances will likely improve prognosis 
for millions of cancer patients within the next decade. 
The primary risk factor for cancer is age, and cancers offer insight into age or mutagen-associated 
mutational processes [160]. Somatic mutations have long been suspected to be an important part of 
the molecular mechanism of aging, and accumulation of DNA lesions and mutations occurs in both 
the germline and soma over time [63,64,161,162]. By chance, these mutations may result in 
malignant transformation, apoptosis, or otherwise hampered cellular function. As visible in cancers, the 
characteristics of acquired mutations differ by tissue type and are dependent upon environmental 
exposure [9]. Furthermore, frequently dividing stem cells and frequently transcribed genomic regions 
have different patterns of mutation that are cell-type specific. 
In both mouse and human, increased rates of somatic mutation and numbers of DNA lesions due 
to either error-prone DNA polymerases or faulty DNA repair mechanisms cause cancer 
predisposition, early aging, and neurodegenerative phenotypes [17]. Increased rates of somatic 
mutation in the nuclear genome cause cancer predisposition, likely due to increased rates of mutation 
in somatic stem cell populations. This has been demonstrated in transgenic mice whose processive 
DNA polymerases lack proofreading. Notably, mice with mutated polymerases  and  develop 
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distinct cancers but do not demonstrate premature aging phenotypes [163–165]. While these mice 
may not live long enough to demonstrate early aging phenotypes, their predisposition towards the 
development of cancer demonstrates a strong link between cancer and somatic mutation. 
Mutations in genes affecting other pathways demonstrate a strong relationship between somatic 
mutations and aging. Mice with error-prone mitochondrial polymerases demonstrate a premature 
aging phenotype without cancer predisposition, although subsequent data by some of the same 
authors demonstrate that mitochondrial point mutations are unlikely the primary cause of aging in 
normal mice [166,167]. Individuals with defects in DNA repair also demonstrate symptoms of 
progeria. Cockayne syndrome (OMIM #216400) is caused by defects in transcription-coupled 
exonucleotide repair leading to an early aging phenotype combined with intellectual disability and 
neurodegeneration without noted predisposition to development of cancer [168]. Mutations in the 
genes encoding RecQ helicases cause Werner syndrome (OMIM #277700) and Rothmund-Thomson 
syndrome (OMIM #268400) [169]. The most prominent phenotype of individuals affected by these 
diseases is premature aging, although these individuals are also predisposed to developing  
cancer [169]. Bloom Syndrome (OMIM #210900) is notable in that it is also caused by mutations in 
a RecQ helicase-like protein and also increases cancer incidence, but does not appear to result in 
progeria. Mutations in numerous other genes are known to cause cancer predisposition. One such 
example is BUB1B. Loss of BUB1B protein function leads to premature chromatid separation and 
mosaic variegated aneuploidy syndrome 1 (OMIM #257300) typically resulting in cancer predisposition 
and intellectual disability [170]. 
Cancer is associated with many genomic changes. Large chromosomal changes occur in a variety 
of noncancerous conditions. An example is Pallister-Killian syndrome (OMIM #601803) is a 
dysmorphic condition caused by mosaicism for tetrasomy 12p. Affected individuals display tissue 
mosaicism, typically with apparently normal karyotypes from lymphocytes but 47 chromosomes in 
skin fibroblasts and chorionic villus and amniotic fluid cells. The extra chromosome is an 
isochromosome for a portion of chromosome 12p. In several cases hexasomy of chromosome 12p 
has been observed. 
3.2. Neurodegenerative Disease 
Somatic mutation is suspected to have a role in neurodegenerative disease [17,18].  
As in cancer, mutations in genes directly involved in DNA repair are implicated in neurodegenerative 
diseases such as ataxia-telangiectasia (OMIM #208900) and ataxia-ocular apraxia 1  
(OMIM #208920) [16,169,171–174]. These neurodegenerative phenotypes are likely caused by an 
increase of somatic mutation in the nervous system leading to cellular dysfunction, indicating a 
possible role for somatic changes and DNA lesions in age-related related neurodegenerative disorders. 
There is evidence that mosaic mutations or accumulated damage to other macromolecules play a 
role in Alzheimer’s disease (OMIM #104300) and Creutzfeldt-Jakob disease (CJD) (OMIM 
#123400). Alzheimer’s disease is characterized by the accumulation of -amyloid (A ) plaques while 
CJD is caused by misfolded protein PRNP [175,176]. Significant incidence of both diseases is 
attributed to familial risk and causal mosaic mutations have been found in sporadic cases [177,178]. 




the brains of mice overexpressing A  leads to disease progression [179–181]. Consistent with the link 
to prions, the pathology of inoculated mice displays phenotypes dependent upon the infecting  
host [180]. This has been corroborated by more recent experiments, which demonstrate that A  
aggregates from distinct sources have unique biophysical characteristics depending on the seeding 
protein [182–184]. While it is possible that sporadic misfolded or damaged proteins act as seeds in 
Alzheimer’s, this is unlikely given the steep increase in disease incidence later in life and the constant 
turnover of cellular proteins [185]. This steep rise in incidence mirrors the rise in incidence of CJD 
in individuals who have predisposing mutations [186]. It is possible that in both diseases misfolded 
proteins arising as a result of age-related somatic mutation or damage to other macromolecules in 
single cells act as seeds for the initial protein aggregates. 
3.3. Monogenic Disease 
A list of diseases suspected to be caused by obligatory somatic mutations has been previously 
described [21] and subsequently updated [19,20]. We note that somatic mutation likely contributes 
significantly to nearly all Mendelian diseases. 
We have described a series of oncogenes and tumor suppressor genes that undergo somatic 
mutation in cancer. These same genes can also acquire somatic mutations that result in 
neurocutaneous disorders or overgrowth syndromes, depending the particular cell type and 
developmental stage at which the mutation occurs. Mutations in GNAQ cause Sturge-Weber 
syndrome and port-wine stain birthmarks as well as uveal melanoma, as discussed above. Similarly, 
somatic mutations in GNAS can cause McCune-Albright syndrome or benign tumors such as 
adenomas. We next highlight several specific examples of such disorders affecting genes encoding 
intracellular signaling pathways (Figure 4). 
Phosphatidylinositol 3-kinases (PIK3s) are lipid kinases that phosphorylate phosphatidylinositol 
and other phosphoinositides, catalyzing intracellular signaling pathways involving a PI3K/AKT/mTOR 
network (Figure 4). Somatic, mosaic, gain-of-function mutations in PIK3CA (OMIM *171834)  
are associated with several syndromes involving overgrowth of the brain or lipomatous body  
overgrowth [191]. These include CLOVE syndrome, megalencephaly-capillary malformation 
syndrome, fibroadipose hyperplasia, and hemimegalencephaly. These conditions are often 
characterized by early segmental overgrowth, abnormal vasculogenesis, digital anomalies, cortical 
brain malformations, and connective tissue dysplasia. Somatic gain-of-function mutations in 
PIK3CA are also found in a broad range of cancers (ovarian, breast, lung, stomach, colorectal, and 
brain). While over 100 activating mutations in PIK3CA are known, mutations in two domains of the 
protein account for 80% of cancer-associated somatic mutations, and these same sites can be mutated 
in overgrowth disorders [192]. 
Clinical presentation of Proteus syndrome (OMIM #176920) includes distorting, progressive 
overgrowth of various tissues including skin, skeleton, adipose, and central nervous system. In most 
patients it is caused by somatic mosaic mutation of AKT1 involving c.49G > A (p.Glu17Lys) [61]. 
This identical mutation is associated with breast, colorectal and ovarian cancers [193]. Mutations in 
the homologs of AKT1, AKT2 and AKT3 are also known to cause somatic disorder. p.Glu17Lys 
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mutations in AKT3 cause hemimegalencephaly and other brain malformations, while the identical 
mutation in AKT2 is causative for hypoglycemia [60,62,194,195]. 
Figure 4. Three intracellular signaling pathways are shown schematically. (At left), 
receptor tyrosine kinase activity leads to activation of PIK3CA, AKT, and mechanistic 
target of rapamycin (mTOR) [187,188]. mTOR participates in complexes (TORC1, 
activated by RHEB; TORC2, inhibited by RHEB) that regulate cell growth, proliferation, 
survival, and cell cycle progression. This pathway includes genes that are frequently 
mutated in tumors such as PIK3CA and PTEN (not shown); (At center), secreted growth 
factors bind to receptor tyrosine kinase receptors on the cell surface leading to activation 
of the low molecular weight G protein Ras and subsequent activation of Raf, MEK 1/2, 
and ERK 1/2 (official gene symbols MAPK3, MAPK1); (At right), a G-protein coupled 
receptor (GPCR) pathway is shown [189,190]. Ligands such as vasopressin, endothelin, 
glutamate, or norepinephrine bind to a GPCR. When bound by ligand, the receptor 
activates a G protein alpha subunit such as G q that binds and hydrolyzes GTP. This 
leads to activation of phospholipase C  producing inositol 1,4,5-triphosphate (IP3) and 
membrane-associated diacylglycerol (DAG). DAG, through activation of protein kinase 
C, may activate the Raf/MEK/ERK pathway. IP3 may bind to an IP3 receptor activating 
calcium signaling pathways (not shown). Other G protein  subunits (such as G s 
encoded by GNAS) activate membrane-bound adenylate cyclase, producing cyclic AMP 





Germline inactivating mutations in the TSC1 gene encoding hamartin cause tuberous sclerosis 1 
(OMIM #191100), while mutations in TSC2 encoding tuberin cause tuberous sclerosis 2 (OMIM 
#613254). Hamartin and tuberin act as tumor suppressors by activating the GTPase function of  
RHEB [196]. Inactivating mutations in a single allele are sufficient to cause tuberous sclerosis. Rare 
somatic inactivating mutations, lack of expression of the second allele or mosaic UDP events give 
rise to the multiple benign tumors, tubers and macules characteristic of the disease [197,198]. 
Neurofibromatosis 1 (OMIM #162200) (NF1) is characterized by the occurrence of at least two 
(of a list of seven) features such as café au lait spots, cutaneous neurofibromas, Lisch nodules 
(hamartomas) of the iris, and inguinal freckles [199]. Clinical diagnosis requires a first-degree relative 
with the condition. It is inherited in an autosomal dominant manner (and is among the most common 
such disorders with a prevalence of 1:3000). Most cases of NF1 are caused by heterozygous  
loss-of-function mutations of the tumor suppressor gene encoding neurofibromin 1. Only 50% of 
NF1 individuals have an affected parent, with another 50% having a de novo mutation. 
Neurofibromin 1 is a negative regulator of the RAS signal transduction pathway, with loss of function 
mutations in neurofibromin 1 leading to RAS activation. 
It is possible that mosaic variation occurring during development may result in disease across 
numerous tissues. One such example is somatic mutation of IDH1 and IDH2 that has been shown to 
cause Ollier disease and Maffucci syndrome. These syndromes are characterized by multiple 
enchondromas (benign bone tumors originating from cartilage). The causative variants for disease 
are typically not detectable outside of the tumors indicating that relatively few cells harbor the 
mutation [200]. 
The application of sensitive approaches for the detection of mosaicism to a smaller subset of genes 
based on a patient’s phenotype may increase the likelihood of finding causative variants.  
Jamuar et al. applied this approach examining two sets of previously implicated genes in 158 
individuals with cerebral cortical defects. Causal mutations were found in 27 individuals, eight of 
who harbored the causative variant in a mosaic fashion. Notably, causal mutations were only 
validated at extremely high read depth (>500×) highlighting both the importance of sequence 
coverage for the detection of mosaic variation and the utility of targeted approaches [201]. 
Somatic mutations are also known to cause reversion to normal mutations in individuals with 
monogenic disease [22,23,25,202,203]. Revertant mosaicism occurs when cells harboring a  
disease-causing mutation revert in vivo to a wild-type allele. The disease-causing mutation could be 
inherited from the germline or somatic. This has been observed for heritable skin diseases such as 
ichthyosis with confetti (OMIM #609165) and epidermolysis bullosa (OMIM #226650) [202,204] 
as well as rare blood disorders such as Fanconi anemia (OMIM #227646) and severe combined 
immunodeficiency resulting from adenosine deaminase deficiency (OMIM #102700) [205,206]. 
These somatic reversions to normal events may significantly ameliorate disease symptoms if the 
reversion occurs early enough in development. 
For many other overgrowth syndromes somatic mutations have yet to be identified.  
Examples include Klippel-Trenaunay-Weber syndrome (OMIM %149,000), which involves 
cutaneous hemangiomata and clinically resembles Sturge-Weber syndrome; and Cobb syndrome 
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(cutaneomeningospinal angiomatosis), which involves vascular cutaneous, muscular, osseous, or 
other lesions of spinal segments. 
3.4. Complex Disease 
Multiple recent papers have proposed that somatic mutation may play a role in the etiology of 
complex disease [3,207,208]. Studies of simplex autism probands have determined that de novo 
mutations account for 2%–15% of disease incidence and that at least 30% of de novo mutations can 
be causally implicated in simplex cases [209–212]. With de novo mutations playing such a large role, 
it is likely that post-zygotic somatic variation also contributes to disease in some individuals. To date, 
most genetic analysis has found few genetic variants to explain complex disease incidence, 
suggesting the occurrence of “missing heritability” [213]. A possible model is that somatic variation 
occurs in conjunction with common and rare inherited variation to cause disease. While this model 
is not directly supported by current evidence, recent experiments indicate that it warrants 
investigation. One surprising result from in situ hybridization experiments on postmortem brain 
tissue is the increased presence of patches of cortical disorganization in individuals with autism 
relative to controls [214]. The authors note that they examined only a small subsection of the brain 
and therefore cortical disorganization is likely widespread in individuals with autism. Furthermore, 
an interesting conclusion of recent large-scale examination of exonic de novo mutations in simplex 
autism is that most de novo variation implicated as causal occurs opposite wild type alleles [212]. 
Given that large CNVs are common in neurons of the cortex [78,80], we propose a model of  
brain-specific somatic mutation occurring opposite inherited de novo or rare mutation resulting in 
sporadic brain-specific loss of gene function and patches of cortical disorganization. 
4. Conclusions 
While the role of somatic mosaicism in disease is currently under active investigation, it is clear 
that functional somatic mosaicism has a significant role in human disease. In the last decade, major 
advances in both cytogenetic and second-generation sequencing techniques have enabled researchers 
to discover causative somatic mutations for an increasing number of diseases, and driver mutations 
in an increasing number of cancers. Furthermore, this increased understanding of the genetic 
underpinnings of disease is likely to lead to improved patient outcomes in the near future. 
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